"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald",52,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald Gradwell, Senior Vice President, Investor Relations and Special Projects. You may begin."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and",307,"Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our second quarter results. Also joining us on the call and available for questions are Alex Gourlay, Executive Vice President and President of Walgreens; and Jeff Berkowitz, Executive Vice President and President of pharma and global market access. 
As a reminder, today's presentation includes certain non-GAAP financial measures, and I will direct you to our website at investor.walgreensbootsalliance.com for reconciliations of the most directly comparable GAAP measures and related information. You can find a link to our website on our Investor Relations website -- sorry to our webcasts on our Investor Relations website. After the call, this presentation and the webcast will be archived on our website for 12 months. 
I'd now read out the safe harbor statement. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after this presentation, whether as a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K and subsequent filings for a discussion of the risk factors as they relate to forward-looking statements. 
Today's presentation include certain non-GAAP financial measures and we refer you to the appendix, to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. With that, I'll hand you over to Stefano for his opening comments"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call of Walgreens Boots Alliance. Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December, 2014. This was a hist",1106,"Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call of Walgreens Boots Alliance. Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December, 2014. This was a historic and pivotal milestone for 2 iconic companies, Walgreens and Alliance Boots, as we completed our merger to establish Walgreens Boots Alliance, forging the new company, the world's first global pharmacy-led health and well-being enterprise. We established a senior management team to bring together our businesses and lead them forward to the next phase of their evolution while making steady progress with the integration and the establishment of a single unified corporate entity and culture. 
Our team worked very hard to accelerate the closing of the deal 2 months ahead of the beginning of the completion window. We raised the funds to complete the transaction and to finance especially all the EBITDA in an efficient manner while going through a complicated process of preparing our first full consolidated earnings and the U.S. GAAP, including eliminating the 3 months reporting lag. The complexity and effort the staff has taken cannot be underestimated. I would ask you to remember that until completion, our business is operated at arm's length as separate entities. We are today only 14 weeks, in fact, 99 days into the creation of this new global entity. It is still very early but we have moved mountains in work that we've done and are still in the first step of our journey. We have achieved the merger in a short time and are moving quickly. We have expanded our restructuring program to create a more competitive cost structure. We're going to access synergies created through the combination and sharpen our focus on our strategic priorities including the sales of the majority interest of our infusion business subsequent to the quarter close. And today, I am pleased to announce a historic quarter, achieved along with all the other tasks that we have undertaken. We are looking forward to the future in 2 years' time.
Our transaction has created the growth which, I believe, is another potential to grow in ways that give us great excitement and optimism for the future. Let's start by looking at our business as we stand today. Based on an in-depth review of our retail pharmacy USA segment, I can say that the world [indiscernible] on its sound structural footing. As you might expect, some parts are better than expected while others saw room for improvement. Our first priority is to understand the business fully, its interdependency and its differentiators. This exercise is underway and will ensure we stay focused on what is truly important, delivering against the needs of our customers in a dependable yet innovative a manner that provides us that we sustainable recurring income a causal part of our business. This will be achieved through a combination of efficient practice [indiscernible] investments in our core business and innovation in our business model. So more [indiscernible] we believe we believe there will be significant scope to announce the performance of our pharmacies through refreshing and differentiating our store, improving customer experience, delivering services to customers and patients and introducing new offerings through innovative partnerships. We believe that through good business practice and application of these and other initiatives, we can over time expand the retail margin, grow market share and prepare ourselves to better address the competitive market-driven headwinds we face in certain areas of our business. 
Let me be perfect to you. Our aim is to help world [indiscernible] further develop strategies so we continue to deliver growth for many years to come. It is vital that we make best use of the assets that we have [indiscernible] to which our arrival portfolio of location across the U.S. We must work tirelessly to drive the best possible return from this asset, and to that end, we have today announced an enlarged [indiscernible] restructuring program to focus the worldwide business but on its core assets. We believe we will come out of this stronger and better positioned to deliver [indiscernible] the full month our premium location command. 
In Retail Pharmacy international, in both, we are working hard to refine the new cycle of our business that will deliver growth in the coming year. We are continuing to develop our online offering and building on our recent success. We are working to further integrate these with our physical stores and logistical network to announce the customer choice while making better use of our resources. The constant work to keep our offering fresh through innovation within store and within our own brand and excluding the product portfolio is continuing to differentiate us in an extremely competitive U.K. retail market. I'm confident that the work which Simon and his team are doing will set us on a path for further growth in the years ahead. 
As you're aware, our retail businesses are also continuing to perform well and it had been a particularly pleasure to welcome our new colleagues in Mexico and Chile to our company, making the expansion of our international retail presence in Latin America through their vision of 2 outstanding business that with excellent [indiscernible] for growth. 
Our pharmaceuticals sales division is continuing to develop at the integrated business model that we introduced many years ago, operating an ever-growing suite of services to the manufacturers that tie up most growth than ever to them as [indiscernible]. On the other side of the supply chain, we are expanding our [indiscernible] pharmacies customers to both align them more globally with our wholesalers and let them improve the quality and economics of their own businesses. While such initiative announced the vertical integration of our sales business and create strength and value, the ever-changing market that we are operating in and the continuous economic pressure the health care system around us present us with several opportunities to expand our network. 
These present themselves in many ways in one extreme through consolidation within market and the other extreme through innovative partnerships and Alliance system and as you have seen us to do with AmerisourceBergen. As our sales is a business announced by volume and market presence, we will continue to explore opportunities to expand our network as they arise. Underpinning all of these, Walgreens Boots Alliance has embarked on the beginning of a new year, a new year that will bring a new attitude, a new culture aligned toward driving performance, serving our customers and creating long-term sustainable shareholder value. Now I will ask George to take us through the quarterly results. George?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overvi",2559,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overview of our restructuring program; and finally, to articulate our views on FY '15 and FY '16 results. 
To summarize, the second quarter was a solid start for our new company. Key highlights include net sales of $26.6 billion, GAAP earnings per share of $1.93 where adjusted EPS was $1.18, cash flow from operations of $1.3 billion and free cash flow of $1 billion. The quarter's financial results are complicated as we began reporting as a consolidated entity partly through the quarter, and the comparability to last year is a challenge and of limited use. 
Before we get into the details of our second quarter financial performance, I'd like to explain some elements of our new reporting structure. Historically, Walgreens has reported as one segment which consisted of the results of Walgreens in the USA, its corporate costs, synergies from the Walgreens Boots Alliance development joint venture, also known as WBAD, and equity earnings from Alliance Boots on a 3-month lag. Our focus was to merge the businesses as soon as possible and eliminate the 3-month reporting lag. This aligns the reporting -- the reported the results of the global enterprise and will make our performance easier to understand going forward. 
As Walgreens Boots Alliance, we now report results in 3 segments: Retail Pharmacy USA, Retail Pharmacy international and Pharmaceutical Wholesale. Segmental reporting includes the allocation of synergy benefits including WBAD and combined corporate costs. Within our Retail Pharmacy USA segment, since the deal closed on December 31, we have reported 1 month of Alliance Boots equity income this quarter versus 3 months in the comparable quarter a year ago, recognizing the 45% stake that Walgreens had in Alliance Boots until end of December. The months of January and February are fully consolidated. Year-over-year comparisons of results require consideration of the foregoing factors and are not directly comparable. 
So now let me take you through our financials in greater detail beginning with the consolidated results. For the quarter, GAAP net earnings attributable to Walgreens Boots Alliance were just over $2 billion or $1.93 per diluted share, while adjusted and earnings were $1.2 billion or $1.18 per diluted share. This compares to $0.74 of GAAP net earnings per share and $0.97 of adjusted earnings per share in the prior-year quarter. Net sales in the second quarter were $26.6 million, an increase of 35.5% versus the prior year. Operating income on a GAAP basis was $1.4 billion and on an adjusted basis was $1.8 billion. The increase in adjusted operating income was driven by growth in our Retail Pharmacy USA segment as well as the consolidation of Alliance Boots results for January and February. We reported $144 million of net interest expense this quarter, which included interest expense associated with prefunding the transaction for the month of December. Consistent with last quarter, our adjusted EPS excludes this interest expense, which will not need to do going forward. 
The adjusted tax rate for this quarter was 27.7%. Now this has been impacted by a number of factors, including a change in the geographic mix forecast profits net of Alliance Boots has been fully consolidated, includes net discrete tax benefits specific to the quarter and the presentation of Alliance Boots taxes in the income statement. Prior to the full merger, Walgreens 45% share of Alliance Boots adjusted results, net of Alliance Boots tax were presented in a single line within operating income. Now following the transaction, Alliance Boots taxes reported within the income tax provision line in our income statement impacting the calculation of the adjusted tax rate. 
Diluted shares outstanding at the end of the quarter were $1.1 billion and average diluted shares outstanding for the quarter were 1.05 billion, resulting from the issuance of 144 million shares on 31 December as part of the consideration for Alliance Boots. 
So now let me walk you through the component pieces to explain the change from GAAP to adjusted EPS. The GAAP earnings per share for the quarter of $1.93 reconciles to an adjusted earnings per share of $1.18. The net adjustment of $0.75 per share, this reflects the removal of net gains on transaction-related item of $0.67 and gains on the warrants we hold over AmerisourceBergen shares of $0.35. This is partially offset by LIFO provision costs of $0.04; acquisition-related amortization expenses of $0.15 which includes $0.08 relating to that industry step-up, which will not reoccur in future quarters; and special items of $0.08 related to optimization costs and asset impairments. 
The components of the net gain on transaction-related items were a gain on Walgreens previously held equity interest in Alliance Boots of $0.77, a foreign currency hedge loss of $0.07 related to the [indiscernible] of the British pound element of the step 2 consideration and a net $0.03 cost transaction fees, tax adjustments and interest cost from prefunding the cash consideration. 
So next, I'd like to provide insights into financial results at the segmental level starting with Retail Pharmacy USA. Reported net sales were $21 billion, up 6.9% on a comparable store basis. In the pharmacy, comparable script store scripts, which includes immunizations, this increased 5% on a 30-day adjusted basis. The increase was driven by the positive impact of a strong cough, cold and flu season by continued growth in Medicare Part D scripts and positive underlying share trends. For the quarter ending 28 February, the division's 30-day adjusted prescription market share in the U.S. reached 19.3% as reported by IMS Health. This represents an increase of 20 basis points versus the same time last year. 
In retail products, comparable store sales increased by 2.5%. This was partially driven by strong December holiday sales, including seasonal sales of cough, cold and flu products. GAAP operating income for the quarter was $1.3 billion while adjusted operating income was $1.6 billion, up 13.4% over the year-ago quarter. Strong expense control and efficiencies offset the expected pharmacy gross margin pressure from declines in reimbursement, generic drug inflation as well as the Med Part D rate step-down that begun on the 1st of January this year. Retail product margins increased this quarter held by seasonal and cough cold and flu mix as well as our focus on reducing less profitable promotions. We remain very pleased with the progress on controlling and reducing SG&A expenses this quarter. Our GAAP SG&A expense declined 0.3% [ph] compared to the prior-year quarter. 
So next let's review the Retail Pharmacy international division, which is pharmacy life health and beauty retail businesses in 8 countries. The biggest contributor is Boots in the U.K. Total sales for the 2 months ended February were just over $2 billion. As the businesses included our Retail Pharmacy international division were acquired as part of the merger of Alliance Boots, no comparable information is included in the WBA consolidated results. On a pro forma constant currency basis, comparable sales for January and February grew by 2.9%. Comparable sales of Boots U.K. were up 2.3% while sales in our businesses in Chile and Mexico, which we acquired by Alliance -- acquired by Alliance Boots back in August 2014, these were up 2.9%. The acquisition brings us over 1,000 [ph] stores in Mexico and over 400 in Chile and provide strong growth opportunities in the Latin American market. Inclusive of this businesses new division combined with contract manufacturing are reflected in the margins. 
Now turning to Pharmaceutical Wholesale, which mainly operates under the Alliance Healthcare brand in 12 countries. Results in any given quarter influenced by performance in larger geographies, including the U.K., Germany, France and Turkey and the division's contribution from WBAD. Total sales for the 2 months ending February was $3.9 billion. Similar to Retail Pharmacy international, our Pharmaceutical Wholesale division was acquired through the merger with Alliance Boots and so no amounts are reported in the comparable period. However, in the pro forma constant currency basis, sales were relatively flat compared with the same period the prior year. 
Now let me spend a minute on our expectations for synergies and how they will be reported going forward. Prior to the merger, the majority of our synergies were flowing through WBAD, the former joint venture between Walgreens and Boots Alliance, which Walgreens fully consolidated and then removed Alliance Boots portion via the noncontrolling interest line item. Following the combination, we're allocating all synergies including those generated by WBAD to the segments, and we're doing this according to the relative proportion of purchases driving the synergy benefits. With regard to performance in the quarter, combined net synergies were $170 million, bringing the fiscal year-to-date total to $310 million, driven primarily by our drug procurement efforts. We remain comfortable with our ability to achieve at least $650 million in combined synergies this fiscal year. For FY '16, we continue to expect at least $1 billion in combined quantifiable net synergies. Consistent with prior reporting, these synergies did not include any benefit from our AmerisourceBergen relationship. 
Now that we're a combined company, as expected, we are focusing on driving incremental synergies from sharing our best practices and working more closely together. However, not all of these can be easily quantified as some of them tend to blend into our normal business.
So moving on to the cash flows. We generated approximately $1.3 billion in cash from operations during the quarter, and our free cash flow was $1.0 billion. We're pleased with the cash generation during the second quarter due in part to an improvement in our primary working capital within our Retail Pharmacy USA division, driven by a reduction in inventory levels. We will continue to focus on working capital and remain confident in future opportunities to increase efficiencies. Net debt as of the quarter end was $14.1 billion. 
With regard to uses of free cash flow beyond reinvestment back into the company, we completed $94 million of share repurchases in the quarter against our $3 billion authorization. We've purchased additional shares post the end of the quarter and the preestablished trading plans, bringing the total purchases to $330 million.
I'd now like to make a few comments on our capital allocation policy. As we've consistently communicated, we remain committed to a solid investment grade rating while looking for ways to enhance our cash generation. This includes driving working capital efficiencies, tightening capital expenditures, controlling costs and of course improving operations. Beyond maintaining a long-term 30% to 35% dividend payout target, our top priorities for free cash include M&A consistent with our strategy and share buybacks. All of these are with a view to optimizing long-term shareholder value. Following on this theme, and as Stefano mentioned, we are focused on becoming a more agile and more productive company. 
As you know, in August, 2014, we announced a 3-year $1 billion cost reduction initiative. After a rigorous analysis, we've identified additional opportunities for cost savings primarily in our Retail Pharmacy USA division. These additional cost opportunities will increase the total expected cost savings program by $500 million to a projected $1.5 billion by the end of fiscal 2017. So [indiscernible] focus include plans to close approximately 200 stores across the USA, to reorganize corporate and field operations, drive operating efficiencies and streamline information technology and other functions. These actions are designed to restructure and invest in our company's future in a way that is better for customers, simpler for our employees resulting in a faster and more agile organization. 
We estimate the total pretax charges associated with this program through our GAAP financial results will be in the range of $1.6 billion to $1.8 billion, of which the cash component is expected to be approximately 60%. The restructuring charges will be recognized over time as the program is implemented in accordance with GAAP. Looking ahead, we will continue to focus on other areas of cost reduction. 
Now let's talk about the rest of fiscal 2015. We understand and appreciate that there are a lot of factors that will impact our results. So in order to help you, we are providing an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Now this range assumes quarterly interest expense of $140 million to $150 million. It assumes a full year adjusted tax rate of approximately 29% and a fiscal year diluted share count generally consistent with the current quarter. It assumes management's estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. Now this guidance also includes recast fiscal Q1 results due to the elimination of the 3-month lag. 
Finally, you will see an increase in the share count in Q3 and Q4 due to the full inclusion of the 144 million shares issued with step 2 of the AB transaction. This will result in approximately 1.1 billion diluted shares per quarter. Any additional share repurchases will impact, of course, the fiscal year diluted share count. 
So moving on to FY '16, our previously published goals were based on a variety of assumptions to arrive at estimate ranges for both sales and adjusted EPS. These included operating assumptions for our businesses and certain below-the-line items, including interest, tax and share count. When we set the goals in August, we made foreign currency assumptions based on exchange rates that were close to market rates at that time. Since then, we've seen significant global currency movements especially the strengthening of the U.S. dollar. Because we report in U.S. dollars, we do have currency translational exposures primarily based on movements in the pound sterling versus the dollar. Simply put, a stronger dollar [indiscernible] our sales in earnings and dollars while a weaker dollar helps them. We estimate that a 1% move in the pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. Despite the FX headwind, I'm confident that we have initiatives and resources in place to address the controllable elements that drive our adjusted EPS goal for FY '16. 
Our revenues have greater potential variability due to the varied mix of businesses, particularly in our wholesale division, which accounts for a significant proportion of our overall revenue. In addition, the geographical spread of the wholesale business increases its exposure to currency variations. This being the case, we view overall revenue as a less relevant measure of our business. So taking these 2 factors into account, we decided to no longer provide our published revenue goal. And please note that our forward-looking statements assume no significant changes to the current exchange rates. 
So I'd like to wrap up today by saying that our reporting structure has changed and comparability is limited, which I know makes it really difficult for you. Therefore, in an effort to be as informative as possible, we provided adjusted EPS guidance for fiscal year 2015, and next week, we'll have a financial session to provide further insights. In addition, we plan to provide operational insights in each of our 3 segments, as well as views on our key financial drivers and future strategy. We really look forward to seeing you then. So with that, I'll turn the call back to Stefano."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. We are working to deliver the benefits of our transaction within our core businesses. It will involve executing our synergies and efficiency programs across",652,"Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. We are working to deliver the benefits of our transaction within our core businesses. It will involve executing our synergies and efficiency programs across the group including the progressive development of our procurement initiatives. We must also properly manage the assets of the business to ensure we are [indiscernible] structured and prepared to address the pressure we face in the pharmacy market world. These pressures may variously be from reimbursement cuts, competitive action or simply changes in consumer behavior. Whatever form and they take, if we are properly structured and prepared to operating an efficient high quality patient-oriented pharmacy service that we will earn the right not just to participate but to be an architect of the changes in our market. We are already seeing the benefits that can be achieved in retail with the initiatives underway at Walgreens and ongoing Boots. We must ensure that we get the best return for our investment and create the best environment for our employees and customers alike. This will require us to operate announced systems and control so that we can monitor and manage our business progress. 
Now many of you will ask where we are on the CEO search. As you know, we formed a search committee of the board and they have been working with one of the top executives [indiscernible] to help us find a new CEO. Currently, we are in the process of reviewing the candidates there, finding candidates with a combination of our attributes that we deem important for the whole is not really challenging as we expected it to be, but we remain confident that in due course we will find the right person for the job. 
Lastly, as the new culture takes hold and find roots in the company, you can see efforts in all parts of the business. I hope that in one particular area, you are seeing the new culture emerge very clearly, and that [indiscernible] now approach to our owners in the financial community in general. I have always viewed investors as my business partner. I hope that they will view me in the same way. 
As an organization, we strongly believe it is our duty to care for our shareholder and to ensure that we are ever flexible, responsible and transparent as we can be. We also believe in being proactive in reaching out to our investors to properly understand their requirement and ensure that in our investor relations effort we have -- we are as mindful of our shareholders as we are in our patients in our pharmacies or our customers and wholesalers. I think that Gerald and his team have done well to demonstrate this new [indiscernible] and that it is a great pleasure to see although there is still more to do. We are in the first step of a long and exciting part and I look forward to currently with you as fellow owners and partners. 
As I said earlier, I am optimistic about the long-term future of our company and have made the significant financial commitment to our future not only as Executive Vice Chairman and Acting CEO but also as a significant shareholder. I am convinced that the formation of Walgreens Boots Alliance is a unique first, which will almost inevitably lead to many other new firsts in our industry. It may not yet be clear, which steps are these will be, but we are determined to continue to show the way and be at the forefront of innovating health care. Our ambition is to build a generally global company and a universal health care champion. We look forward to providing a more comprehensive outlook on our future strategy and value creation next week at our first Analyst Day. With that, we are now ready to take your questions."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs.",15,"[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I know we'll get a little more detail on that next week at the Analyst, but I thought maybe I'd start on the incremental cost you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just curious",103,"I know we'll get a little more detail on that next week at the Analyst, but I thought maybe I'd start on the incremental cost you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just curious if you could give an update on how we should think about the cost-cutting over the next 3 years. And then related to that, given that there's an additional $500 million in cost-cutting obviously reiterating the fiscal '16 guidance, wondering if there is any negative offsets that you've realized since giving that '16 guidance."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","[indiscernible] after that Alex can give you, I believe a satisfactory answer.",12,"[indiscernible] after that Alex can give you, I believe a satisfactory answer."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, our first priority, I think remember we merged relatively short time key priorities to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a lot of this will be into the year",148,"Well, our first priority, I think remember we merged relatively short time key priorities to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a lot of this will be into the year and to 2017. So it's really over the next 2 and a bit years is how I would look at that in terms of driving performance. I think the piece I would really reiterate of the guidance that we've given is please do remember the change in the currency, and remember, the sterling is about 1.48 today and it was about 1.68 back in August just as a reminder. So in setting  the guidance and in reaffirming the guidance, you got to take into account that we've had an unfavorable wind on the currency versus some of what we're doing in other areas."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's fair. And then I guess just maybe more near term looking at the U.S. SG&A quite a bit lower than we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clarity on",90,"That's fair. And then I guess just maybe more near term looking at the U.S. SG&A quite a bit lower than we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clarity on what went on within the U.S. SG&A line. Is that reduction that we saw there in any part of the result of these cost initiatives? Or is there other things at play within the U.S. cost structure?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex?",1,"Alex?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex here. Yes, the combination of both. First of all, the additional $500 million is going to be almost all be in '17, so this is what we've been doing over really in the last 9 months as we've really deeply understood the current operating model and we",222,"Alex here. Yes, the combination of both. First of all, the additional $500 million is going to be almost all be in '17, so this is what we've been doing over really in the last 9 months as we've really deeply understood the current operating model and we tried to [indiscernible] for the new operating model that we're going to do through the business. We've been really successful, the team had done a great job and [indiscernible] in terms of being able to find a cost savings that do not affect the customer. The most pleasing thing about this beyond these cost savings is the fact that we're still growing volume ahead of the market both in pharmacy and in retail products and also we're seeing internally our measure and cause of the delay improving. The whole idea that for customers simpler for our teams and more faster and agile organizations was driving all of this and we'll keep on going as -- we'll keep on working the model and trading these processes the IT structures for new models. So yes, we're delighted with the SG&A savings in this quarter [indiscernible] materially in their GP last year. And part of the restructuring we start already [indiscernible] but a lot of this is also due to the ongoing cost control and cost management."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser of Morgan Stanley."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need i",67,"When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need in the U.S. market? Or are there still areas that you think that you might be missing or below scale?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because t",225,"Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because the margin [indiscernible] everywhere, the government is more and more in charge of the cost of the health care business and so for sure as they will exercise their power to increase the cost as much as possible as we have seen in Europe for decades. And so the complex structure of delivering the medicines to the patients will have to be rationalized. And as a consequence, it's easy to believe that we will have additional synergies coming from M&A activities. This could be, of course, at the level of horizontal consolidation, but in many layers of the chain, the consolidation is still up and it's still quite advanced. So it's very likely that we will also see vertical consolidation, and the opportunities are there for everybody and we will see what happens about that. As I have said before, we want that to be as we have been in the past at the forefront of changes. And so if there is a need for reconsolidation, we'll be concerned, and we will try to be a part of it."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how do you think about promotional activities for the rest of the year and also about private label penetrati",47,"Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how do you think about promotional activities for the rest of the year and also about private label penetration?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex.",1,"Alex."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alex here. Yes, the team has built [indiscernible] and some good data so this has been driven really from implementation of Balance Rewards, the insights we're getting and they're driving that to the merchant. So the merchant teams have done a really",280,"It's Alex here. Yes, the team has built [indiscernible] and some good data so this has been driven really from implementation of Balance Rewards, the insights we're getting and they're driving that to the merchant. So the merchant teams have done a really great job in terms of understanding more precisely where customers truly value promotions and where actually don't. And you can see that growth in the front end margin. You can also see the growth in product sales at the same time. So we've really been able to tell these 2 things together. And then [indiscernible] with the new sales we've got and the [indiscernible] we're developing, both are [indiscernible] higher. Linda has come into us and Linda we believe will accelerate our journey given her tremendous experience in more markets [ph] in particular. So that feels pretty good. In terms of more brand penetration, we've created a new division within our organization within Walgreens Boots Alliance led by Ken Murphy, and again, we're able to think about how do we understand what coincides [indiscernible] and also global insight in America and Ken will speak more about this next week, and therefore that we get the right products and the right brands into the American consumers' hands in the [indiscernible] channel. And having said that, we've done a couple of things recently. We've issued 2 new [indiscernible] cosmetic brands that [indiscernible] that's happened in the last 2 or 3 weeks. So we're not waiting for that to happen. We continue to walk on the base of growing own brand penetration. So I think on both fronts we made make good solid progress and there's more to come."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Lisa Gill from JPMorgan.",9,"Our next question comes from Lisa Gill from JPMorgan."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, as I look at the first half versus the second half, it looks like there's a deceleration in earnings. Can you talk about what the primary contributors are there? Just curious if the Medicare Part D, while you talked about the trends being positive",60,"George, as I look at the first half versus the second half, it looks like there's a deceleration in earnings. Can you talk about what the primary contributors are there? Just curious if the Medicare Part D, while you talked about the trends being positive from a script perspective, we know that there's been pressure there on the reimbursement front."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, George.",2,"Yes, George."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","There's a number of factors and I know what makes it really complicated so that we can [indiscernible] half-year and half-year to close [indiscernible] the deal removed from the 3-month lag et cetera. I mean in terms of we made these the step-down, obviou",164,"There's a number of factors and I know what makes it really complicated so that we can [indiscernible] half-year and half-year to close [indiscernible] the deal removed from the 3-month lag et cetera. I mean in terms of we made these the step-down, obviously, firstly, we got 2 months results in Q2 given this kicks in at the beginning of the year but will impact us for the full quarters in each of Q3 and 4. The second half of the fiscal year is seasonally weaker than the first half normally, and of course, I know we haven't got all the comparables to sort of give you the overall seasonality which makes it tough to model. And then of course, we've got the exchange rate issues as well coming in because of the exchange rate has moved over the last number of the last 6 months, and of course, we're still bringing in the 45% that we'll be at that point in time."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, if you can add something.",6,"Alex, if you can add something."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings and therefore, we've been able to take a few more of the cost savings in the first half relative t",86,"Absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings and therefore, we've been able to take a few more of the cost savings in the first half relative to the first half of last year and then the remainder of the year we have still cost savings coming through. So we actually had quite a lot of cost savings in Q4 of last year to go against."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And then my second question, which would be around generics, if we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generic pipeline for the back half of the year, it looks to be improv",103,"And then my second question, which would be around generics, if we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generic pipeline for the back half of the year, it looks to be improving. Can you maybe talk about what you're seeing, one, on drug price inflation and the impact that it's having. Are you being able to offset that with your procurement entity? And then secondly, kind of your outlook for incremental generics that are going to come as we go through the next couple of quarters."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer the question?",6,"Jeff, can you answer the question?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and improve the delays in the ways that we've come to expect, which is what has been driving the inflationary environment, but we do continue to see a similar range",195,"Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and improve the delays in the ways that we've come to expect, which is what has been driving the inflationary environment, but we do continue to see a similar range of inflation as we see in the past 12 months or so. The teams of WBAD, Walgreens, ABC and Alliance Healthcare all continue to work extremely effectively together to ensure that is the biggest buyer of generics in the world that we are properly managing the industry dynamic. The teams have particular gone very sharp and have a number of effective mechanisms in place and are working very collaboratively with the generic drug manufacturers to really manage through this dynamic. They've gotten very flexible and nimble in understanding the marketplace where there might be issues and really managing them proactively. In terms of the generic pipeline, we've recently seen in February the entry of NEXIUM, but we haven't seen it go multi-source and we're looking forward to that and we are seeing the list of generics that are coming out. We are looking forward to maximizing those opportunities as they come."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that kind of a complete evaluation and could there be upside to th",90,"And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that kind of a complete evaluation and could there be upside to this figure. And how should we think about the earnings profile of these stores? We would assume that they're less profitable than the composite business, but is there any chance that they're losing money and there's going to be a positive margin lift from this."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex.",1,"Alex."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Hi George, Alex here. Yes, we have done a thorough review. Again, we've been doing this for a while. We've also reviewed the performance of the closure of these stores that we've made in the last year as well, and the good news there was that we saw more",225,"Hi George, Alex here. Yes, we have done a thorough review. Again, we've been doing this for a while. We've also reviewed the performance of the closure of these stores that we've made in the last year as well, and the good news there was that we saw more retention of customers and we saw that we'll also to retain a lot of people results is really important as a team and as a business. So we feel confident about the number you've give out, approximately 200, and of course, we will tell the people first where we're going to go and actually make these closures. Another key point is that we'll be opening up about 200 stores in the same period. So this really is just getting the right stores in the right place. And also think it's about the right cash and the right turns per-store basis. This is a very individual store base decision. And of course the stores, which we are potentially going to be closed, we look carefully at the markets today and the numbers of customers in them and how they're shopping that market and also hold the proper [indiscernible] forward over the course of these stores being open and a few of these stores which really the population is moving away from and less future opportunity than today."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And maybe if I can go with a quick follow-up, you guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the lifecycle of that relationship? I",91,"Okay, that's helpful. And maybe if I can go with a quick follow-up, you guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the lifecycle of that relationship? I Guess How much cost can be taken out and maybe from an inventory perspective what can still be taken out? And I guess, is there are lot of store inventory left that could be taken out and kind of better served through the DSD delivery of ABC?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex.",1,"Alex."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alex again. Yes, we've made great progress in terms of [indiscernible] reduction, and the sales are working really closely together. It's really end-to-end view from the pharma manufacturers all the way through ABC into [indiscernible] are doing in t",175,"It's Alex again. Yes, we've made great progress in terms of [indiscernible] reduction, and the sales are working really closely together. It's really end-to-end view from the pharma manufacturers all the way through ABC into [indiscernible] are doing in the stores. We're also seeing importantly service levels improve as well. So again, we've seen this nice thing when you get [indiscernible] at the system. You improve costs and then you improve working capital and you importantly improve service levels. So again, we'll continue to work at this. There are more opportunities and we'll do in a really balanced way to make sure that we care for customers first, get right going forward capital and am confident that the working relationship with ABC will continue to improve. And of course working in Europe as I did before with [indiscernible] and the team of Alliance Healthcare really worked this well for a number of years so more and more opportunities which we can see very clearly in the U.K. business performance in wholesale in this division."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Steve falcon of UBS.",12,"Our next question comes from the line of Steve falcon of UBS."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think you mentioned that you've done an inventory step-up charges as well. So I apologize if I missed this, b",135,"So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think you mentioned that you've done an inventory step-up charges as well. So I apologize if I missed this, but I guess did you provide the fully adjusted gross margin for the quarter just to make it a little bit easier for us? And also part 2 is then just curious, all the talk about the U.S. Medicare Part D rate reductions that went into effect on 1/1/15, is there any way just to get a rough sense for how much that impacted the gross margin in the quarter? Was it perhaps 100 basis points year-over-year, maybe something greater than that? Just trying to get a sense for that."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George, you can answer the first part.",7,"George, you can answer the first part."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The infancy step-up. I mean it was $0.08 because under -- that is in the legacy AB businesses. So it's in the Retail Pharmacy international and Pharmaceutical Wholesale, and that is one of the key differences between adjusted and the U.S. GAAP results, an",195,"The infancy step-up. I mean it was $0.08 because under -- that is in the legacy AB businesses. So it's in the Retail Pharmacy international and Pharmaceutical Wholesale, and that is one of the key differences between adjusted and the U.S. GAAP results, and that's simply because when you're doing the purchase currency and we've done the provisional purchase accounting allocation that we've got a year to finalize that, what you have to do is revalue the inventory at the price less than a small margin. So we're not valuing the industry -- the inventory cost. So what it does is it essentially artificially takes down the the U.S. GAAP profit in those 2 divisions as a result. So that's why we've stripped it out to show the operating results with that. It has no impact at all on the comparables because it doesn't impact the Retail Pharmacy USA segment. I'm sorry there are so many of these adjustments. Next week, I'll try to take you back through them a little more detail. It really does make it very difficult to articulate the story as clearly as we would like and you would like."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer the second question?",7,"Jeff, can you answer the second question?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, that was just the impact of the Medicare Part D within the quarter, just roughly how much that might have impacted the overall gross margin. That was the second question.",31,"Yes, that was just the impact of the Medicare Part D within the quarter, just roughly how much that might have impacted the overall gross margin. That was the second question."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, so Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward right now. We're in the midst of negotiations for",64,"Yes, so Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward right now. We're in the midst of negotiations for the 2016 year. They're very productive right now but it's very early days in terms of the impacting moving forward."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","From a volume point of view, we were pleased with [indiscernible] and really the margins come through as expected. So again, it really has been a solid selling season and we feel good about the[indiscernible]",35,"From a volume point of view, we were pleased with [indiscernible] and really the margins come through as expected. So again, it really has been a solid selling season and we feel good about the[indiscernible]"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And we have time for 2 more questions. Our next question comes from the line of Marc Miller of William Blair.",21,"And we have time for 2 more questions. Our next question comes from the line of Marc Miller of William Blair."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So thinking about the opportunities with both horizontal and vertical consolidation that obviously goes in many different dimensions, but when you think about the opportunities, is it more about getting leverage with suppliers or more about getting levera",96,"So thinking about the opportunities with both horizontal and vertical consolidation that obviously goes in many different dimensions, but when you think about the opportunities, is it more about getting leverage with suppliers or more about getting leverage with payers in pharmacy and then I guess that point to that is getting more scale within the retail operations? Or is it more about strategic moves that allow you to drive more share across your own network and then specifically thinking about better managing the payer relationships and potentially having some type of pharmacy benefit management relationship."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, Stefano, of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk about opp",209,"Well, Stefano, of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk about opportunities, of course, we don't exclude atypical M&A opportunities, but there are many, many opportunities, which are not related to an acquisition or to a merger but are related to a potential joint venture, commercial joint venture as we did initially with WBAD. When we approached Walgreens, so when we started our discussion, the first thing that we decided was to create these joint ventures to buy together and these joint venture would have been there even without the merger. So there are many ways to deliver synergies, and of course, we are open to any kind of organization which can improve the value of our company and we are analyzing many, many different alternatives. And of course, it depends also on the maturity of the potential partner from the willingness they have to do something with us. What I was saying is that the market that goes clearly in one direction and sooner or later these kinds of things will happen."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And then I assume speaking about this real-time that you believe the organization is ready to move when the opportunities develop I mean given everything that's going on with the consolidation of Walgreens Alliance Boots.",36,"And then I assume speaking about this real-time that you believe the organization is ready to move when the opportunities develop I mean given everything that's going on with the consolidation of Walgreens Alliance Boots."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have always been able to face the opportunities because, of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course we have to integrate the 2 companies. The integration did very well I hav",147,"We have always been able to face the opportunities because, of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course we have to integrate the 2 companies. The integration did very well I have to say, higher than my expectation, but still there is a lot to do. But the fact that we have not yet finished this job doesn't mean that we cannot do something else in the meantime. So of course, if we had an opportunity, we will take the opportunity. And any [indiscernible] important opportunities be it M&A activity, be it a joint venture, a commercial joint venture, take months to be perfection to come to life. So we will have time to continue our integration while discussing with other possibilities. So of course, if we will see opportunities, we will be ready."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's helpful. And just quickly George, does the EPS guidance, can you clarify whether that includes additional share repurchase?",20,"That's helpful. And just quickly George, does the EPS guidance, can you clarify whether that includes additional share repurchase?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We've obviously got our $3 billion program authorized. So I think that should give you an indication of our thinking in that respect. We've obviously not being specific on this, but we wouldn't put a program in place if we felt that we don't have the abil",62,"We've obviously got our $3 billion program authorized. So I think that should give you an indication of our thinking in that respect. We've obviously not being specific on this, but we wouldn't put a program in place if we felt that we don't have the ability to generate the necessary cash to complete that program whilst maintaining solid investment grade."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Edward Kelly of Crdit Suisse.",13,"Our next question comes from the line of Edward Kelly of Crdit Suisse."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Several questions on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth profit dollar growth by division that you",48,"Several questions on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth profit dollar growth by division that you sort of contemplated here?"
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","In terms of the overall guidance, really today just reaffirming what the guidance that was provided in the summer last year recognizing that the currency has gone against us. We've not been through obviously our intensive detailed budgeting exercises as a",173,"In terms of the overall guidance, really today just reaffirming what the guidance that was provided in the summer last year recognizing that the currency has gone against us. We've not been through obviously our intensive detailed budgeting exercises as a combined group and we're getting everything on a comparable basis under U.S. GAAP. So we're going through quite a bit of change to try and then to go through this process. What we'll try and do next week when we meet is try and give you a little bit more insight into the drivers as we go through each division section and then we got the half day on the financial modeling on the first day. So hopefully, we'll be able to give you a little bit more insight on that. It is quite complicated because of the lack of comparability because we have obviously put the segments in place that particularly reflects in terms of where the synergies are -- we're putting the synergies whether we can all [indiscernible] activity happening."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week.",26,"We don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","All right, that make sense. One quick follow-up for you on real estate, obviously getting smaller. It's not necessarily something that you may want to do in the U.S. pharmacy, but do you still have other stores that you would consider underperforming or l",66,"All right, that make sense. One quick follow-up for you on real estate, obviously getting smaller. It's not necessarily something that you may want to do in the U.S. pharmacy, but do you still have other stores that you would consider underperforming or lower margin stores? And I guess the question would be, what's the real answer to improving those stores if it's not necessarily closing."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean obviously, we have a range of stress. I said before that I'm really get a look at this and this is like 2% of our estate that we talked about this morning. So therefore, 98% of the estate is either good or satisfactory order. And I think also",169,"Yes, I mean obviously, we have a range of stress. I said before that I'm really get a look at this and this is like 2% of our estate that we talked about this morning. So therefore, 98% of the estate is either good or satisfactory order. And I think also we're doing a lot of work on the front end. We are becoming more confident about our ability to not just improve the front end through margin expansion but develop potential new formats, integrate assets to become a [indiscernible] channel. Some of the work really designed and the team had done in Boots has been great in that respect in the last couple of years. So with the different strategies that we will apply over the months and years ahead to meet the very [indiscernible]is a great set of assets. Stefan said this in the introduction. We have got the best company in America and we still think we have really important assets to feature the Walgreens company."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And also, Stefan here. Also we are talking of a few hundred stores, the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers should, let's",245,"And also, Stefan here. Also we are talking of a few hundred stores, the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers should, let's say, have a program on maintenance for their stores. And when you have such a vast territory, such a high number of stores, [indiscernible] you will have some stores which have been may have been maybe profitable in the past and are not particularly exciting today and you will need to open stores in areas which didn't even exist in the past. So the reality, you see a certain concentration which is still [indiscernible] because a few hundred out of 8,300 [ph] stores not a big number, but you'll see it certain concentration because this program has not been done in the past in an orderly fashion. In the future, once we have, let's say, recreated this new base, I believe we should every year look after -- review all the stores. And if we have every year, if we have to close 10 stores or 5 stores or 15 stores, we will have to do it in order not to have this concentration of stores just in 1 year because it's better to do this gently over time. Practically, this will be business as usual and nobody will see it in reality even inside the company."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","EAnd that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for his closing comments.",28,"E
And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for his closing comments."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, ladies and gentlemen. I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be",97,"Thank you, ladies and gentlemen. I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be webcast live and will be archived on our Investor Relations site. So I hope as many of you as possible can participate in that. We'll address as many of your additional questions if we can then. And thank you very much and thank everyone for participating today."
93624,283101937,788430,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald",52,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald Gradwell, Senior Vice President, Investor Relations and Special Projects. You may begin."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and",308,"Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our second quarter results. Also joining us on the call and available for questions are Alec Gourlay, Executive Vice President and President of Walgreens; and Jeff Berkowitz, Executive Vice President and President of Pharma & Global Market Access. 
As a reminder, today's presentation includes certain non-GAAP financial measures, and I will direct you to our website at investor.walgreensbootsalliance.com for reconciliations of the most directly comparable GAAP measures and related information. You can find a link to our website on our Investor Relations website -- sorry, to our webcast on our Investor Relations website. After the call, this presentation and the webcast will be archived on our website for 12 months. 
And now to read out the Safe Harbor statement. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current markets, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K and subsequent filings for a discussion of the risk factors as they relate to forward-looking statements. 
Today's presentation include certain non-GAAP financial measures, and we refer you to the appendix, to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll hand you over to Stefano for his opening comments."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a hi",1112,"Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. 
Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a historic and pivotal milestone for 2 iconic companies, Walgreens and Alliance Boots, as we completed our merger to establish Walgreens Boots Alliance, forging the new company, the world's first global pharmacy-led health and well-being enterprise. 
We established a senior management team to bring together our businesses and lead them forward to the next phase of their evolution while making steady progress with the integration and the establishment of a single unified corporate identity and culture. 
Our team worked very hard to accelerate the closing of the deal 2 months ahead of the beginning of the completion window. We raised the funds to complete the transaction and to finance essentially all the AB debt in an efficient manner while going through a complicated process of preparing our first full consolidated earnings under U.S. GAAP, including eliminating the 3-month reporting lag. The complexity [ph] and effort these tasks have taken cannot be underestimated. I would ask you to remember that until completion, our businesses have to operate at arm's length as separate entities. We are today only 14 weeks, in fact 99 days, into the creation of this new global entity. It is still very early, but we have moved mountains in what we have done and are still in the first steps of our journey. 
We have achieved the merger in a short time and are moving quickly. We have expanded our restructuring program to create a more competitive cost structure, begun to access synergies created through the combination and sharpened our focus on our strategic priorities, including the sales of a majority interest of our infusion business subsequent to the quarter close. And today, I am pleased to announce a strong quarter, achieved along with all the other tasks that we have undertaken. We are looking forward to the future with enthusiasm.
Our transaction has created a group which, I believe, has enormous potential to grow in ways that give us great excitement and optimism for the future. Let's start by looking at our business as we stand today. 
Based on an in-depth review of our Retail Pharmacy USA segment, I can say that Walgreens is on a sound structural footing. As you might expect, some parts are better than expected while others offer room for improvement. Our first priority is to understand the business fully, its interdependency and its differentiators. This exercise is under way, and we'll ensure we stay focused on what is truly important: delivering against the needs of our customers in a dependable yet innovative manner that provides us with sustainable and growing income a crucial part of our business. This will be achieved through a combination of efficient practice, [indiscernible] and insight, investments in our core business and innovation in our business model. From what we have seen already, we believe there to  be significant scope to enhance the performance of our pharmacies through refreshing and differentiating our store, improving customer experience, delivering products and services to customers and patients and introducing new offerings through innovative partnership. We believe that through good business practice and the application of these and other initiatives, we can over time expand the retail margin, grow market share and prepare ourselves to better address the competitive and market-driven headwinds we face in certain areas of our business. 
Let me be perfectly clear. Our aim is to help Walgreens further develop strategies that will continue to deliver growth for many years to come. It is vital that we make best use of the assets that we have, core to which is our unrivaled portfolio of locations across the U.S. We must work tirelessly to drive the best possible return from these assets. And to that end, we have today announced an enlarged but necessary restructuring program to focus the Walgreens business back on its core assets. We believe we will come out of this stronger and better positioned to deliver enhanced performance that our premium locations should command. 
In Retail Pharmacy International in Boots, we are working hard to refine the new cycle of our business that will deliver growth in the coming year. We are continuing to develop our online offering and building on our recent successes. We are working to further integrate these with our physical stores and logistical network to enhance the customer choice while making better use of our resources. The constant work to keep our offering fresh through innovation within store and within our own brand and exclusive product portfolio is continuing to differentiate us in the extremely competitive U.K. retail market. I'm confident that the work which Simon and his team are doing will set us on a path for further growth in the years ahead. 
As you're aware, our retail businesses are also continuing to perform well, and it has been a particular pleasure to welcome our new colleagues in Mexico and Chile to our company, making the expansion of our international retail presence in Latin America through their vision of 2 outstanding businesses with excellent prospects for growth. 
Our Pharmaceutical Wholesale division is continuing to develop the integrated business model that we introduced many years ago, operating an ever-growing suite of services to the manufacturers that tie up most growth than ever to them as partners. On the other side of the supply chain, we are expanding our offering to our pharmacies customers to both align them more globally with our -- the wholesalers and let them improve the quality and economics of their own businesses. While such initiative enhance the vertical integration of our wholesale businesses and create strength and value, the ever-changing market that we are operating in and the continuous economic pressure that health care systems are under present us with several opportunities to expand our network. 
These present themselves in many ways. In one extreme, through consolidation within markets; and at the other extreme, through innovative partnerships and alliance systems, as you have seen us to do with AmerisourceBergen. As wholesale is a business that is enhanced by volume and market presence, we will continue to explore opportunities to expand our network as they arise. Underpinning all of these, Walgreens Boots Alliance has embarked on the beginning of a new year, a new year that will bring a new attitude, a new culture aligned toward driving performance, serving our customers and creating long-term, sustainable shareholder value. 
Now I will ask George to take us through the quarterly results. George?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overvi",2567,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overview of our restructuring program; and finally, to articulate our views on FY '15 and FY '16 results. 
To summarize, the second quarter was a solid start for our new company. Key highlights include net sales of $26.6 billion, GAAP earnings per share of $1.93 while adjusted EPS was $1.18, cash flow from operations of $1.3 billion and free cash flow of $1 billion. The quarter's financial results are complicated as we began reporting as a consolidated entity partly through the quarter and the comparability to last year is a challenge and of limited use. 
Before we get into the details of our second quarter financial performance, I'd like to explain some elements of our new reporting structure. Historically, Walgreens has reported as one segment, which consisted of the results of Walgreens in the USA; its corporate costs; synergies from the Walgreens Boots Alliance Development joint venture, also known as WBAD; and equity earnings from Alliance Boots on a 3-month lag. Our focus was to merge the businesses as soon as possible and eliminate the 3-month reporting lag. This aligns the reporting -- the reported results of the global enterprise and will make our performance easier to understand going forward. 
As Walgreens Boots Alliance, we now report results in 3 segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. Segmental reporting includes the allocation of synergy benefits, including WBAD and combined corporate costs. Within our Retail Pharmacy USA segment, since the deal closed on December 31, we have reported 1 month of Alliance Boots equity income this quarter versus 3 months in the comparable quarter a year ago, recognizing the 45% stake that Walgreens had in Alliance Boots until end December. The months of January and February are fully consolidated. Year-over-year comparisons of results required consideration of the foregoing factors and are not directly comparable. 
So now let me take you through our financials in greater detail, beginning with the consolidated results. 
For the quarter, GAAP net earnings attributable to Walgreens Boots Alliance were just over $2 billion or $1.93 per diluted share, while adjusted and earnings were $1.2 billion or $1.18 per diluted share. This compares to $0.74 of GAAP net earnings per share and $0.97 of adjusted earnings per share in the prior year quarter. 
Net sales in the second quarter were $26.6 billion, an increase of 35.5% versus the prior year. 
Operating income on a GAAP basis was $1.4 billion and on an adjusted basis was $1.8 billion. The increase in adjusted operating income was driven by growth in our Retail Pharmacy USA segment as well as the consolidation of Alliance Boots' results for January and February. 
We reported $144 million of net interest expense this quarter, which included interest expense associated with prefunding the transaction for the month of December. Consistent with last quarter, our adjusted EPS excludes this interest expense, which we'll not need to do going forward. 
The adjusted tax rate for this quarter was 27.7%. Now this has been impacted by a number of factors, including a change in the geographic mix of forecast profits now that Alliance Boots has been fully consolidated, includes net discrete tax benefits specific to the quarter and the presentation of Alliance Boots' taxes in the income statement. Prior to the full merger, Walgreens 45% share of Alliance Boots' adjusted results, net of Alliance Boots' tax, were presented in a single line within operating income. Now following the transaction, Alliance Boots' tax is reported within the income tax provision line in our income statement, impacting the calculation of the adjusted tax rate. 
Diluted shares outstanding at the end of the quarter were $1.1 billion and average diluted shares outstanding for the quarter were 1.05 billion resulting from the issuance of 144 million shares on 31st December as part of the consideration for Alliance Boots. 
So now let me walk you through the component pieces to explain the change from GAAP to adjusted EPS. The GAAP earnings per share for the quarter of $1.93 reconciles to an adjusted earnings per share of $1.18. The net adjustment of $0.75 per share, this reflects the removal of net gains on transaction-related item of $0.67 and gains on the warrants we hold over AmerisourceBergen shares of $0.35. This is partially offset by LIFO provision costs of $0.04; acquisition-related amortization expenses of $0.15, which includes $0.08 relating to an -- to the inventory step-up which will not reoccur in future quarters; and special items of $0.08 related to optimization costs and asset impairments. 
The components of the net gain on transaction-related items were a gain on Walgreens' previously held equity interest in Alliance Boots of $0.77; a foreign currency hedge loss of $0.07 related to the delivery of the British pound element of the Step 2 consideration; and a net $0.03 cost of transaction fees, tax adjustments and interest costs from prefunding the cash consideration. 
So next, I'd like to provide insights into financial results at the segmental level, starting with Retail Pharmacy USA. Reported net sales were $21 billion, up 6.9% on a comparable store basis. In the pharmacy, comparable store scripts, which includes immunizations, this increased 5% on a 30-day adjusted basis. The increase was driven by the positive impact of a strong cough, cold and flu season; by continued growth in Medicare Part D scripts; and positive underlying share trends. For the quarter ending 28 February, the division's 30-day adjusted retail prescription market share in the U.S. reached 19.3%, as reported by IMS Health. This represents an increase of 20 basis points versus the same time last year. In retail products, comparable store sales increased by 2.5%. This was partially driven by strong December holiday sales, including seasonal sales of cough, cold and flu products. 
GAAP operating income for the quarter was $1.3 billion while adjusted operating income was $1.6 billion, up 13.4% over the year-ago quarter. Strong expense control and efficiencies offset the expected pharmacy gross margin pressure from declines in reimbursement, generic drug inflation as well as the Med Part D rate step-down that began on the 1st of January this year. 
Retail product margins increased this quarter, helped by seasonal and cough, cold, flu mix as well as our focus on reducing less profitable promotions. We remain very pleased with the progress on controlling and reducing SG&A expenses this quarter. Our GAAP SG&A expense declined 0.3% compared to the prior year quarter. 
So next, let's review the Retail Pharmacy International division, which is pharmacy-led health and beauty retail businesses in 8 countries. The biggest contributor is Boots in the U.K. 
Total sales for the 2 months ended February were just over $2 billion. As the businesses included in our Retail Pharmacy International division were acquired as part of the merger with Alliance Boots, no comparable information is included in the WBA consolidated results. On a pro forma constant currency basis, comparable sales for January and February grew by 2.9%. Comparable sales of Boots U.K. were up 2.3% while sales in our businesses in Chile and Mexico, which we acquired by Alliance -- acquired by Alliance Boots back in August 2014, these were up 2.9%. The acquisition brings us over 1,000 stores in Mexico and over 400 in Chile and provides strong growth opportunities in the Latin American market. The inclusion of these businesses in the division, combined with contract manufacturing, are reflected in the margins. 
Now turning to Pharmaceutical Wholesale, which mainly operates under the Alliance Healthcare brand in 12 countries. Results in any given quarter are influenced by performance in larger geographies, including the U.K., Germany, France and Turkey and the division's contribution from WBAD. 
Total sales for the 2 months ending February were $3.9 billion. Similar to Retail Pharmacy International, our Pharmaceutical Wholesale division was acquired through the merger with Alliance Boots, and so no amounts are reported in the comparable period. However, on a pro forma constant currency basis, sales were relatively flat compared with the same period the prior year. 
Now let me spend a minute on our expectations for synergies and how they will be reported going forward. Prior to the merger, the majority of our synergies were flowing through WBAD, the former joint venture between Walgreens and Alliance Boots, which Walgreens fully consolidated and then removed Alliance Boots' portion via the noncontrolling interest line item. Following the combination, we're allocating all synergies, including those generated by WBAD, to the segments, and we're doing this according to the relative proportion of purchases driving the synergy benefits. 
With regard to performance in the quarter, combined net synergies were $170 million, bringing the fiscal year-to-date total to $310 million, driven primarily by our drug procurement efforts. We remain comfortable with our ability to achieve at least $650 million in combined synergies this fiscal year. For FY '16, we continue to expect at least $1 billion in combined quantifiable net synergies. Consistent with prior reporting, these synergies do not include any benefit from our AmerisourceBergen relationship. 
Now that we're a combined company, as expected we are focusing on driving incremental synergies from sharing our best practices and working more closely together. However, not all of these can be easily quantified as some of them tend to blend into our normal business.
So moving on to the cash flows. We generated approximately $1.3 billion in cash from operations during the quarter, and our free cash flow was $1.0 billion. We're pleased with the cash generation during the second quarter due in part to an improvement in our primary working capital within our Retail Pharmacy USA division, driven by a reduction in inventory levels. We will continue to focus on working capital and remain confident in future opportunities to increase efficiencies. 
Net debt as of the quarter end was $14.1 billion. 
With regard to uses of free cash flow beyond reinvestment back into the company, we completed $94 million of share repurchases in the quarter against our $3 billion authorization. We purchased additional shares post the end of the quarter under preestablished trading plans, bringing the total purchases to $330 million.
I'd now like to make a few comments on our capital allocation policy. As we've consistently communicated, we remain committed to a solid investment-grade rating while looking for ways to enhance our cash generation. This includes driving working capital efficiencies, tightening capital expenditures, controlling costs and, of course, improving operations. Beyond maintaining a long-term 30% to 35% dividend payout target, our top priorities for free cash include M&A consistent with our strategy and share buybacks. All of these are with a view to optimizing long-term shareholder value. 
Following on this theme, and as Stefano mentioned, we are focused on becoming a more agile and more productive company. As you know, in August 2014, we announced a 3-year $1 billion cost reduction initiative. After a rigorous analysis, we've identified additional opportunities for cost savings primarily in our Retail Pharmacy USA division. These additional cost opportunities will increase the total expected cost savings program by $500 million to a projected $1.5 billion by the end of fiscal 2017. So moving to areas of focus, they include plans to close approximately 200 stores across the U.S.A., to reorganize corporate and field operations, drive operating efficiencies and streamline information technology and other functions. These actions are designed to restructure and invest in our company's future in a way that is better for customers, simpler for our employees, resulting in a faster and more agile organization. 
We estimate that total pretax charges associated with this program to our GAAP financial results will be in the range of $1.6 billion to $1.8 billion, of which the cash component is expected to be approximately 60%. The restructuring charges will be recognized over time as the program is implemented in accordance with GAAP. Looking ahead, we will continue to focus on other areas of cost reduction. 
So now let's talk about the rest of fiscal 2015. We understand and appreciate that there are lots of factors that will impact our results. So in order to help you, we are providing an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Now this range assumes quarterly interest expense of $140 million to $150 million. It assumes a full year adjusted tax rate of approximately 29% and a fiscal year diluted share count generally consistent with the current quarter. It assumes management's estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. Now this guidance also includes recast fiscal Q1 results due to the elimination of the 3-month lag. Finally, you will see an increase in the share count in Q3 and Q4 due to the full inclusion of the 144 million shares issued with Step 2 of the AB transaction. This will result in approximately 1.1 billion diluted shares per quarter. Any additional share repurchases will impact, of course, the fiscal year diluted share count. 
So moving on to FY '16. Our previously published goals were based on a variety of assumptions to arrive at estimate ranges for both sales and adjusted EPS. These included operating assumptions for our businesses and certain below-the-line items, including interest, tax and share count. When we set the goals in August, we made foreign currency assumptions based on exchange rates that were close to market rates at that time. Since then, we've seen significant global currency movements, especially the strengthening of the U.S. dollar. Because we report in U.S. dollars, we do have currency translational exposures primarily based on movements in the pound sterling versus the dollar. Simply put, a stronger dollar hurts our sales and earnings in dollars while a weaker dollar helps them. We estimate that a 1% move in the pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. Despite the FX headwind, I'm confident that we have initiatives and resources in place to address the controllable elements that drive our adjusted EPS goal for FY '16. 
Our revenues have greater potential variability due to the varied mix of businesses, particularly in our Wholesale division, which accounts for a significant proportion of our overall revenue. In addition, the geographical spread of the Wholesale business increases its exposure to currency variations. This being the case, we view overall revenue as a less relevant measure of our business. So taking these 2 factors into account, we decided to no longer provide our published revenue goal. And please note that our forward-looking statements assume no significant changes to the current exchange rates. 
So I'd like to wrap up today by saying that our reporting structure has changed and comparability is limited, which I know makes it really difficult for you. Therefore, in an effort to be as informative as possible, we've provided adjusted EPS guidance for fiscal year 2015. And next week, we'll have a financial session to provide further insights. In addition, we plan to provide operational insights in each of our 3 segments as well as views on our key financial drivers and future strategy. We really look forward to seeing you then. 
So with that, I'll turn the call back to Stefano."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs ac",667,"Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. 
We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs across the group, including the progressive development of our procurement initiatives. We must also properly manage the assets of the business to ensure we are [indiscernible] structured and prepared to address the pressures we face as the pharmacy markets evolve. These pressures may variously be from reimbursement cuts, competitive action or simply changes in consumer behavior. Whatever form they take, if we are properly structured and prepared, operating an efficient, high-quality, patient-oriented pharmacy service, that we will earn the right not just to participate but to be an architect of the changes in our market. We are already seeing the benefits that can be achieved in retail with the initiatives under way at Walgreens and ongoing at Boots. We must ensure that we get the best return for our investment and create the best environment for our employees and customers alike. This will require us to operate enhanced systems and control so that we can monitor and manage our business properly. 
Now many of you have asked where we are on the CEO search. As you know, we formed a search committee of the board and they have been working with one of the top executive recruiting firms to help us find a new CEO. Currently, we are in the process of reviewing the candidates they have proposed. Finding candidates with the combination of attributes that we deem important for the role is not really challenging as we expected that -- it to be. But we remain confident that in due course, we will find the right person for the job. 
Lastly, as the new culture takes hold and find roots in a company, you can see echoes [ph] of it in all parts of the business. I hope that in one particular area, you are seeing the new culture emerge very clearly and that -- and the easy [ph] now approach to our owners and the financial community in general. I have always viewed investors as my business partner, and I hope that they will view me in the same way. 
As an organization, we strongly believe it is our duty to care for our shareholders and to ensure that we are as accessible, responsive and transparent as we can be. We also believe in being proactive in reaching out to our investors to properly understand their requirements and to ensure that in our investor relations effort, we have as mindful -- we are as mindful of our shareholders as we are of the patients in our pharmacies or our customers in wholesale. I think that Gerald and his team have done well to demonstrate this new [indiscernible], and it is a great pleasure to see, although there is still more to do. We are in the first steps of a long and exciting path, and I look forward to carving [ph] it with you as fellow owners and partners. 
As I said earlier, I am optimistic about the long-term future of our company and have made a significant personal commitment to our future not only as the Executive Vice Chairman and acting CEO but also as a significant shareholder. I am convinced that the formation of Walgreens Boots Alliance is a unique first, which will almost inevitably lead to many other new firsts in our industry. It may not yet be clear which steps these will be, but we are determined to continue to show the way and be at the forefront of innovating health care. Our ambition is to build a generally global company and a universal health care champion. We look forward to providing a more comprehensive outlook on our future strategy and value creation next week at our first Analyst Day. 
With that, we are now ready to take your questions."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs.",15,"[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just cur",106,"I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just curious if you can give an update on how we should think about the cost cutting over the next 3 years. And then related to that, given that there's an additional $500 million in cost cutting, obviously reiterating the fiscal '16 guidance, I'm wondering if there was any negative offsets that you've realized since giving that '16 guidance."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George. And after, Alex can give you, I believe, a satisfactory answer.",13,"So George. And after, Alex can give you, I believe, a satisfactory answer."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a",163,"Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a lot of this will be into the year and into 2017. So it's really over the next 2 and a bit years is how I would look at that in terms of driving performance. I think what 's -- when we're -- the piece I would really reiterate on the guidance that we've given is please do remember the change in currency. I mean, remember, the sterling is about $1.48 today and it was about $1.68 back in August, just as a reminder. So in setting the guidance and in reaffirming the guidance, you've got to take into account that we've had an unfavorable wind on the currency versus some of what we're doing in other areas."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clar",90,"That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clarity on what went on within the U.S. SG&A line. Is that reduction that we saw there in any part a result of these cost initiatives? Or is there other things at play within the U.S. cost structure?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex?",1,"Alex?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alex here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operat",235,"It's Alex here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operating model and really tried to lay out the grounds for the new operating model that we're going to do through the business. We've been really successful. The team has done a great job in Walgreens in terms of being able to find cost savings that do not affect the customer. The most pleasing thing about this beyond these cost savings is the fact that we're still growing volume ahead of the market, both in pharmacy and in retail products. And also, we're seeing internally our measure in cost of the delay improving. The whole idea of better for customers, simpler for our teams and more faster, agile organization is what's driving all of this, and we'll keep on going as we'll keep on working the old model and trading these processes, the IT structures for new model. So yes, we're delighted with the SG&A savings in this quarter and they are materially better than the SG&A last year. And as part of the restructuring we started already, they're near, but a lot of this also is just due to ongoing cost control and cost management."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser of Morgan Stanley."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need i",68,"When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need in the U.S. market? Or are there still areas that you think that you might be missing or below scale at?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because t",224,"Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because the margins are squeezed everywhere. The government is more and more in charge for the cost of the health care business. And so for sure, they will exercise their power to squeeze the costs as much as possible, as we have seen in Europe for decades. And so the complex structure of the -- of delivering the medicines to the patients will have to be rationalized. And as a consequence, it's easy to believe that we will have additional synergies coming from M&A activities. These could be, of course, at the level of horizontal consolidation. But in many layers of the chain, the consolidation is still up and is still quite advanced. So it's very likely that we'll see also vertical consolidation. And the opportunities are there for everybody, and we will see what happens. But as I have said before, we want to be, as we have been in the past, at the forefront of changes. And so if there is a need for a consolidation, we'll be concerned. We will try to be part of it."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?",46,"Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex?",1,"Alex?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alex here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that to their -- to the merchants. So the",302,"It's Alex here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that to their -- to the merchants. So the merchant teams have done a really great job in terms of understanding more precisely where customers truly value promotions and where actually they don't. And you can see the growth in the front-end margin. You can also see the growth in product sales at the same time. So we've really been able to tie [ph] these 2 things together. And we feel confident with the new tools we've got and the key tools we're developing going forward. Both are a grade higher. Linda, Linda Filler, has come into us. And again, Linda, we believe, will accelerate our journey given her tremendous experience in Walmart and Sam's Club in particular. So that feels pretty good. In terms of more brand penetration, we've created a new division within our organization, within Walgreens Boots Alliance, led by Ken Murphy. And again, we're able to think about how do we understand local insights in America and also global insights, and Ken will speak more about this next week, and how therefore do we get the right products and the right brands into the American consumers' hands in the direct sales channel. Having said that, we've done a couple of things recently. We've issued 2 new masstige cosmetic brands, CIRCA and Colour Prevails. That's happened in the last 2 or 3 weeks. So we're not waiting for that to happen. We continue to work on the basis of growing own brand penetration. So I think in both fronts, we made good, solid progress and there's more to come."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill of JPMorgan.",12,"Our next question comes from the line of Lisa Gill of JPMorgan."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being po",62,"George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being positive from a script perspective, we know that there's been pressure there on the reimbursement front."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean...",3,"Yes. I mean..."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean, there's a number of factors. And I know what makes it really complicated so that we can  half year on half year to close the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obviously, first",180,"Yes. I mean, there's a number of factors. And I know what makes it really complicated so that we can  half year on half year to close the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obviously, firstly, we've got 2 months' results in Q2 given this kicks in at the beginning of the year but will impact us for the cool -- the full quarters in each of Q3 and 4. The second half of the fiscal year is seasonally weaker than the first half normally. And of course, I know we haven't got all the comparables to sort of give you the overall seasonality, which makes it tough to model. And then, of course, we've got the exchange rate issues as well coming in because of what's -- where the exchange moved -- the exchange rate has moved over the last number of -- the last 6 months. And of course, we are still bringing in the 45% of AB at that point in time."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, if you can add something.",6,"Alex, if you can add something."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half rela",87,"Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half relative to the first half of last year. And then the remainder of the year, we have still cost savings coming through. So we actually had quite a lot of cost savings in Q4 of last year to go against."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improv",106,"And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improving. Can you maybe talk about what you're seeing, one, on drug price inflation and the impact that it's having? Are you be -- are you able to offset that with your procurement entity? And then secondly, kind of your outlook for incremental generics that are going to come as we go through the next couple of quarters."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer this question?",6,"Jeff, can you answer this question?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inf",195,"Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inflation as we've seen in the past 12 months or so. The teams at WBAD, Walgreens, ABC and Alliance Healthcare all continue to work extremely effectively together to assure that is the biggest buyer in -- of generics in the world, that we are properly managing the industry dynamic. The teams in particular have gone very sharp and have a number of effective mechanisms in place and are working very collaboratively with the generic drug manufacturers to really manage through this dynamic. They've gotten very flexible and nimble in understanding the marketplace where there might be issues and really managing them proactively. In terms of the generic pipeline, we've recently seen in February the entry of NEXIUM, but we haven't seen it go multi-source and we're looking forward to that. And we are seeing the list of generics that are coming out. We're looking forward to maximizing those opportunities as they come."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill of Deutsche Bank.",13,"Our next question comes from the line of George Hill of Deutsche Bank."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to",95,"And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to this figure? And how should we think about the earnings profile of these stores? They're -- we would assume that they're less profitable than the composite of the business. But is there any chance that they're losing money and there's going to be a positive margin lift from this?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex?",1,"Alex?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more ret",235,"It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more retention of customers and we saw that they'll be able also to retain a lot of our people as well, which is really important to us as a team and as a business. So we feel confident about the number we've given out, approximately 200. And of course, we will tell our people first where we're going to go when actually making these closures. Another key point is that we'll be opening up about 200 stores in the same period. So this really is just getting the right stores in the right place. And I also think it's about the right cash and the right returns per store basis. This is a very individual store-based decision. And of course, the stores which are potentially going to be closed, we have looked carefully at the markets today and the numbers of customers in them and how they shop in that market and also how the population explodes [ph] over the course of these stores being open. And  we've seen stores which really the population is moving away from and there's less future opportunity than today."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? H",96,"Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? How much -- I guess how much cost can continue to be taken out? And maybe from an inventory perspective, what can still be taken out? And I guess there are lot of store inventory left that can be taken out and kind of better served through the DSD delivery of ABC?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex?",1,"Alex?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Al again. Yes, we've made really good progress in terms of inventory reduction. And the sales and Jeff [ph] are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the",198,"It's Al again. Yes, we've made really good progress in terms of inventory reduction. And the sales and Jeff [ph] are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the Rachel Ashworth [ph] is doing in the stores. We're also seeing importantly our service levels improve as well. So again, we've seen this nice thing. When you get less bulk at the system, you improve costs and then you improve working capital. And importantly, you improve service levels. So again, we'll continue to work at this. There are more opportunities and we'll do in a really balanced way to make sure that we care for customers first, get it right going forward and reduce working capital out. And I'm confident that the working relationship with ABC will continue to improve. And of course, working in Europe, as I did before with Ronald [ph] and the team in Alliance Healthcare, we really worked as well for a number of years and saw more and more opportunities which comes through very clearly in the U.K. business performance for both the Wholesale and the Boots division."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Steven Valiquette of UBS.",12,"Our next question comes from the line of Steven Valiquette of UBS."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been a inventory step-up charge as well. So I apologize if I missed",141,"So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been a inventory step-up charge as well. So I apologize if I missed this, but I guess did you provide the fully adjusted gross margin for the quarter just to make it a little bit easier for us? And also, part 2 is then that just curious, all the talk about the U.S. Medicare Part D rate reductions that went into effect on 1/1/15, is there any way just to get a rough sense for how much that impacted the gross margin in the quarter? Was it perhaps 100 basis points year-over-year or maybe something greater than that? I'm just trying to get a sense for that."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Right.",1,"Right."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George can answer to the first part of that.",10,"So George can answer to the first part of that."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key",222,"Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key differences between adjusted and the U.S. GAAP results. And that's simply because under -- when you're doing the purchase accounting, and we've done the provisional purchase accounting allocation and we've got a year to finalize that, what you have to do is revalue the inventory at a selling price less a small margin. So we're not valuing the industry -- the inventory at cost. So that gets -- what it does is it essentially artificially takes down the U.S. GAAP profit in those 2 divisions as a result. So that's why we've stripped it out to show the operating results with that out. it has no impact at all on the comparables because it doesn't impact the Retail Pharmacy USA segment. I'm sorry it's got so many of these adjustments. We'll try -- next week, I'll try to take you back through them in a little more detail. It really does make it very difficult to articulate the story as clearly as we would -- I'm sure you would like and we would like."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer to the second question?",8,"Jeff, can you answer to the second question?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question.",35,"Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations fo",67,"Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations for the 2016 year. They're very productive right now, but we're very -- it's very early days in terms of the impact moving forward."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total.",41,"Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair.",21,"And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting lever",97,"So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting leverage with payers in pharmacy? And then I guess sub-point to that is getting more scale within the retail operations. Or is it more about strategic moves that allow you to drive more share across your own network and then specifically thinking about better managing the payer relationships and potentially having a -- some type of pharmacy benefit management relationship?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk a",210,"Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk about opportunities, of course we don't exclude typical M&A opportunities. But there are many, many opportunities which are not related to an acquisition or to a merger, related to a potential joint venture, commercial joint venture, as we did initially with WBAD. When we approached Walgreens, so when we started our discussion, the first thing that we decided was to create these joint ventures to buy together, and this joint venture would have been there even without the merger. So there are many ways to deliver synergies. And of course, we are open to any kind of organization which can improve the value of our company, and we are analyzing many, many different alternatives. And of course, it depends also on the maturity of the potential partner, from the willingness they have to do something with us. What I was saying is that the market, that goes clearly in one direction, and sooner or later these kinds of things will happen."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?",37,"And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration between -- very",157,"We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration between -- very well. I have to say higher than my expectation. But still, there is a lot to do. But the fact that we have not yet finished this job doesn't mean that we cannot do something else in the meantime. So of course, if we had an opportunity, we will take this opportunity. And any big, important opportunities, be it an M&A activity, be it a joint venture, a commercial joint venture, takes months to be perfection, I said, to come to life. And so we will have time to continue our integration while discussing the -- with other possibilities. So of course, you'll -- if we will see opportunities, we will be ready."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?",22,"That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we",65,"I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we have the ability to generate the necessary cash to complete that program whilst maintaining solid investment grade."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And our next question comes from the line of Edward Kelly of Crdit Suisse.",14,"And our next question comes from the line of Edward Kelly of Crdit Suisse."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division t",52,"I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division that you've sort of contemplated here?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed b",184,"I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed budgeting exercises as a combined group, and we're getting everything on a comparable basis under U.S. GAAP. So we're going through quite a bit of change to try and then be -- to go through this process. What we'll try and do next week when we meet is try and give you a little bit more insight into the drivers as we go through each division's section and then we've got the half day on the financial modeling on the first day. So hopefully, we'll be able to give you a little bit more insight on that. It is quite complicated because of the lack of comparability because we have obviously put the segments in place that particularly reflects where the -- in terms of where the synergies are, where we're putting the synergies and where the real economic activity is happening."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week.",28,"And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming",66,"All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming or lower-margin stores? And I guess the question would be, what's the real answer to improving those stores if it's not necessarily closing?"
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And",181,"Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And I think also, we've done a lot of work on the front end. We are becoming more confident about our ability to not just improve the front end through margin expansion but to develop potential new formats, integrate additional assets to become a new channel. Some of the work really design the team have done in Boots has been great in that respect in the last couple of years. So we have different strategies that we will apply over the months and years ahead to make the very most of what is a great set of assets. Stefano said this in the introduction. We have got the best companies [ph] in America, and we will try -- and then we still think we have really important assets that feature the Walgreens company."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers",255,"But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers should, let's say, have a program on maintenance for their stores. And if -- when you have such a vast territory, such a high number of stores, that  inevitably you will have some stores which have been maybe profitable in the past and are not particularly exciting today, and you will need to open stores in areas which didn't even exist in the past. So the reality, you see a certain concentration which is still small because a few hundred out of 8,300 stores is not a big number, but you'll see it's a certain concentration because this program has not been done in the past in an orderly fashion. In the future, once we have, let's say, recreated this new base, I believe we should every year look after -- review all the stores. And if we have -- every year, if we have to close 10 stores or 5 stores or 15 stores, we have to -- we will have to do it in order not to have this concentration of stores just in 1 year. Because it's better to do this gently over time, practically this will be business as usual and nobody will see it in reality even inside the company."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments.",27,"And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be",96,"Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be webcast live and will be archived on our Investor Relations site. So I hope as many of you as possible can participate in that. We'll address as many of your additional questions as we can then. And thank you very much indeed, everyone, for participating today."
93624,283101937,788529,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald",52,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald Gradwell, Senior Vice President, Investor Relations and Special Projects. You may begin."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and",308,"Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our second quarter results. Also joining us on the call and available for questions are Alec Gourlay, Executive Vice President and President of Walgreens; and Jeff Berkowitz, Executive Vice President and President of Pharma & Global Market Access. 
As a reminder, today's presentation includes certain non-GAAP financial measures, and I will direct you to our website at investor.walgreensbootsalliance.com for reconciliations of the most directly comparable GAAP measures and related information. You can find a link to our website on our Investor Relations website -- sorry, to our webcast on our Investor Relations website. After the call, this presentation and the webcast will be archived on our website for 12 months. 
And now to read out the Safe Harbor statement. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current markets, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K and subsequent filings for a discussion of the risk factors as they relate to forward-looking statements. 
Today's presentation includes certain non-GAAP financial measures, and we refer you to the appendix, to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll hand you over to Stefano for his opening comments."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a hi",1109,"Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. 
Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a historic and pivotal milestone for 2 iconic companies, Walgreens and Alliance Boots, as we completed our merger to establish Walgreens Boots Alliance, forging the new company, the world's first global pharmacy-led health and well-being enterprise. 
We established a senior management team to bring together our businesses and lead them forward to the next phase of their evolution while making steady progress with the integration and the establishment of a single unified corporate identity and culture. 
Our team worked very hard to accelerate the closing of the deal 2 months ahead of the beginning of the completion window. We raised the funds to complete the transaction and refinance essentially all the AB debt in an efficient manner while going through a complicated process of preparing our first full consolidated earnings under U.S. GAAP, including eliminating the 3-month reporting lag. The complexity and effort these tasks have taken cannot be underestimated. I would ask you to remember that until completion, our businesses have to operate at arm's length as separate entities. We are today only 14 weeks, in fact 99 days, into the creation of this new global entity. It is still very early, but we have moved mountains in what we have done and are still in the first steps of our journey. 
We have achieved much in a short time and are moving quickly. We have expanded our restructuring program to create a more competitive cost structure, begun to access synergies created through the combination and sharpened our focus on our strategic priorities, including the sales of a majority interest of our infusion business subsequent to the quarter close. And today, I am pleased to announce a strong quarter, achieved along with all the other tasks that we have undertaken. We are looking forward to the future with enthusiasm.
Our transaction has created a group which, I believe, has enormous potential to grow in ways that give us great excitement and optimism for the future. Let's start by looking at our business as we stand today. 
Based on an in-depth review of our Retail Pharmacy USA segment, I can say that Walgreens is on a sound structural footing. As you might expect, some parts are better than expected while others offer room for improvement. Our first priority is to understand the business fully, its interdependency and its differentiators. This exercise is under way, and we'll ensure we stay focused on what is truly important: delivering against the needs of our customers in a dependable yet innovative manner that provides us with sustainable and growing income across all parts of our business. This will be achieved through a combination of efficient practice, research and insight, investments in our core business and innovation in our business model. From what we have seen already, we believe there to be significant scope to enhance the performance of our pharmacies through refreshing and differentiating our store, improving customer experience, delivering products and services to customers and patients and introducing new offerings through innovative partnership. We believe that through good business practice and the application of these and other initiatives, we can over time expand the retail margin, grow market share and prepare ourselves to better address the competitive and market-driven headwinds we face in certain areas of our business. 
Let me be perfectly clear. Our aim is to help Walgreens further develop strategies that will continue to deliver growth for many years to come. It is vital that we make best use of the assets that we have, core to which is our unrivaled portfolio of locations across the U.S. We must work tirelessly to drive the best possible return from these assets. And to that end, we have today announced an enlarged but necessary restructuring program to focus the Walgreens business back on its core assets. We believe we will come out of this stronger and better positioned to deliver enhanced performance that our premium locations should command. 
In Retail Pharmacy International in Boots, we are working hard to refine the new cycle of our business that will deliver growth in the coming year. We are continuing to develop our online offering and building on our recent successes. We are working to further integrate these with our physical stores and logistical network to enhance the customer choice while making better use of our resources. The constant work to keep our offering fresh through innovation within store and within our own brand and exclusive product portfolio is continuing to differentiate us in the extremely competitive U.K. retail market. I'm confident that the work which Simon and his team are doing will set us on a path for further growth in the years ahead. 
As you're aware, our retail businesses are also continuing to perform well, and it has been a particular pleasure to welcome our new colleagues in Mexico and Chile to our company, making the expansion of our international retail presence in Latin America through their vision of 2 outstanding businesses with excellent prospects for growth. 
Our Pharmaceutical Wholesale division is continuing to develop the integrated business model that we introduced many years ago, operating an ever-growing suite of services to the manufacturers that tie up most growth than ever to them as partners. On the other side of the supply chain, we are expanding our offering to our pharmacies customers to both align them more globally with our -- the wholesalers and let them improve the quality and economics of their own businesses. While such initiative enhance the vertical integration of our wholesale businesses and create strength and value, the ever-changing market that we are operating in and the continuous economic pressure that health care systems are under present us with several opportunities to expand our network. 
These present themselves in many ways. In one extreme, through consolidation within markets; and at the other extreme, through innovative partnerships and alliance systems, as you have seen us to do with AmerisourceBergen. As wholesale is a business that is enhanced by volume and market presence, we will continue to explore opportunities to expand our network as they arise. Underpinning all of these, Walgreens Boots Alliance has embarked on the beginning of a new year, a new year that will bring a new attitude, a new culture aligned toward driving performance, serving our customers and creating long-term, sustainable shareholder value. 
Now I will ask George to take us through the quarterly results. George?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overvi",2567,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overview of our restructuring program; and finally, to articulate our views on FY '15 and FY '16 results. 
To summarize, the second quarter was a solid start for our new company. Key highlights include net sales of $26.6 billion, GAAP earnings per share of $1.93 while adjusted EPS was $1.18, cash flow from operations of $1.3 billion and free cash flow of $1 billion. The quarter's financial results are complicated as we began reporting as a consolidated entity partly through the quarter and the comparability to last year is a challenge and of limited use. 
Before we get into the details of our second quarter financial performance, I'd like to explain some elements of our new reporting structure. Historically, Walgreens has reported as one segment, which consisted of the results of Walgreens in the USA; its corporate costs; synergies from the Walgreens Boots Alliance Development joint venture, also known as WBAD; and equity earnings from Alliance Boots on a 3-month lag. Our focus was to merge the businesses as soon as possible and eliminate the 3-month reporting lag. This aligns the reporting -- the reported results of the global enterprise and will make our performance easier to understand going forward. 
As Walgreens Boots Alliance, we now report results in 3 segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. Segmental reporting includes the allocation of synergy benefits, including WBAD and combined corporate costs. Within our Retail Pharmacy USA segment, since the deal closed on December 31, we have reported 1 month of Alliance Boots equity income this quarter versus 3 months in the comparable quarter a year ago, recognizing the 45% stake that Walgreens had in Alliance Boots until end December. The months of January and February are fully consolidated. Year-over-year comparisons of results required consideration of the foregoing factors and are not directly comparable. 
So now let me take you through our financials in greater detail, beginning with the consolidated results. 
For the quarter, GAAP net earnings attributable to Walgreens Boots Alliance were just over $2 billion or $1.93 per diluted share, while adjusted and earnings were $1.2 billion or $1.18 per diluted share. This compares to $0.74 of GAAP net earnings per share and $0.97 of adjusted earnings per share in the prior year quarter. 
Net sales in the second quarter were $26.6 billion, an increase of 35.5% versus the prior year. 
Operating income on a GAAP basis was $1.4 billion and on an adjusted basis was $1.8 billion. The increase in adjusted operating income was driven by growth in our Retail Pharmacy USA segment as well as the consolidation of Alliance Boots' results for January and February. 
We reported $144 million of net interest expense this quarter, which included interest expense associated with prefunding the transaction for the month of December. Consistent with last quarter, our adjusted EPS excludes this interest expense, which we'll not need to do going forward. 
The adjusted tax rate for this quarter was 27.7%. Now this has been impacted by a number of factors, including a change in the geographic mix of forecast profits now that Alliance Boots has been fully consolidated, includes net discrete tax benefits specific to the quarter and the presentation of Alliance Boots' taxes in the income statement. Prior to the full merger, Walgreens 45% share of Alliance Boots' adjusted results, net of Alliance Boots' tax, were presented in a single line within operating income. Now following the transaction, Alliance Boots' tax is reported within the income tax provision line in our income statement, impacting the calculation of the adjusted tax rate. 
Diluted shares outstanding at the end of the quarter were $1.1 billion and average diluted shares outstanding for the quarter were 1.05 billion resulting from the issuance of 144 million shares on 31st December as part of the consideration for Alliance Boots. 
So now let me walk you through the component pieces to explain the change from GAAP to adjusted EPS. The GAAP earnings per share for the quarter of $1.93 reconciles to an adjusted earnings per share of $1.18. The net adjustment of $0.75 per share, this reflects the removal of net gains on transaction-related item of $0.67 and gains on the warrants we hold over AmerisourceBergen shares of $0.35. This is partially offset by LIFO provision costs of $0.04; acquisition-related amortization expenses of $0.15, which includes $0.08 relating to an -- to the inventory step-up which will not reoccur in future quarters; and special items of $0.08 related to optimization costs and asset impairments. 
The components of the net gain on transaction-related items were a gain on Walgreens' previously held equity interest in Alliance Boots of $0.77; a foreign currency hedge loss of $0.07 related to the delivery of the British pound element of the Step 2 consideration; and a net $0.03 cost of transaction fees, tax adjustments and interest costs from prefunding the cash consideration. 
So next, I'd like to provide insights into financial results at the segmental level, starting with Retail Pharmacy USA. Reported net sales were $21 billion, up 6.9% on a comparable store basis. In the pharmacy, comparable store scripts, which includes immunizations, this increased 5% on a 30-day adjusted basis. The increase was driven by the positive impact of a strong cough, cold and flu season; by continued growth in Medicare Part D scripts; and positive underlying share trends. For the quarter ending 28 February, the division's 30-day adjusted retail prescription market share in the U.S. reached 19.3%, as reported by IMS Health. This represents an increase of 20 basis points versus the same time last year. In retail products, comparable store sales increased by 2.5%. This was partially driven by strong December holiday sales, including seasonal sales of cough, cold and flu products. 
GAAP operating income for the quarter was $1.3 billion while adjusted operating income was $1.6 billion, up 13.4% over the year-ago quarter. Strong expense control and efficiencies offset the expected pharmacy gross margin pressure from declines in reimbursement, generic drug inflation as well as the Med Part D rate step-down that began on the 1st of January this year. 
Retail product margins increased this quarter, helped by seasonal and cough, cold, flu mix as well as our focus on reducing less profitable promotions. We remain very pleased with the progress on controlling and reducing SG&A expenses this quarter. Our GAAP SG&A expense declined 0.3% compared to the prior year quarter. 
So next, let's review the Retail Pharmacy International division, which is pharmacy-led health and beauty retail businesses in 8 countries. The biggest contributor is Boots in the U.K. 
Total sales for the 2 months ended February were just over $2 billion. As the businesses included in our Retail Pharmacy International division were acquired as part of the merger with Alliance Boots, no comparable information is included in the WBA consolidated results. On a pro forma constant currency basis, comparable sales for January and February grew by 2.9%. Comparable sales of Boots U.K. were up 2.3% while sales in our businesses in Chile and Mexico, which we acquired by Alliance -- acquired by Alliance Boots back in August 2014, these were up 2.9%. The acquisition brings us over 1,000 stores in Mexico and over 400 in Chile and provides strong growth opportunities in the Latin American market. The inclusion of these businesses in the division, combined with contract manufacturing, are reflected in the margins. 
Now turning to Pharmaceutical Wholesale, which mainly operates under the Alliance Healthcare brand in 12 countries. Results in any given quarter are influenced by performance in larger geographies, including the U.K., Germany, France and Turkey and the division's contribution from WBAD. 
Total sales for the 2 months ending February were $3.9 billion. Similar to Retail Pharmacy International, our Pharmaceutical Wholesale division was acquired through the merger with Alliance Boots, and so no amounts are reported in the comparable period. However, on a pro forma constant currency basis, sales were relatively flat compared with the same period the prior year. 
Now let me spend a minute on our expectations for synergies and how they will be reported going forward. Prior to the merger, the majority of our synergies were flowing through WBAD, the former joint venture between Walgreens and Alliance Boots, which Walgreens fully consolidated and then removed Alliance Boots' portion via the noncontrolling interest line item. Following the combination, we're allocating all synergies, including those generated by WBAD, to the segments, and we're doing this according to the relative proportion of purchases driving the synergy benefits. 
With regard to performance in the quarter, combined net synergies were $170 million, bringing the fiscal year-to-date total to $310 million, driven primarily by our drug procurement efforts. We remain comfortable with our ability to achieve at least $650 million in combined synergies this fiscal year. For FY '16, we continue to expect at least $1 billion in combined quantifiable net synergies. Consistent with prior reporting, these synergies do not include any benefit from our AmerisourceBergen relationship. 
Now that we're a combined company, as expected we are focusing on driving incremental synergies from sharing our best practices and working more closely together. However, not all of these can be easily quantified as some of them tend to blend into our normal business.
So moving on to the cash flows. We generated approximately $1.3 billion in cash from operations during the quarter, and our free cash flow was $1.0 billion. We're pleased with the cash generation during the second quarter due in part to an improvement in our primary working capital within our Retail Pharmacy USA division, driven by a reduction in inventory levels. We will continue to focus on working capital and remain confident in future opportunities to increase efficiencies. 
Net debt as of the quarter end was $14.1 billion. 
With regard to uses of free cash flow beyond reinvestment back into the company, we completed $94 million of share repurchases in the quarter against our $3 billion authorization. We purchased additional shares post the end of the quarter under preestablished trading plans, bringing the total purchases to $330 million.
I'd now like to make a few comments on our capital allocation policy. As we've consistently communicated, we remain committed to a solid investment-grade rating while looking for ways to enhance our cash generation. This includes driving working capital efficiencies, tightening capital expenditures, controlling costs and, of course, improving operations. Beyond maintaining a long-term 30% to 35% dividend payout target, our top priorities for free cash include M&A consistent with our strategy and share buybacks. All of these are with a view to optimizing long-term shareholder value. 
Following on this theme, and as Stefano mentioned, we are focused on becoming a more agile and more productive company. As you know, in August 2014, we announced a 3-year $1 billion cost reduction initiative. After a rigorous analysis, we've identified additional opportunities for cost savings primarily in our Retail Pharmacy USA division. These additional cost opportunities will increase the total expected cost savings program by $500 million to a projected $1.5 billion by the end of fiscal 2017. So moving to areas of focus, they include plans to close approximately 200 stores across the U.S.A., to reorganize corporate and field operations, drive operating efficiencies and streamline information technology and other functions. These actions are designed to restructure and invest in our company's future in a way that is better for customers, simpler for our employees, resulting in a faster and more agile organization. 
We estimate that total pretax charges associated with this program to our GAAP financial results will be in the range of $1.6 billion to $1.8 billion, of which the cash component is expected to be approximately 60%. The restructuring charges will be recognized over time as the program is implemented in accordance with GAAP. Looking ahead, we will continue to focus on other areas of cost reduction. 
So now let's talk about the rest of fiscal 2015. We understand and appreciate that there are lots of factors that will impact our results. So in order to help you, we are providing an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Now this range assumes quarterly interest expense of $140 million to $150 million. It assumes a full year adjusted tax rate of approximately 29% and a fiscal year diluted share count generally consistent with the current quarter. It assumes management's estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. Now this guidance also includes recast fiscal Q1 results due to the elimination of the 3-month lag. Finally, you will see an increase in the share count in Q3 and Q4 due to the full inclusion of the 144 million shares issued with Step 2 of the AB transaction. This will result in approximately 1.1 billion diluted shares per quarter. Any additional share repurchases will impact, of course, the fiscal year diluted share count. 
So moving on to FY '16. Our previously published goals were based on a variety of assumptions to arrive at estimate ranges for both sales and adjusted EPS. These included operating assumptions for our businesses and certain below-the-line items, including interest, tax and share count. When we set the goals in August, we made foreign currency assumptions based on exchange rates that were close to market rates at that time. Since then, we've seen significant global currency movements, especially the strengthening of the U.S. dollar. Because we report in U.S. dollars, we do have currency translational exposures primarily based on movements in the pound sterling versus the dollar. Simply put, a stronger dollar hurts our sales and earnings in dollars while a weaker dollar helps them. We estimate that a 1% move in the pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. Despite the FX headwind, I'm confident that we have initiatives and resources in place to address the controllable elements that drive our adjusted EPS goal for FY '16. 
Our revenues have greater potential variability due to the varied mix of businesses, particularly in our Wholesale division, which accounts for a significant proportion of our overall revenue. In addition, the geographical spread of the Wholesale business increases its exposure to currency variations. This being the case, we view overall revenue as a less relevant measure of our business. So taking these 2 factors into account, we decided to no longer provide our published revenue goal. And please note that our forward-looking statements assume no significant changes to the current exchange rates. 
So I'd like to wrap up today by saying that our reporting structure has changed and comparability is limited, which I know makes it really difficult for you. Therefore, in an effort to be as informative as possible, we've provided adjusted EPS guidance for fiscal year 2015. And next week, we'll have a financial session to provide further insights. In addition, we plan to provide operational insights in each of our 3 segments as well as views on our key financial drivers and future strategy. We really look forward to seeing you then. 
So with that, I'll turn the call back to Stefano."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs ac",664,"Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. 
We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs across the group, including the progressive development of our procurement initiatives. We must also properly manage the assets of the business to ensure we are suitably structured and prepared to address the pressures we face as the pharmacy markets evolve. These pressures may variously be from reimbursement cuts, competitive action or simply changes in consumer behavior. Whatever form they take, if we are properly structured and prepared, operating an efficient, high-quality, patient-oriented pharmacy service, that we will earn the right not just to participate but to be an architect of the changes in our market. We are already seeing the benefits that can be achieved in retail with the initiatives under way at Walgreens and ongoing at Boots. We must ensure that we get the best return for our investment and create the best environment for our employees and customers alike. This will require us to operate enhanced systems and control so that we can monitor and manage our business properly. 
Now many of you have asked where we are on the CEO search. As you know, we formed a search committee of the board and they have been working with one of the top executive recruiting firms to help us find a new CEO. Currently, we are in the process of reviewing the candidates they have proposed. Finding candidates with the combination of attributes that we deem important for the role is naturally challenging as we expected that -- it to be. But we remain confident that in due course, we will find the right person for the job. 
Lastly, as the new culture takes hold and finds roots in a company, you can see echoes of it in all parts of the business. I hope that in one particular area, you are seeing the new culture emerge very clearly and that -- and the different [ph] now approach to our owners and the financial community in general. I have always viewed investors as my business partner, and I hope that they will view me in the same way. 
As an organization, we strongly believe it is our duty to care for our shareholders and to ensure that we are as accessible, responsive and transparent as we can be. We also believe in being proactive in reaching out to our investors to properly understand their requirements and to ensure that in our investor relations effort, we have as mindful -- we are as mindful of our shareholders as we are of the patients in our pharmacies or our customers in wholesale. I think that Gerald and his team have done well to demonstrate this new [indiscernible], and it is a great pleasure to see, although there is still more to do. We are in the first steps of a long and exciting path, and I look forward to traveling it with you as fellow owners and partners. 
As I said earlier, I am optimistic about the long-term future of our company and have made a significant personal commitment to our future not only as the Executive Vice Chairman and acting CEO but also as a significant shareholder. I am convinced that the formation of Walgreens Boots Alliance is a unique first, which will almost inevitably lead to many other new firsts in our industry. It may not yet be clear which steps these will be, but we are determined to continue to show the way and be at the forefront of innovating health care. Our ambition is to build a generally global company and a universal health care champion. We look forward to providing a more comprehensive outlook on our future strategy and value creation next week at our first Analyst Day. 
With that, we are now ready to take your questions."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs.",15,"[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just cur",106,"I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just curious if you can give an update on how we should think about the cost cutting over the next 3 years. And then related to that, given that there's an additional $500 million in cost cutting, obviously reiterating the fiscal '16 guidance, I'm wondering if there was any negative offsets that you've realized since giving that '16 guidance."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George. And after, Alec can give you, I believe, a satisfactory answer.",13,"So George. And after, Alec can give you, I believe, a satisfactory answer."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a",163,"Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a lot of this will be into the year and into 2017. So it's really over the next 2 and a bit years is how I would look at that in terms of driving performance. I think what 's -- when we're -- the piece I would really reiterate on the guidance that we've given is please do remember the change in currency. I mean, remember, the sterling is about $1.48 today and it was about $1.68 back in August, just as a reminder. So in setting the guidance and in reaffirming the guidance, you've got to take into account that we've had an unfavorable wind on the currency versus some of what we're doing in other areas."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clar",90,"That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clarity on what went on within the U.S. SG&A line. Is that reduction that we saw there in any part a result of these cost initiatives? Or is there other things at play within the U.S. cost structure?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operat",237,"It's Alec here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operating model and really tried to lay out the grounds for the new operating model that we're going to do through the business. We've been really successful. The team has done a great job in Walgreens in terms of being able to find cost savings that do not affect the customer. The most pleasing thing about this beyond these cost savings is the fact that we're still growing volume ahead of the market, both in pharmacy and in retail products. And also, we're seeing internally our measure in cost of the delay improving. The whole idea of better for customers, simpler for our teams and more faster, agile organization is what's driving all of this, and we'll keep on going as we'll keep on working the old model and trading these processes, the IT structures for new model. So yes, we're delighted with the SG&A savings in this quarter and they are materially better than the same period last year. And as part of the restructuring we started already is in there, but a lot of this also is just due to ongoing cost control and cost management."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser of Morgan Stanley."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need i",68,"When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need in the U.S. market? Or are there still areas that you think that you might be missing or below scale at?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because t",224,"Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because the margins are squeezed everywhere. The government is more and more in charge for the cost of the health care business. And so for sure, they will exercise their power to squeeze the costs as much as possible, as we have seen in Europe for decades. And so the complex structure of the -- of delivering the medicines to the patients will have to be rationalized. And as a consequence, it's easy to believe that we will have additional synergies coming from M&A activities. These could be, of course, at the level of horizontal consolidation. But in many layers of the chain, the consolidation is still up and is still quite advanced. So it's very likely that we'll see also vertical consolidation. And the opportunities are there for everybody, and we will see what happens. But as I have said before, we want to be, as we have been in the past, at the forefront of changes. And so if there is a need for a consolidation will be confirmed. We will try to be part of it."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?",46,"Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that through better tools to the merchants",301,"It's Alec here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that through better tools to the merchants. So the merchant teams have done a really great job in terms of understanding more precisely where customers truly value promotions and where actually they don't. And you can see the growth in the front-end margin. You can also see the growth in product sales at the same time. So we've really been able to pull these 2 things off together. And we feel confident with the new tools we've got and the key tools we're developing going forward. Also a great hire. Linda, Linda Filler, has come into us. And again, Linda, we believe, will accelerate our journey given her tremendous experience in Walmart and Sam's Club in particular. So that feels pretty good. In terms of own brand penetration, we've created a new division within our organization, within Walgreens Boots Alliance, led by Ken Murphy. And again, we're able to think about how do we understand local insights in America and also global insights, and Ken will speak more about this next week, and how therefore do we get the right products and the right brands into the American consumers' hands in the drug store channel. Having said that, we've done a couple of things recently. We've issued 2 new masstige cosmetic brands, CIRCA and Colour Prevails. That's happened in the last 2 or 3 weeks. So we're not waiting for that to happen. We continue to work on the basis of growing own brand penetration. So I think in both fronts, we made good, solid progress and there's more to come."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill of JPMorgan.",12,"Our next question comes from the line of Lisa Gill of JPMorgan."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being po",62,"George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being positive from a script perspective, we know that there's been pressure there on the reimbursement front."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean...",3,"Yes. I mean..."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean, there's a number of factors. And I know what makes it really complicated looking at half year on half year, and of course it includes the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obv",181,"Yes. I mean, there's a number of factors. And I know what makes it really complicated looking at half year on half year, and of course it includes the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obviously, firstly, we've got 2 months' results in Q2 given this kicks in at the beginning of the year but will impact us for the cool -- the full quarters in each of Q3 and 4. The second half of the fiscal year is seasonally weaker than the first half normally. And of course, I know we haven't got all the comparables to sort of give you the overall seasonality, which makes it tough to model. And then, of course, we've got the exchange rate issues as well coming in because of what's -- where the exchange moved -- the exchange rate has moved over the last number of -- the last 6 months. And of course, we are still bringing in the 45% of AB at that point in time."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec, if you can add something.",6,"Alec, if you can add something."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half rela",87,"Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half relative to the first half of last year. And then the remainder of the year, we have still cost savings coming through. So we actually had quite a lot of cost savings in Q4 of last year to go against."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improv",106,"And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improving. Can you maybe talk about what you're seeing, one, on drug price inflation and the impact that it's having? Are you be -- are you able to offset that with your procurement entity? And then secondly, kind of your outlook for incremental generics that are going to come as we go through the next couple of quarters."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer this question?",6,"Jeff, can you answer this question?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inf",195,"Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inflation as we've seen in the past 12 months or so. The teams at WBAD, Walgreens, ABC and Alliance Healthcare all continue to work extremely effectively together to assure that is the biggest buyer in -- of generics in the world, that we are properly managing the industry dynamic. The teams in particular have gotten very sharp and have a number of effective mechanisms in place and are working very collaboratively with the generic drug manufacturers to really manage through this dynamic. They've gotten very flexible and nimble in understanding the marketplace where there might be issues and really managing them proactively. In terms of the generic pipeline, we've recently seen in February the entry of NEXIUM, but we haven't seen it go multi-source and we're looking forward to that. And we are seeing the list of generics that are coming out. We're looking forward to maximizing those opportunities as they come."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill of Deutsche Bank.",13,"Our next question comes from the line of George Hill of Deutsche Bank."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to",95,"And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to this figure? And how should we think about the earnings profile of these stores? They're -- we would assume that they're less profitable than the composite of the business. But is there any chance that they're losing money and there's going to be a positive margin lift from this?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more ret",234,"It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more retention of customers and we saw that they'll be able also to retain a lot of our people as well, which is really important to us as a team and as a business. So we feel confident about the number we've given out, approximately 200. And of course, we will tell our people first where we're going to go when actually making these closures. Another key point is that we'll be opening up about 200 stores in the same period. So this really is just getting the right stores in the right place. And I also think it's about the right cash and the right returns per store basis. This is a very individual store-based decision. And of course, the stores which are potentially going to be closed, we have looked carefully at the markets today and the numbers of customers in them and how they shop in that market and also how the population flowed over the course of these stores being open. And we've seen stores which really the population is moving away from and there's less future opportunity than today."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? H",96,"Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? How much -- I guess how much cost can continue to be taken out? And maybe from an inventory perspective, what can still be taken out? And I guess there are lot of store inventory left that can be taken out and kind of better served through the DSD delivery of ABC?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Al again. Yes, we've made really good progress in terms of inventory reduction. And myself and Jeff are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the Rachel",197,"It's Al again. Yes, we've made really good progress in terms of inventory reduction. And myself and Jeff are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the Rachel Ashworth [ph] is doing in the stores. We're also seeing importantly our service levels improve as well. So again, we've seen this nice thing. When you get less stock out the system, you improve costs and then you improve working capital. And importantly, you improve service levels. So again, we'll continue to work at this. There are more opportunities and we'll do in a really balanced way to make sure that we care for customers first, get it right going forward and we take working capital out. And I'm confident that the working relationship with ABC will continue to improve. And of course, working in Europe, as I did before with Ronald [ph] and the team in Alliance Healthcare, we really worked as well for a number of years and saw more and more opportunities which comes through very clearly in the U.K. business performance for both the Wholesale and the Boots division."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Steven Valiquette of UBS.",12,"Our next question comes from the line of Steven Valiquette of UBS."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been an inventory step-up charge as well. So I apologize if I missed",141,"So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been an inventory step-up charge as well. So I apologize if I missed this, but I guess did you provide the fully adjusted gross margin for the quarter just to make it a little bit easier for us? And also, part 2 is then that just curious, all the talk about the U.S. Medicare Part D rate reductions that went into effect on 1/1/15, is there any way just to get a rough sense for how much that impacted the gross margin in the quarter? Was it perhaps 100 basis points year-over-year or maybe something greater than that? I'm just trying to get a sense for that."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Right.",1,"Right."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George can answer to the first part of that.",10,"So George can answer to the first part of that."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key",222,"Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key differences between adjusted and the U.S. GAAP results. And that's simply because under -- when you're doing the purchase accounting, and we've done the provisional purchase accounting allocation and we've got a year to finalize that, what you have to do is revalue the inventory at a selling price less a small margin. So we're not valuing the industry -- the inventory at cost. So that gets -- what it does is it essentially artificially takes down the U.S. GAAP profit in those 2 divisions as a result. So that's why we've stripped it out to show the operating results with that out. It has no impact at all on the comparables because it doesn't impact the Retail Pharmacy USA segment. I'm sorry it's got so many of these adjustments. We'll try -- next week, I'll try to take you back through them in a little more detail. It really does make it very difficult to articulate the story as clearly as we would -- I'm sure you would like and we would like."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer to the second question?",8,"Jeff, can you answer to the second question?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question.",35,"Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations fo",67,"Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations for the 2016 year. They're very productive right now, but we're very -- it's very early days in terms of the impact moving forward."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total.",41,"Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair.",21,"And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting lever",97,"So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting leverage with payers in pharmacy? And then I guess sub-point to that is getting more scale within the retail operations. Or is it more about strategic moves that allow you to drive more share across your own network and then specifically thinking about better managing the payer relationships and potentially having a -- some type of pharmacy benefit management relationship?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk a",210,"Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk about opportunities, of course we don't exclude typical M&A opportunities. But there are many, many opportunities which are not related to an acquisition or to a merger, related to a potential joint venture, commercial joint venture, as we did initially with WBAD. When we approached Walgreens, so when we started our discussion, the first thing that we decided was to create these joint ventures to buy together, and this joint venture would have been there even without the merger. So there are many ways to deliver synergies. And of course, we are open to any kind of organization which can improve the value of our company, and we are analyzing many, many different alternatives. And of course, it depends also on the maturity of the potential partner, from the willingness they have to do something with us. What I was saying is that the market, that goes clearly in one direction, and sooner or later these kinds of things will happen."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?",37,"And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration is doing very we",157,"We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration is doing very well. I have to say higher than my expectation. But still, there is a lot to do. But the fact that we have not yet finished this job doesn't mean that we cannot do something else in the meantime. So of course, if we had an opportunity, we will take this opportunity. And any big, important opportunities, be it an M&A activity, be it a joint venture, a commercial joint venture, takes months to be perfection, I said, to come to life. And so we will have time to continue our integration while discussing the -- with other possibilities. So of course, you'll -- if we will see opportunities, we will be ready."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?",22,"That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we",65,"I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we have the ability to generate the necessary cash to complete that program whilst maintaining solid investment grade."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And our next question comes from the line of Edward Kelly of Crdit Suisse.",14,"And our next question comes from the line of Edward Kelly of Crdit Suisse."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division t",52,"I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division that you've sort of contemplated here?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed b",183,"I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed budgeting exercises as a combined group, and we're getting everything on a comparable basis under U.S. GAAP. So we're going through quite a bit of change to try and then be -- to go through this process. What we'll try and do next week when we meet is try and give you a little bit more insight into the drivers as we go through each division's section and then we've got the half day on the financial modeling on the Thursday. So hopefully, we'll be able to give you a little bit more insight on that. It is quite complicated because of the lack of comparability because we have obviously put the segments in place that particularly reflects where the -- in terms of where the synergies are, where we're putting the synergies in where the real economic activity is happening."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week.",28,"And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming",66,"All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming or lower-margin stores? And I guess the question would be, what's the real answer to improving those stores if it's not necessarily closing?"
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And",181,"Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And I think also, we've done a lot of work on the front end. We are becoming more confident about our ability to not just improve the front end through margin expansion but to develop potential new formats, integrate digital assets to become a new channel. Some of the work Simon and the team have done in Boots has been great in that respect in the last couple of years. So we have different strategies that we will apply over the months and years ahead to make the very most of what is a great set of assets. Stefano said this in the introduction. We have got the best corners in America, and we have looked at them and we still think we have a really important asset that feature the Walgreens company."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers",255,"But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers should, let's say, have a program on maintenance for their stores. And if -- when you have such a vast territory, such a high number of stores, that inevitably you will have some stores which have been maybe profitable in the past and are not particularly exciting today, and you will need to open stores in areas which didn't even exist in the past. So the reality, you see a certain concentration which is still small because a few hundred out of 8,300 stores is not a big number, but you'll see it's a certain concentration because this program has not been done in the past in an orderly fashion. In the future, once we have, let's say, recreated this new base, I believe we should every year look after -- review all the stores. And if we have -- every year, if we have to close 10 stores or 5 stores or 15 stores, we have to -- we will have to do it in order not to have this concentration of stores just in 1 year. Because it's better to do this gently over time, practically this will be business as usual and nobody will see it in reality even inside the company."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments.",27,"And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be",96,"Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be webcast live and will be archived on our Investor Relations site. So I hope as many of you as possible can participate in that. We'll address as many of your additional questions as we can then. And thank you very much indeed, everyone, for participating today."
93624,283101937,788557,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald",52,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Second Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Gerald Gradwell, Senior Vice President, Investor Relations and Special Projects. You may begin."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and",308,"Thank you, Nicole, and good morning, everyone. Welcome to our fiscal 2015 second quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Acting Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our second quarter results. Also joining us on the call and available for questions are Alec Gourlay, Executive Vice President and President of Walgreens; and Jeff Berkowitz, Executive Vice President and President of Pharma & Global Market Access. 
As a reminder, today's presentation includes certain non-GAAP financial measures, and I will direct you to our website at investor.walgreensbootsalliance.com for reconciliations of the most directly comparable GAAP measures and related information. You can find a link to our website on our Investor Relations website -- sorry, to our webcast on our Investor Relations website. After the call, this presentation and the webcast will be archived on our website for 12 months. 
And now to read out the Safe Harbor statement. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current markets, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K and subsequent filings for a discussion of the risk factors as they relate to forward-looking statements. 
Today's presentation includes certain non-GAAP financial measures, and we refer you to the appendix, to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll hand you over to Stefano for his opening comments."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a hi",1109,"Thank you, Gerald. Good morning, everyone, and welcome to the first ever earnings conference call for Walgreens Boots Alliance. 
Let me begin by underscoring how pleased we were to finally bring the 2 companies together on 31 December 2014. This was a historic and pivotal milestone for 2 iconic companies, Walgreens and Alliance Boots, as we completed our merger to establish Walgreens Boots Alliance, forging the new company, the world's first global pharmacy-led health and well-being enterprise. 
We established a senior management team to bring together our businesses and lead them forward to the next phase of their evolution while making steady progress with the integration and the establishment of a single unified corporate identity and culture. 
Our team worked very hard to accelerate the closing of the deal 2 months ahead of the beginning of the completion window. We raised the funds to complete the transaction and refinance essentially all the AB debt in an efficient manner while going through a complicated process of preparing our first full consolidated earnings under U.S. GAAP, including eliminating the 3-month reporting lag. The complexity and effort these tasks have taken cannot be underestimated. I would ask you to remember that until completion, our businesses have to operate at arm's length as separate entities. We are today only 14 weeks, in fact 99 days, into the creation of this new global entity. It is still very early, but we have moved mountains in what we have done and are still in the first steps of our journey. 
We have achieved much in a short time and are moving quickly. We have expanded our restructuring program to create a more competitive cost structure, begun to access synergies created through the combination and sharpened our focus on our strategic priorities, including the sales of a majority interest of our infusion business subsequent to the quarter close. And today, I am pleased to announce a strong quarter, achieved along with all the other tasks that we have undertaken. We are looking forward to the future with enthusiasm.
Our transaction has created a group which, I believe, has enormous potential to grow in ways that give us great excitement and optimism for the future. Let's start by looking at our business as we stand today. 
Based on an in-depth review of our Retail Pharmacy USA segment, I can say that Walgreens is on a sound structural footing. As you might expect, some parts are better than expected while others offer room for improvement. Our first priority is to understand the business fully, its interdependency and its differentiators. This exercise is under way, and we'll ensure we stay focused on what is truly important: delivering against the needs of our customers in a dependable yet innovative manner that provides us with sustainable and growing income across all parts of our business. This will be achieved through a combination of efficient practice, research and insight, investments in our core business and innovation in our business model. From what we have seen already, we believe there to be significant scope to enhance the performance of our pharmacies through refreshing and differentiating our store, improving customer experience, delivering products and services to customers and patients and introducing new offerings through innovative partnership. We believe that through good business practice and the application of these and other initiatives, we can over time expand the retail margin, grow market share and prepare ourselves to better address the competitive and market-driven headwinds we face in certain areas of our business. 
Let me be perfectly clear. Our aim is to help Walgreens further develop strategies that will continue to deliver growth for many years to come. It is vital that we make best use of the assets that we have, core to which is our unrivaled portfolio of locations across the U.S. We must work tirelessly to drive the best possible return from these assets. And to that end, we have today announced an enlarged but necessary restructuring program to focus the Walgreens business back on its core assets. We believe we will come out of this stronger and better positioned to deliver enhanced performance that our premium locations should command. 
In Retail Pharmacy International in Boots, we are working hard to refine the new cycle of our business that will deliver growth in the coming year. We are continuing to develop our online offering and building on our recent successes. We are working to further integrate these with our physical stores and logistical network to enhance the customer choice while making better use of our resources. The constant work to keep our offering fresh through innovation within store and within our own brand and exclusive product portfolio is continuing to differentiate us in the extremely competitive U.K. retail market. I'm confident that the work which Simon and his team are doing will set us on a path for further growth in the years ahead. 
As you're aware, our retail businesses are also continuing to perform well, and it has been a particular pleasure to welcome our new colleagues in Mexico and Chile to our company, making the expansion of our international retail presence in Latin America through their vision of 2 outstanding businesses with excellent prospects for growth. 
Our Pharmaceutical Wholesale division is continuing to develop the integrated business model that we introduced many years ago, operating an ever-growing suite of services to the manufacturers that tie up most growth than ever to them as partners. On the other side of the supply chain, we are expanding our offering to our pharmacies customers to both align them more globally with our -- the wholesalers and let them improve the quality and economics of their own businesses. While such initiative enhance the vertical integration of our wholesale businesses and create strength and value, the ever-changing market that we are operating in and the continuous economic pressure that health care systems are under present us with several opportunities to expand our network. 
These present themselves in many ways. In one extreme, through consolidation within markets; and at the other extreme, through innovative partnerships and alliance systems, as you have seen us to do with AmerisourceBergen. As wholesale is a business that is enhanced by volume and market presence, we will continue to explore opportunities to expand our network as they arise. Underpinning all of these, Walgreens Boots Alliance has embarked on the beginning of a new year, a new year that will bring a new attitude, a new culture aligned toward driving performance, serving our customers and creating long-term, sustainable shareholder value. 
Now I will ask George to take us through the quarterly results. George?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overvi",2567,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I would like to cover the following 3 topics: first, to provide detail on our fiscal 2015 second quarter performance; second, to provide you with an overview of our restructuring program; and finally, to articulate our views on FY '15 and FY '16 results. 
To summarize, the second quarter was a solid start for our new company. Key highlights include net sales of $26.6 billion, GAAP earnings per share of $1.93 while adjusted EPS was $1.18, cash flow from operations of $1.3 billion and free cash flow of $1 billion. The quarter's financial results are complicated as we began reporting as a consolidated entity partly through the quarter and the comparability to last year is a challenge and of limited use. 
Before we get into the details of our second quarter financial performance, I'd like to explain some elements of our new reporting structure. Historically, Walgreens has reported as one segment, which consisted of the results of Walgreens in the USA; its corporate costs; synergies from the Walgreens Boots Alliance Development joint venture, also known as WBAD; and equity earnings from Alliance Boots on a 3-month lag. Our focus was to merge the businesses as soon as possible and eliminate the 3-month reporting lag. This aligns the reporting -- the reported results of the global enterprise and will make our performance easier to understand going forward. 
As Walgreens Boots Alliance, we now report results in 3 segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. Segmental reporting includes the allocation of synergy benefits, including WBAD and combined corporate costs. Within our Retail Pharmacy USA segment, since the deal closed on December 31, we have reported 1 month of Alliance Boots equity income this quarter versus 3 months in the comparable quarter a year ago, recognizing the 45% stake that Walgreens had in Alliance Boots until end December. The months of January and February are fully consolidated. Year-over-year comparisons of results required consideration of the foregoing factors and are not directly comparable. 
So now let me take you through our financials in greater detail, beginning with the consolidated results. 
For the quarter, GAAP net earnings attributable to Walgreens Boots Alliance were just over $2 billion or $1.93 per diluted share, while adjusted and earnings were $1.2 billion or $1.18 per diluted share. This compares to $0.74 of GAAP net earnings per share and $0.97 of adjusted earnings per share in the prior year quarter. 
Net sales in the second quarter were $26.6 billion, an increase of 35.5% versus the prior year. 
Operating income on a GAAP basis was $1.4 billion and on an adjusted basis was $1.8 billion. The increase in adjusted operating income was driven by growth in our Retail Pharmacy USA segment as well as the consolidation of Alliance Boots' results for January and February. 
We reported $144 million of net interest expense this quarter, which included interest expense associated with prefunding the transaction for the month of December. Consistent with last quarter, our adjusted EPS excludes this interest expense, which we'll not need to do going forward. 
The adjusted tax rate for this quarter was 27.7%. Now this has been impacted by a number of factors, including a change in the geographic mix of forecast profits now that Alliance Boots has been fully consolidated, includes net discrete tax benefits specific to the quarter and the presentation of Alliance Boots' taxes in the income statement. Prior to the full merger, Walgreens 45% share of Alliance Boots' adjusted results, net of Alliance Boots' tax, were presented in a single line within operating income. Now following the transaction, Alliance Boots' tax is reported within the income tax provision line in our income statement, impacting the calculation of the adjusted tax rate. 
Diluted shares outstanding at the end of the quarter were $1.1 billion and average diluted shares outstanding for the quarter were 1.05 billion resulting from the issuance of 144 million shares on 31st December as part of the consideration for Alliance Boots. 
So now let me walk you through the component pieces to explain the change from GAAP to adjusted EPS. The GAAP earnings per share for the quarter of $1.93 reconciles to an adjusted earnings per share of $1.18. The net adjustment of $0.75 per share, this reflects the removal of net gains on transaction-related item of $0.67 and gains on the warrants we hold over AmerisourceBergen shares of $0.35. This is partially offset by LIFO provision costs of $0.04; acquisition-related amortization expenses of $0.15, which includes $0.08 relating to an -- to the inventory step-up which will not reoccur in future quarters; and special items of $0.08 related to optimization costs and asset impairments. 
The components of the net gain on transaction-related items were a gain on Walgreens' previously held equity interest in Alliance Boots of $0.77; a foreign currency hedge loss of $0.07 related to the delivery of the British pound element of the Step 2 consideration; and a net $0.03 cost of transaction fees, tax adjustments and interest costs from prefunding the cash consideration. 
So next, I'd like to provide insights into financial results at the segmental level, starting with Retail Pharmacy USA. Reported net sales were $21 billion, up 6.9% on a comparable store basis. In the pharmacy, comparable store scripts, which includes immunizations, this increased 5% on a 30-day adjusted basis. The increase was driven by the positive impact of a strong cough, cold and flu season; by continued growth in Medicare Part D scripts; and positive underlying share trends. For the quarter ending 28 February, the division's 30-day adjusted retail prescription market share in the U.S. reached 19.3%, as reported by IMS Health. This represents an increase of 20 basis points versus the same time last year. In retail products, comparable store sales increased by 2.5%. This was partially driven by strong December holiday sales, including seasonal sales of cough, cold and flu products. 
GAAP operating income for the quarter was $1.3 billion while adjusted operating income was $1.6 billion, up 13.4% over the year-ago quarter. Strong expense control and efficiencies offset the expected pharmacy gross margin pressure from declines in reimbursement, generic drug inflation as well as the Med Part D rate step-down that began on the 1st of January this year. 
Retail product margins increased this quarter, helped by seasonal and cough, cold, flu mix as well as our focus on reducing less profitable promotions. We remain very pleased with the progress on controlling and reducing SG&A expenses this quarter. Our GAAP SG&A expense declined 0.3% compared to the prior year quarter. 
So next, let's review the Retail Pharmacy International division, which is pharmacy-led health and beauty retail businesses in 8 countries. The biggest contributor is Boots in the U.K. 
Total sales for the 2 months ended February were just over $2 billion. As the businesses included in our Retail Pharmacy International division were acquired as part of the merger with Alliance Boots, no comparable information is included in the WBA consolidated results. On a pro forma constant currency basis, comparable sales for January and February grew by 2.9%. Comparable sales of Boots U.K. were up 2.3% while sales in our businesses in Chile and Mexico, which we acquired by Alliance -- acquired by Alliance Boots back in August 2014, these were up 2.9%. The acquisition brings us over 1,000 stores in Mexico and over 400 in Chile and provides strong growth opportunities in the Latin American market. The inclusion of these businesses in the division, combined with contract manufacturing, are reflected in the margins. 
Now turning to Pharmaceutical Wholesale, which mainly operates under the Alliance Healthcare brand in 12 countries. Results in any given quarter are influenced by performance in larger geographies, including the U.K., Germany, France and Turkey and the division's contribution from WBAD. 
Total sales for the 2 months ending February were $3.9 billion. Similar to Retail Pharmacy International, our Pharmaceutical Wholesale division was acquired through the merger with Alliance Boots, and so no amounts are reported in the comparable period. However, on a pro forma constant currency basis, sales were relatively flat compared with the same period the prior year. 
Now let me spend a minute on our expectations for synergies and how they will be reported going forward. Prior to the merger, the majority of our synergies were flowing through WBAD, the former joint venture between Walgreens and Alliance Boots, which Walgreens fully consolidated and then removed Alliance Boots' portion via the noncontrolling interest line item. Following the combination, we're allocating all synergies, including those generated by WBAD, to the segments, and we're doing this according to the relative proportion of purchases driving the synergy benefits. 
With regard to performance in the quarter, combined net synergies were $170 million, bringing the fiscal year-to-date total to $310 million, driven primarily by our drug procurement efforts. We remain comfortable with our ability to achieve at least $650 million in combined synergies this fiscal year. For FY '16, we continue to expect at least $1 billion in combined quantifiable net synergies. Consistent with prior reporting, these synergies do not include any benefit from our AmerisourceBergen relationship. 
Now that we're a combined company, as expected we are focusing on driving incremental synergies from sharing our best practices and working more closely together. However, not all of these can be easily quantified as some of them tend to blend into our normal business.
So moving on to the cash flows. We generated approximately $1.3 billion in cash from operations during the quarter, and our free cash flow was $1.0 billion. We're pleased with the cash generation during the second quarter due in part to an improvement in our primary working capital within our Retail Pharmacy USA division, driven by a reduction in inventory levels. We will continue to focus on working capital and remain confident in future opportunities to increase efficiencies. 
Net debt as of the quarter end was $14.1 billion. 
With regard to uses of free cash flow beyond reinvestment back into the company, we completed $94 million of share repurchases in the quarter against our $3 billion authorization. We purchased additional shares post the end of the quarter under preestablished trading plans, bringing the total purchases to $330 million.
I'd now like to make a few comments on our capital allocation policy. As we've consistently communicated, we remain committed to a solid investment-grade rating while looking for ways to enhance our cash generation. This includes driving working capital efficiencies, tightening capital expenditures, controlling costs and, of course, improving operations. Beyond maintaining a long-term 30% to 35% dividend payout target, our top priorities for free cash include M&A consistent with our strategy and share buybacks. All of these are with a view to optimizing long-term shareholder value. 
Following on this theme, and as Stefano mentioned, we are focused on becoming a more agile and more productive company. As you know, in August 2014, we announced a 3-year $1 billion cost reduction initiative. After a rigorous analysis, we've identified additional opportunities for cost savings primarily in our Retail Pharmacy USA division. These additional cost opportunities will increase the total expected cost savings program by $500 million to a projected $1.5 billion by the end of fiscal 2017. So moving to areas of focus, they include plans to close approximately 200 stores across the U.S.A., to reorganize corporate and field operations, drive operating efficiencies and streamline information technology and other functions. These actions are designed to restructure and invest in our company's future in a way that is better for customers, simpler for our employees, resulting in a faster and more agile organization. 
We estimate that total pretax charges associated with this program to our GAAP financial results will be in the range of $1.6 billion to $1.8 billion, of which the cash component is expected to be approximately 60%. The restructuring charges will be recognized over time as the program is implemented in accordance with GAAP. Looking ahead, we will continue to focus on other areas of cost reduction. 
So now let's talk about the rest of fiscal 2015. We understand and appreciate that there are lots of factors that will impact our results. So in order to help you, we are providing an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Now this range assumes quarterly interest expense of $140 million to $150 million. It assumes a full year adjusted tax rate of approximately 29% and a fiscal year diluted share count generally consistent with the current quarter. It assumes management's estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. Now this guidance also includes recast fiscal Q1 results due to the elimination of the 3-month lag. Finally, you will see an increase in the share count in Q3 and Q4 due to the full inclusion of the 144 million shares issued with Step 2 of the AB transaction. This will result in approximately 1.1 billion diluted shares per quarter. Any additional share repurchases will impact, of course, the fiscal year diluted share count. 
So moving on to FY '16. Our previously published goals were based on a variety of assumptions to arrive at estimate ranges for both sales and adjusted EPS. These included operating assumptions for our businesses and certain below-the-line items, including interest, tax and share count. When we set the goals in August, we made foreign currency assumptions based on exchange rates that were close to market rates at that time. Since then, we've seen significant global currency movements, especially the strengthening of the U.S. dollar. Because we report in U.S. dollars, we do have currency translational exposures primarily based on movements in the pound sterling versus the dollar. Simply put, a stronger dollar hurts our sales and earnings in dollars while a weaker dollar helps them. We estimate that a 1% move in the pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. Despite the FX headwind, I'm confident that we have initiatives and resources in place to address the controllable elements that drive our adjusted EPS goal for FY '16. 
Our revenues have greater potential variability due to the varied mix of businesses, particularly in our Wholesale division, which accounts for a significant proportion of our overall revenue. In addition, the geographical spread of the Wholesale business increases its exposure to currency variations. This being the case, we view overall revenue as a less relevant measure of our business. So taking these 2 factors into account, we decided to no longer provide our published revenue goal. And please note that our forward-looking statements assume no significant changes to the current exchange rates. 
So I'd like to wrap up today by saying that our reporting structure has changed and comparability is limited, which I know makes it really difficult for you. Therefore, in an effort to be as informative as possible, we've provided adjusted EPS guidance for fiscal year 2015. And next week, we'll have a financial session to provide further insights. In addition, we plan to provide operational insights in each of our 3 segments as well as views on our key financial drivers and future strategy. We really look forward to seeing you then. 
So with that, I'll turn the call back to Stefano."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs ac",664,"Thank you, George. Let me finish today by reminding you of our key priorities as we look forward. 
We are working to deliver the benefits of our transaction within our core businesses. These will involve executing our synergies and efficiency programs across the group, including the progressive development of our procurement initiatives. We must also properly manage the assets of the business to ensure we are suitably structured and prepared to address the pressures we face as the pharmacy markets evolve. These pressures may variously be from reimbursement cuts, competitive action or simply changes in consumer behavior. Whatever form they take, if we are properly structured and prepared, operating an efficient, high-quality, patient-oriented pharmacy service, that we will earn the right not just to participate but to be an architect of the changes in our market. We are already seeing the benefits that can be achieved in retail with the initiatives under way at Walgreens and ongoing at Boots. We must ensure that we get the best return for our investment and create the best environment for our employees and customers alike. This will require us to operate enhanced systems and control so that we can monitor and manage our business properly. 
Now many of you have asked where we are on the CEO search. As you know, we formed a search committee of the board and they have been working with one of the top executive recruiting firms to help us find a new CEO. Currently, we are in the process of reviewing the candidates they have proposed. Finding candidates with the combination of attributes that we deem important for the role is naturally challenging as we expected that -- it to be. But we remain confident that in due course, we will find the right person for the job. 
Lastly, as the new culture takes hold and finds roots in a company, you can see echoes of it in all parts of the business. I hope that in one particular area, you are seeing the new culture emerge very clearly and that -- and the different [ph] now approach to our owners and the financial community in general. I have always viewed investors as my business partner, and I hope that they will view me in the same way. 
As an organization, we strongly believe it is our duty to care for our shareholders and to ensure that we are as accessible, responsive and transparent as we can be. We also believe in being proactive in reaching out to our investors to properly understand their requirements and to ensure that in our investor relations effort, we have as mindful -- we are as mindful of our shareholders as we are of the patients in our pharmacies or our customers in wholesale. I think that Gerald and his team have done well to demonstrate this new [indiscernible], and it is a great pleasure to see, although there is still more to do. We are in the first steps of a long and exciting path, and I look forward to traveling it with you as fellow owners and partners. 
As I said earlier, I am optimistic about the long-term future of our company and have made a significant personal commitment to our future not only as the Executive Vice Chairman and acting CEO but also as a significant shareholder. I am convinced that the formation of Walgreens Boots Alliance is a unique first, which will almost inevitably lead to many other new firsts in our industry. It may not yet be clear which steps these will be, but we are determined to continue to show the way and be at the forefront of innovating health care. Our ambition is to build a generally global company and a universal health care champion. We look forward to providing a more comprehensive outlook on our future strategy and value creation next week at our first Analyst Day. 
With that, we are now ready to take your questions."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs.",15,"[Operator Instructions] Our first question comes from the line of Robert Jones from Goldman Sachs."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just cur",106,"I know we'll get a little more detail next week at the Analyst Day, but I thought maybe I'd start on the incremental cost cutting you introduced today. I believe the previous expectation was for the bulk of the cost cutting to come in fiscal '16. Just curious if you can give an update on how we should think about the cost cutting over the next 3 years. And then related to that, given that there's an additional $500 million in cost cutting, obviously reiterating the fiscal '16 guidance, I'm wondering if there was any negative offsets that you've realized since giving that '16 guidance."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George. And after, Alec can give you, I believe, a satisfactory answer.",13,"So George. And after, Alec can give you, I believe, a satisfactory answer."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a",163,"Well, and our first priority, I think -- now remember, we're -- when merged at a relatively short time, our key priority is to see what additional savings were achievable. The second, the increase of $0.5 billion will take time to come through. So quite a lot of this will be into the year and into 2017. So it's really over the next 2 and a bit years is how I would look at that in terms of driving performance. I think what 's -- when we're -- the piece I would really reiterate on the guidance that we've given is please do remember the change in currency. I mean, remember, the sterling is about $1.48 today and it was about $1.68 back in August, just as a reminder. So in setting the guidance and in reaffirming the guidance, you've got to take into account that we've had an unfavorable wind on the currency versus some of what we're doing in other areas."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clar",90,"That's fair. And then I guess just maybe more near term looking at the U.S. SG&A, quite a bit lower than what we were looking for and obviously quite a bit lower than it was a year ago this time. I'm just wondering if you could give a little bit more clarity on what went on within the U.S. SG&A line. Is that reduction that we saw there in any part a result of these cost initiatives? Or is there other things at play within the U.S. cost structure?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operat",237,"It's Alec here. Yes, it's a combination of both. First of all, the additional $500 million is going to be almost all be in '17. So this is a result of what we've been doing over really the last 9 months as we've really deeply understood the current operating model and really tried to lay out the grounds for the new operating model that we're going to do through the business. We've been really successful. The team has done a great job in Walgreens in terms of being able to find cost savings that do not affect the customer. The most pleasing thing about this beyond these cost savings is the fact that we're still growing volume ahead of the market, both in pharmacy and in retail products. And also, we're seeing internally our measure in cost of the delay improving. The whole idea of better for customers, simpler for our teams and more faster, agile organization is what's driving all of this, and we'll keep on going as we'll keep on working the old model and trading these processes, the IT structures for new model. So yes, we're delighted with the SG&A savings in this quarter and they are materially better than the same period last year. And as part of the restructuring we started already is in there, but a lot of this also is just due to ongoing cost control and cost management."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser of Morgan Stanley."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need i",68,"When we think about the space, the consolidation obviously continues. We just heard the news last week on kind of like how United is thinking about the supply chain in the payer world. Do you think that you now have all the relevant pieces that you need in the U.S. market? Or are there still areas that you think that you might be missing or below scale at?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because t",224,"Well, what we think is not really important. The reality is that, as I have said many times and I have realized immediately after being for 2 weeks in the job, is that this market, the American market, is ready for another round of consolidation because the margins are squeezed everywhere. The government is more and more in charge for the cost of the health care business. And so for sure, they will exercise their power to squeeze the costs as much as possible, as we have seen in Europe for decades. And so the complex structure of the -- of delivering the medicines to the patients will have to be rationalized. And as a consequence, it's easy to believe that we will have additional synergies coming from M&A activities. These could be, of course, at the level of horizontal consolidation. But in many layers of the chain, the consolidation is still up and is still quite advanced. So it's very likely that we'll see also vertical consolidation. And the opportunities are there for everybody, and we will see what happens. But as I have said before, we want to be, as we have been in the past, at the forefront of changes. And so if there is a need for a consolidation will be confirmed. We will try to be part of it."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?",46,"Okay. And then just as we think about the trends on the front end, can you talk a little bit about promotional activities in the quarter and just how you think about promotional activities for the rest of the year and also about private label penetration?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that through better tools to the merchants",301,"It's Alec here. Yes, we -- the team has built a new tool and some good data. And so that's -- so this has been driven really from implementation of Balance Rewards, the insights we're getting. And they're driving that through better tools to the merchants. So the merchant teams have done a really great job in terms of understanding more precisely where customers truly value promotions and where actually they don't. And you can see the growth in the front-end margin. You can also see the growth in product sales at the same time. So we've really been able to pull these 2 things off together. And we feel confident with the new tools we've got and the key tools we're developing going forward. Also a great hire. Linda, Linda Filler, has come into us. And again, Linda, we believe, will accelerate our journey given her tremendous experience in Walmart and Sam's Club in particular. So that feels pretty good. In terms of own brand penetration, we've created a new division within our organization, within Walgreens Boots Alliance, led by Ken Murphy. And again, we're able to think about how do we understand local insights in America and also global insights, and Ken will speak more about this next week, and how therefore do we get the right products and the right brands into the American consumers' hands in the drug store channel. Having said that, we've done a couple of things recently. We've issued 2 new masstige cosmetic brands, CIRCA and Colour Prevails. That's happened in the last 2 or 3 weeks. So we're not waiting for that to happen. We continue to work on the basis of growing own brand penetration. So I think in both fronts, we made good, solid progress and there's more to come."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill of JPMorgan.",12,"Our next question comes from the line of Lisa Gill of JPMorgan."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being po",62,"George, as I look at the first half versus the second half, it looks like there was a deceleration in earnings. Can you talk about what the primary contributors are there? I'm just curious if the Medicare Part D, while you talked about the trends being positive from a script perspective, we know that there's been pressure there on the reimbursement front."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean...",3,"Yes. I mean..."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I mean, there's a number of factors. And I know what makes it really complicated looking at half year on half year, and of course it includes the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obv",181,"Yes. I mean, there's a number of factors. And I know what makes it really complicated looking at half year on half year, and of course it includes the deal and remove the 3-month lag, et cetera. I mean, in terms of Med D steps -- Med D, the step-down, obviously, firstly, we've got 2 months' results in Q2 given this kicks in at the beginning of the year but will impact us for the cool -- the full quarters in each of Q3 and 4. The second half of the fiscal year is seasonally weaker than the first half normally. And of course, I know we haven't got all the comparables to sort of give you the overall seasonality, which makes it tough to model. And then, of course, we've got the exchange rate issues as well coming in because of what's -- where the exchange moved -- the exchange rate has moved over the last number of -- the last 6 months. And of course, we are still bringing in the 45% of AB at that point in time."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec, if you can add something.",6,"Alec, if you can add something."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half rela",87,"Yes, absolutely. We've also got some cost savings timing. So for example, we've got much closer to the plan of how we're going to actually drive the cost savings. And therefore, we've been able to take a few more of the cost savings in the first half relative to the first half of last year. And then the remainder of the year, we have still cost savings coming through. So we actually had quite a lot of cost savings in Q4 of last year to go against."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improv",106,"And then my second question would just be around generics. If we think back to last summer, a lot of talk about drug price inflation on generics being a headwind. As I think about the generics pipeline for the back half of your year, it looks to be improving. Can you maybe talk about what you're seeing, one, on drug price inflation and the impact that it's having? Are you be -- are you able to offset that with your procurement entity? And then secondly, kind of your outlook for incremental generics that are going to come as we go through the next couple of quarters."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer this question?",6,"Jeff, can you answer this question?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inf",195,"Sure. Thanks, Lisa. The generic manufacturers are continuing to react to the supply issues and approval delays in ways that we've come to expect, which is what has been driving the inflationary environment. But we do continue to see a similar range of inflation as we've seen in the past 12 months or so. The teams at WBAD, Walgreens, ABC and Alliance Healthcare all continue to work extremely effectively together to assure that is the biggest buyer in -- of generics in the world, that we are properly managing the industry dynamic. The teams in particular have gotten very sharp and have a number of effective mechanisms in place and are working very collaboratively with the generic drug manufacturers to really manage through this dynamic. They've gotten very flexible and nimble in understanding the marketplace where there might be issues and really managing them proactively. In terms of the generic pipeline, we've recently seen in February the entry of NEXIUM, but we haven't seen it go multi-source and we're looking forward to that. And we are seeing the list of generics that are coming out. We're looking forward to maximizing those opportunities as they come."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill of Deutsche Bank.",13,"Our next question comes from the line of George Hill of Deutsche Bank."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to",95,"And I'll echo the congratulations on getting the transaction closed. You highlighted in the press release a target of closing about 200 stores. I guess the first thing I'm wondering is, is that a kind of a complete evaluation? And could there be upside to this figure? And how should we think about the earnings profile of these stores? They're -- we would assume that they're less profitable than the composite of the business. But is there any chance that they're losing money and there's going to be a positive margin lift from this?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more ret",234,"It's Alec here. Yes, we have done a thorough review. And again, we're -- we've been doing this for a while. We've also reviewed the performance of the closure of the stores we made in the last year as well, and the good news there was that we saw more retention of customers and we saw that they'll be able also to retain a lot of our people as well, which is really important to us as a team and as a business. So we feel confident about the number we've given out, approximately 200. And of course, we will tell our people first where we're going to go when actually making these closures. Another key point is that we'll be opening up about 200 stores in the same period. So this really is just getting the right stores in the right place. And I also think it's about the right cash and the right returns per store basis. This is a very individual store-based decision. And of course, the stores which are potentially going to be closed, we have looked carefully at the markets today and the numbers of customers in them and how they shop in that market and also how the population flowed over the course of these stores being open. And we've seen stores which really the population is moving away from and there's less future opportunity than today."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? H",96,"Okay, that's helpful. And maybe if I can go with a quick follow-up. You guys also highlighted that your synergy targets explicitly exclude the ABC relationship. And I guess where should we think about where we are in the life cycle of that relationship? How much -- I guess how much cost can continue to be taken out? And maybe from an inventory perspective, what can still be taken out? And I guess there are lot of store inventory left that can be taken out and kind of better served through the DSD delivery of ABC?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alec?",1,"Alec?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Al again. Yes, we've made really good progress in terms of inventory reduction. And myself and Jeff are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the Rachel",197,"It's Al again. Yes, we've made really good progress in terms of inventory reduction. And myself and Jeff are working really close in this together. It's really end-to-end view from the pharma manufacturers all the way through ABC into the work the Rachel Ashworth [ph] is doing in the stores. We're also seeing importantly our service levels improve as well. So again, we've seen this nice thing. When you get less stock out the system, you improve costs and then you improve working capital. And importantly, you improve service levels. So again, we'll continue to work at this. There are more opportunities and we'll do in a really balanced way to make sure that we care for customers first, get it right going forward and we take working capital out. And I'm confident that the working relationship with ABC will continue to improve. And of course, working in Europe, as I did before with Ronald [ph] and the team in Alliance Healthcare, we really worked as well for a number of years and saw more and more opportunities which comes through very clearly in the U.K. business performance for both the Wholesale and the Boots division."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Steven Valiquette of UBS.",12,"Our next question comes from the line of Steven Valiquette of UBS."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been an inventory step-up charge as well. So I apologize if I missed",141,"So I guess for me just a clarification question on the gross margin for the quarter. I think the LIFO adjustment is pretty straightforward, but I think I heard you mention there may have been an inventory step-up charge as well. So I apologize if I missed this, but I guess did you provide the fully adjusted gross margin for the quarter just to make it a little bit easier for us? And also, part 2 is then that just curious, all the talk about the U.S. Medicare Part D rate reductions that went into effect on 1/1/15, is there any way just to get a rough sense for how much that impacted the gross margin in the quarter? Was it perhaps 100 basis points year-over-year or maybe something greater than that? I'm just trying to get a sense for that."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Right.",1,"Right."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So George can answer to the first part of that.",10,"So George can answer to the first part of that."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key",222,"Okay, I can answer to the inventory step-up. Well, I mean, it was an -- it was $0.08 because under -- and that is in the legacy AB businesses. So it's in the Retail Pharmacy International and Pharmaceutical Wholesale. And that's -- we've -- one of the key differences between adjusted and the U.S. GAAP results. And that's simply because under -- when you're doing the purchase accounting, and we've done the provisional purchase accounting allocation and we've got a year to finalize that, what you have to do is revalue the inventory at a selling price less a small margin. So we're not valuing the industry -- the inventory at cost. So that gets -- what it does is it essentially artificially takes down the U.S. GAAP profit in those 2 divisions as a result. So that's why we've stripped it out to show the operating results with that out. It has no impact at all on the comparables because it doesn't impact the Retail Pharmacy USA segment. I'm sorry it's got so many of these adjustments. We'll try -- next week, I'll try to take you back through them in a little more detail. It really does make it very difficult to articulate the story as clearly as we would -- I'm sure you would like and we would like."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Jeff, can you answer to the second question?",8,"Jeff, can you answer to the second question?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question.",35,"Yes, that was just the impact on the Medicare Part D, the -- yes, within the quarter, just roughly how much that might have impacted the overall gross margin. Yes, that was the second question."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations fo",67,"Yes. So Medicare Part D is an important component of the business. We're not commenting specifically on the gross margin impacts. You know that we've said that it's about 1/3 of our business moving forward. Right now, we're in the midst of negotiations for the 2016 year. They're very productive right now, but we're very -- it's very early days in terms of the impact moving forward."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total.",41,"Yes, from a volume point of view, we're pleased that volume and really the margins come through as we expected. And so again, there's really -- it really has been a solid selling season and we feel good about the total."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair.",21,"And we have time for 2 more questions. Our next question comes from the side of Mark Miller of William Blair."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting lever",97,"So thinking about the opportunities with both horizontal and vertical consolidation, that obviously goes in many different dimensions. But when you think about the opportunities, is it more about getting leverage with suppliers or more about getting leverage with payers in pharmacy? And then I guess sub-point to that is getting more scale within the retail operations. Or is it more about strategic moves that allow you to drive more share across your own network and then specifically thinking about better managing the payer relationships and potentially having a -- some type of pharmacy benefit management relationship?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk a",210,"Well -- Stefano. In -- of course, we are looking at the market. I have already said that we have been here for a little more than 3 months. I believe that we are starting to understand quite well the market and there are many opportunities. When we talk about opportunities, of course we don't exclude typical M&A opportunities. But there are many, many opportunities which are not related to an acquisition or to a merger, related to a potential joint venture, commercial joint venture, as we did initially with WBAD. When we approached Walgreens, so when we started our discussion, the first thing that we decided was to create these joint ventures to buy together, and this joint venture would have been there even without the merger. So there are many ways to deliver synergies. And of course, we are open to any kind of organization which can improve the value of our company, and we are analyzing many, many different alternatives. And of course, it depends also on the maturity of the potential partner, from the willingness they have to do something with us. What I was saying is that the market, that goes clearly in one direction, and sooner or later these kinds of things will happen."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?",37,"And I assume, if we're speaking about this real time, that you believe the organization is ready to move when the opportunities develop, I mean, given everything that's going on with the consolidation of Walgreens Alliance Boots?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration is doing very we",157,"We have always been able to face the opportunities because -- of course, it will take time to create the platform here in Walgreens Boots Alliance, a solid platform, because of course, we have to integrate the 2 companies. The integration is doing very well. I have to say higher than my expectation. But still, there is a lot to do. But the fact that we have not yet finished this job doesn't mean that we cannot do something else in the meantime. So of course, if we had an opportunity, we will take this opportunity. And any big, important opportunities, be it an M&A activity, be it a joint venture, a commercial joint venture, takes months to be perfection, I said, to come to life. And so we will have time to continue our integration while discussing the -- with other possibilities. So of course, you'll -- if we will see opportunities, we will be ready."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?",22,"That's helpful. And then just quickly, George, does the EPS guidance -- can you clarify whether that includes additional share repurchase?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we",65,"I mean, we -- we've obviously got our $3 billion program authorized, so I think that should give you an indication of our thinking in that respect. We've obviously not been specific on this, but we wouldn't put a program in place if we hadn't felt that we have the ability to generate the necessary cash to complete that program whilst maintaining solid investment grade."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And our next question comes from the line of Edward Kelly of Crdit Suisse.",14,"And our next question comes from the line of Edward Kelly of Crdit Suisse."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division t",52,"I just have a question on your guidance particularly as it relates to getting to 2016. Could you just give us a little bit of color on what your expectations are for the underlying growth of the business, maybe growth -- profit dollar growth by division that you've sort of contemplated here?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed b",183,"I mean, in terms of the overall guidance, really today, just reaffirming what the guidance that was put out in the summer last year, recognizing that currency has gone against us, we've not been through, obviously, our detailed -- our intensive detailed budgeting exercises as a combined group, and we're getting everything on a comparable basis under U.S. GAAP. So we're going through quite a bit of change to try and then be -- to go through this process. What we'll try and do next week when we meet is try and give you a little bit more insight into the drivers as we go through each division's section and then we've got the half day on the financial modeling on the Thursday. So hopefully, we'll be able to give you a little bit more insight on that. It is quite complicated because of the lack of comparability because we have obviously put the segments in place that particularly reflects where the -- in terms of where the synergies are, where we're putting the synergies in where the real economic activity is happening."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week.",28,"And so you don't have to be too impatient. At the end of the day, you have to leave us with something to tell you next week."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming",66,"All right, that makes sense. And then just one quick follow-up for you on real estate. Obviously, getting smaller is not necessarily something that you want to do in U.S. pharmacy. But do you still have other stores that you would consider underperforming or lower-margin stores? And I guess the question would be, what's the real answer to improving those stores if it's not necessarily closing?"
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And",181,"Yes, I mean, obviously, we have a range of stores. I've said before that I'm really going to look at this and this is about 2% of our estate we've talked about this morning. And so therefore, 98% of the estate is in either good or satisfactory order. And I think also, we've done a lot of work on the front end. We are becoming more confident about our ability to not just improve the front end through margin expansion but to develop potential new formats, integrate digital assets to become a new channel. Some of the work Simon and the team have done in Boots has been great in that respect in the last couple of years. So we have different strategies that we will apply over the months and years ahead to make the very most of what is a great set of assets. Stefano said this in the introduction. We have got the best corners in America, and we have looked at them and we still think we have a really important asset that feature the Walgreens company."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers",255,"But also -- Stefano here. Also, we are talking of a few hundred stores that we -- the stores that we have already closed, a few hundred stores. It means a few percent, a few unit percent of the number of stores that we have. In reality, all the retailers should, let's say, have a program on maintenance for their stores. And if -- when you have such a vast territory, such a high number of stores, that inevitably you will have some stores which have been maybe profitable in the past and are not particularly exciting today, and you will need to open stores in areas which didn't even exist in the past. So the reality, you see a certain concentration which is still small because a few hundred out of 8,300 stores is not a big number, but you'll see it's a certain concentration because this program has not been done in the past in an orderly fashion. In the future, once we have, let's say, recreated this new base, I believe we should every year look after -- review all the stores. And if we have -- every year, if we have to close 10 stores or 5 stores or 15 stores, we have to -- we will have to do it in order not to have this concentration of stores just in 1 year. Because it's better to do this gently over time, practically this will be business as usual and nobody will see it in reality even inside the company."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments.",27,"And that is all the time we have for questions today. I would like to hand the call back over to Gerald Gradwell for any closing comments."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be",96,"Thank you. Ladies and gentlemen, I know there have been plenty of other questions we haven't had time for today. We are looking forward to seeing as many of you as possible next week at our analyst event on the 15th and 16th in New York. That will also be webcast live and will be archived on our Investor Relations site. So I hope as many of you as possible can participate in that. We'll address as many of your additional questions as we can then. And thank you very much indeed, everyone, for participating today."
93624,283101937,788618,"Walgreens Boots Alliance, Inc., Q2 2015 Earnings Call, Apr 09, 2015",2015-04-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. That does conclude today's program. You may all disconnect. Have a great day, everyone."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now turn the call over to your host, Gerald Gradwell",43,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now turn the call over to your host, Gerald Gradwell. Please go ahead."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stephanie, and good morning, everyone. Welcome to our fiscal 2015 third quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Glob",250,"Thank you, Stephanie, and good morning, everyone. Welcome to our fiscal 2015 third quarter earnings conference call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Global Chief Financial Officer, will take you through our third quarter results. Also joining us on the call and available for question is Alex Gourlay, Executive Vice President and President of Walgreens. You can find a link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and our webcast will be archived on our website for 12 months. 
Certain statements and projections of future results made in this presentation constitute forward-looking statements but are based on our current market competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after this presentation whether as a result of new information, future events, changes and assumptions or otherwise. Please see our latest Form 10-K, Form 10-Q and other filings for a discussion of risk factors as they relate to forward-looking statements. 
As a reminder, today's presentation include certain non-GAAP financial measures and we refer you to the appendix to the presentation materials available on our Investor Relations website for a reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll turn the call over to Stefano for some opening comments."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months had been significant progress in delivering on the benefit of the merger. Restructuring the business for the future, but there is a lot mor",560,"Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months had been significant progress in delivering on the benefit of the merger. Restructuring the business for the future, but there is a lot more to do. 
As you have seen today, I have been appointed by the board as Chief Executive Officer, replacing the interim appointment that I was previously fulfilling. The board has decided that building in mind the pace of change and the amount that we have to do, there is a benefit to stability at the senior level of the organization. And to focus on the operational and strategic part rather than appointing, orientating and educating someone new to the business. 
The role presents me with certain personnel and logistical challenges, but with the support of the board and particularly, James Skinner, as our Executive Chairman, I happily accept the appointment in the best interest of the company, my colleagues and, of course, my fellow shareholder. 
Today, I am pleased to be announcing another strong financial performance in this the first quarter to reflect a full 3 months of the combined company. Although it may not always from outside the business but it has been a very busy period for us since I last talked to you. As I have mentioned, our focus has naturally been on putting in place the changes and the restructuring we need in order to deliver the full benefits of that enlarge company and position the company for growth in the immediate and long term. 
Given that the deal was consummated only 6 months ago, we are still in the early stages of the process but we have been working hard and faster to deliver on our plan in fact, better than our plan and I am pleased to say that the benefits of this work are already beginning to be seen in our results, which is growth in revenues and margins and continued strong innovation. The first [indiscernible] which you can see the impact are strict cost control and disciplined financial management, but I want to assure you that we give our operation the investment they need to grow and prosper. 
We have accelerated our cost-reduction process and they reap the certain benefits earlier than expected in this quarter. Of course, we cannot extract this benefits more than one, however, the purchase of identifying benefit is ongoing so when we have completed this first wave of restructuring we will reveal review our progress of our business to identify further potential cost savings. 
I must comment my colleague that throughout the company for their willingness and openness to  accept change even when it is the most uncomfortable in the interest of improving and growing your company, and I would assure them that change is a sign of life and is in place in this manner becomes more of an allied than an enemy. 
It's a reminder that why we must prioritize our work if we are to achieve everything we want to and I promise to we cannot ignore and the element of the business when it comes to efficiency and best practices. 
I will hand over to George now for him to take you through the results for the quarter and give you some color for what I have just said. George?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insight into the performan",2776,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insight into the performance of each of our 3 divisions before updating you on progress we have made in implementing our cost savings and continuing to execute our synergy programs. I will conclude by taking you through our updated guidance for fiscal year '15 and comment on our fiscal year '16 goals. 
As Stefano said, the benefits of the work carried out since Walgreens Boots Alliance was formed in December are already beginning to be seen in our financial results, enabling us to deliver another strong quarter. 
Looking at the highlights. Net sales for the quarter were $28.8 billion, an increase of 48.4% versus the comparable quarter in the prior year. Operating income on a GAAP basis was $1.4 billion and on an adjusted basis was $1.7 billion. The increase in adjusted operating income was driven by the consolidation of Alliance Boots, as well as growth in our Retail Pharmacy USA segment. 
GAAP net earnings attributable to Walgreens Boots Alliance were $1.3 billion or $1.18 per diluted share, while adjusted net earnings were $1.1 billion or $1.02 per diluted share. This represents an increase of 59.5% in GAAP net earnings per diluted share and an increase of 22.9% in adjusted earnings per diluted share over the comparable quarter in the prior year. 
Net interest expense in the quarter was $151 million and our adjusted tax rate was 30%. Finally, the average number of diluted shares outstanding for the quarter was 1.1 billion. This includes, of course, the 144 million shares issued on the 31st December as part of the second step consideration for Alliance Boots. It should also be noted that the third quarter results last year included 3 months equity earnings as a result of Walgreens' 45% interest in Alliance Boots compared to fully consolidated results in this year's third quarter. 
Now I will take you through the walk from GAAP diluted EPS to adjusted diluted EPS. GAAP earnings of $1.18 per diluted share this quarter reconciles to adjusted earnings of $1.02 per diluted share. The net adjustment of $0.16 per share reflects additions of $0.05 of LIFO provision cost in Retail Pharmacy USA, $0.06 of amortization of acquisition-related intangibles and an additional $0.11 of restructuring-related cost from our cost optimization and store closure program. These additions were more than offset by removal of the $0.29 gain on our warrants to acquire AmerisourceBergen shares and a net 9% gain from special items, which includes the release of a capital loss valuation allowance, totaling $0.12 combined with a $0.01 loss on the sale of Walgreens infusion services and $0.02 for an adjusted tax rate true-up. 
So now, I would take it to the performance of each of our divisions in the quarter. To remind you, our results were reported in 3 segments: Retail Pharmacy USA; Retail Pharmacy International; and Pharmaceutical Wholesale. The segments we're reporting includes the allocation of synergy benefits, including WBAD as well as an allocation of corporate-related overhead costs. 
Responding to feedback received at our Analyst Day in April, you will see that we are providing additional detail on segment performance, both in the press release and in this presentation. This quarter, we have provided gross profit SG&A and operating profit on a GAAP and adjusted basis for each of our segments. We plan to continue this practice going forward. 
So now let's start with the Retail Pharmacy USA segment. Retail Pharmacy USA total sales for the quarter were $20.4 billion, an increase of 5.3% over the third quarter in the prior year. Please remember, of course, that we sold a majority stake in Walgreens infusion services on the 7th of April. With our minority position, our share of earnings in the company now flow through the post-tax earnings from equity method investments in the income statement. Sales in the division on a comparable store basis increased by 6.3%. SG&A on a GAAP basis was $4.5 billion and on an adjusted basis was $4.3 billion. We continue to see strong progress in controlling SG&A expenses this quarter, including benefits associated with our cost savings program. This was a significant driver of the quarterly year-on-year performance. As a result, GAAP operating income for Retail Pharmacy USA was $1 billion and adjusted operating income was $1.3 billion. 
So looking now at the pharmacy part of Retail Pharmacy USA in more detail. Comparable-store sales for pharmacy were up 9.1% for the quarter. We filled 226 million prescriptions, including immunizations on a 30-day adjusted basis, that was an increase of 3.8% over last year's quarter of prescriptions filled in comparable stores, up 4.1%. We continue to see a positive impact and further growth in Medicare Part D scripts along with positive underlying share trends. 
Our retail prescription market share on a 30-day adjusted basis increased to 19.3% in the quarter, up 20 basis points. The benefit of positive sales growth was however substantially offset by pharmacy gross margin pressure, consistent with our expectations. 
Retail product sales increased by 2% in total. Comparable store sales increasing by 1.6%. The growth in retail sales was driven by performance in key destination category, including health and wellness. We are pleased with our progress in driving profitable sales growth and margin expansion while at the same time, focusing on operating efficiencies and focusing on working capital efficiencies. 
Additionally, we continue to enhance our successful Balance Rewards program by recently releasing Balance Rewards with everyday points. We now provide our active customers with a more consistent platform to receive loyalty points on most pharmacy and retail product transactions. We also encourage healthy lifestyle choices by rewarding points for positive health and well-being positions. 
So turning now to the results of our Retail Pharmacy International division. The Retail Pharmacy International division is pharmacy-led health and BT retail businesses in 8 countries. At the end of the quarter, we operated 4,565 retail stores and adding net increase 6 stores during the quarter. As a reminder, our biggest operation of Boots in the U.K. followed by Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. 
Total sales in the division for the quarter were $3.3 billion. GAAP operating income was $205 million, while adjusted operating income was $249 million. Adjusted operating margin of 7.6% in the quarter was 1.5 percentage points higher than in the second quarter, which remember included only January and February performance. The margin is typically lower in these early months of the year reflecting the seasonality of sales. 
So now let's move -- let's look more closely at the performance for the division. On a pro forma constant currency basis, comparable-store sales growth for the quarter was 3.1%. This reflects Boots U.K. growth of 2.4%, complemented by higher growth in emerging markets, most notably in Mexico and Chile, where we are making good progress in integrating these businesses acquired by Alliance Boots in August 2014. 
In the U.K., Boots retail sales were driven by good performances in both the beauty and retail healthcare categories. Orders on our U.K. website at Boots.com and orders during the quarter, were up approximately 50% over the same period last year, with approximately 2/3 of our website orders collected in-store. 
stay back in April, we talked about the importance of our product brands. We're very pleased with the growth in sales during the quarter of number 7, our award-winning beauty brand. This was in part due to the May launch of a new marketing program in the U.K., the number 7 protect and protected advanced serum. We're able to state for the first time in the U.K. that this innovative product was the first serum clinically proven to deliver ground-breaking anti-wrinkle results that get even better over time. 
As well as developing our existing product brands, we continue to advanced our portfolio, which resonates with our customers. Following on from the acquisition of last year, we are delighted to announce today that we've acquired Liz Earle. Liz Earle is an award-winning premium skincare range that uses naturally-active ingredients and is recognized as none of the leading botanical brands in the U.K. 
So turning now to our Pharmaceutical Wholesale division. Pharmaceutical Wholesale division total sales for the quarter were $5.7 billion. On a pro forma basis, which is constant currency and excludes acquisitions and disposals, sales increased 0.2% compared with the same quarter in the prior year. 
As we discussed in the last earnings call, wholesale performance in any quarter is impacted performance in larger geographies, including the U.K., Germany, France and Turkey as well as unique business model. GAAP operating income for the division was $162 million, while adjusted operating income was $171 million. Adjusted operating income margin was 3%, broadly flat versus the second quarter, and consistent with our expectations. 
The key driver for profit growth continues to be our synergy program. division in the third quarter totaled $194 million, making a total of $504 million for the fiscal year-to-date. 
As we've said before, synergies this year continue to come primarily from our drug procurement activities. As you can see from the numbers, we are on track to reach our target of at least $650 million net synergies in fiscal year 2015. 
For fiscal year 2016, we continue to expect at least $1 billion of combined quantifiable net synergies. As we work increasingly close together as a combined management team, there are, of course, an increasing number of other synergies being identified in action. Many of which was simply not practicable to quantify. 
Consistent with our prior reporting, these synergies are allocated across each segment and do not include any benefit from our relationship with AmerisourceBergen. At the same time, as driving our synergy program, as you know, we are very focused on costs. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. The expected pretax charges associated with this program, as previously stated, of between $1.6 billion and $1.8 billion in which the cash component is expected to be approximately 60%. 
Good progress was made during the quarter and reorganizing our Retail Pharmacy USA field operations with work continuing on the optimization of the divisions corporate office. Approximately 200 planned store closures in the program, 9 stores were closed in the quarter and approximately 70 to 80 additional stores planned to be closed by the end of fiscal year. We also reduced the IT cost structure in the USA to help enable significant store system investments over the coming years. 
In addition, during June, we announced the reduction of approximately 700 non-store base drawers in Retail Pharmacy International. During the quarter, we incurred pretax charges of $160 million on the program. This comprise $102 million of asset impairments, $34 million of severance costs and real estate costs of $24 million. 
So moving on now to cash flow and the deployment of capital. GAAP operating cash flow was $1.8 billion in the quarter and $4.2 billion in the first 9 months of the year. Free cash flow was $1.6 billion in the quarter and $3.3 billion in the first 9 months of the year. Net debt at the end of the quarter was $11.8 billion. 
Investing to drive future growth is our first priority for capital deployment, both in terms of capital expenditure and selective M&A. During the quarter, we invested $247 million in capital expenditure, making a total of $890 million for the first 9 months of the year. Here is a couple of investments continue to be store investment as well as IT and digital capabilities, which are vital to building and maintaining a sustainable competitive advantage and are increasingly omni-channel world. To some degree, this quarter disproportionately benefited from the imposition of stricter capital investment controls. And while we expect to maintain a rigid control on capital expenditure, to assure appropriate returns on every dollar we spend, we will clearly not deprive the business of the investment it needs to drive. You should therefore, expect to see future quarters return to higher level of capital expenditure than we are reporting today. 
We remained focus on generating cash through working capital efficiency particularly in Retail Pharmacy USA. The primary area of focus is inventory management both in pharmacies and retail products. For the quarter, we improved our inventory days of supply in the U.S. by approximately 6 days versus the prior year quarter. We continue to see further opportunity for working capital improvements over time. 
At the same time, we're working hard to optimize our real estate assets, including carrying out sale-leaseback transaction. In the third quarter, we executed approximately $300 million of such transactions. 
As we have said previously, our philosophy is to run an efficient balance sheet. As such, we completed approximately $237 million share repurchases in the quarter against our $3 billion authorization, bringing the total purchases under this program to $331 million. The program is ongoing and we remain committed to completing the plan by the end of fiscal 2016. 
In addition, we announced today that in order for us to manage our balance sheet, we're intending to redeem legacy Walgreens bonds with relatively short periods until they expire with a total principal amount of approximately $1.75 billion. This redemption will be funded from existing cash resources. You will see that cash and cash equivalents totaled $4.4 billion at quarter end, so we have the capacity to do this and continue to exercise on our share repurchase program. 
So turning to the dividend. We announced today a 6.7% increase in our quarterly dividend to $0.36 per share. This raises the annual rate from $1.35 per share to $1.44 per share. We remain committed to a long-term dividend payout ratio target of 30% to 35%. 
So now let me talk about the full year outlook for fiscal 2015. In our second quarter earnings release, we had issued an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Given our solid third quarter results and increased visibility as we look to the year-end, we are pleased to both increase and narrow our adjusted EPS fiscal year guidance to a range of $3.70 to $3.80. This range assumes adjusted interest expense of approximately $150 million in the fourth quarter, a full year adjusted tax rate of approximately 29%, a fiscal year diluted share count of approximately 1.05 billion shares and estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. 
I remind you that when we issued our fiscal year '15 guidance in April, we view the second half of the fiscal year differently than the first half. Specifically, we indicated that adjusted earnings per diluted share would be lower than in the second half, with the third quarter being higher than the fourth quarter. As we update our guidance, this still holds true. We expect quarter 4 adjusted earnings per diluted share to be sequentially lower for the following reasons. The primary component is seasonality, which impacts sales and product mix. And in summer months tend to be our we get, particularly in our Retail Pharmacy USA segment. Within the U.S., we tend to see sequential declines in the growth of both pharmacy volume and retail product sales. Also, as we continue to work through our cost plan in the U.S., the phasing and timing of certain expenses will impact the fourth quarter relative to the third quarter. 
So moving onto fiscal year 2016. We are reaffirming our previously stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. This range assumes an annual adjusted tax rate in high 20s, a full year average weight diluted share count of approximately 1.1 billion and no significant changes in currency exchange rate. 
Please remember, of course, that since we establish the goal a year ago, we've seen material appreciation of the dollar. As you know, we have currency translation exposure base primarily on movements in the pound sterling versus the dollar. And as a reminder, we estimate that a 1% move in pounds sterling versus the dollar in current levels would impact our adjusted EPS by approximately $0.01 per share. 
Given the current situation in Greece, where we fortunately have no business interest, we anticipate a certain level of volatility in the currency markets in the forthcoming months. 
So with that, I will turn the call back to Stephan no."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So I hope that we agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it would take to deliver everything we want. [indiscernibl",228,"Thank you, George. So I hope that we agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it would take to deliver everything we want. [indiscernible] but we are making good progress and traveling in the right direction. I and I believe all of my colleagues recognize that the challenges and the work we need to overcome them, but as convinced as ever about the immense potential of our company as a global pharmacy led health and well-being enterprise we are a market that are changing here in the U.S. that you are seeing quite dramatically but as I have said many times we are at the beginning of a new chapter for our company and are actively reviewing every opportunity that the changing environment offers us as we work to deliver the true potential of our company. 
I strongly believe that we have a significant role to play in shaping the future of our. I thank you for your continued support but also acknowledged that the best way to thank you is to deliver on our promises. And I can assure you, we fully intend to continue to do so. With that, I think, we will now open it up for questions. Gerald?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Stephanie, do you want to take over?",9,"Thank you. Stephanie, do you want to take over?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from Meredith Adler from Barclays.",11,"[Operator Instructions] Our first question comes from Meredith Adler from Barclays."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Questioning from Eric Percher who is not available today. I think our main question would be talking about the big difference the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bit about what the dri",75,"Questioning from Eric Percher who is not available today. I think our main question would be talking about the big difference the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bit about what the drivers are. Some of it is Hep C, but maybe you could talk a little bit about inflation in both branded and generic drugs. And then I have one other question."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, here. Yes, the inflation, we're managing the effect of that inflation to the business. We have good plans and the team has done a good job to get that done so the spread you are seeing is the completion pretty satisfactory and of course, built into",52,"Alex, here. Yes, the inflation, we're managing the effect of that inflation to the business. We have good plans and the team has done a good job to get that done so the spread you are seeing is the completion pretty satisfactory and of course, built into our future guidance as well."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you describe inflation in branded pharmaceuticals as a positive for the margin.",14,"And would you describe inflation in branded pharmaceuticals as a positive for the margin."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think it's marginal in terms of that but again, for example, a slight improvement because of generic coming to the market this year and next year. But again, the key thing here is we forecasted this, we are planning it and consistent with our expectatio",47,"I think it's marginal in terms of that but again, for example, a slight improvement because of generic coming to the market this year and next year. But again, the key thing here is we forecasted this, we are planning it and consistent with our expectations."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","If I can add something. You have also to take into account that we have a different business within our company and some of these business like WBAD are really taking advantage of a certain information.",36,"If I can add something. You have also to take into account that we have a different business within our company and some of these business like WBAD are really taking advantage of a certain information."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin but the gross margin. But maybe you could talk a little bit about changes that y",69,"Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin but the gross margin. But maybe you could talk a little bit about changes that you might have made in terms of promotional strategies or layer marketing that might have driven a better gross margin in the front-end?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's Alex again. We made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. The key thing that we have done is we stop really promotions that were are driving sales particularly in some consumable ca",181,"It's Alex again. We made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. The key thing that we have done is we stop really promotions that were are driving sales particularly in some consumable cash but not really helping the profit at all and are focusing much more on the mix and make sure that we are more focused on really the health and wellness and beauty care. And actually proven beneficial. George has said in the script today, everyday points and others to make sure again that people will have come into this regularly picking on a destination categories are getting a better platform and more reason to come back to Walgreens. Still it's early days we have a lot of work to do and a lot of opportunity I had of us and it will be step-by-step process. But the basic things we're doing is reducing promotions and making sure that where focus more on investment in our best customers and more investment in our destination categories."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from John Heinbockel with Guggenheim.",9,"Our next question comes from John Heinbockel with Guggenheim."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So 2 questions, one, on Walgreens USA, what would you guys peg the normal increase, annual increase in SG&A at? Would it be 2% to 3%, absent cost-cutting? And then of the $1.5 billion that you've identified, di you see any of that in the third quarter and",88,"So 2 questions, one, on Walgreens USA, what would you guys peg the normal increase, annual increase in SG&A at? Would it be 2% to 3%, absent cost-cutting? And then of the $1.5 billion that you've identified, di you see any of that in the third quarter and how much? And what do you see in the fourth? And then just lastly it did look like pharmacy improved a decent amount sequentially, which is a little surprising what we're the couple of things that may have driven that."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, maybe you can.",4,"Alex, maybe you can."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So starting over the cost question. I think, as George said, clearly, we made solid progress against our $1.5 billion cost program and in fact, a bit earlier in the U.S. in terms of what we announced. And I would say that we are seeing our SG&A in the U.S",188,"So starting over the cost question. I think, as George said, clearly, we made solid progress against our $1.5 billion cost program and in fact, a bit earlier in the U.S. in terms of what we announced. And I would say that we are seeing our SG&A in the U.S. business down year-on-year on a comparative basis, which is pleasing but also really what we have planned to do. And I think as George also said, there's been a fading here in quarter 3 and quarter 4. And importantly, continuation of business point of view we are in quarter for this year we're making sure that we are continuing to invest in the things that customers value to make sure that we keep the growth going forward and investing more in customers and customers speed. Again, finally, on the cost side, again, as George has said, some of these restructuring as George said, 9 stores in the previous quarter. We're on track to add another 8 to 19 in the periods ahead. Again, that's very much on plan and benefit still to come over a period of time."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Your first question on pharmacy margin and really just reinforcing what I said earlier. As we did see in the U.S. the positive sales growth, but that was substantially offset by the pharmacy gross margin pressure but that was absolutely consistent with ou",59,"Your first question on pharmacy margin and really just reinforcing what I said earlier. As we did see in the U.S. the positive sales growth, but that was substantially offset by the pharmacy gross margin pressure but that was absolutely consistent with our expectation. So there's no change from what we would expect when we last talked to you."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Did it get better substantially or no, right?",8,"Did it get better substantially or no, right?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was what we expected when the renewals come through in what we're seeing is what we were expecting.",33,"We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was what we expected when the renewals come through in what we're seeing is what we were expecting."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The market is is definitely here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you march it. And I believe that this year we are doing exactly this. We are absolutely alig",53,"The market is is definitely here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you march it. And I believe that this year we are doing exactly this. We are absolutely aligned with what we are expecting."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Stefano, you talked about the challenges that the U.S. market and other markets are facing, we hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically what do think needs to be positioned",111,"Stefano, you talked about the challenges that the U.S. market and other markets are facing, we hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically what do think needs to be positioned? We're seeing lots of consolidation, whether it's managed care and other players. Just that we need to be the biggest retail provider in the U.S. and therefore, best positioned to partner with those that are taking on risk? Do you view yourself as more of a risk-bearing entity over time? How do you think about your relationship whether its with managed care or PBMs and strengthening those going forward?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time, with the right partner. We are open",97,"I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time, with the right partner. We are open to any kind of combination the value of our company and we are looking actively around us to understand, which is the best option for us. But please, don't forget that we are looking actively, not just in the U.S. but other country because we consider ourselves a global company."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you say the priorities were more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?",27,"And would you say the priorities were more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, the priority is the things that you can do and it depends on where you can see it.",19,"Well, the priority is the things that you can do and it depends on where you can see it."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inn",88,"Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inning are we in as well obtaining data synergies obtaining from WBAD. Are we close to getting the full benefit from them? Or there are still a good portion of the future synergies that will still come from the procurement side?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We are absolutely with what we are forecasting and maybe George, you can give them more details about that we will do what we are expecting and what we announced.",30,"We are absolutely with what we are forecasting and maybe George, you can give them more details about that we will do what we are expecting and what we announced."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Although I would just like to add us what I have said is we are very much on track to achieve the target this year in our -- the goal of $1 billion. For what I would describe as hard quantifiable synergies that we can measure. But what we are really seein",161,"Although I would just like to add us what I have said is we are very much on track to achieve the target this year in our -- the goal of $1 billion. For what I would describe as hard quantifiable synergies that we can measure. But what we are really seeing is know that we are and emerged organization we're seeing lots of other areas of best practice and ideas that we're sharing, that we're implementing. But clearly, as we become more and more integrated these are simply that you cannot quantify to the standard but you can through the number we are very much moving into this phase. Those types of synergies as we know from previous transactions us a remember from the merger of Alliance and Boots, these are very important synergies and we can see time and time again. We're moving people around more. And this what would help us to become a much, much stronger organization."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I would add, George, that as you said, we are thinking of the synergies and certain synergies, which are quite redundant easily forecast. But it will be for sure, as you're saying, George, many synergies appear evident, become evident in future because wh",62,"I would add, George, that as you said, we are thinking of the synergies and certain synergies, which are quite redundant easily forecast. But it will be for sure, as you're saying, George, many synergies appear evident, become evident in future because when you put 2 companies together you find [indiscernible] for 3, 4 years, you find new ways to deliver synergies."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from George Hill with Deutsche Bank.",10,"Our next question comes from George Hill with Deutsche Bank."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","First one is for Alex. People have jumped in a bit on what margins look like. I guess, we're getting further along here. Can you what negotiations are looking like for kind of a 1 1 16 contract restarts? And I guess, if things are proceeding according to",63,"First one is for Alex. People have jumped in a bit on what margins look like. I guess, we're getting further along here. Can you what negotiations are looking like for kind of a 1 1 16 contract restarts? And I guess, if things are proceeding according to expectation and how that squares with the fiscal '16 guidance that you guys have provided."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely it does. So really as we expected and square on guidance we've given as well and I think the team have done a good job in anticipating and making sure that we have projected well and manage leaderships in a very good way.",45,"Yes, absolutely it does. So really as we expected and square on guidance we've given as well and I think the team have done a good job in anticipating and making sure that we have projected well and manage leaderships in a very good way."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then a follow-up, I guess, for George and for a Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution",83,"Okay. And then a follow-up, I guess, for George and for a Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution from ABC equity earnings built in to this fiscal '16 guidance? And does Walgreens want to be a larger stock owner of AmerisourceBergen or should we think of the warrants as a value-creation vehicle for Walgreens?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","When we did the deal, we did the deal, of course, to improve our profit but also from a strategic reason because as you know we have always believed a better coordination between wholesaler and retailer again create quite substantial synergies. So the rea",73,"When we did the deal, we did the deal, of course, to improve our profit but also from a strategic reason because as you know we have always believed a better coordination between wholesaler and retailer again create quite substantial synergies. So the reason for the deal are still there. So we have announced what we intend to do and at the right time, you will see the effect of this agreement. George?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I have really not a lot to add at the right time take the decision in terms of accounting again we will have to look at that at the appropriate time. But from where we are today, where we exercise the warrant spend, we will anticipate being able to equity",59,"I have really not a lot to add at the right time take the decision in terms of accounting again we will have to look at that at the appropriate time. But from where we are today, where we exercise the warrant spend, we will anticipate being able to equity method investment that clearly help to the confirmed [indiscernible]"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with more details on the headwinds versus the tailwinds that we should be thinking of",49,"Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with more details on the headwinds versus the tailwinds that we should be thinking of between the third and fourth quarter."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, I think really the first point, as I have sort of touch on the prepared comments, the primary component than we have got to think about is the seasonality between the quarters, which impacts the sales and product mix. And thinking about the summer m",230,"Well, I think really the first point, as I have sort of touch on the prepared comments, the primary component than we have got to think about is the seasonality between the quarters, which impacts the sales and product mix. And thinking about the summer months tends to be our weakest months particularly as Alex the Retail Pharmacy USA division, where we would see typically the sequential declines in the growth of pharmacy volume and retail product sales. The other factor is the phasing and timing of certain expenses in terms of the fourth quarter relative to the third quarter. And clearly, when you go through the sort of programs that we are already trying and as fast as you can. But equally, you need to keep everyone very focused on the business and driving through all the programs that Alex is working on. And so there's always an element of timing on those eventually how quickly we can deliver some of those. We are clearly going as fast as we feel we can in a straight line. The other areas I talked about and clearly currency is a factor as I touched on. But I think increasingly, we have, in terms of the internal factors, we got ready good visibility on our forecasting process and hence, we're confident to both narrow and increase the guidance range for this year."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I know you talked about shutting closing down another 70 to 80 stores in the upcoming quarter. So should we see that through the gross margin line or SG&A line?",30,"I know you talked about shutting closing down another 70 to 80 stores in the upcoming quarter. So should we see that through the gross margin line or SG&A line?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, you'll see that particularly through the SG&A line. Obviously, we alluded a few sales successfully transferred to adjacent stores. I think, as you know, we also closed a number of stores last year, which we are very confident about. So SG&A will come",58,"Yes, you'll see that particularly through the SG&A line. Obviously, we alluded a few sales successfully transferred to adjacent stores. I think, as you know, we also closed a number of stores last year, which we are very confident about. So SG&A will come down and overall benefit and we'll lose few sales, a few bits of margins."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just 1 market-related question. We're seeing a lot of your competitors making strategic moves around specialty. When you think about kind of like specialty opportunity for you, do you think that this is something that you can build i",83,"Okay, great. And then just 1 market-related question. We're seeing a lot of your competitors making strategic moves around specialty. When you think about kind of like specialty opportunity for you, do you think that this is something that you can build internally by leveraging the retail infrastructure in the U.S.? Or is this something that you think you need to go outside to add these capabilities? And also, how do you think about the special opportunity in U.S. versus ex-U.S. and Europe?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We don't exclude any opportunity. We are looking around, as we have said many times. So we are analyzing all the opportunities for growth that we enter at the right time and if the right opportunity come, we would be able to face them.",45,"We don't exclude any opportunity. We are looking around, as we have said many times. So we are analyzing all the opportunities for growth that we enter at the right time and if the right opportunity come, we would be able to face them."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","If I could also add as well Ricci were also focus on our organic growth as well. We've got a very good model in the U.S. in specialty pharmacy and we are building that out relationships with [indiscernible] Pharma manufacturers also like HIV, cystic fibro",74,"If I could also add as well Ricci were also focus on our organic growth as well. We've got a very good model in the U.S. in specialty pharmacy and we are building that out relationships with [indiscernible] Pharma manufacturers also like HIV, cystic fibrosis, we have that opportunity to grow organically. So again, we're not stopping this. This is an important business from us ever going to grow organically, particularly in the USA."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Obviously, a number of moving pieces but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program. But is there any more detail you can share with us on the savi",81,"Obviously, a number of moving pieces but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program. But is there any more detail you can share with us on the savings that you've been able to generate to date. And then any breakdown of those savings, obviously, across the segments will be really helpful enough being able to track the underlying business a little bit better."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have made an effort to be as clear as possible.",11,"We have made an effort to be as clear as possible."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I really do appreciate -- with the margin coming through but obviously, there's a lot of playing their it's not practicable for us to work through and try and restate everything on a comparable basis in the cost side and the margin side. That's why we try",252,"I really do appreciate -- with the margin coming through but obviously, there's a lot of playing their it's not practicable for us to work through and try and restate everything on a comparable basis in the cost side and the margin side. That's why we try to give you the adjusted figures. Clearly, in terms of the cost saving program, that is the big -- that is primarily in Retail Pharmacy USA, as we said the last time, but we are progressing in the international but that is at a much, much smaller part of the program but we're very much on track with where we expect to be. As I said earlier, what has always to go a straight line discipline structured way. That's why we've tried to give you a little bit of a feel actually looking at comparability. I tried to touch on the Retail Pharmacy International margin, which I you know some of you felt a little bit lower than you are expecting in the second quarter. But it only have the 2 months in and that is a seasonal business. And the last quarter was at the time when we seasonally we have lower sales as we come up the important Christmas time and we've got leverage the cost base and therefore, the net margin will reflect that when you look at the seasonality. But I do appreciate how tricky it is to look at the model, which is why we gave the guidance going forward."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I respect that too. I understand the comparability year-over-year is tough. I guess, I was talking more specifically about just identifying what the cost cutting was in the actual quarter and this quarter itself. Maybe I'm missing something I would do thi",53,"I respect that too. I understand the comparability year-over-year is tough. I guess, I was talking more specifically about just identifying what the cost cutting was in the actual quarter and this quarter itself. Maybe I'm missing something I would do think that would be that difficult to identify store closings, headcount reduction."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","If I could add a little bit. We got a good review of all of the projects that we are focused on the future. I think we've been really clear within the business that we're focusing back on our core business, of our Retail Pharmacy, front-end products, spec",230,"If I could add a little bit. We got a good review of all of the projects that we are focused on the future. I think we've been really clear within the business that we're focusing back on our core business, of our Retail Pharmacy, front-end products, specialty and therefore, all of the other areas where we are building out potential future products to reduce the spend on some of these areas. So more focused back on the core business. So that really has been a lot of projects. And I'm really very confident than before on the $1.5 billion in savings that can be achieved. To really reinforce what Alex has said, we've been putting a lot of internal work on the whole process of evaluate new initiatives, how we are track initiatives and perhaps, and then you stop them and you don't let them drag on. If something really isn't working, you give it a good go and then you stop it new initiatives we have got a lot of what I would describe us financial rigor that has been increasingly put in place really over the last 12 months, Alex, you put a lot of please overall responsibility for the Walgreen business and will continue to do that and I think it is that rigor that we're seeing in terms of some of the SG&A coming through."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That make sense. And I guess just 1 quick follow-up on Part D network specifically is a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to your expect",70,"That make sense. And I guess just 1 quick follow-up on Part D network specifically is a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to your expectations. I know it's only about 6 months in. And then based on that feedback any thoughts on your continued participation in these preferred networks going forward."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, it's Alex again. It's a really important -- customer are really important growing rapidly so we remain very committed to this. And in terms of -- what I've said before, we are in terms of next year's plan complete all the contracts and to the expecta",136,"Yes, it's Alex again. It's a really important -- customer are really important growing rapidly so we remain very committed to this. And in terms of -- what I've said before, we are in terms of next year's plan complete all the contracts and to the expectation in terms of margin that we planned for. So very committed to this business and we are done a good job with pleased with where we are and committed. Importantly, for us of course, we are only end of the first stage on the second stage how you make sure how we cast the patients and the customers who come to your pharmacy and make sure you get the appropriate level of volume through your assets and that is a bit we are trying to turn our attention to."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Alvin Concepcion with Citi.",9,"Our next question comes from Alvin Concepcion with Citi."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","My question is just really around beauty. Just curious how the tests are going in your clinics. Are there any findings you can share from that? Particularly interested if you're getting a sales list in the I'll and if you're seeing much traction from numb",46,"My question is just really around beauty. Just curious how the tests are going in your clinics. Are there any findings you can share from that? Particularly interested if you're getting a sales list in the I'll and if you're seeing much traction from number 7?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Of course. You know, the important that we give to our brands, and number 7 is having a fantastic trend in the U.K. and internationally. And it's one of our really hold as part of the future in the U.S. But maybe Alex you can see what you are doing now fo",61,"Of course. You know, the important that we give to our brands, and number 7 is having a fantastic trend in the U.K. and internationally. And it's one of our really hold as part of the future in the U.S. But maybe Alex you can see what you are doing now for number 7 and what you are expecting from them."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've rolled number 7 into 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just 12 months old to be able to the major impact both number 7 sales brand product sales and also on the beauty categories and",193,"Yes, we've rolled number 7 into 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just 12 months old to be able to the major impact both number 7 sales brand product sales and also on the beauty categories and we are pleased what we're seeing now it is time to plan for the next stage of evolution of number 7 and the Boots brand in Walgreens and Duane Reade in the USA and will come out with these plans when they are ready, but we are pleased with the results. I'm also pleased we are able to acquire in the previous quarter this this morning Liz Earle. Going forward, the more unique products that we're able to get into the Walgreens beauty and healthcare offer then a more unique it will make our offer going forward in what is a very competitive marketplace. So again, very pleased with the brand's performance, very pleased with progress the team have made whole brands organizations still very young and looking forward to getting these unique products in front of our customers in Walgreens in the future."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","As a follow-up, what are you making for the timing of the full rollout.",15,"As a follow-up, what are you making for the timing of the full rollout."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we'll come back with that. I mean, we're really -- As we've said before, we're just doing the walk now. We have got to get a right. This is our bigger stage. This is up fantastic brand. Europe is going really well in Europe. So we'll come back when w",58,"Yes, we'll come back with that. I mean, we're really -- As we've said before, we're just doing the walk now. We have got to get a right. This is our bigger stage. This is up fantastic brand. Europe is going really well in Europe. So we'll come back when we're ready, but we're in a good position."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Mark Wiltamuth with Jefferies.",9,"Our next question comes from Mark Wiltamuth with Jefferies."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it look like there were some overhead allocations that changed versus a year ago.",32,"I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it look like there were some overhead allocations that changed versus a year ago."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","but not directly comparable. Clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of where the economic bene",95,"but not directly comparable. Clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of where the economic benefit is. So those results importantly are not directly comparable so come with that very health warning. But I think what we have said is we are very pleased with the progress that we're making in reducing SG&A and we're very much on target to deliver the program that we announced in the last quarter."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So the numbers presented were down. But I guess on an apples-to-apples, was the SG&A percentage down?",17,"So the numbers presented were down. But I guess on an apples-to-apples, was the SG&A percentage down?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","There isn't an apples-to-apples basis. That's the challenge that we got. I think we said the time we did the deal our priority was to get the deal done quickly but one of the things but that didn't enable us to do go back and rework everything on an apple",72,"There isn't an apples-to-apples basis. That's the challenge that we got. I think we said the time we did the deal our priority was to get the deal done quickly but one of the things but that didn't enable us to do go back and rework everything on an apples-to-apples basis. But we are making good progress that is the key message I can see it is not getting everything apples-to-apples."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, and I understand you're not announcing the international segments year-ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those international segments even though you don't ha",45,"Okay, and I understand you're not announcing the international segments year-ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those international segments even though you don't have a GAAP presentation for us."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think we can say that we are pleased with the performance. We look at the Retail Pharmacy International obviously, Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that mar",235,"I think we can say that we are pleased with the performance. We look at the Retail Pharmacy International obviously, Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that market. You see what's happening in the supermarket sector, for example, but I think this demonstrates the strength of the offer. It's very important how we differentiate it retail offer particularly in the beauty, where Boots is renowned the got off a very strong loyalty card program Alex talked obviously about the great work that's being done here and taking past rewards forward past program equally important in the U.K. and then the piece that I touch on the presentation is really omni-channel, where ordering online through boots.com and picking up in store to purchase is important. And of course, with the geography that we've got in the U.K. 2,500 [ph] points we can do that. We can actually leverage our was organization and we are able to do that in a profitable way that really meets the expectation of our customers. So that's the key point component in there. And wholesale, in any year, being in a number of markets, you get market that perform better markets that are more challenging such the way that but the division delivered a solid performance and as its continue to do for many years."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","On the international retail pharmacy, there is some commentary the Analyst Meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to driving sale",43,"On the international retail pharmacy, there is some commentary the Analyst Meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to driving sales?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We've obviously not given the specifics on the comparability because we don't have the numbers on U.S. a GAAP basis but I continue to say that the business was performing solidly. We are pleased with the performance and what has been a tough retail enviro",120,"We've obviously not given the specifics on the comparability because we don't have the numbers on U.S. a GAAP basis but I continue to say that the business was performing solidly. We are pleased with the performance and what has been a tough retail environment and in the U.K. and that's fundamentally. On the pharmacy side, clearly, the government continue to retain health care expenditure and we haven't actually seen the details of the settlement yet that's probably going to towards the autumn we just have to wait and see the timing of that but we continue to see pressure in that area of sensing for a number of years but not a real change but that pressure continues."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our final question comes from Ross Muken with Evercore.",9,"Our final question comes from Ross Muken with Evercore."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So as you think about sort of the M&A landscape happening around you. So obviously, as far as you talked about lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space. Where do you think in terms of what",99,"So as you think about sort of the M&A landscape happening around you. So obviously, as far as you talked about lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space. Where do you think in terms of what is happening around you is most relevant to kind of your business or what are you watching most? And how do they particularly on the managed care side, any of the changes there? How does that make you think about your longer-term positioning from a healthcare perspective in this market?"
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our -- I mean this is happening. In reality, I believe that this is a good news for us because the consolidation -- always consolidation will creat",110,"As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our -- I mean this is happening. In reality, I believe that this is a good news for us because the consolidation -- always consolidation will create clear market and would give us more opportunities in the future. What we will be able to do specifically is a little too early to say. But I repeat, we want to be one of the players in this space and we see a lot of opportunity. And the opportunities are really open along the chain -- along the face of the healthcare industry."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I guess, just quickly just staying on the M&A scene and this is my last question. You and your team have been remarkably savvy deal makers over the course of your long career and have created massive amounts of value. How much of a challenge of it is",123,"And I guess, just quickly just staying on the M&A scene and this is my last question. You and your team have been remarkably savvy deal makers over the course of your long career and have created massive amounts of value. How much of a challenge of it is it today with where global equity markets are from a valuation standpoint. Obviously, understanding the financing markets are wide open, but valuations are pretty elevated. So how do you think about that in the context of your capital allocation goals, particularly on the deal side? Does it argued smaller transactions or certain geography? I'm just trying to get a sense how that plays into your thinking and your -- the timing aspects of it."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As you know, we have been always disciplined with potential acquisition. So we will -- if we will have an opportunity, we will analyze these opportunities very rationally and we will do it if this will create additional value. So it's true the market is n",100,"As you know, we have been always disciplined with potential acquisition. So we will -- if we will have an opportunity, we will analyze these opportunities very rationally and we will do it if this will create additional value. So it's true the market is now quite bullish, but it's also true that the cost of the money is still quite low and there are other ways to create value, not just through acquisitions. So we are analyzing all the opportunities if we will see an opportunity which fits our strategy and which can create value, we will take action."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or if you have any further questions. I know some of you do. With that, thank you very much indeed. We'll conclude our call. Thank you",47,"Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or if you have any further questions. I know some of you do. With that, thank you very much indeed. We'll conclude our call. Thank you."
93624,304033436,832514,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect and everyone, have a great day.",20,"Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect and everyone, have a great day."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to your host, Gerald Gradwell.",43,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to your host, Gerald Gradwell. Please go ahead."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stephanie, and good morning, everyone. Welcome to our Fiscal 2015 Third Quarter Earnings Conference Call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Glob",249,"Thank you, Stephanie, and good morning, everyone. Welcome to our Fiscal 2015 Third Quarter Earnings Conference Call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Global Chief Financial Officer, will take you through our third quarter results. Also joining us on the call and available for questions is Alex Gourlay, Executive Vice President and President of Walgreens. 
You can find the link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and the webcast will be archived on our website for 12 months. 
Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. 
Please see our latest Form 10-K, Form 10-Q and other filings for a discussion of risk factors as they relate to forward-looking statements. 
As a reminder, today's presentation include certain non-GAAP financial measures and we refer you to the appendix to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll turn the call over to Stefano for some opening comments."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months have been significant progress in delivering on the benefit out of the merger, structuring the business for the future. But there is a lot",575,"Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months have been significant progress in delivering on the benefit out of the merger, structuring the business for the future. But there is a lot more to do. 
As you have seen today, I have been appointed by the board as Chief Executive Officer, replacing the interim appointment that I was previously fulfilling. The board has decided that bearing in mind the pace of change and the amount that we have still to do, there is a benefit to stability at the senior level in the organization and to focus this on the operational and strategic part before us rather than appointing, orientating and educating someone new to the business during this period
The role presents me with certain personnel and logistical challenges, but with the support of the board and particularly of Jim Skinner as our Executive Chairman, I happily accept the appointment in the best interest of the company, my colleagues, and of course, my fellow shareholder. 
Today, I am pleased to be announcing another strong financial performance in this -- the first quarter to reflect a full 3 months of the combined company. Although it may not always appear so from outside the business, it has been a very busy period for us since I last talked to you. As I have mentioned, our focus has naturally been on putting in place the changes and the restructuring we need in order to deliver the full benefits of the enlarged company and position the company for growth in the immediate and long term. 
Given that the deal was consummated only 6 months ago, we are still in the early stages of this process, but we have been working hard and fast to deliver on our plan, in fact, better than our plan and I am pleased to say that the benefits of this work are already beginning to be seen in our results with reasonable growth in revenues and margins and continued strong innovation. Clearly, the first areas in which you can see the impact are strict cost control and disciplined financial management, but I want to assure you that we give our operation the investment they need to grow and prosper. 
We have accelerated our cost-reduction process and there reap the certain benefits earlier than expected in this quarter. Of course, we cannot extract these benefits more than once. However, the process of identifying benefits is ongoing, not final. So when we have completed this first wave of restructuring, we will reveal -- review all areas of our business to identify further potential cost savings. 
I must commend my colleagues throughout the company for their willingness and openness to accept change even when it is the most uncomfortable in the interest of improving and growing our company, and I would assure them that change is a sign of life, and if embraced in this manner, becomes more of an ally than an enemy. It's a reminder that while we must prioritize our work if we are to achieve everything we want to and promise to, we cannot ignore any element of the business when it comes to our drive for efficiency and best practice. 
I will hand over to George now for him to take you through the results for the quarter and give you some color on what I have just said. George?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insights into the performa",2797,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insights into the performance of each of our 3 divisions before updating you on progress we have made in implementing our cost savings and continuing to execute our synergy programs. I will conclude by taking you through our updated guidance for fiscal year '15 and comment on our fiscal year '16 goals. 
As Stefano said, the benefits of the work carried out since Walgreens Boots Alliance was formed at the end of December are already beginning to be seen in our financial results, enabling us to deliver another strong quarter. 
Looking at the highlights. Net sales for the quarter were $28.8 billion, an increase of 48.4% versus the comparable quarter in the prior year. Operating income on a GAAP basis was $1.4 billion, and on an adjusted basis, was $1.7 billion. The increase in adjusted operating income was driven by the consolidation of Alliance Boots as well as growth in our Retail Pharmacy USA segment. GAAP net earnings attributable to Walgreens Boots Alliance were $1.3 billion or $1.18 per diluted share while adjusted net earnings were $1.1 billion or $1.02 per diluted share. This represents an increase of 59.5% in GAAP net earnings per diluted share and an increase of 22.9% in adjusted earnings per diluted share over the comparable quarter in the prior year. 
Net interest expense in the quarter was $151 million and our adjusted tax rate was 30%. Finally, the average number of diluted shares outstanding for the quarter was 1.1 billion. This includes, of course, the 144 million shares issued on the 31st December as part of the second step consideration for Alliance Boots. It should also be noted that the third quarter results last year included 3 months equity earnings as a result of Walgreens' 45% interest in Alliance Boots compared to fully consolidated results in this year's third quarter. 
Now I will take you through the walk from GAAP diluted EPS to adjusted diluted EPS. GAAP earnings of $1.18 per diluted share this quarter reconciles to adjusted earnings of $1.02 per diluted share. The net adjustment of $0.16 per share reflects additions of $0.05 of LIFO provision costs in Retail Pharmacy USA, $0.06 of amortization of acquisition-related intangibles and an additional $0.11 of restructuring-related costs from our cost optimization and store closure program. These additions were more than offset by removal of a $0.29 gain on our warrants to acquire AmerisourceBergen shares and a net 9% gain from special items, which includes the release of a capital loss valuation allowance totaling $0.12 combined with a $0.01 loss on the sale of Walgreens Infusion Services and $0.02 for an adjusted tax rate true-up. 
So now I will take you through the performance of each of our divisions in the quarter. To remind you, our results are reported in 3 segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The segments we're reporting include the allocation of synergy benefits including WBAD as well as an allocation of corporate-related overhead costs. 
Responding to feedback received at our Analyst Day in April, you will see that we are providing additional detail on segmental performance, both in the press release and in this presentation. This quarter, we have provided gross profit, SG&A and operating profit on a GAAP and adjusted basis for each of our segments. We plan to continue this practice going forward. 
So now let's start with the Retail Pharmacy USA segment. Retail Pharmacy USA total sales for the quarter were $20.4 billion, an increase of 5.3% over the third quarter in the prior year. Please remember, of course, that we sold a majority stake in Walgreens Infusion Services on the 7th of April. With our minority position, our share of earnings in the company now flow through the post-tax earnings from equity method investments in the income statement. Sales in the division on a comparable store basis increased by 6.3%. SG&A on a GAAP basis was $4.5 billion and on an adjusted basis was $4.3 billion. We continue to see strong progress in controlling SG&A expenses this quarter including benefits associated with our cost-savings program. This was a significant driver of the quarterly year-on-year performance. As a result, GAAP operating income for Retail Pharmacy USA was $1 billion and adjusted operating income was $1.3 billion. 
So looking now at the pharmacy part of Retail Pharmacy USA in more detail. Comparable-store sales for pharmacy were up 9.1% for the quarter. We filled 226 million prescriptions including immunizations on a 30-day adjusted basis, that was an increase of 3.8% over last year's quarter with prescriptions filled in comparable stores up 4.1%. We continue to see a positive impact and further growth in Medicare Part D scripts along with positive underlying share trends. Our retail prescription market share on a 30-day adjusted basis increased to 19.3% in the quarter, up 20 basis points. The benefit of positive sales growth was, however, substantially offset by pharmacy gross margin pressure consistent with our expectations. 
Retail product sales increased by 2% in total, comparable store sales increasing by 1.6%. The growth in retail sales was driven by performance in key destination categories including health and wellness. We are pleased with our progress in driving profitable sales growth and margin expansion while at the same time focusing on operating efficiencies and focusing on working capital efficiencies. 
Additionally, we continue to enhance our successful Balance Rewards program by recently releasing Balance Rewards with every day points. We now provide our active customers with a more consistent platform to receive loyalty points on most pharmacy and retail product transactions. We also encourage healthy lifestyle choices by rewarding points for positive health and well-being decisions. 
So turning now to the results of our Retail Pharmacy International division. The Retail Pharmacy International division has pharmacy-led health and beauty retail businesses in 8 countries. At the end of the quarter, we operated 4,565 retail stores and adding net increase of 6 stores during the quarter. As a reminder, our biggest operations are Boots from the U.K. followed by Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. 
Total sales in the division for the quarter were $3.3 billion. GAAP operating income was $205 million while adjusted operating income was $249 million. Adjusted operating margin at 7.6% for the quarter was 1.5 percentage points higher than in the second quarter, which, remember, included only January and February performance. The margin is typically lower in these early months of the year reflecting the seasonality of sales. 
So now let's look more closely at the performance for the division. On a pro forma constant currency basis, comparable store sales growth for the quarter was 3.1%. This reflects Boots UK growth of 2.4%, complemented by higher growth in emerging markets, most notably in Mexico and Chile where we are making good progress in integrating these businesses acquired by Alliance Boots in August 2014. 
In the U.K., Boots retail sales were driven by good performances in both the beauty and retail health care categories. Orders on our U.K. website at boots.com and orders during the quarter were up approximately 50% over the same period last year with approximately 2/3 of our website orders collected in-store. 
At our Analyst Day back in April, we talked about the importance of our product brands. We're very pleased with the growth in sales during the quarter of No7, our award-winning beauty brand. This was in part due to the May launch of a new marketing program in the U.K., the No7 Protect & Perfect Advanced Serum. We were able to state for the first time in the U.K. that this innovative product was the first serum clinically proven to deliver ground-breaking anti-wrinkle results that get even better over time. 
As well as developing our existing product brands, we continue to add brands to our portfolio, which resonate with our customers. Following on from the acquisition of Soap & Glory last year, we are delighted to announce today that we've acquired Liz Earle from Avon. Liz Earle is an award-winning premium skincare range that uses naturally active ingredients and is recognized as one of the leading botanical brands in the U.K. 
So turning now to our Pharmaceutical Wholesale division. Pharmaceutical Wholesale division total sales for the quarter were $5.7 billion. On a pro forma basis, which is in constant currency and excludes acquisitions and disposals, sales increased 0.2% compared with the same quarter in the prior year. 
As we discussed in the last earnings call, Wholesale performance in any quarter is impacted by performance in larger geographies including the U.K., Germany, France and Turkey as well as by the unique business model. 
GAAP operating income for the division was $162 million while adjusted operating income was $171 million. Adjusted operating income margin was 3%, broadly flat versus the second quarter and consistent with our expectations. 
The key driver of profit growth continues to be our synergy program. Net synergies in the third quarter totaled $194 million, making a total of $504 million for the fiscal year-to-date. As we've said before, synergies this year continue to come primarily from our drug procurement activities. 
As you can see from the numbers, we are on track to reach our target of at least $650 million net synergies in fiscal year 2015. For fiscal year 2016, we continue to expect at least $1 billion of combined quantifiable net synergies. As we work increasingly close together as a combined management team, there are, of course, an increasing number of other synergies being identified and actioned, many of which are simply not practicable to quantify. 
Consistent with our prior reporting, these synergies are allocated across each segment and do not include any benefit from our relationship with AmerisourceBergen. 
At the same time as driving our synergy program, as you know, we are very focused on costs. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. The expected pretax charges associated with this program, as previously stated, are between $1.6 billion and $1.8 billion in which the cash component is expected to be approximately 60%. 
Good progress was made during the quarter in reorganizing our Retail Pharmacy USA field operations with work continuing on the optimization of the division's corporate office. Of the approximately 200 planned U.S. store closures in the program, 9 stores were closed in the quarter with approximately 70 to 80 additional stores planned to be closed by the end of fiscal year. We also reduced the IT cost structure in the USA to help enable significant store system investments over the coming years. 
In addition, during June, we announced the reduction of approximately 700 nonstore-based roles in Retail Pharmacy International. 
During the quarter, we incurred pretax charges of $160 million on the program. These comprised $102 million of asset impairments, $34 million of severance costs and real estate costs of $24 million. 
So moving on now to cash flow and the deployment of capital. GAAP operating cash flow was $1.8 billion in the quarter and $4.2 billion in the first 9 months of the year. Free cash flow was $1.6 billion in the quarter and $3.3 billion in the first 9 months of the year. Net debt at the end of the quarter was $11.8 billion. 
Investing to drive future growth is our first priority for capital deployment, both in terms of capital expenditure and selective M&A. During the quarter, we invested $247 million in capital expenditure, making a total of $890 million for the first 9 months of the year. Here, a couple of investments continue to be store investments as well as IT and digital capabilities, which are vital to building and maintaining a sustainable, competitive advantage in our increasingly omni-channel world. 
To some degree, this quarter disproportionately benefited from the imposition of stricter capital investment controls. And while we expect to maintain a rigid control on capital expenditure to assure appropriate returns on every dollar we spend, we will clearly not deprive the business of the investment it needs to thrive. You should therefore expect to see future quarters return to slightly higher level of capital expenditure than we are reporting today. 
We remain focus on generating cash through working capital efficiencies particularly in Retail Pharmacy USA. The primary area of focus is inventory management, both in pharmacy and retail products. For the quarter, we improved our inventory days of supply in the U.S. by approximately 6 days versus the prior year quarter. We continue to see further opportunity for working capital improvement over time. 
At the same time, we're working hard to optimize our real estate assets, including carrying out sale and leaseback transactions. In the third quarter, we executed approximately $300 million of such transactions. 
As we have said previously, our philosophy is to run an efficient balance sheet. As such, we completed approximately $237 million of share repurchases in the quarter against our $3 billion authorization bringing the total purchases under this program to $331 million. The program is ongoing and we remain committed to completing the plan by the end of fiscal 2016. 
In addition, we announced today that in order for us to manage our balance sheet, we're intending to redeem legacy Walgreens bonds with relatively short periods until they expire with a total principal amount of approximately $1.75 billion. This redemption will be funded from existing cash resources. You will see that cash and cash equivalents totaled $4.4 billion at quarter end, so we have the capacity to do this and continue to exercise on our share repurchase program. 
So turning to dividend. We announced today a 6.7% increase in our quarterly dividend to $0.36 per share. This raises the annual rate from $1.35 per share to $1.44 per share. We remain committed to a long-term dividend payout ratio target of 30% to 35%. 
So now let me talk about the full year outlook for fiscal 2015. In our second quarter earnings release, we had issued an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Given our solid third quarter results and increased visibility as we look to the year-end, we are pleased to both increase and narrow our adjusted EPS fiscal year guidance to a range of $3.70 to $3.80. This range assumes adjusted interest expense of approximately $150 million in the fourth quarter, a full year adjusted tax rate of approximately 29%, a fiscal year diluted share count of approximately 1.05 billion shares and estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. 
I'll remind you that when we issued our fiscal year '15 guidance in April, we viewed the second half of the fiscal year differently than the first half. Specifically, we indicated that adjusted earnings per diluted share would be lower than in the second half with the third quarter being higher than the fourth quarter. As we update our guidance, this still holds true. 
We expect quarter 4 adjusted earnings per diluted share to be sequentially lower for the following reasons. The primary component is seasonality, which impacts sales and product mix. The summer months tend to be our weakest, particularly in our Retail Pharmacy USA segment. Within the U.S., we tend to see sequential declines in the growth of both pharmacy volume and retail product sales. Also, as we continue to work through our cost plan in the U.S., the phasing and timing of certain expenses will impact the fourth quarter relative to the third quarter. 
So moving on to fiscal year 2016. We are reaffirming our previously stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. This range assumes an annual adjusted tax rate in the high 20s, a full year average weight diluted share count of approximately 1.1 billion and no significant changes to currency exchange rates. 
Please remember, of course, that since we established the goal a year ago, we've seen material appreciation of the dollar. 
As you know, we have currency translation exposure based primarily on movements in the pound sterling versus the dollar. And as a reminder, we estimate that a 1% move in pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. 
Given the current situation in Greece where we fortunately have no business interest, we anticipate a certain level of volatility in the currency markets in the forthcoming months. 
So with that, I will turn the call back to Stefano."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So I hope that you will agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it will take to deliver everything we want and that",232,"Thank you, George. So I hope that you will agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it will take to deliver everything we want and that promise, but we are making good progress and traveling in the right direction. And I believe all of my colleagues recognize the challenges and the work will be needed to overcome them, but as convinced as ever about the immense potential of our company as a global pharmacy-led health and well-being enterprise. 
We are in markets that are changing here in the U.S. that you are seeing this quite dramatically, but as I have said many times we are at the beginning of a new chapter for our company and are actively reviewing every opportunity that the changing environment offers us as we work to deliver the true potential of our company. 
I strongly believe that we have a significant role to play in shaping the future of our WBA [ph]. I thank you for your continued support, but also acknowledge that the best way to thank you is to deliver on our promises and I can assure you we fully intend to continue to do so. 
With that, I think, we will now open it up for questions. Gerald?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Stephanie, do you want to take over?",9,"Thank you. Stephanie, do you want to take over?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from Meredith Adler with Barclays.",11,"[Operator Instructions] Our first question comes from Meredith Adler with Barclays."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I'm asking questions for myself and Eric Percher who is not available today. I think our main question would be talking about the big difference the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bit",81,"I'm asking questions for myself and Eric Percher who is not available today. I think our main question would be talking about the big difference the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bit about what the drivers are, some of it is hep C, but maybe you could talk a little bit about inflation in both branded and generic drugs. And then I will have one other question."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","All right. Alex, here. Thanks for the question. Yes, the inflation, we're managing the effect of that inflation pretty well in the business. We have good plans and the team has done a good job to get that done. So one differences in the spread you're seei",69,"All right. Alex, here. Thanks for the question. Yes, the inflation, we're managing the effect of that inflation pretty well in the business. We have good plans and the team has done a good job to get that done. So one differences in the spread you're seeing is generic inflation, but we're managing that really pretty satisfactory and that, of course, is built into our future guidance as well."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you describe inflation in branded pharmaceuticals as a positive for the margin?",14,"And would you describe inflation in branded pharmaceuticals as a positive for the margin?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think it's marginal at the moment in terms of that, but again, for example, slight improvement because of generics coming to market both this year and next year. But again, the key thing here is that we forecasted this, we're planning it and it's really",51,"I think it's marginal at the moment in terms of that, but again, for example, slight improvement because of generics coming to market both this year and next year. But again, the key thing here is that we forecasted this, we're planning it and it's really consistent with our expectations."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","If I can add something. You have also to take into account that we have a different businesses in our company and some of these businesses like the Wholesale business or like WBAD are really taking advantage of certain inflation.",40,"If I can add something. You have also to take into account that we have a different businesses in our company and some of these businesses like the Wholesale business or like WBAD are really taking advantage of certain inflation."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin, but the gross margin. Maybe you could talk a little bit about changes that you",71,"Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin, but the gross margin. Maybe you could talk a little bit about changes that you might have made in terms of promotional strategies or the way you're marketing that might have driven a better gross margin in the front end."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, Meredith, Alex again. Yes, we've made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. And the key things that we have done is we stopped really promotions that were driving sales, particularl",200,"Yes, Meredith, Alex again. Yes, we've made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. And the key things that we have done is we stopped really promotions that were driving sales, particularly in some consumable categories, but not really helping the profit at all. And we're focused much more on the mix and making sure that we're much more focused on really the health and wellness and beauty care categories and that's really proven beneficial. And as George has said in the script today, we've launched a new platform called every day points and that really is to make sure again that people who are coming to us more regularly and are picking up on the destination categories are getting a better platform and more reason to come back to Walgreens. It still is early days. We have a lot of work to do and a lot of opportunity ahead of us and it will be a step-by-step process. But the basic things we're doing is reducing unprofitable promotions and making sure that we focus more investment in our best customers and more investment in our destination categories."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from John Heinbockel with Guggenheim.",9,"Our next question comes from John Heinbockel with Guggenheim."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So 2 questions, one on Walgreens USA cost. What would you guys peg the normal increase, annual increase, in SG&A at? Would it be 2% to 3% absent cost cutting? And then of the $1.5 billion that you've identified, did you see any of that in the third quarte",93,"So 2 questions, one on Walgreens USA cost. What would you guys peg the normal increase, annual increase, in SG&A at? Would it be 2% to 3% absent cost cutting? And then of the $1.5 billion that you've identified, did you see any of that in the third quarter and how much? And what do you think you see in the fourth? And then just lastly, it did look like Pharmacy margin improved a decent amount sequentially, which was a little surprising. What were the couple of things that may have driven that?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, maybe you can...",4,"Alex, maybe you can..."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. So many questions there, John. So starting over the cost question. I think, as George said really clearly, we've made a solid progress against our $1.5 billion cost program and of course, in fact, a bit earlier in the U.S. in terms of what we announc",216,"Yes. So many questions there, John. So starting over the cost question. I think, as George said really clearly, we've made a solid progress against our $1.5 billion cost program and of course, in fact, a bit earlier in the U.S. in terms of what we announced. And I would say that we are seeing SG&A in the U.S. business down slightly year-on-year on a comparative basis, which is pleasing, but also really what we had planned to do. And I think as George also said, there's a bit of phasing here between quarter 3 and quarter 4. And importantly, from a continuation of business point of view, we are -- in quarter 4 this year, we're making sure that we'll continue to invest in the things that customers value the most from us to make sure we keep the growth there going forward and investing more in customers and more in the things that customers see. Again, finally, on the cost side, again, as George has said, we started some of the restructuring. We've closed, I think, George said, 9 stores in the previous quarter and we're on track to close another 80 to 90 in the period ahead. Again, that's very much on plan and benefit still to come over the period of time."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think, John, you also have a question on the Pharmacy margin and really just reinforcing what I said earlier, that we did see in the U.S. the positive sales growth, but that was substantially offset by the Pharmacy gross margin pressure, but that was ab",65,"I think, John, you also have a question on the Pharmacy margin and really just reinforcing what I said earlier, that we did see in the U.S. the positive sales growth, but that was substantially offset by the Pharmacy gross margin pressure, but that was absolutely consistent with our expectation. So there's no change from what we were expecting when we last talked to you."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Did it get better -- it usually got sequentially or no, right?",12,"Did it get better -- it usually got sequentially or no, right?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was -- it was as we expected, I mean when the renewals come through and what we're seeing is what we were expecting.",38,"We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was -- it was as we expected, I mean when the renewals come through and what we're seeing is what we were expecting."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The market is -- Stefano here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you budget and I believe that this year we are doing exactly this. We are absolutely aligned wi",52,"The market is -- Stefano here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you budget and I believe that this year we are doing exactly this. We are absolutely aligned with what we were expecting."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Stefano, you talked about the challenges that the U.S. market and other markets are facing. We hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically where do you think Walgreens needs t",114,"Stefano, you talked about the challenges that the U.S. market and other markets are facing. We hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically where do you think Walgreens needs to be positioned? We're seeing lots of consolidation, whether it's managed care or other players. Is it that we need to be the biggest retail provider in the U.S. and therefore best positioned to partner with those that are taking on risk? Do you view yourself as more of a risk-bearing entity over time? How do you think about your relationship, whether it's with managed care or PBMs and strengthening those going forward?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time with the right partner. We are open",102,"I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time with the right partner. We are open to any kind of combination, which could improve the value of our company. And we are looking actively around us to understand which is the best option for us. But please, don't forget that we are looking actively not just in the U.S., but even in other countries because we consider ourselves a global company."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you say the priorities are more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?",27,"And would you say the priorities are more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, the priority is the deal that you can do and it depends on where you can fit.",18,"Well, the priority is the deal that you can do and it depends on where you can fit."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inn",91,"Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inning are we in as far as obtaining the synergies that you expected from WBAD. Are we close to getting the full benefit from them? Or is there still a good portion of the future synergies that will still come from the procurement side."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We are absolutely in line with what we were forecasting and maybe, George, you can give more details about we will do what we were expecting and what we announced.",30,"We are absolutely in line with what we were forecasting and maybe, George, you can give more details about we will do what we were expecting and what we announced."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","What I would just add to that is what I'd said is that we are very much on track to achieve the target this year and our -- the goal of $1 billion from what I would describe as hard quantifiable synergies that we can measure. But what we're really seeing",173,"What I would just add to that is what I'd said is that we are very much on track to achieve the target this year and our -- the goal of $1 billion from what I would describe as hard quantifiable synergies that we can measure. But what we're really seeing as the -- know that we're a merged organization. We are seeing lots of other areas of best practice and ideas that we're sharing, that we're implementing. But clearly, as we become more and more integrated, these are simply the sites that you cannot quantify to the standard, but you can put in a number and we're very much moving through this -- into this phase. And those types of synergies, as we know from previous transactions, I remember from the merger of Alliance UniChem and Boots, these are very important synergies and we can see them time and time again. We're moving people around more. And these are really what would help us to become a much, much stronger organization."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I would add, George, that as you said, we are thinking of the buying synergies, of certain synergies, which are quite redundant that we can easily forecast. But there will be for sure, as you are saying, George, many synergies there that will appear evide",77,"I would add, George, that as you said, we are thinking of the buying synergies, of certain synergies, which are quite redundant that we can easily forecast. But there will be for sure, as you are saying, George, many synergies there that will appear evident -- become evident in future because when you put 2 companies together, you find a way for years, I would say, for 3, 4 years, you find new ways to deliver synergies."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And congratulations, Stefano, on becoming CEO. I'm glad that they named you so.",15,"Okay, great. And congratulations, Stefano, on becoming CEO. I'm glad that they named you so."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from George Hill with Deutsche Bank.",10,"Our next question comes from George Hill with Deutsche Bank."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","First one is for Alex. People have jumped in a bit on what margins have looked like. I guess, we're getting further along in the year. Can you talk about what prior negotiations are looking like for kind of a 1/1/16 contract restarts. And I guess if thing",67,"First one is for Alex. People have jumped in a bit on what margins have looked like. I guess, we're getting further along in the year. Can you talk about what prior negotiations are looking like for kind of a 1/1/16 contract restarts. And I guess if things are proceeding according to expectations and how that squares with the fiscal '16 guidance that you guys have provided."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely, it does. So really, as we expected and square on the guidance that we've given as well and I think the team have done a good job, again, in anticipating and making sure that we've projected well and managed the relationships in a very goo",48,"Yes, absolutely, it does. So really, as we expected and square on the guidance that we've given as well and I think the team have done a good job, again, in anticipating and making sure that we've projected well and managed the relationships in a very good way."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then a follow-up, I guess, for George and for Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution fr",81,"Okay. And then a follow-up, I guess, for George and for Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution from ABC equity earnings built into the fiscal '16 guidance. And does Walgreens want to be a larger stock owner of AmerisourceBergen? Or should we think of the warrants as a value-creation vehicle for Walgreens?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","When we did the deal, we did the deal, of course, to improve our profit, but also for strategical reasons because, as you know, we have always believed that a better coordination between wholesaler and retailer again create quite substantial synergies. So",73,"When we did the deal, we did the deal, of course, to improve our profit, but also for strategical reasons because, as you know, we have always believed that a better coordination between wholesaler and retailer again create quite substantial synergies. So the reasons for the deal are still there. So we have announced what we intend to do and at the right time you will see the effect of this agreement. George?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I've really not a lot to add to that. I mean, we will look at the right time to take the decision at the time. In terms of the accounting, again we will have to look at that at the appropriate time. But from where we are today, were we to exercise the war",90,"I've really not a lot to add to that. I mean, we will look at the right time to take the decision at the time. In terms of the accounting, again we will have to look at that at the appropriate time. But from where we are today, were we to exercise the warrant spend, we will anticipate being able to account for that as an equity method investment, but clearly that will be -- that would have to be confirmed and looked at were we to exercise it."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with us more details on the headwinds versus the tailwinds that we should be thinking",50,"Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with us more details on the headwinds versus the tailwinds that we should be thinking of between the fourth and third quarter?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, I think really the first real point to come through, as I sort of touched on in the prepared comments, was the primary component than we've got to think about is the seasonality between the quarters, which impacts the sales and product mix. I'm thin",243,"Well, I think really the first real point to come through, as I sort of touched on in the prepared comments, was the primary component than we've got to think about is the seasonality between the quarters, which impacts the sales and product mix. I'm thinking about the summer months very much tend to be our weakest months particularly in Alex's business, the Retail Pharmacy USA segment, where we would see typically the sequential declines in the growth of both pharmacy volume and retail product sales. The other factor is around the phasing and timing of certain expenses in terms of the fourth quarter relative to the third quarter. And clearly, when you go through the sort of programs that we are already trying and push as fast as you can, but equally, you need to keep everyone very focused on the business and driving through all the programs that Alex is working on. So there's always an element of timing on those where they eventually as to how quickly we can deliver some of those. We're clearly going as fast as we feel we can in a straight line. The other areas I've talked about, I mean, clearly currency is a factor as I touched on. But I think, increasingly, we have, in terms of the internal factors, we've got pretty good visibility through our forecasting process and hence we're confident to both narrow and increase the guidance range for this year."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And when we -- I know you talked about, I think, shutting -- closing down another 70 to 80 stores in the upcoming quarter. Should we see that through the gross margin line or SG&A line?",36,"And when we -- I know you talked about, I think, shutting -- closing down another 70 to 80 stores in the upcoming quarter. Should we see that through the gross margin line or SG&A line?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, you see that particularly through the SG&A line. Obviously, we lose a few sales, but most of these sales we've successfully transferred into adjacent stores. I think, as you know, we also closed a number of stores there last year and we've got a pret",78,"Yes, you see that particularly through the SG&A line. Obviously, we lose a few sales, but most of these sales we've successfully transferred into adjacent stores. I think, as you know, we also closed a number of stores there last year and we've got a pretty predictive model now, which we're very confident about. So SG&A will come down and overall we'll have an EBIT benefit and we'll lose a few sales and a few bits of margin."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just one market-related question. We're seeing a lot of kind of like your competitors making strategic moves around specialty. When you think about kind of like the specialty opportunity for you, do you think that this is something t",87,"Okay, great. And then just one market-related question. We're seeing a lot of kind of like your competitors making strategic moves around specialty. When you think about kind of like the specialty opportunity for you, do you think that this is something that you can build internally by leveraging your retail infrastructure in the U.S.? Or is this something that you think you need to go outside to add these capabilities? And also, how do you think about the special opportunity U.S. versus x U.S. and Europe?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We don't exclude any opportunity. We are looking around, as we have said many times, so we are analyzing all the opportunities for growth that we have and at the right time. And if the right opportunities come, we would be able to face them.",46,"We don't exclude any opportunity. We are looking around, as we have said many times, so we are analyzing all the opportunities for growth that we have and at the right time. And if the right opportunities come, we would be able to face them."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, and if I could also add as well, Ricky, that we are very focused on organic growth as well. We've got a very good model in the U.S. in community pharmacy and we're building that out through our relationships there with doctor and with also any access",93,"Yes, and if I could also add as well, Ricky, that we are very focused on organic growth as well. We've got a very good model in the U.S. in community pharmacy and we're building that out through our relationships there with doctor and with also any access we get to the pharma manufacturers also. So in areas like HIV and cystic fibrosis, we have that opportunity that we can grow organically. So again, we are not stopping. This is an important business for us and they're growing organically, particularly in the USA."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Stefano, congratulations on the appointment. Obviously, a number of moving pieces, but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program, but is there any",87,"Stefano, congratulations on the appointment. Obviously, a number of moving pieces, but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program, but is there any more detail you can share with us on the savings that you've been able to generate to date? And then any breakdown of those savings obviously across the segments would be really helpful in us being able to track the underlying business a little bit better."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have made an effort to be as clear as possible.",11,"We have made an effort to be as clear as possible."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I really do appreciate how tricky it is with the margin coming through, and obviously, as we said the last time, we were -- it was not practical for us to work through and try and restate everything on a comparable basis, the cost side and the margin side",274,"I really do appreciate how tricky it is with the margin coming through, and obviously, as we said the last time, we were -- it was not practical for us to work through and try and restate everything on a comparable basis, the cost side and the margin side. So that's why we've tried to give you the adjusted figures. Clearly, in terms of the cost-saving program, that is the big -- it is primarily in Retail Pharmacy USA, as we said the last time, but we are progressing in the International, but that is a much, much smaller part of the program, but we're very much on track with where we expect to be. But as I said earlier, what's important is always to go in a straight line in a disciplined, structured way. That's why we've tried to give you a little bit of a feel when you're actually looking at comparability. I've tried to touch on the Retail Pharmacy International margin, which I you know some of you felt -- looked at the profit a little bit lower than you were expecting in the second quarter, but it only has the 2 months in and that is a seasonal business. And the last quarter was at the time when we seasonally would have lower sales. Clearly, as we come up to the important Christmas time and we've got the leverage of the fixed cost base and therefore the net margin will start -- will reflect that when you look at the seasonality. But I do appreciate how tricky it is to model, which is why we gave the guidance going forward."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","No, I respect that, too, and I understand the comparability year-over-year is tough. I guess I was talking more specifically about just identifying what the cost cutting was in the actual quarter or this quarter itself and maybe I'm missing something that",57,"No, I respect that, too, and I understand the comparability year-over-year is tough. I guess I was talking more specifically about just identifying what the cost cutting was in the actual quarter or this quarter itself and maybe I'm missing something that I wouldn't think that would be that difficult to identify, store closings, headcount reduction, but..."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Bob, if I can maybe help a little bit. I mean, we've done a good review of all of the projects that we'll focus on the future. I think we've been really clear within the business that we're focusing back on our core business of Retail Pharmacy front-end p",115,"Bob, if I can maybe help a little bit. I mean, we've done a good review of all of the projects that we'll focus on the future. I think we've been really clear within the business that we're focusing back on our core business of Retail Pharmacy front-end products, specialty. And therefore, all of the other areas where we were building out maybe potential future products we'll look further, in fact, to reduce the spend in some of these areas. So more focus back on the core business. So that really has been reducing a lot of projects and we're really very confident there before, on the $1.5 billion in savings that can be achieved."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","To really reinforce what Alex has said, we've been putting a lot of internal work into the whole process of how we evaluate new initiatives, how we track initiatives that perhaps are not working and then you stop them, you don't let them drag on. If somet",128,"To really reinforce what Alex has said, we've been putting a lot of internal work into the whole process of how we evaluate new initiatives, how we track initiatives that perhaps are not working and then you stop them, you don't let them drag on. If something really isn't working, you give it a good go then you stop it. New initiatives, we've got a lot of what I would describe as financial rigor that has been increasingly put in place really over the last 12 months, Alex, you put a lot in place when you took overall responsibility for the Walgreen business and we're continuing to do that and I think it's that rigor that we're seeing then in terms of some of the SG&A coming through."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That make sense. And I guess just one quick follow-up on Part D network, specifically, there's a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to yo",70,"That make sense. And I guess just one quick follow-up on Part D network, specifically, there's a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to your expectations, I know it's only about 6 months in. And then based on that feedback, any thoughts on your continued participation in these preferred networks going forward."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, it's Alex again. No, this is a really important customer, a really important market segment. That segment is growing rapidly so we remain very committed to this. And in terms of, I've said before, we are, in terms of next year's plans, have almost co",154,"Yes, it's Alex again. No, this is a really important customer, a really important market segment. That segment is growing rapidly so we remain very committed to this. And in terms of, I've said before, we are, in terms of next year's plans, have almost completed all the contracts and to the expectation in terms of margins that we planned for. So very committed to this business and we are -- seems done a good job. We're pleased with where we are and committed to next year. Importantly, for us of course, we're only at the end of first stage. The second stage, which is how we needed access to make sure that you really -- we can serve the patients and the customers who come to your pharmacy and make sure you get the appropriate level of draw-through and volume through your assets and that's a bit we're now turning our attention to."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Alvin Concepcion with Citi.",9,"Our next question comes from Alvin Concepcion with Citi."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Congratulations, Stefano. My question is just really around beauty. Just curious how the tests are going in New York and Phoenix. Are there any findings you could share from that? Particularly interested in if you're getting a sales lift in the aisle and",50,"Congratulations, Stefano. My question is just really around beauty. Just curious how the tests are going in New York and Phoenix. Are there any findings you could share from that? Particularly interested in if you're getting a sales lift in the aisle and if you're seeing much traction from No7?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Of course. You know the importance that we give to our brands and No7 is having a fantastic trend in the U.K. and internationally and it's one of our really hope for the future in the U.S. But maybe, Alex, you can say what you are doing now for No7 and wh",57,"Of course. You know the importance that we give to our brands and No7 is having a fantastic trend in the U.K. and internationally and it's one of our really hope for the future in the U.S. But maybe, Alex, you can say what you are doing now for No7 and what you are expecting from it."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've rolled No7 into just over 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just over 12 months old and we'll be able to the measure the impact both on No7 sales, on Boots brand product sales and al",216,"Yes, we've rolled No7 into just over 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just over 12 months old and we'll be able to the measure the impact both on No7 sales, on Boots brand product sales and also on the beauty categories and we're pleased with what we're seeing. So it's time to plan for the next stage of evolution of No7 and the Boots brand in Walgreens and Duane Reade in the USA and we'll come out with these plans when they're ready, but we are pleased with the results. Personally, I'm also pleased that we were able to acquire Soap & Glory, I think, out in the previous quarter and obviously this morning we've seen Liz Earle. But going forward, the more unique products that we're able to get into the Walgreens beauty and health care offer, then the more unique it will make our offer going forward in what is a very competitive marketplace. So again, very pleased with the brand's performance, very pleased with the progress that Ken Murphy and the team have made in the Global Brands organization, still very young. I'm looking forward to getting these unique products in front of our customers in Walgreens in the future."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And as a follow-up, what were you thinking for the timing of the full rollout?",16,"And as a follow-up, what were you thinking for the timing of the full rollout?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we'll come back with that. I mean, we're really -- I've said before, we're just doing the walk now. We've got to get this right. This is a bigger stage. It's a fantastic brand, as Stefano said, in Europe and is growing really well in Europe. So we'll",61,"Yes, we'll come back with that. I mean, we're really -- I've said before, we're just doing the walk now. We've got to get this right. This is a bigger stage. It's a fantastic brand, as Stefano said, in Europe and is growing really well in Europe. So we'll come back there when we're ready, but we're in a good position."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Mark Wiltamuth with Jefferies.",9,"Our next question comes from Mark Wiltamuth with Jefferies."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it looked like there were some overhead allocations that changed versus a year ago?",32,"I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it looked like there were some overhead allocations that changed versus a year ago?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So I mean, they're not directly comparable because, clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of",101,"So I mean, they're not directly comparable because, clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of where the economic benefit is. So those results, unfortunately, are not directly comparable so they come with that very big health warning. But I think what we have said is we are very pleased with the progress that we're making in reducing SG&A and we're very much on target to deliver the program that we announced in the last quarter."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So -- and the numbers that presented were down, but I guess on an apples-to-apples was the SG&A percentage down?",20,"So -- and the numbers that presented were down, but I guess on an apples-to-apples was the SG&A percentage down?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","There isn't an apples-and-apples basis. That's the -- I guess, that's challenge that we got and simply. And I think we said at the time we did the deal, our priority was to get the deal done quickly, but one of the things that, that didn't enable us to do",85,"There isn't an apples-and-apples basis. That's the -- I guess, that's challenge that we got and simply. And I think we said at the time we did the deal, our priority was to get the deal done quickly, but one of the things that, that didn't enable us to do was to go back and rework everything on an apples-and-apples basis. But we're making good progress, that's the key message I can see. But I know how difficult it is not getting everything apples-and-apples."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And I understand you're not announcing the International segment's year ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those International segments even though you don't h",46,"Okay. And I understand you're not announcing the International segment's year ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those International segments even though you don't have a GAAP presentation for us."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think we can say that we're pleased with the performance. When we look at Retail Pharmacy International, obviously Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that mar",243,"I think we can say that we're pleased with the performance. When we look at Retail Pharmacy International, obviously Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that market, you see what's happening in some of the supermarket sector, for example. But I think this demonstrates the strength of the offer. It's very important to have a differentiated retail offer particularly in beauty where Boots is renowned. We've got a very strong loyalty card program. Alex talked obviously about the great work that's being done here and taking Balance Rewards forward, the Advantage Card program equally important in the U.K. And then the piece that I touched on in my presentation is really omni-channel where ordering online through boots.com and picking up in-store to purchase is important. And of course, with the geography that we've got in the U.K. in the 2,500 points we can do that and we can actually leverage our Wholesale organization for delivery we're able to do that in a profitable way that really meets the expectations of our customers. So that's the key component in there. And Wholesale, in any year, being in a number of markets, you get markets that perform better and markets that are more challenging, such is the way it always is, but the division's delivered a solid performance and -- as it's continued to do for many years."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, on the international Retail Pharmacy, there was some commentary in the analyst meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to",46,"I guess, on the international Retail Pharmacy, there was some commentary in the analyst meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to driving sales?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We've obviously not given the specifics on the comparability because we don't have the numbers on the same U.S. GAAP basis, but I continue to say that the business has performed solidly. We're pleased with the performance in what's been a tough retail env",128,"We've obviously not given the specifics on the comparability because we don't have the numbers on the same U.S. GAAP basis, but I continue to say that the business has performed solidly. We're pleased with the performance in what's been a tough retail environment in the U.K. and that's fundamentally -- on the NHS side, on the pharmacy side, clearly the government continued to contain growth in health care expenditure and so we haven't actually seen the details of the settlement yet. That's probably going to be towards the autumn. We'll just have to wait and see on the timing of that, but we continue to see pressure in that area as we've seen for a number of years. So no real change, but that pressure continues."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our final question comes from Ross Muken with Evercore.",9,"Our final question comes from Ross Muken with Evercore."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So as you think about sort of the M&A landscape happening around you, obviously, Stefano, as you talked about, lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space, where do you think in terms of what",99,"So as you think about sort of the M&A landscape happening around you, obviously, Stefano, as you talked about, lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space, where do you think in terms of what is happening around you it's most relevant to kind of your business? Or what are you watching most? And how do you think, particularly on the managed care side, any of the changes there? How does that make you think about your longer-term positioning from a health care perspective in this market?"
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our industry and this is happening. In reality, I believe that this is a good news for us because the consolidation will create a clear market and",108,"As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our industry and this is happening. In reality, I believe that this is a good news for us because the consolidation will create a clear market and will give us more opportunities in the future. What we will be able to do specifically is a little too early to say. But I repeat, we want to be one of the players in this space and we see a lot of opportunity. And the opportunities are really open along the chain -- along the face of this health care industry."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I guess, just quickly, just staying on the M&A scene and I'll keep this is my last question, but you and your team have been remarkably savvy dealmakers over the course of your long career and have created massive amounts of value. How much of a chall",128,"And I guess, just quickly, just staying on the M&A scene and I'll keep this is my last question, but you and your team have been remarkably savvy dealmakers over the course of your long career and have created massive amounts of value. How much of a challenge of it is it today with where global equity markets are from a valuation standpoint. Obviously, understanding the financing markets are wide open, but valuations are pretty elevated. And so how do you think about that in the context of your capital allocation goals, particularly on the deal side? Does it argue to smaller transactions or certain geography? I'm just trying to get a sense for how that plays into your thinking and your -- the timing aspects of it."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As you know, we have been always disciplined with potential acquisitions. So we will -- if we will have an opportunity, we will analyze these opportunities very rationally and we will do it just if this will create additional value. It's true that the mar",101,"As you know, we have been always disciplined with potential acquisitions. So we will -- if we will have an opportunity, we will analyze these opportunities very rationally and we will do it just if this will create additional value. It's true that the market is now quite bullish, but it's also true that the cost of the money is still quite low and there are other ways to create value, not just the acquisitions. So we are analyzing all the opportunities. If we will see an opportunity which fits our strategy and which can create value, we will take action."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or Ashish if you have any further questions, I know some of you do. And with that, thank you very much, indeed. We'll conclude our cal",49,"Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or Ashish if you have any further questions, I know some of you do. And with that, thank you very much, indeed. We'll conclude our call. Thank you."
93624,304033436,832576,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect, and everyone, have a great day.",20,"Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect, and everyone, have a great day."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to your host, Gerald Gradwell.",43,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance Third Quarter 2015 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to your host, Gerald Gradwell. Please go ahead."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stephanie, and good morning, everyone. Welcome to our Fiscal 2015 Third Quarter Earnings Conference Call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Glob",249,"Thank you, Stephanie, and good morning, everyone. Welcome to our Fiscal 2015 Third Quarter Earnings Conference Call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; George Fairweather, our Executive Vice President and Global Chief Financial Officer, will take you through our third quarter results. Also joining us on the call and available for questions is Alex Gourlay, Executive Vice President and President of Walgreens. 
You can find the link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and the webcast will be archived on our website for 12 months. 
Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. 
Please see our latest Form 10-K, Form 10-Q and other filings for a discussion of risk factors as they relate to forward-looking statements. 
As a reminder, today's presentation include certain non-GAAP financial measures and we refer you to the appendix to the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. 
With that, I'll turn the call over to Stefano for some opening comments."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months have been significant progress in delivering on the benefit of the merger, structuring the business for the future. But there is a lot more",575,"Thank you, Gerald. Good morning, everyone, and welcome to our fiscal third quarter earnings call. The past 6 months have been significant progress in delivering on the benefit of the merger, structuring the business for the future. But there is a lot more to do. 
As you have seen today, I have been appointed by the board as Chief Executive Officer, replacing the interim appointment that I was previously fulfilling. The board has decided that bearing in mind the pace of change and the amount that we have still to do, there is a benefit to stability at the senior level in the organization and to focus on the operational and strategic path before us rather than appointing, orientating and educating someone new to the business during this period
The role presents me with certain personnel and logistical challenges, but with the support of the board and particularly of Jim Skinner as our Executive Chairman, I happily [ph] accept the appointment in the best interest of the company, my colleagues, and of course, my fellow shareholder. 
Today, I am pleased to be announcing another strong financial performance in this -- the first quarter to reflect a full 3 months of the combined company. Although it may not always appear so from outside the business, it has been a very busy period for us since I last talked to you. As I have mentioned, our focus has naturally been on putting in place the changes and the restructuring we need in order to deliver the full benefits of the enlarged company and position the company for growth in the immediate and long term. 
Given that the deal was consummated only 6 months ago, we are still in the early stages of this process, but we have been working hard and fast to deliver on our plan, in fact, better than our plan and I am pleased to say that the benefits of this work are already beginning to be seen in our results with reasonable growth in revenues and margins and continued strong [indiscernible] innovation. Clearly, the first areas in which you can see the impact are strict cost control and disciplined financial management, but I want to assure you that we give our operations the investment they need to grow and prosper. 
We have accelerated our cost-reduction process and there reap the certain benefits earlier than expected in this quarter. Of course, we cannot extract these benefits more than once. However, the process of identifying benefits is ongoing, not final. So when we have completed this first wave of restructuring, we will reveal -- review other areas of our business to identify further potential cost savings. 
I must commend my colleagues throughout the company for their willingness and openness to accept change even when it is the most uncomfortable in the interest of improving and growing our company, and I would assure them that change is a sign of life, and if embraced in this manner, becomes more of an ally than an enemy. It's a reminder that while we must prioritize our work if we are to achieve everything we want to and promise to, we cannot ignore any element of the business when it comes to our drive for efficiency and best practice. 
I will hand over to George now for him to take you through the results for the quarter and give you some color on what I have just said. George?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insights into the performa",2796,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I will begin my remarks by taking you through key highlights of our fiscal 2015 third quarter results. I will then give you some insights into the performance of each of our 3 divisions before updating you on progress we have made in implementing our cost savings and continuing to execute our [ph] synergy programs. I will conclude by taking you through our updated guidance for fiscal year '15 and comment on our fiscal year '16 goals. 
As Stefano said, the benefits of the work carried out since Walgreens Boots Alliance was formed at the end of December are already beginning to be seen in our financial results, enabling us to deliver another strong quarter. 
Looking at the highlights. Net sales for the quarter were $28.8 billion, an increase of 48.4% versus the comparable quarter in the prior year. Operating income on a GAAP basis was $1.4 billion, and on an adjusted basis, was $1.7 billion. The increase in adjusted operating income was driven by the consolidation of Alliance Boots as well as growth in our Retail Pharmacy USA segment. GAAP net earnings attributable to Walgreens Boots Alliance were $1.3 billion or $1.18 per diluted share while adjusted net earnings were $1.1 billion or $1.02 per diluted share. This represents an increase of 59.5% in GAAP net earnings per diluted share and an increase of 22.9% in adjusted earnings per diluted share over the comparable quarter in the prior year. 
Net interest expense in the quarter was $151 million and our adjusted tax rate was 30%. Finally, the average number of diluted shares outstanding for the quarter was 1.1 billion. This includes, of course, the 144 million shares issued on the 31st December as part of the second step consideration for Alliance Boots. It should also be noted that the third quarter results last year included 3 months' equity earnings as a result of Walgreens' 45% interest in Alliance Boots compared to fully consolidated results in this year's third quarter. 
Now I will take you through the walk from GAAP diluted EPS to adjusted diluted EPS. GAAP earnings of $1.18 per diluted share this quarter reconciles to adjusted earnings of $1.02 per diluted share. The net adjustment of $0.16 per share reflects additions of $0.05 of LIFO provision costs in Retail Pharmacy USA, $0.06 of amortization of acquisition-related intangibles and an additional $0.11 of restructuring-related costs from our cost optimization and store closure program. These additions were more than offset by removal of a $0.29 gain on our warrants to acquire AmerisourceBergen shares and a net 9% gain from special items, which includes the release of a capital loss valuation allowance totaling $0.12 combined with a $0.01 loss on the sale of Walgreens Infusion Services and $0.02 for an adjusted tax rate true-up. 
So now I will take you through the performance of each of our divisions in the quarter. To remind you, our results are reported in 3 segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The segments we're reporting include the allocation of synergy benefits including WBAD as well as an allocation of corporate-related overhead costs. 
Responding to feedback received at our Analyst Day in April, you will see that we are providing additional detail on segmental performance, both in the press release and in this presentation. This quarter, we have provided gross profit, SG&A and operating profit on a GAAP and adjusted basis for each of our segments. We plan to continue this practice going forward. 
So now let's start with the Retail Pharmacy USA segment. Retail Pharmacy USA total sales for the quarter were $20.4 billion, an increase of 5.3% over the third quarter in the prior year. Please remember, of course, that we sold a majority stake in Walgreens Infusion Services on the 7th of April. With our minority position, our share of earnings in the company now flow through the post-tax earnings from equity method investments in the income statement. Sales in the division on a comparable store basis increased by 6.3%. SG&A on a GAAP basis was $4.5 billion and on an adjusted basis was $4.3 billion. We continue to see strong progress in controlling SG&A expenses this quarter including benefits associated with our cost-savings program. This was a significant driver of the quarterly year-on-year performance. As a result, GAAP operating income for Retail Pharmacy USA was $1 billion while adjusted operating income was $1.3 billion. 
So looking now at the pharmacy part of Retail Pharmacy USA in more detail. Comparable-store sales for pharmacy were up 9.1% for the quarter. We filled 226 million prescriptions including immunizations on a 30-day adjusted basis, that was an increase of 3.8% over last year's quarter with prescriptions filled in comparable stores up 4.1%. We continue to see a positive impact and further growth in Medicare Part D scripts along with positive underlying share trends. Our retail prescription market share on a 30-day adjusted basis increased to 19.3% in the quarter, up 20 basis points. The benefit of positive sales growth was, however, substantially offset by pharmacy gross margin pressure consistent with our expectations. 
Retail product sales increased by 2% in total, comparable store sales increasing by 1.6%. The growth in retail sales was driven by performance in key destination categories including health and wellness. We are pleased with our progress in driving profitable sales growth and margin expansion while at the same time focusing on operating efficiencies and focusing on working capital efficiencies. 
Additionally, we continue to enhance our successful Balance Rewards program by recently releasing Balance Rewards with every day points. We now provide our active customers with a more consistent platform to receive loyalty points on most pharmacy and retail product transactions. We also encourage healthy lifestyle choices by rewarding points for positive health and well-being decisions. 
So turning now to the results of our Retail Pharmacy International division. The Retail Pharmacy International division has pharmacy-led health and beauty retail businesses in 8 countries. At the end of the quarter, we operated 4,565 retail stores and adding net increase of 6 stores during the quarter. As a reminder, our biggest operations are Boots from the U.K. followed by Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. 
Total sales in the division for the quarter were $3.3 billion. GAAP operating income was $205 million while adjusted operating income was $249 million. Adjusted operating margin at 7.6% for the quarter was 1.5 percentage points higher than in the second quarter, which, remember, included only January and February performance. The margin is typically lower in these early months of the year reflecting the seasonality of sales. 
So now let's look more closely at the performance for the division. On a pro forma constant currency basis, comparable store sales growth for the quarter was 3.1%. This reflects Boots UK growth of 2.4%, complemented by higher growth in emerging markets, most notably in Mexico and Chile where we are making good progress in integrating these businesses acquired by Alliance Boots in August 2014. 
In the U.K., Boots retail sales were driven by good performances in both the beauty and retail health care categories. Orders on our U.K. website at boots.com and orders during the quarter were up approximately 50% over the same period last year with approximately 2/3 of our website orders collected in-store. 
At our Analyst Day back in April, we talked about the importance of our product brands. We're very pleased with the growth in sales during the quarter of No7, our award-winning beauty brand. This was in part due to the May launch of a new marketing program in the U.K., the No7 Protect & Perfect Advanced Serum. We were able to state for the first time in the U.K. that this innovative product was the first serum clinically proven to deliver ground-breaking anti-wrinkle results that get even better over time. 
As well as developing our existing product brands, we continue to add brands to our portfolio, which resonate with our customers. Following on from the acquisition of Soap & Glory last year, we are delighted to announce today that we've acquired Liz Earle from Avon. Liz Earle is an award-winning premium skincare range that uses naturally active ingredients and is recognized as one of the leading botanical brands in the U.K. 
So turning now to our Pharmaceutical Wholesale division. Pharmaceutical Wholesale division total sales for the quarter were $5.7 billion. On a pro forma basis, which is in constant currency and excludes acquisitions and disposals, sales increased 0.2% compared with the same quarter in the prior year. 
As we discussed in the last earnings call, Wholesale performance in any quarter is impacted by performance in larger geographies including the U.K., Germany, France and Turkey as well as by the unique business model. 
GAAP operating income for the division was $162 million while adjusted operating income was $171 million. Adjusted operating income margin was 3%, broadly flat versus the second quarter and consistent with our expectations. 
The key driver of profit growth continues to be our synergy program. Net synergies in the third quarter totaled $194 million, making a total of $504 million for the fiscal year-to-date. As we've said before, synergies this year continue to come primarily from our drug procurement activities. 
As you can see from the numbers, we are on track to reach our target of at least $650 million net synergies in fiscal year 2015. For fiscal year 2016, we continue to expect at least $1 billion of combined quantifiable net synergies. As we work increasingly close together as a combined management team, there are, of course, an increasing number of other synergies being identified and actioned, many of which are simply not practicable to quantify. 
Consistent with our prior reporting, these synergies are allocated across each segment and do not include any benefit from our relationship with AmerisourceBergen. 
At the same time as driving our synergy program, as you know, we are very focused on costs. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. The expected pretax charges associated with this program, as previously stated, are between $1.6 billion and $1.8 billion in which the cash component is expected to be approximately 60%. 
Good progress was made during the quarter in reorganizing our Retail Pharmacy USA field operations with work continuing on the optimization of the division's corporate office. Of the approximately 200 planned U.S. store closures in the program, 9 stores were closed in the quarter with approximately 70 to 80 additional stores planned to be closed by the end of fiscal year. We also reduced the IT cost structure in the U.S.A. to help enable significant store system investments over the coming years. 
In addition, during June, we announced the reduction of approximately 700 nonstore-based roles in Retail Pharmacy International. 
During the quarter, we incurred pretax charges of $160 million on the program. These comprised $102 million of asset impairments, $34 million of severance costs and real estate costs of $24 million. 
So moving on now to cash flow and the deployment of capital. GAAP operating cash flow was $1.8 billion in the quarter and $4.2 billion in the first 9 months of the year. Free cash flow was $1.6 billion in the quarter and $3.3 billion in the first 9 months of the year. Net debt at the end of the quarter was $11.8 billion. 
Investing to drive future growth is our first priority for capital deployment, both in terms of capital expenditure and selective M&A. During the quarter, we invested $247 million in capital expenditure, making a total of $890 million for the first 9 months of the year. Here, capital investment continue to be store investments as well as IT and digital capabilities, which are vital to building and maintaining a sustainable, competitive advantage in our increasingly omni-channel world. 
To some degree, this quarter disproportionately benefited from the imposition of stricter capital investment controls. And while we expect to maintain a rigid control on capital expenditure to assure appropriate returns on every dollar we spend, we will clearly not deprive the business of the investment it needs to thrive. You should therefore expect to see future quarters return to slightly higher level of capital expenditure than we are reporting today. 
We remain focus on generating cash through working capital efficiencies particularly in Retail Pharmacy USA. The primary area of focus is inventory management, both in pharmacy and retail products. For the quarter, we improved our inventory days of supply in the U.S. by approximately 6 days versus the prior year quarter. We continue to see further opportunity for working capital improvement over time. 
At the same time, we're working hard to optimize our real estate assets, including carrying out sale and leaseback transactions. In the third quarter, we executed approximately $300 million of such transactions. 
As we have said previously, our philosophy is to run an efficient balance sheet. As such, we completed approximately $237 million of share repurchases in the quarter against our $3 billion authorization bringing the total purchases under this program to $331 million. The program is ongoing and we remain committed to completing the plan by the end of fiscal 2016. 
In addition, we announced today that in order for us to manage our balance sheet, we're intending to redeem legacy Walgreens bonds with relatively short periods until they expire with a total principal amount of approximately $1.75 billion. This redemption will be funded from existing cash resources. You will see that cash and cash equivalents totaled $4.4 billion at quarter end, so we have the capacity to do this and continue to exercise on our share repurchase program. 
So turning to dividend. We announced today a 6.7% increase in our quarterly dividend to $0.36 per share. This raises the annual rate from $1.35 per share to $1.44 per share. We remain committed to a long-term dividend payout ratio target of 30% to 35%. 
So now let me talk about the full year outlook for fiscal 2015. In our second quarter earnings release, we had issued an adjusted EPS guidance range of $3.45 to $3.65 for fiscal year 2015. Given our solid third quarter results and increased visibility as we look to the year-end, we are pleased to both increase and narrow our adjusted EPS fiscal year guidance to a range of $3.70 to $3.80. This range assumes adjusted interest expense of approximately $150 million in the fourth quarter, a full year adjusted tax rate of approximately 29%, a fiscal year diluted share count of approximately 1.05 billion shares and estimates for foreign exchange rates that reflect current market rates over the balance of the fiscal year. 
I'll remind you that when we issued our fiscal year '15 guidance in April, we viewed the second half of the fiscal year differently than the first half. Specifically, we indicated that adjusted earnings per diluted share would be lower in the second half with the third quarter being higher than the fourth quarter. As we update our guidance, this still holds true. 
We expect quarter 4 adjusted earnings per diluted share to be sequentially lower for the following reasons. The primary component is seasonality, which impacts sales and product mix. The summer months tend to be our weakest, particularly in our Retail Pharmacy USA segment. Within the U.S., we tend to see sequential declines in the growth of both pharmacy volume and retail product sales. Also, as we continue to work through our cost plan in the U.S., the phasing and timing of certain expenses will impact the fourth quarter relative to the third quarter. 
So moving on to fiscal year 2016. We are reaffirming our previously stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. This range assumes an annual adjusted tax rate in the high 20s, a full year average weight diluted share count of approximately 1.1 billion and no significant changes to current currency exchange rates. 
Please remember, of course, that since we established the goal a year ago, we've seen material appreciation of the dollar. 
As you know, we have currency translation exposure based primarily on movements in the pound sterling versus the dollar. And as a reminder, we estimate that a 1% move in pound sterling versus the dollar from current levels would impact our adjusted EPS by approximately $0.01 per share. 
Given the current situation in Greece where we fortunately have no business interest, we anticipate a certain level of volatility in the currency markets in the forthcoming months. 
So with that, I will turn the call back to Stefano."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So I hope that you will agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it will take to deliver everything we want and that",234,"Thank you, George. So I hope that you will agree that these are a very solid set of results. We still have a lot to do and we are far from being complacent about the challenges we face and the hard work it will take to deliver everything we want and that promise, but we are making a good progress and traveling in the right direction. And I believe all of my colleagues recognize that the challenges and the work will be needed to overcome them, but as convinced as ever about the immense potential of our company as a global pharmacy-led health and well-being enterprise. 
We are in markets that are changing here in the U.S. that you are seeing this quite dramatically, but as I have said many times, we are at the beginning of a new chapter for our company and are actively reviewing every opportunity that the changing environment offers us as we work to deliver the true potential of our company. 
I strongly believe that we have a significant role to play in shaping the future of our WBA [ph]. I thank you for your continued support, but also acknowledge that the best way to thank you is to deliver on our promises and I can assure you we fully intend to continue to do so. 
With that, I think, we will now open it up for questions. Gerald?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Stephanie, do you want to take over?",9,"Thank you. Stephanie, do you want to take over?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from Meredith Adler with Barclays.",11,"[Operator Instructions] Our first question comes from Meredith Adler with Barclays."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I'm asking questions for myself and Eric Percher who is not available today. I think our main question would be talking about the big difference, the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bi",81,"I'm asking questions for myself and Eric Percher who is not available today. I think our main question would be talking about the big difference, the spread between the growth in pharmacy scripts and the growth in dollars. Maybe you could talk a little bit about what the drivers are, some of it is hep C, but maybe you could talk a little bit about inflation in both branded and generic drugs. And then I will have one other question."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","All right. Alex, here. Thanks for the question. Yes, the inflation, we're managing the effect of that inflation pretty well in the business. We have good plans and the team has done a good job to get that done. So one differences in the spread you're seei",70,"All right. Alex, here. Thanks for the question. Yes, the inflation, we're managing the effect of that inflation pretty well in the business. We have good plans and the team has done a good job to get that done. So one differences in the spread you're seeing is generic inflation, but we're managing that effect really pretty satisfactory and that, of course, is built into our future guidance as well."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you describe inflation in branded pharmaceuticals as a positive for the margin?",14,"And would you describe inflation in branded pharmaceuticals as a positive for the margin?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think it's marginal at the moment in terms of that, but again, for example, slight improvement because of generics coming to market both this year and next year. But again, the key thing here is that we forecasted this, we're planning it and it's really",51,"I think it's marginal at the moment in terms of that, but again, for example, slight improvement because of generics coming to market both this year and next year. But again, the key thing here is that we forecasted this, we're planning it and it's really consistent with our expectations."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","If I can add something. You have also to take into account that we have different businesses in our company and some of these businesses like the Wholesale business or like WBAD are really taking advantage of certain inflation.",39,"If I can add something. You have also to take into account that we have different businesses in our company and some of these businesses like the Wholesale business or like WBAD are really taking advantage of certain inflation."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin, but the gross margin. Maybe you could talk a little bit about changes that you",71,"Okay, that's very helpful. And then I just have a follow-up question to talk about on the front-end margin improved and I think you talked about not just the operating margin, but the gross margin. Maybe you could talk a little bit about changes that you might have made in terms of promotional strategies or the way you're marketing that might have driven a better gross margin in the front end."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, Meredith, Alex again. Yes, we've made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. And the key things that we have done is we stopped really promotions that were driving sales, particularl",200,"Yes, Meredith, Alex again. Yes, we've made -- we've been really on this strategy now for 5 quarters. So we're pleased with the progress we're making. And the key things that we have done is we stopped really promotions that were driving sales, particularly in some consumable categories, but not really helping the profit at all. And we're focused much more on the mix and making sure that we're much more focused on really the health and wellness and beauty care categories and that's really proven beneficial. And as George has said in the script today, we've launched a new platform called every day points and that really is to make sure again that people who are coming to us more regularly and are picking up on the destination categories are getting a better platform and more reason to come back to Walgreens. It still is early days. We have a lot of work to do and a lot of opportunity ahead of us and it will be a step-by-step process. But the basic things we're doing is reducing unprofitable promotions and making sure that we focus more investment in our best customers and more investment in our destination categories."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from John Heinbockel with Guggenheim.",9,"Our next question comes from John Heinbockel with Guggenheim."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So 2 questions, one on Walgreens USA cost. What would you guys peg the normal increase, annual increase, in SG&A at? Would it be 2% to 3% absent cost cutting? And then of the $1.5 billion that you've identified, did you see any of that in the third quarte",93,"So 2 questions, one on Walgreens USA cost. What would you guys peg the normal increase, annual increase, in SG&A at? Would it be 2% to 3% absent cost cutting? And then of the $1.5 billion that you've identified, did you see any of that in the third quarter and how much? And what do you think you see in the fourth? And then just lastly, it did look like Pharmacy margin improved a decent amount sequentially, which was a little surprising. What were the couple of things that may have driven that?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Alex, maybe you can...",4,"Alex, maybe you can..."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. So many questions there, John. So starting over the cost question. I think, as George said really clearly, we've made a solid progress against our $1.5 billion cost program and of course, we factored [ph] a bit earlier in the U.S. in terms of what we",217,"Yes. So many questions there, John. So starting over the cost question. I think, as George said really clearly, we've made a solid progress against our $1.5 billion cost program and of course, we factored [ph] a bit earlier in the U.S. in terms of what we announced. And I would say that we are seeing SG&A in the U.S. business down slightly year-on-year on a comparative basis, which is pleasing, but also really what we had planned to do. And I think as George also said, there's a bit of phasing here between quarter 3 and quarter 4. And importantly, from a continuation of business point of view, we are -- in quarter 4 this year, we're making sure that we'll continue to invest in the things that customers value the most from us to make sure we keep the growth going forward and investing more in customers and more in the things that customers see. Again, finally, on the cost side, again, as George has said, we started some of the restructuring. We've closed, I think, George said, 9 stores in the previous quarter and we're on track to close another 80 to 90 [ph] in the period ahead. Again, that's very much on plan and benefit still to come over the period of time."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think, John, you also asked a question on the Pharmacy margin and really just reinforcing what I said earlier, that we did see in the U.S. the positive sales growth, but that was substantially offset by the Pharmacy gross margin pressure, but that was a",65,"I think, John, you also asked a question on the Pharmacy margin and really just reinforcing what I said earlier, that we did see in the U.S. the positive sales growth, but that was substantially offset by the Pharmacy gross margin pressure, but that was absolutely consistent with our expectation. So there's no change from what we were expecting when we last talked to you."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Did it get better -- it looked like it got sequentially or no, right?",14,"Did it get better -- it looked like it got sequentially or no, right?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was -- it was as we expected, I mean when the renewals come through and what we're seeing is what we were expecting.",38,"We're talking about -- obviously, we're reporting John, on year-on-year, quarter-on-quarter. But it really was -- it was as we expected, I mean when the renewals come through and what we're seeing is what we were expecting."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The market is -- Stefano here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you budget and I believe that this year we are doing exactly this. We are absolutely aligned wi",52,"The market is -- Stefano here. Of course, the market is evolving. What is important is to be able to anticipate what happens and to take this into account when you budget and I believe that this year we are doing exactly this. We are absolutely aligned with what we were expecting."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Stefano, you talked about the challenges that the U.S. market and other markets are facing. We hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically where do you think Walgreens needs t",114,"Stefano, you talked about the challenges that the U.S. market and other markets are facing. We hear CMS talking about 50% of payments moving towards what they are calling fee-for-value. Can you talk about strategically where do you think Walgreens needs to be positioned? We're seeing lots of consolidation, whether it's managed care or other players. Is it that we need to be the biggest retail provider in the U.S. and therefore best positioned to partner with those that are taking on risk? Do you view yourself as more of a risk-bearing entity over time? How do you think about your relationship, whether it's with managed care or PBMs and strengthening those going forward?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time with the right partner. We are open",102,"I have said many times that I believe that the American market will go through a substantial wave of consolidation horizontally and vertically. I have said very clearly that we want to be part of this at the right time with the right partner. We are open to any kind of combination, which could improve the value of our company. And we are looking actively around us to understand which is the best option for us. But please, don't forget that we are looking actively not just in the U.S., but even in other countries because we consider ourselves a global company."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And would you say the priorities are more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?",27,"And would you say the priorities are more U.S. driven or globally driven? Or does it depend on the specific opportunity that comes across your desk?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, the priority is the deal that you can do and it depends on where you can fit.",18,"Well, the priority is the deal that you can do and it depends on where you can fit."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inn",91,"Okay, great. And then just my follow-up question would just be around the synergies and you talked a lot about them coming from the procurement side of things. Can you maybe talk about where you think you are, George or Alex or Stefano, as far as what inning are we in as far as obtaining the synergies that you expected from WBAD. Are we close to getting the full benefit from them? Or is there still a good portion of the future synergies that will still come from the procurement side?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We are absolutely in line with what we were forecasting and maybe, George, you can give more details about we will do what we were expecting and what we announced.",30,"We are absolutely in line with what we were forecasting and maybe, George, you can give more details about we will do what we were expecting and what we announced."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","What I would just add to that is what I'd said is that we are very much on track to achieve the target this year and our -- the goal of $1 billion from what I would describe as hard, quantifiable synergies that we can measure. But what we're really seeing",173,"What I would just add to that is what I'd said is that we are very much on track to achieve the target this year and our -- the goal of $1 billion from what I would describe as hard, quantifiable synergies that we can measure. But what we're really seeing is the -- now that we're a merged organization, we are seeing lots of other areas of best practice and ideas that we're sharing, that we're implementing. But clearly, as we become more and more integrated, these are simply the sites that you cannot quantify to the standard that you can put in a number and we're very much moving through this -- into this phase. And those types of synergies, as we know from previous transactions, I remember from the merger of Alliance UniChem and Boots, these are very important synergies and we can see them time and time again. We're moving people around more. And these are really what would help us to become a much, much stronger organization."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I would add, George, that as you said, we are thinking of the buying synergies, of certain synergies, which are quite redundant that we can easily forecast. But there will be for sure, as you are saying, George, many synergies there that will appear evide",77,"I would add, George, that as you said, we are thinking of the buying synergies, of certain synergies, which are quite redundant that we can easily forecast. But there will be for sure, as you are saying, George, many synergies there that will appear evident -- become evident in future because when you put 2 companies together, you find a way for years, I would say, for 3, 4 years, you find new ways to deliver synergies."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And congratulations, Stefano, on becoming CEO. I'm glad that they named you so.",15,"Okay, great. And congratulations, Stefano, on becoming CEO. I'm glad that they named you so."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from George Hill with Deutsche Bank.",10,"Our next question comes from George Hill with Deutsche Bank."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","First one is for Alex. People have jumped in a bit on what margins have looked like. I guess, we're getting further along in the year. Can you talk about what payer negotiations are looking like for kind of a 01/01/16 contract restarts. And I guess if thi",67,"First one is for Alex. People have jumped in a bit on what margins have looked like. I guess, we're getting further along in the year. Can you talk about what payer negotiations are looking like for kind of a 01/01/16 contract restarts. And I guess if things are proceeding according to expectations and how that squares with the fiscal '16 guidance that you guys have provided."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, absolutely, it does. So really, as we expected and square on the guidance that we've given as well and I think the team have done a good job, again, in anticipating and making sure that we've projected well and managed the relationships in a very goo",48,"Yes, absolutely, it does. So really, as we expected and square on the guidance that we've given as well and I think the team have done a good job, again, in anticipating and making sure that we've projected well and managed the relationships in a very good way."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then a follow-up, I guess, for George and for Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution fr",81,"Okay. And then a follow-up, I guess, for George and for Stefano, which is we're not too far away now from March of '16 when the first tranche of the ABC warrants become exercisable. I guess, should we think about whether or not there's any contribution from ABC equity earnings built into the fiscal '16 guidance. And does Walgreens want to be a larger stock owner of AmerisourceBergen? Or should we think of the warrants as a value-creation vehicle for Walgreens?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","When we did the deal, we did the deal, of course, to improve our profit, but also for strategical reasons because, as you know, we have always believed that a better coordination between wholesaler and retailer again create quite substantial synergies. So",73,"When we did the deal, we did the deal, of course, to improve our profit, but also for strategical reasons because, as you know, we have always believed that a better coordination between wholesaler and retailer again create quite substantial synergies. So the reasons for the deal are still there. So we have announced what we intend to do and at the right time you will see the effect of this agreement. George?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I've really not a lot to add to that. I mean, we will look at the right time to take the decision at the time. In terms of the accounting, again we will have to look at that at the appropriate time. But from where we are today, were we to exercise the war",90,"I've really not a lot to add to that. I mean, we will look at the right time to take the decision at the time. In terms of the accounting, again we will have to look at that at the appropriate time. But from where we are today, were we to exercise the warrant spend, we will anticipate being able to account for that as an equity method investment, but clearly that will be -- that would have to be confirmed and looked at, were we to exercise it."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with us more details on the headwinds versus the tailwinds that we should be thinking",50,"Just a couple of questions here. First of all, just George, you've highlighted some of the differences between this quarter and the upcoming quarter. Can you just share with us more details on the headwinds versus the tailwinds that we should be thinking of between the fourth and third quarter?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, I think really the first real point to come through, as I sort of touched on in the prepared comments, was the primary component than we've got to think about is the seasonality between the quarters, which impacts the sales and product mix. I'm thin",243,"Well, I think really the first real point to come through, as I sort of touched on in the prepared comments, was the primary component than we've got to think about is the seasonality between the quarters, which impacts the sales and product mix. I'm thinking about the summer months very much tend to be our weakest months particularly in Alex's business, the Retail Pharmacy USA segment, where we would see typically the sequential declines in the growth of both pharmacy volume and retail product sales. The other factor is around the phasing and timing of certain expenses in terms of the fourth quarter relative to the third quarter. And clearly, when you go through the sort of programs that we are already trying and push as fast as you can, but equally, you need to keep everyone very focused on the business and driving through all the programs that Alex is working on. So there's always an element of timing on those where they eventually as to how quickly we can deliver some of those. We're clearly going as fast as we feel we can in a straight line. The other areas I've talked about, I mean, clearly currency is a factor as I touched on. But I think, increasingly, we have, in terms of the internal factors, we've got pretty good visibility through our forecasting process and hence we're confident to both narrow and increase the guidance range for this year."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And when we -- I know you talked about, I think, shutting -- closing down another 70 to 80 stores in the upcoming quarter. Should we see that through the gross margin line or SG&A line?",36,"And when we -- I know you talked about, I think, shutting -- closing down another 70 to 80 stores in the upcoming quarter. Should we see that through the gross margin line or SG&A line?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, you see that particularly through the SG&A line. Obviously, we lose a few sales, but most of these sales we've successfully transferred into adjacent stores. I think, as you know, we also closed a number of stores there last year and we've got a pret",78,"Yes, you see that particularly through the SG&A line. Obviously, we lose a few sales, but most of these sales we've successfully transferred into adjacent stores. I think, as you know, we also closed a number of stores there last year and we've got a pretty predictive model now, which we're very confident about. So SG&A will come down and overall we'll have an EBIT benefit and we'll lose a few sales and a few bits of margin."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, great. And then just one market-related question. We're seeing a lot of kind of like your competitors making strategic moves around specialty. When you think about kind of like the specialty opportunity for you, do you think that this is something t",87,"Okay, great. And then just one market-related question. We're seeing a lot of kind of like your competitors making strategic moves around specialty. When you think about kind of like the specialty opportunity for you, do you think that this is something that you can build internally by leveraging your retail infrastructure in the U.S.? Or is this something that you think you need to go outside to add these capabilities? And also, how do you think about the specialty opportunity U.S. versus x U.S. and Europe?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We don't exclude any opportunity. We are looking around, as we have said many times, so we are analyzing all the opportunities for growth that we have and at the right time. And if the right opportunities come, we would be able to face them.",46,"We don't exclude any opportunity. We are looking around, as we have said many times, so we are analyzing all the opportunities for growth that we have and at the right time. And if the right opportunities come, we would be able to face them."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, and if I could also add as well, Ricky, that we are very focused on organic growth as well. We've got a very good model in the U.S. in community pharmacy and we're building that out through our relationships there with doctors and with also any acces",93,"Yes, and if I could also add as well, Ricky, that we are very focused on organic growth as well. We've got a very good model in the U.S. in community pharmacy and we're building that out through our relationships there with doctors and with also any access we get to the pharma manufacturers also. So in areas like HIV and cystic fibrosis, we have that opportunity that we can grow organically. So again, we are not stopping. This is an important business for us and they're growing organically, particularly in the USA."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Stefano, congratulations on the appointment. Obviously, a number of moving pieces, but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program, but is there any",87,"Stefano, congratulations on the appointment. Obviously, a number of moving pieces, but just really trying to get a better gauge of the underlying core U.S. business. You guys talked about making good progress on the restructuring program, but is there any more detail you can share with us on the savings that you've been able to generate to date? And then any breakdown of those savings obviously across the segments would be really helpful in us being able to track the underlying business a little bit better."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have made an effort to be as clear as possible.",11,"We have made an effort to be as clear as possible."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I really do appreciate how tricky it is with the margin coming through, and obviously, as we said the last time, we were -- it was not practical for us to work through and try and restate everything on a comparable basis, the cost side and the margin side",274,"I really do appreciate how tricky it is with the margin coming through, and obviously, as we said the last time, we were -- it was not practical for us to work through and try and restate everything on a comparable basis, the cost side and the margin side. So that's why we've tried to give you the adjusted figures. Clearly, in terms of the cost-saving program, that is the big -- it is primarily in Retail Pharmacy USA, as we said the last time, but we are progressing in the International, but that is a much, much smaller part of the program, but we're very much on track with where we expect to be. But as I said earlier, what's important is always to go in a straight line in a disciplined, structured way. That's why we've tried to give you a little bit of a feel when you're actually looking at comparability. I've tried to touch on the Retail Pharmacy International margin, which I you know some of you felt -- looked at the profit a little bit lower than you were expecting in the second quarter, but it only has the 2 months in and that is a seasonal business. And the last quarter was at the time when we seasonally would have lower sales. Clearly, as we come up to the important Christmas time and we've got the leverage of the fixed cost base and therefore the net margin will start -- will reflect that when you look at the seasonality. But I do appreciate how tricky it is to model, which is why we gave the guidance going forward."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","No, I respect that, too, and I understand the comparability year-over-year is tough. I guess I was talking more specifically about just identifying what the cost cutting was in the actual quarter or this quarter itself and maybe I'm missing something that",57,"No, I respect that, too, and I understand the comparability year-over-year is tough. I guess I was talking more specifically about just identifying what the cost cutting was in the actual quarter or this quarter itself and maybe I'm missing something that I wouldn't think that would be that difficult to identify, store closings, headcount reduction, but..."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Bob, if I can maybe help a little bit. I mean, we've done a good review of all of the projects that we'll focus on the future. I think we've been really clear within the business that we're focusing back on our core business of Retail Pharmacy front-end p",115,"Bob, if I can maybe help a little bit. I mean, we've done a good review of all of the projects that we'll focus on the future. I think we've been really clear within the business that we're focusing back on our core business of Retail Pharmacy front-end products, specialty. And therefore, all of the other areas where we were building out maybe potential future products we'll look further, in fact, to reduce the spend in some of these areas. So more focus back on the core business. So that really has been reducing a lot of projects and we're really very confident there before, on the $1.5 billion in savings that can be achieved."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","To really reinforce what Alex has said, we've been putting a lot of internal work into the whole process of how we evaluate new initiatives, how we track initiatives that perhaps are not working and then you stop them, you don't let them drag on. If somet",128,"To really reinforce what Alex has said, we've been putting a lot of internal work into the whole process of how we evaluate new initiatives, how we track initiatives that perhaps are not working and then you stop them, you don't let them drag on. If something really isn't working, you give it a good go then you stop it. New initiatives, we've got a lot of what I would describe as financial rigor that has been increasingly put in place really over the last 12 months, Alex, you put a lot in place when you took overall responsibility for the Walgreen business and we're continuing to do that and I think it's that rigor that we're seeing then in terms of some of the SG&A coming through."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That make sense. And I guess just one quick follow-up on Part D network, specifically, there's a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to yo",70,"That make sense. And I guess just one quick follow-up on Part D network, specifically, there's a big initiative from your predecessors to get deeper into some of these preferred networks. I'm curious how the economics of those networks have compared to your expectations, I know it's only about 6 months in. And then based on that feedback, any thoughts on your continued participation in these preferred networks going forward."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, it's Alex again. No, this is a really important customer, a really important market segment. That segment is growing rapidly so we remain very committed to this. And in terms of, I've said before, we are, in terms of next year's plans, have almost co",155,"Yes, it's Alex again. No, this is a really important customer, a really important market segment. That segment is growing rapidly so we remain very committed to this. And in terms of, I've said before, we are, in terms of next year's plans, have almost completed all the contracts and to the expectation in terms of margins that we planned for. So very committed to this business and we are -- Steve's [ph] done a good job. We're pleased with where we are and committed to next year. Importantly, for us of course, we're only at the end of first stage. The second stage, which is how [indiscernible] access to make sure that you really -- we can serve the patients and the customers who come to your pharmacy and make sure you get the appropriate level of their draw-through and volume through your assets and that's a bit we're now turning our attention to."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Alvin Concepcion with Citi.",9,"Our next question comes from Alvin Concepcion with Citi."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Congratulations, Stefano. My question is just really around beauty. Just curious how the tests are going in New York and Phoenix. Are there any findings you could share from that? Particularly interested in if you're getting a sales lift in the aisle and",50,"Congratulations, Stefano. My question is just really around beauty. Just curious how the tests are going in New York and Phoenix. Are there any findings you could share from that? Particularly interested in if you're getting a sales lift in the aisle and if you're seeing much traction from No7?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Of course. You know the importance that we give to our brands and No7 is having a fantastic trend in the U.K. and internationally and it's one of our really hope for the future in the U.S. But maybe, Alex, you can say what you are doing now for No7 and wh",57,"Of course. You know the importance that we give to our brands and No7 is having a fantastic trend in the U.K. and internationally and it's one of our really hope for the future in the U.S. But maybe, Alex, you can say what you are doing now for No7 and what you are expecting from it."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've rolled No7 into just over 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just over 12 months old and we'll be able to the measure the impact both on No7 sales, on Boots brand product sales and al",218,"Yes, we've rolled No7 into just over 400 Walgreens and Duane Reade stores in Phoenix and in New York City. And the Phoenix market is just over 12 months old and we'll be able to the measure the impact both on No7 sales, on Boots brand product sales and also on the beauty categories and we're pleased with what we're seeing. So now it's time to plan for the next stage of evolution of No7 and the Boots brand in Walgreens and Duane Reade in the U.S.A. and we'll come out with these plans when they're ready, but we are pleased with the results. Personally, I'm also pleased that we were able to acquire Soap & Glory, I think that happened in the previous quarter and obviously this morning we've seen Liz Earle. But going forward, the more unique products that we're able to get into the Walgreens beauty and health care offer, then the more unique it will make our offer going forward in what is a very competitive marketplace. So again, very pleased with the brand's performance, very pleased with the progress that Ken Murphy and the team have made in the Global Brands organization, still very young. I'm looking forward to getting these unique products in front of our customers in Walgreens in the future."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And as a follow-up, what were you thinking for the timing of the full rollout?",16,"And as a follow-up, what were you thinking for the timing of the full rollout?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we'll come back with that. I mean, we're really -- I've said before, we're just doing the walk [ph] now. We've got to get this right. This is a bigger stage. It's a fantastic brand, as Stefano said, in Europe and is growing really well in Europe. So",62,"Yes, we'll come back with that. I mean, we're really -- I've said before, we're just doing the walk [ph] now. We've got to get this right. This is a bigger stage. It's a fantastic brand, as Stefano said, in Europe and is growing really well in Europe. So we'll come back there when we're ready, but we're in a good position."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from Mark Wiltamuth with Jefferies.",9,"Our next question comes from Mark Wiltamuth with Jefferies."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it looked like there were some overhead allocations that changed versus a year ago?",32,"I just wanted to inquire how comparable the U.S. SG&A number is on a year-over-year basis because it looked like there were some overhead allocations that changed versus a year ago?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","So I mean, they're not directly comparable because, clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of",101,"So I mean, they're not directly comparable because, clearly, the corporate expense, for example, as I've said in my presentation, has to get allocated across the 3 divisions. Clearly, we're also allocating the synergies, which we talked about in terms of where the economic benefit is. So those results, unfortunately, are not directly comparable so they come with that very big health warning. But I think what we have said is we are very pleased with the progress that we're making in reducing SG&A and we're very much on target to deliver the program that we announced in the last quarter."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So -- and the numbers that presented were down, but I guess on an apples-to-apples was the SG&A percentage down?",20,"So -- and the numbers that presented were down, but I guess on an apples-to-apples was the SG&A percentage down?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","There isn't an apples-and-apples basis. That's the -- I guess, that's challenge that we got, simply. And I think we said at the time we did the deal, our priority was to get the deal done quickly, but one of the things that, that didn't enable us to do wa",84,"There isn't an apples-and-apples basis. That's the -- I guess, that's challenge that we got, simply. And I think we said at the time we did the deal, our priority was to get the deal done quickly, but one of the things that, that didn't enable us to do was to go back and rework everything on an apples-and-apples basis. But we're making good progress, that's the key message I can see. But I know how difficult it is not getting everything apples-and-apples."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And I understand you're not announcing the International segment's year ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those International segments even though you don't h",46,"Okay. And I understand you're not announcing the International segment's year ago performance as well, but is there anything you can give us in terms of health indicators for margin and profitability on those International segments even though you don't have a GAAP presentation for us?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think we can say that we're pleased with the performance. When we look at Retail Pharmacy International, obviously Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that mar",243,"I think we can say that we're pleased with the performance. When we look at Retail Pharmacy International, obviously Boots is the largest component there. We're delivering solid performance in a market where there are quite a lot of challenges in that market, you see what's happening in some of the supermarket sector, for example. But I think this demonstrates the strength of the offer. It's very important to have a differentiated retail offer particularly in beauty where Boots is renowned. We've got a very strong loyalty card program. Alex talked obviously about the great work that's being done here and taking Balance Rewards forward, the Advantage Card program equally important in the U.K. And then the piece that I touched on in my presentation is really omni-channel where ordering online through boots.com and picking up in-store to purchase is important. And of course, with the geography that we've got in the U.K. in the 2,500 points we can do that and we can actually leverage our Wholesale organization for delivery, we're able to do that in a profitable way that really meets the expectations of our customers. So that's the key component in there. And Wholesale, in any year, being in a number of markets, you get markets that perform better and markets that are more challenging, such is the way it always is, but the division's delivered a solid performance and -- as it's continued to do for many years."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, on the international Retail Pharmacy, there was some commentary in the analyst meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to",46,"I guess, on the international Retail Pharmacy, there was some commentary in the analyst meeting that the margin focus for growth was really shifting away to more of a sales growth story. Was there gross margin declines as you go through that transition to driving sales?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We've obviously not given the specifics on the comparability because we don't have the numbers on the same U.S. GAAP basis, but I continue to say that the business has performed solidly. We're pleased with the performance in what's been a tough retail env",128,"We've obviously not given the specifics on the comparability because we don't have the numbers on the same U.S. GAAP basis, but I continue to say that the business has performed solidly. We're pleased with the performance in what's been a tough retail environment in the U.K. and that's fundamentally important. On the NHS side, on the pharmacy side, clearly the government continued to contain growth in health care expenditure and so we haven't actually seen the details of the settlement yet. That's probably going to be towards the autumn. We'll just have to wait and see on the timing of that, but we continue to see pressure in that area as we've seen for a number of years. So no real change, but that pressure continues."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our final question comes from Ross Muken with Evercore.",9,"Our final question comes from Ross Muken with Evercore."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","So as you think about sort of the M&A landscape happening around you, obviously, Stefano, as you talked about, lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space, where do you think in terms of what",99,"So as you think about sort of the M&A landscape happening around you, obviously, Stefano, as you talked about, lots of consolidation happening in managed care, we've seen it in generics, we've seen it in the PBM space, where do you think in terms of what is happening around you is most relevant to kind of your business? Or what are you watching most? And how do you think, particularly on the managed care side, any of the changes there? How does that make you think about your longer-term positioning from a health care perspective in this market?"
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our industry and this is happening. In reality, I believe that this is a good news for us because the consolidation -- the horizontal consolidation",112,"As I have said, we can clearly see the need or the opportunity for horizontal and vertical consolidation in our industry and this is happening. In reality, I believe that this is a good news for us because the consolidation -- the horizontal consolidation will create a clear market and will give us more opportunities in the future. What we will be able to do specifically is a little too early to say. But I repeat, we want to be one of the players in this space and we see a lot of opportunities. And the opportunities are really open along the chain -- along the face of this health care industry."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","And I guess, just quickly, just staying on the M&A scene and I'll keep this is my last question, but you and your team have been remarkably savvy dealmakers over the course of your long career and have created massive amounts of value. How much of a chall",128,"And I guess, just quickly, just staying on the M&A scene and I'll keep this is my last question, but you and your team have been remarkably savvy dealmakers over the course of your long career and have created massive amounts of value. How much of a challenge of it is it today with where global equity markets are from a valuation standpoint? Obviously, understanding the financing markets are wide open, but valuations are pretty elevated. And so how do you think about that in the context of your capital allocation goals, particularly on the deal side? Does it argue to smaller transactions or certain geography? I'm just trying to get a sense for how that plays into your thinking and your -- the timing aspects of it."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","As you know, we have been always disciplined with potential acquisitions. So we will -- if we will have an opportunity, we will analyze this opportunity very rationally and we will do it just if this will create additional value. It's true that the market",101,"As you know, we have been always disciplined with potential acquisitions. So we will -- if we will have an opportunity, we will analyze this opportunity very rationally and we will do it just if this will create additional value. It's true that the market is now quite bullish, but it's also true that the cost of the money is still quite low and there are other ways to create value, not just the acquisitions. So we are analyzing all the opportunities. If we will see an opportunity which fits our strategy and which can create value, we will take action."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or Ashish if you have any further questions, I know some of you do. And with that, thank you very much, indeed. We'll conclude our cal",49,"Okay, ladies and gentlemen, that was our final question. Thank you all for joining us today. Feel free to contact myself or Ashish if you have any further questions, I know some of you do. And with that, thank you very much, indeed. We'll conclude our call. Thank you."
93624,304033436,832632,"Walgreens Boots Alliance, Inc., Q3 2015 Earnings Call, Jul 09, 2015",2015-07-09,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect, and everyone, have a great day.",20,"Thank you, ladies and gentlemen. That does conclude today's conference. You may all disconnect, and everyone, have a great day."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] I now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Invest",47,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] I now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Investor Relations and Special Projects. You have the floor, sir."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Andrew. Good morning, or afternoon, or wherever you may be for everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call.Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweat",265,"Thank you, Andrew. Good morning, or afternoon, or wherever you may be for everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call.
Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our results on greater detail. Also joining us on the call and available for questions is Alex Gourlay, Executive Vice President and President of Walgreens.
You can find the link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and the webcast will be archived on our website for 12 months.
Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions or otherwise.
Please see our second quarter Form 10-Q and subsequent filings, including our fiscal 2011 From 10-K when filed for a discussion of risk factors as they relate to forward-looking statements.
As a reminder, today's presentation includes certain non-GAAP financial measures and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.
With that, I'll hand you over to Stefano to make some opening comments."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Jerome. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a wholly combined company but also, [indiscernible] we a",1027,"Thank you, Jerome. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a wholly combined company but also, [indiscernible] we are announcing the acquisition of Rite Aid, a transaction that would significantly accelerate our plan to expand our pharmacy in. With this acquisition, we are accelerating long-term objective that we knew we needed to address, to strengthen our presence and coverage internationally outside the U.S. I have to say that we have reached an agreement with Rite Aid that reflect what we believe to be very fair terms, which will help us to unlock real value for the transaction. 
The addition of Rite Aid will accelerate our strategy by completing our network, providing a larger and more comprehensive portfolio, which within we can deploy our knowledge and skill and creating a more comprehensive and stronger platform for the development of our brand presence and the future growth of our business. 
Clearly, there is still a lot to be done to complete the transaction with Rite Aid. Our teams have done a lot of work on these and we will work closely with the regulators to bring the transaction to a conclusion as soon as possible. George will give you more details about our agreement to acquire Rite Aid in a few moments. 
But first, let me review the progress we have made in the past year and our work to transform our business [indiscernible] across the company. When I spoke to you in July, I refer to the extraordinary amount of work that has been going on inside the company to establish the processes and systems in which to build the more responsive and efficient and relevant business. This is critical for what is today a rapidly changing business environment, with new and different dynamics that the company [indiscernible]. 
In all of our markets, we faced tough challenges, be it from competitors or from governments, relentless drive to manage health care costs. That said, I don't believe any one of these would not say that same thing on their business. Our job is to [indiscernible] we'll continue to be to identify, address and if we can lead the market to efficient scale inside and innovation. Of course, with the completion of our transaction to form Walgreens Boots Alliance and the subsequent executive and management changes, it has taken us a little time to come with the business. And as part of these, we have been actively working to strengthen and simplify our management reporting system to ensure that we can build a reliable and accurate picture of book and understand our strengths and weaknesses. 
We have to spent some time restructuring, refocusing a number of part of the business and a number of areas of management. In some areas, we have found to bring in people and skills from outside the group, recognizing that for our U.S. business, to dovetail the management reporting of recent extensive international network that requires something different in terms of systems and expertise than running a U.S.-based domestic business. Internationally, our management have to take some time to understand how they are impacted by the shift in the nature of our business is inevitable given the scale of our U.S. business. 
The practical and cultural issues that these changes have raised our complex parts and have been helping part by the relationships and connection we begin to forge in the years before initial announcement of our deal and the final completion. And has been achieved within the company, but we remain very much at the beginning of our journey. Alex and his team have been working hard to ensure that we are operating in an efficient and effective manner, optimize as far as possible to the needs of the communities that it serves. 
They have made a lot of progress but there is a lot more to do. Our work to understand the demand and potential of a more unique of our brand product during the Boots part of the M&A is now beyond stage and is beginning to rollout in a managed way across the network. 
We are restructuring the front end of our stores to set us on the right path of future growth [Indiscernible] as anticipated. This is the short term loss of something, however, this short-term impact is compensated for by the improved margins that this restructuring has delivered. We are also continuing to innovate in new channels to stay relevant and continue to pour the strengths of our brand into future growth. Every bit as much as in the physical one. I will be doing a great disservice to many people outside the U.S. if I did not mention that there are outstanding efforts as well. That this result -- resulted in solid performance from our international pharmacy and international sales businesses. 
So the fourth quarter results have been strong and the year as a whole has been good for us. We are confident that our synergy program is on track to deliver at least $1 billion in 2016 and as we have said, we are well into the process of reviewing the restructuring and refocusing our people to deliver on our plan for many years to come, reinvigorating and different today our business every market we operate in. 
Let's say, after the completion of our formal synergy programs resulting from the more recent Alliance Boots, we will expect to result to work to the more normalized economic profile for the business in 2017 and beyond. Overall, therefore, this is an exciting and busy time and although I am never satisfied with what we have achieved as I believe in general that we can ensure to reach for more. I am also realistic and acknowledge the work that they've done and recognize that this has been a good year for the company. 
I will now hand you over to George will talk through the results and give you a bit more detail on our [indiscernible]. I will come back to you after George."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon, to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights int",3961,"Thank you, Stefano. Good morning, everyone, and good afternoon, to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights into the performance of our 3 divisions before updating you on the progress that we've made in our synergy cost savings programs. I will conclude by providing some details on the Rite Aid agreement before taking you through our guidance for fiscal year 2016.
I will begin by reminding you that our fiscal year 2015 results are not likely comparable to fiscal 2014. It is primarily due to 3 key elements associated with completing the second step of our transaction on the first [ph] of December 2014. Firstly, we eliminated the 3 months performing lag for Alliance Boots and the recast prior year results with no lag. Secondly, segments were reporting from first January '15 includes the allocation of synergy benefits, including WBAD and combined corporate costs. And lastly, fiscal 2015 results include equity earnings of Alliance Boots in the 4 month of September to December 2014 and full consolidation of Alliance Boots earnings for the 8 months from January to August 2015. 
I'm proud of our achievements and accomplishments in fiscal 2015, out transaction and delivering strong financial performance and reporting a combined results for WBA require great teamwork across the organization. 
Approaching now in our overall performance for the year. Net sales for fiscal year 2015 were $103.4 billion. On a GAAP basis, operating income was $4.7 billion, management expense $605 million, the tax rate was 19.9% and net earnings to Walgreens Boots Alliance was $4.2 billion or $4.00 per diluted share. 
On an adjusted basis, our operating income was $6.2 billion as compared to fiscal 2014, the key factors which drove our fiscal 2015 results for the full consolidation of Alliance Boots operations combined with growth in the Retail Pharmacy USA segment. Adjusted net interest expense for the year was $464 million, reflecting increased level of debt associated with the second step of the Alliance Boots transaction. 
Adjusted tax rate was 27.8%, which was lower than we were expecting due to business mix and certain discrete items that benefited us from our early in the fourth quarter. This result in adjusted net earnings typical to Walgreens Boots Alliance in fiscal 2015 of $4.1 billion accretive to $3.88 per diluted share. 
So now I will quickly take you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fiscal year. For GAAP earnings typical to Walgreens Boots Alliance in fiscal year 2015 of $4.00 per diluted share reconciles the adjusted earnings of $3.88 per diluted share. Net adjustment of $0.12 per share reflects additions of $0.17 of LIFO provision cost in Retail Pharmacy USA, $0.35 of restructuring related costs, that's from our cost optimization and store closure program, and net favorable $0.02 transaction and acquisition-related items from executing step 2 of the merger with Alliance Boots. 
These additions were more than offset by removal of a $0.54 gain on our once acquire AmerisourceBergen shares and an additional net $0.12 gain from [indiscernible] Reconciliation of all component items is included as an Appendix to the slides. 
So moving on to our fourth quarter results. Net sales in the fourth quarter were $28.5 billion, an increase of 50% versus the comparable quarter in the prior year. On a GAAP basis, operating income for the quarter was $836 million, and net earnings attributable to Walgreens Boots Alliance of $26 million, creating $0.02 per diluted share. 
On an adjusted basis, operating income increased to $1.5 billion, lead primarily by the consolidation of Alliance Boots. Adjusted net earnings typical to Walgreens Boots Alliance were $969 million or $0.88 per diluted share. This represents an increase of 14.3% on adjusted earnings per diluted share over the comparable quarter in the prior year. It should also be noted that the fourth quarter results last year included 3 months equity earnings as a result of Walgreens 45% interest in Alliance Boots compared to [indiscernible] consolidated results in this year's fourth quarter. 
Let me now that you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fourth quarter. GAAP earnings of $0.02 per diluted share for the quarter reconciles the adjusted earnings of $0.88 per diluted share. The net adjustment of $0.86 per share incorporates the following additions: $0.05 of LIFO cost in Retail Pharmacy USA; $0.20 of restructuring-related costs; $0.21 of 10 transaction and acquisition-related items and [indiscernible] to step 2 of the merger with Alliance Boots; a $0.37 loss on our once acquire AmerisourceBergen's shares; and net $0.03 from special items. 
So now I will take you through the performance of each of our 3 divisions, starting with Retail Pharmacy USA. Firstly, please remember we sold a majority stake in our infusion business in[indiscernible] with the minority position of share earnings and options care [indiscernible] now flows through the income statement as post-tax earnings from equity method investments. So looking first in the division's fiscal year performance. Total sales were $81 billion, a year-over-year increase of 6.0% [ph]. Sales on a comparable store basis increased by 6.4% for the full year. On a GAAP basis for fiscal 2015, gross profit was $21.8 billion while SG&A was $18.2 billion resulting in operating income of $3.9 billion. On an adjusted basis, gross profit for the full year was $22.1 billion, SG&A was $17.2 billion and operating income was $5.1 billion. 
Adjusted operating income increased 4.8%, driven by strong sales performance and tight cost control. Please remember when assessing this increase that the benefit of these 2 factors were partially offset by the inclusion of Walgreens share of equity earnings in Alliance Boots and operating income in the prior year-over-year. 
So, excluding this impact, adjusted operating income in the division grew by 12.5%. Substantial progress was made in controlling SG&A during the year, as a result of benefits associated with our cost-savings program. This was a significant driver of the division's year-on-year performance. On an adjusted basis, SG&A expenses decreased by 85 basis points year-over-year. At the end of fiscal year, the division operate it's 8,173 retail stores. 
So now let's turn to the divisions fourth quarter performance. Retail Pharmacy USA's total sales in the quarter were $19.9 billion, an increase of 4.7% over the fourth quarter in the prior year. The total sales in comparable stores increased [ph] by 6.5%. 
On a GAAP basis for the quarter, gross profit of $5.3 billion while SG&A was $4.7 billion, resulting in operating income of $511 million. On an adjusted basis, gross profit was $5.4 billion while SG&A was $4.3 billion. Adjusted operating income in the fourth quarter of $1.1 billion was down 10.1% over the comparable quarter in the prior year. This was primarily due [indiscernible] new equity earnings in Alliance Boots [indiscernible] versus 3 months in the comparable period. Excluding this impact, adjusted operating income grew by 1.2%.
We were able to increase adjusted gross profit dollars compared to the final quarter of fiscal 2014 despite lower gross margins, while at the same time delivering SG&A efficiencies through our cost-savings program. 
So let's now look at pharmacy part of Retail Pharmacy USA in more detail. Comparable pharmacy sales were up 9.3% for the fiscal year. We filled 894 million prescriptions, including immunizations, that's on a 30-day adjusted basis, an increase of 4.4% over last year. Prescriptions filled in comparable stores, up 4.6% year-on-year. In the fourth quarter, comparable pharmacy sales were up 10.0% as we filled 222 million prescriptions, an increase of 4.6% over the equivalent quarter in the prior year. 
Prescriptions filled in comparable stores, up 5.1%. Year-over-year we continue to see a positive impact and further growth in Medicare Part D and ACA funded scripts, resulting in our retail prescription market share on a 30-day adjusted basis increasing to 19.1% for the year ended for the year ended 31st of August, an increase of approximately 20 basis points. 
The benefits of positive sales growth was substantially offset by pharmacy gross margin pressure, consistent with our expectations. Pharmacy margins were negatively impacted in the fiscal year by lower third-party reimbursements, an increase in Medicare Part D mix, including the strategy to continue driving 90-day prescriptions at retail and the mix of specialty products, which carry a lower margin percentage. 
The decrease in pharmacy margins is partially offset by additional branded generic conversions compared with the prior fiscal year. While we continue to anticipate margin pressure, we remain confident in our strategies to drive access, clinical programs such us Medicare Part D and deepen our payer relationships to grow our pharmacy business over time. 
Moving now into the retail products performance within Retail Pharmacy USA. Retail sales increased by 1.9% for fiscal year 2015, while comparable sales increased 1.5%. As anticipated, the rate of sales growth was slightly slower in the fourth quarter as we continue to remove our more inefficient promotions, reduced store numbers and optimize opening hours. Sales increased 0.8% in total and by 0.4% on a comparable stores basis. Overall, our strategy continues to be to drive sales growth and improve profitability, and I am pleased to report that gross profit margins have increased for the sixth quarter in succession. 
Over the past 18 months, we've improved our product mix in our key health and wellness categories, [indiscernible] to higher proportion of total sales. We've also enhanced our merchandising tools, continue to optimize our promotional performance and upgraded on shelf availability during products store at the right price. And finally, we have improved sourcing with a higher level of our own branded products. 
In fiscal year 2016, we plan to continue to invest to drive our strategy and improve our customer offer. We will take what we've learned from our successful No7 test in Phoenix and New York City, where we saw positive lift in both beauty and overall sales and rollout the new beauty offering to an additional 1,600 stores for a total of 2,000. 
With this new offer, we will elevate the customer experience, better fixtures, improve customer care, space optimization and selected store upgrades. We're also advancing the first optimization of our Balance Rewards program, more offers targeted to our everyday points program to our health and beauty customers. 
To these efforts, we're striking to improve our customers experience, expand our profit margin in the front of store and continue to grow sales in key customer category. With that, let me turn to the results of our Retail Pharmacy International division, which is pharmacy-led health and beauty businesses in 8 countries. 
As a quick reminder, our biggest operations are Boots in the U.K. followed by a Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. We ended the fiscal year with division operated 4,582 retail stores. Our focus my commentary for this division primarily on the most recent quarterly results as the fiscal year only has 8 months of data and therefore, isn't all that meaningful particularly as it does not cover the important holiday season. 
Total sales in the division for the quarter were $3.5 billion, sales growth when compared with our third quarter was mainly due to the expected strongest sales in seasonal categories combined with currency benefits, mainly the British pound strengthening versus the dollar. On a GAAP basis for the fourth quarter, gross profit was $1.5 billion and SG&A was $1.3 billion, resulting in operating income of $196 million. 
On an adjusted basis, gross profit for the fourth quarter was $1.5 billion and SG&A expense was $1.2 billion, which resulted in operating income of $242 million [indiscernible]. Adjusted operating margin was 7.0% for the quarter, which was in line with postacquisition figure over the last 8 months of the fiscal year. 
To note, let's look more closely at the operating performance of the division. On a pro forma constant currency basis, comparable store sales growth for the quarter was 4.3%. Comparable store retail sales growth of 4.5%, being somewhat stronger than pharmacy at 4.1%. Comparable store sales growth in U.K. was 3.5% in the quarter. Growth across all retail sales categories resulted in comparable store retail sales [indiscernible] of 4.9%, performance in beauty and offering being the largest factors. 
In beauty, No7, our award winning beauty brand celebrated its 80th anniversary with another good quarter, with both skin care and cosmetics delivering double-digit sales growth in the U.K. Sales of No7 Protect & Perfect Advanced Serum continue to be strong, [indiscernible] 1 year on from their launch, supported by their continuing market program, which highlights the clinically proven product benefits, which I talked about on our last earnings call. 
During the quarter, we also launched No7 advanced day and night cream with a new color cosmetics campaign. Both of these initiatives were well-received by our customers. Our U.K. website, boots.com, continues to see strong growth with orders during the order up more than 65% over the same period last year. 
The beginning of August, we further enhance the convenience of our order and collect offer by enabling customers to order by 8:00 p.m. still collect in-store from 12 noon the following day. In the fourth quarter, nearly 70% of all our online orders in the U.K. were collected in-store. 
Outside the U.K., our businesses in Mexico, Thailand and the Republic of Ireland all delivered pro forma constant currency comparable store sales for the quarter, while above the average of the division as the [indiscernible] competition U.K. 
So turning now to our Pharmaceutical Wholesale division. Total sales in the Pharmaceutical Wholesale division in the fourth quarter work $5.8 billion. On a pro forma basis, assuming constant currency and excluding acquisitions and disposals, sales increased by 5.0% over the same quarter in the prior year. 
Sales growth was particularly strong in Norway where our wholesale business won a major new contract pharmacy, which we began right on the start of calendar 2015 and 5 other countries where our businesses each achieved double-digit comparable sales growth in the quarter. This included 2 of our largest wholesale businesses in Turkey and Germany. 
GAAP operating income in the fourth quarter was up $133 million, though adjusted operating income was $158 million. Adjusted operating income margin for the quarter was 2.7% compared to 2.9% for the 8 months postacquisition. This, in part, lies the seasonal nature of pharmaceutical wholesaling. 
So having covered our divisional performance, I would now like to turn to our synergy program, some of the key drivers of profit growth. So combining that synergies for fiscal 2015 was $799 million, significantly above our target of at least $650 million. This includes $81 million plus [indiscernible] synergies in the fourth quarter, which relates to activities commencing in prior fiscal years. 
Consistent with our prior reporting, this synergies are allocated across each segment. They do not include any benefit from our long-term relationship with AmerisourceBergen or the benefits of refinancing the legacy Alliance Boots indebtedness at a lower cost. 
For fiscal year 2016, we continue to expect at least to reach at least $1 billion in combined net synergies. As time goes on and the combined management team works closely together, there are, of course, a number of other synergies being identified and actioned, but many of them are simply not practical to quantify as they blend into our core operations. 
So moving now to our cost-savings program, which is as you know, is another key area of focus. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. We expect the reach pretax charges associated with this program, as previously stated, of reaching $1.6 billion and $1.8 billion, with cash component is expected to be approximately 60%. We continue to make good progress towards this goals and have achieved more than half of the program's expected savings as of the end of the fiscal year. 
In the Retail Pharmacy USA division, which is the primary driver of this program, this included closing 75 stores in the quarter, making a total of 84 store closures in fiscal 2015 as part of our plan to close approximately 200 stores total. 
Actions taken during fiscal 2015 have resulted in pretax charges totaling $542 million, including $223 million for asset impairments, $202 million for real estate closures and $$117 million for severance and other business transactions and fixed costs. 
So now I've now like to look at cash flow and capital deployment. GAAP operating profit cash flow was $5.7 billion for the full fiscal year and $1.5 billion in the quarter. Free cash flow was $4.4 billion for the full year and $1.1 billion in the quarter. 
Although it's hard for you to gauge our cash generating abilities from today's results, I'd like to give you some insight into our operating cash flow and working capital priorities. We remain intensely focused in driving cash flow across our 3 business segments. 
So in our Retail Pharmacy USA division, during the year, we've improved inventory management, both pharmacy and retail products. We have more opportunities in inventory covering focus on accounts receivable and accounts payable, all with the aim of driving further working capital savings. We will continue to apply the same discipline in Retail Pharmacy International, Pharmaceutical Wholesale. 
Total capital expenditure was $1.3 billion for the full fiscal year and $361 million in the quarter. After the merger, we put in place operational governance procedures to approve capital and then show that we are prudently maintaining our infrastructure, while investing in the right growth initiatives to generate return to shareholders. This processes working well. 
You will see a step-up in capital spend from the third to fourth quarter, which has lead to our renewed drive to invest in in key areas and develop our customer proposition, including information technology. 
So moving on to our key financing activities. In line with our philosophy of having an efficient balance sheet, we completed $395 million of share repurchases in the quarter against our $3 billion authorization, bringing the total purchase under this program to $726 million by the fiscal year-end. Since then, an existing 10b5-1 program is being completed, in which we acquired an additional $110 million of shares. We now have $2.2 billion of value remaining under our authorized bond. 
In addition, as we previously announced, we redeemed the $1.75 billion of legacy Walgreens debt in August As we've said before, we remain committed to a long-term dividend payout target between 30% and 35% of adjusted net earnings. 
But before I finish and hand back to Stefano, let me just spend a few minutes on the impact of our agreement to acquire Rite Aid on fiscal 2016 guidance. As you know, the agreed price per share for Rite Aid is $9, representing a total enterprise value of approximately $17.2 billion, including acquired net debt. The consideration for the shares will be paid in cash from existing new resource. The transaction is, as you will expect, subject to approval by Rite Aid shareholders, regulatory clearances and other customary closing conditions. We have done significant analysis on how we can bring the 2 companies together, including antitrust [indiscernible] closely with regulators to bring the transaction to completion as soon as possible. That said, we anticipate the transaction closing in the second half of calendar 2016. The exact timing of this will clearly determine the impact on our financial results. 
Clearly, we are very confident in taking everything into account, the transaction will be suitably accretive for us. We have been prudent in our assumptions for the business and have been realistic about the expectations for the markets in which we operate. That said, we expect the transaction to be accretive during the first full year after completion on our usual adjusted basis. 
In addition to timing, there are a number of other factors that will impact us. We've identified an excess $1 billion [ph] per gross synergy that we must -- that we will start working to capture as soon as completion takes place. But we must recognize that while some of these are relatively easy to identify, others will require investment and will take time to deliver. 
As we are paying cash for the acquisition, we have taken the decision to suspend our share repurchase program and intend to redeploy that cash to partly fund the transaction. This means that in 2016, we will not enjoy the earnings accretion of the buybacks we originally planned. In fact, we will be running a road to the inefficient balance sheet for a short period of time. 
The transaction will also cause a temporary increase in leverage, but this does not represent an underlying tension financial policy. We'll put in place a guide path to deliver metrics consistent with our commitment to solid investment-grade. 
So with all that said, let me conclude by talking about our outlook for fiscal year 2016. As you know, we've previously had stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. We committed on our Analyst Meeting meeting in April, that on completion of our budgeting process, we will come back to you to give an updated view of 2016. 
Based on our budget and further evaluation of both risks and opportunity, which factors in our currency headwind of around $0.13 since the previous Walgreens management initially provided our FY '16 adjusted EPS goal back in August 2014. We're issuing new guidance for fiscal year 2016 of $4.25 to $4.55. This change is primarily to reflect the impact suspending our share buyback program, to apply these funds towards the consideration for the transaction. This guidance assumes no material accretion from the planned acquisition of Rite Aid, which is expected to close in the second half of calendar 2016. Please also remember that we have translational exposure primarily based on movements in the pound sterling versus the dollar. Not only does this impact our adjusted operating income and EPS, but it can also cause particularly volatility in the sales, gross margin and SG&A items as it did this quarter. 
As Stefano indicated, we anticipate the published numerical synergy targets from the merger between Walgreens and Alliance Boots to be met in 2016, and we'd advice you after we will have achieved that target. The synergies and benefits from the transaction with Rite Aid will be almost entirely within our U.S. retail pharmacy division and so it will be reflected in these figures rather than a separate itemized programs. 
Clearly, we will continue to drive hard efficiencies across [indiscernible] but we see this as normal working practice rather than unique and discrete projects. And so going further beyond 2016, we would expect our earnings growth to return a more normal fiscal challenge low double-digit growth. 
In terms of the shape of the quarters, please remember that both our first and second quarters of fiscal year '16 are noncomparable given that we close the merger on the 31st of December 2014. Seasonality is most prominent in our retail pharmacy segments with the first quarter typically the weakest. Our second quarter picks up most of the holiday season, which will be more prominent going forward as we will consolidate December results of for Retail Pharmacy International. This would include Boots performance in December, which is typically it's most important trading month. We also expect the shape of the second half of the fiscal year to be generally consistent with what we saw in fiscal 2015, with adjusted earnings per share in Q3 and Q4, stepping down sequentially from Q2. 
So with that, I will turn the call back to Stefano."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So another good year. That the year of transition brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our on track and maintain ou",417,"Thank you, George. So another good year. That the year of transition brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our on track and maintain our momentum in our businesses, both in the U.S. and around the world, while at the same time be able to study and understand the renewal markets and deliver corporation [indiscernible]. 
As CEO, I very much recognize my role is both to support my team in achieving, also in creating the opportunities and the for them to out perform and identify sources of growth in value enhancement environment helping market to sustain its secure the future for the company beyond [indiscernible]. As we said today, we have potential opportunities in many businesses in many geographies. We continue to review all the opportunities open to us to assess where to best deploy our capital to provide the best feature of our [indiscernible]. 
The health care market is extraordinarily dynamic with many moving parts, and these dynamics create new opportunities and new ideas for the time. The key part of my role is to make sure that we pursue these opportunities where they're desirable to do so and not waste time and resources to [indiscernible]. And to ensure that we do that without the distracting our teams on delivering on our long- and short-term plans of our existing business. Over time, you can expect to see us complement the development of our existing businesses with further additions will help us identify and differentiate our business. 
As we look at opportunities around the globe, even the unique dynamic of the U.S. market, it is not surprising that the best opportunity we have found this year has been here. While as aware of our expensive included some of the and small bolt-on acquisitions to our original business. 
The global health care market and perhaps the U.S. markets more than any of ready persistent openness to new ideas and new approaches while it provides care. As a leading global health care company, we have the potential to play a tiny role in this evolution. We have always been for that and willingness to find the innovative solution and think about things in new ways and these are quantities I am glad to be spread across the group and I believe will from the foundation for the success of the business going forward. 
Now let's open up for questions. Gerald, Please?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Andrew, we will take questions now.",8,"Thank you. Andrew, we will take questions now."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Edward Kelly from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Edward Kelly from Credit Suisse."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call by the way didn't really have any reference to your appetite for FTC risk. So does the merger agreement have [indiscernible]? And if it does, can",112,"Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call by the way didn't really have any reference to your appetite for FTC risk. So does the merger agreement have [indiscernible]? And if it does, can you provide more detail here? And as you think about FTC, I mean, there is history that we can sort of look back to, in 2007, when Rite Aid bought Eckert, for instance, in terms of the parameters that they look at, that's still a relative way to think about it? Any thoughts related to all these, I think would be very helpful to people."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's a very difficult to comment about that, of course, before doing that, doing these decisions, taking the decisions and doing the steps, we have analyzed things very carefully. We have tried to figure out what would happen. But, of course, this have be",81,"It's a very difficult to comment about that, of course, before doing that, doing these decisions, taking the decisions and doing the steps, we have analyzed things very carefully. We have tried to figure out what would happen. But, of course, this have been down within the of our company. In this situation, it's a very difficult for us to make public comments. You now when we have a public authorities, it's better for us not to interfere at all."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, just 1 follow up to that, I mean, because the merger agreement is going to come out soon, I would think so. How much divestiture risk are you assuming within this agreement? Is there a certain number of stories? How would you frame that in the ag",49,"I guess, just 1 follow up to that, I mean, because the merger agreement is going to come out soon, I would think so. How much divestiture risk are you assuming within this agreement? Is there a certain number of stories? How would you frame that in the agreement?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have put the top because, of course, we have to take certain precautions. But we are not speculating at all about the number of stores that we will have divested.",31,"We have put the top because, of course, we have to take certain precautions. But we are not speculating at all about the number of stores that we will have divested."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And just sorry, 1 -- I apologize, but could you give us the numbers that you sort of cap this at?",22,"Okay. And just sorry, 1 -- I apologize, but could you give us the numbers that you sort of cap this at?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I can not give you the number [indiscernible] .",9,"I can not give you the number [indiscernible] ."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser from Morgan Stanley."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, so congratulations on your underwriting deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think about when y",92,"Yes, so congratulations on your underwriting deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think about when you kind of put together Alliance Boots and Walgreens, you've also communicated synergy number and you've kind of like unabated it that the drug purchasing front end, et cetera. So if you can give us some similar context for the Rite Aid deal, it would be very helpful."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've not given the specific details on this but I'm sure you can imagine as with any deal of this nature, there are different classifications of synergies, the procurement synergies, the G&A cost synergies or the other cost-saving synergies. And the",167,"Yes, we've not given the specific details on this but I'm sure you can imagine as with any deal of this nature, there are different classifications of synergies, the procurement synergies, the G&A cost synergies or the other cost-saving synergies. And these we will -- these synergies we will access in a structured way much as we have done with the Walgreens Alliance Boots transaction. We've got a team here very experienced in accessing those synergies. We're very confident that we -- in our numbers. As ever, synergies date of this gross synergies take time to time to access. Some of them can be achieved faster than others. Some would require investment and we will work through that. That there will be an element of investment to get these synergies. But clearly, go over the coming time, we will work through our best to achieve these. But we've done a lot of work as ever to be really feel confident in the number that we have published."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","You have to understand, in this case, the synergies are coming mainly by internal efficiency. By the fact that maybe we can have a better network to sell our brands for our products, which is still the main component of our strategy. And so these will not",54,"You have to understand, in this case, the synergies are coming mainly by internal efficiency. By the fact that maybe we can have a better network to sell our brands for our products, which is still the main component of our strategy. And so these will not happen overnight, it will take some time."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Finally, to add to that, I mean, this -- the program in a sense is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to report the synergy separately in the way that we did",63,"Finally, to add to that, I mean, this -- the program in a sense is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to report the synergy separately in the way that we did from [indiscernible] essentially being shared half and half between Alliance Boots and Walgreens."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But I want to stress what George has said, we have done a lot of work and we are very confident that this deal will deliver for us.",28,"But I want to stress what George has said, we have done a lot of work and we are very confident that this deal will deliver for us."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?",23,"Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Maybe, Alex can give you. We will discuss about the -- their PBM business and Alex can do something about it.",21,"Maybe, Alex can give you. We will discuss about the -- their PBM business and Alex can do something about it."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, as we note today, it's an important but relatively small PBM business. It's top 10 [ph], but not a big 1. It's business with a lot of capability in IT. So other movement [indiscernible] beyond the closure of the SSA reviewed the understand my",130,"Yes, I mean, as we note today, it's an important but relatively small PBM business. It's top 10 [ph], but not a big 1. It's business with a lot of capability in IT. So other movement [indiscernible] beyond the closure of the SSA reviewed the understand my what the business and how we can really help us understand access to the Medicare better. I mean, we have issue with the Rite Aid is to improve the quality of pharmacy and to really just across the market the measure that we rate a market, which is more affordable and more accessible with everyone and government policy. So we think this could be our way into that in terms of vision. But clearly, we understand more and we understand more [indiscernible] review."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And it will be a good opportunity for us to learn more and we are always open to learn.",19,"And it will be a good opportunity for us to learn more and we are always open to learn."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from that line of Meredith Adler from Barclays.",12,"Our next question comes from that line of Meredith Adler from Barclays."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes.",36,"We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, Meredith. It's alex here. Yes, we moved to something called everyday points here. We talked about that [indiscernible] as well basis for the majority of the front-end products we're able to offer points and also extended the points in our pharmacy bu",206,"Yes, Meredith. It's alex here. Yes, we moved to something called everyday points here. We talked about that [indiscernible] as well basis for the majority of the front-end products we're able to offer points and also extended the points in our pharmacy business to other scheme [indiscernible] Medicaid and Medicare where appropriate. We are really pleased with what's happened, the customers are designed into this program. We have, I think, it's about 27 million of customers into it and quite a few points. And more importantly, as we analyze how we're redeeming the points, we're seeing encouraging behavior. People are slightly more and more brand products and bigger baskets and products that may not otherwise be bought. So it's really every I mean, and the program the behavior we're seeing in these customers are encouraging and exactly the behavior we have seen in other loyalty programs that we know of well in the group. So we are, of course, we and then as we have done progressively since we launched the program just over 3 years ago now to invest wisely and carefully to ensure we get back our investments and [indiscernible] invest more in this program and we will do so in the years ahead."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I have a question about Rite Aid. I think the company, Rite Aid's management has been fairly upfront about this ad today, pretty large number of underperforming stores. I think they've been hesitant to close too many stores, plus the leases hav",69,"Great. And I have a question about Rite Aid. I think the company, Rite Aid's management has been fairly upfront about this ad today, pretty large number of underperforming stores. I think they've been hesitant to close too many stores, plus the leases have not yet run out. Could you please talk about your observations of the store base and what your approach would be to those underperforming stores?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's very difficult to adjust the operator, the management because we should understand all the different events and all of the different conditions in which the management has to operate. They have a lot of complaints, as you know, so I believe they've d",89,"It's very difficult to adjust the operator, the management because we should understand all the different events and all of the different conditions in which the management has to operate. They have a lot of complaints, as you know, so I believe they've done a good job of the situation that they were in. We will approach in our usual way, in a very rational way trying to do work to create value. So we are not emotional on that, and we will be rationale, if ever. Alex?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, and I think that it's clear that we are working hard to moving to really develop the front end and George gave the progress of the midyear in terms of being able to improve the operational margin in the front end over the last 6 quarters. So as we de",224,"Yes, and I think that it's clear that we are working hard to moving to really develop the front end and George gave the progress of the midyear in terms of being able to improve the operational margin in the front end over the last 6 quarters. So as we develop that, the best 5 years in Walgreens, as we take the best 5 years from that on Alliance Boots and again George update that we intend to expand our beauty product into 2,000 Walgreens stores have controlled test in both Phoenix and New York City. And also, as we really run some of the outside that the Rite Aid team have done in their new wellness format, we have the opportunity to grow that together. Once we do that, review and see how we can improve performance in all of our network across America and to provide you better front-end performance through, a more appropriate offer to America supporting our better quality pharmacy experience and of course, low cost. So as our intention obviously once we go through the process of SEC we'll be able to work more closely with the teams understand it. We think there's opportunity both in Walgreens and clearly, the team at Rite Aid see an improvement in the wellness format and will be in terms of the reporting."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I just have one more question. You highlight some of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel comfort",54,"Great. And I just have one more question. You highlight some of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel comfortable working with a Retail Pharmacy that still sells tobacco."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean we've chosen to invest to help people to stop smoking, to lose weight, a balanced healthy choice programs launched back 12 [ph] months ago has been very successful and even the taxpayer because we believe that there was less than 3% of tobacco sold",133,"I mean we've chosen to invest to help people to stop smoking, to lose weight, a balanced healthy choice programs launched back 12 [ph] months ago has been very successful and even the taxpayer because we believe that there was less than 3% of tobacco sold today in the drugstore channel. was there already in other places, of course, we continue to review and reflect this issue and other categories that we happen to sell. There are fundamental choices to best to help people who already want to stop and we've made really good progress there and what we've done. So at this stage, we have nothing else to update on apart from that we are pleased with the progress we've made our investments to help people across America to stop smoking."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments you feel the company need to make as you try to bring the 2 businesses together? I know the Walgreens executives has commented in the past that the IT infr",95,"I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments you feel the company need to make as you try to bring the 2 businesses together? I know the Walgreens executives has commented in the past that the IT infrastructure at Walgreens needs a little bit of work. I think the same thing is safe to say needs to work at Rite Aid. I guess us to try to think about gross synergies versus net synergies from your announcement, is there any more color you can give us there?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. Just a word on IT. I mean, as I touched in the presentation, one of the reasons that we saw a step up in the fourth quarter versus the third quarter was IT program and so we, as Walgreens Boots Alliance have been doing a lot of work since the merger",246,"Okay. Just a word on IT. I mean, as I touched in the presentation, one of the reasons that we saw a step up in the fourth quarter versus the third quarter was IT program and so we, as Walgreens Boots Alliance have been doing a lot of work since the merger [indiscernible] to structure our IT so that we're able to use our global scale and capability to invest in IT in a cost-efficient way to best help the needs of both the business internationally but more importantly our customers. So there's a lot of work on IT underway. In terms of the gross synergies, it's really I mean, this will come in a year after, as we have said, which is why it becomes harder to separate out than in the -- as we stop start to integrate the operations plus being able to complete the transaction. But the synergies that will come will be procurement synergies, where clearly isn't an investment requirement but then it will be investment over time and there is like an IT in upgrading the stores and we will do that in a thoughtful structured way. We will be working at stores on a store-by-store basis as we always do looking for the returns that we continue to seek. So the investment will always take a little bit longer to come. It will be down over time because of the nature of that, part of the integration takes longer."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And maybe a quick follow-up for Alex, if you're still. Could you provide us color on what the reimbursement rate environment is looking like for 2016. And how do you affect these conversations to evolve on a longer-term basis once there transactions",44,"Okay. And maybe a quick follow-up for Alex, if you're still. Could you provide us color on what the reimbursement rate environment is looking like for 2016. And how do you affect these conversations to evolve on a longer-term basis once there transactions close?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I can't comment [indiscernible] but what I can tell you is that we have anticipated that we have an enrollment. We're pleased we've been able to expand your partnerships with peers, for example, we announced that EDNA is a new partner for us and we're rea",107,"I can't comment [indiscernible] but what I can tell you is that we have anticipated that we have an enrollment. We're pleased we've been able to expand your partnerships with peers, for example, we announced that EDNA is a new partner for us and we're really pleased with that. So we are feeling as planned, of course, the reduction from last year's rate but as planned, as with expected, we've been able to try of our strategy of improving access and improving volumes to meet partnerships. We [indiscernible] won [ph] of 3 4-year contracts, and we don't comment on this contracts probably as you are aware."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Robert Jones from Goldman Sachs.",13,"Our next question comes from the line of Robert Jones from Goldman Sachs."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just 1 high-level 1 for Stefano and then just a couple of quick ones for George. I guess from a big picture perspective, why we're getting bigger in the the retail space the right move strategically right now? And then I guess my specifically as it relate",68,"Just 1 high-level 1 for Stefano and then just a couple of quick ones for George. I guess from a big picture perspective, why we're getting bigger in the the retail space the right move strategically right now? And then I guess my specifically as it relates to that, how much more negotiating leverage do you think this expanded network will give you versus payers and PBMs?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Bob, we have not done this to increase our negotiating power. We stay PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I'd say from internal service and the amortization of prices and",206,"Bob, we have not done this to increase our negotiating power. We stay PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I'd say from internal service and the amortization of prices and amortization improvement, the amortization of our know-how something, of course, in the combination of the stores as we were discussing before. There's something more products. So we are not thinking of really improving our position with the payers because at the end of the day, we are in an environment where the margin are decreasing [indiscernible] so decreasing, we are in an environment where there is a lot of competition and the fact that we put together 2 companies would not reduce the competition. That just the competition among pharmacies, think of the other mail order, think of the people who are specialized in certain categories, like the specialty for instance. So there are many people working in this area. I don't believe that this is really gave us an addition of power. But we have not accounted on that when we have put together our guidance. We have put together our numbers very, very carefully and very prudent have [indiscernible]."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Got it. And then I guess, George, just I know I'm sure you can appreciate it's difficult to have a visibility into the core pharmacy businesses just given out of the moving pieces not the least, of which is the synergies. Looks like the total synergies in",88,"Got it. And then I guess, George, just I know I'm sure you can appreciate it's difficult to have a visibility into the core pharmacy businesses just given out of the moving pieces not the least, of which is the synergies. Looks like the total synergies in the quarter are about $295 million. Is there any sense at all you can give us on how we should be advocating those across the business just to get a little bit better perspective on how the core businesses are tracking?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, we very much try and allocate the synergy based on the activities. So I do appreciate that made the segment analysis a little tougher for you to follow but by doing it on this basis of procurement, we really are therefore reflecting where the",207,"Yes, I mean, we very much try and allocate the synergy based on the activities. So I do appreciate that made the segment analysis a little tougher for you to follow but by doing it on this basis of procurement, we really are therefore reflecting where the volume is, where the activity is. Another result, obviously, with the Retail Pharmacy USA being, by far, our biggest segment then you should think of the synergies being heavily, heavily weighted towards the U.S. segment. It's the basis I would always think about. I mean, as we think annualized through, as we get to the third quarter, which I guess will be our first  year-on-year quarter and it will be a little bit easier for you to see. And of course, it's the hard synergies, which are the ones that we're quantifying. Not really a lot of the what are in effect synergies, but they're not the ones that we can quantify. These are the ones that are really coming through as we know the are increasingly I think our integrated combined management team are working very much together on many of the programs, sharing best practice and that's very much business as usual rather than run through synergy [indiscernible]."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","But that's really helpful. And then just the last 1, more of a clarification, George. Did I here you correctly the EPS growth beyond 2016 is anticipated to be low double digits? And if that's right, any sense you can give us and was convicted in capital o",54,"But that's really helpful. And then just the last 1, more of a clarification, George. Did I here you correctly the EPS growth beyond 2016 is anticipated to be low double digits? And if that's right, any sense you can give us and was convicted in capital on these relative to the target."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, yes, that's as far as we've indicated. Just to try and give you a sense of how we see the business going forward. So in relation to capital allocation. . .",33,"I mean, yes, that's as far as we've indicated. Just to try and give you a sense of how we see the business going forward. So in relation to capital allocation. . ."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Is that contemplated in the low double-digit target?",9,"Is that contemplated in the low double-digit target?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","That's got a typical investment program. So absolutely everything is in there. I mean, we're being quite prudent as you would expect in this area.",26,"That's got a typical investment program. So absolutely everything is in there. I mean, we're being quite prudent as you would expect in this area."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But when we are talking of next year, there is part of next year, which if you take -- if you do the math and then take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this i",157,"But when we are talking of next year, there is part of next year, which if you take -- if you do the math and then take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this is substantially on organic growth. So in the retail business, to have an organic growth of double-digit, low double-digit is not easy. We have done this for many, many areas. I have to say we have never had 1 year without double-digit growth in our history. But I can tell you that is not easy because it's relatively easy to announce earnings per share, buying back a lot of shares or buying additional businesses. The business if we are buying this time, we'll not have an effect next year. So we have the look at the numbers o9f next year as organic growth."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill from JPMorgan.",12,"Our next question comes from the line of Lisa Gill from JPMorgan."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, I just want to go about the the synergies on the Rite Aid deal for a minute and just give the time of your expectation on the procurement side. My understanding is that Rite Aid has released with moccasin for procurement that runs through March of",87,"George, I just want to go about the the synergies on the Rite Aid deal for a minute and just give the time of your expectation on the procurement side. My understanding is that Rite Aid has released with moccasin for procurement that runs through March of 2019. So the assumption that there's way to break that relationship and you'll get procurement earlier? Or is it that the time line is unknown on this because it may have to wait until then the end of the contract?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Lisa, first of all, I have to say we have not taken any decisions about the contract. Not to say we have to change substantially the contract in order to get the synergies. We are -- we believe we can have and at the rate we will discuss with the contract",135,"Lisa, first of all, I have to say we have not taken any decisions about the contract. Not to say we have to change substantially the contract in order to get the synergies. We are -- we believe we can have and at the rate we will discuss with the contract and of course, we will try to discuss the interest of the our company, that's obvious. But you don't have to assume the fact we will change the contract or we'll move the contract, of course, we have very good relationship with. But I have to tell you that we have a lot of respect for McKesson and a lot of respect for Julian and we will see. We will see at the time. It's obvious that we will try as much as possible."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And then Stef, you talked about the market open to change your belief in the role you answered an earlier question around the small PBM that's going to be part of the transaction. Can you maybe just give us any idea as to how you thi",82,"Okay, that's helpful. And then Stef, you talked about the market open to change your belief in the role you answered an earlier question around the small PBM that's going to be part of the transaction. Can you maybe just give us any idea as to how you think about that potential role that you play. And from your strategic view, how you think the U.S. market is changing and what role that a bigger Walgreens will pay here in the U.S.?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, for sure I can tell you that I have several ideas but before making these ideas probably, I would like to check this idea with the reality, which is around that. So now we have [indiscernible] a potential deal. We just started -- we just announced a",89,"Well, for sure I can tell you that I have several ideas but before making these ideas probably, I would like to check this idea with the reality, which is around that. So now we have [indiscernible] a potential deal. We just started -- we just announced a potential deal. We started this deal for 2 [ph] months we will really be absorbed in this deal. We will continue to think but for a few months, we won't be able to tell you where we want to go next."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, -- I'm sorry, maybe the opportunity is the beginning of next year? We'll get together in January and maybe will have to make some incremental ideas out you think about this?",32,"Okay, -- I'm sorry, maybe the opportunity is the beginning of next year? We'll get together in January and maybe will have to make some incremental ideas out you think about this?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I think it's about customer probably have more choice. I think with a fantastic group of people under Walgreens and the brand that they represent across America and where we have the biggest opportunity, I think.",37,"I think it's about customer probably have more choice. I think with a fantastic group of people under Walgreens and the brand that they represent across America and where we have the biggest opportunity, I think."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, appreciate that and congratulations on Rite Aid.",8,"Okay, appreciate that and congratulations on Rite Aid."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you very much. Have time for that in the future.",11,"Thank you very much. Have time for that in the future."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And the last question we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch.",23,"And the last question we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, you think you can raise from sale leaseback deal in fiscal '16?",27,"Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, you think you can raise from sale leaseback deal in fiscal '16?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward? We obviously, as you can see, done quite a bit sale-leaseback in the last particular year. We haven't set an internal target. We will continue to work th",79,"Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward? We obviously, as you can see, done quite a bit sale-leaseback in the last particular year. We haven't set an internal target. We will continue to work through these in a normal we've got very committed to having an efficient manage it, as I said on many locations. That's the answer to the second 1. So the first  one was. . ."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","The Rite Aid NOLs?",4,"The Rite Aid NOLs?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The rite Aid NOLs able anticipate over time to be able to utilize the NOLs.",15,"The rite Aid NOLs able anticipate over time to be able to utilize the NOLs."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, and just the clarity on the sale-leaseback. Walgreens have had 20% of their stores, I mean, do you envision bringing that number down meaningfully over time whatever the period?",30,"Okay, and just the clarity on the sale-leaseback. Walgreens have had 20% of their stores, I mean, do you envision bringing that number down meaningfully over time whatever the period?"
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, I would answer is I'm not weighted on having to won retail pharmacy locations kludgy that will be inserted of patients will very devoted the right thing to do it's not something we feel is necessary for our business model. So we will continue to loo",240,"Well, I would answer is I'm not weighted on having to won retail pharmacy locations kludgy that will be inserted of patients will very devoted the right thing to do it's not something we feel is necessary for our business model. So we will continue to look at sale and leaseback, where we believe it's the right thing to do. Really taking to the timing of the tenure of leases and when the lease breaks off. So we have a balance in our portfolio go we forward and then have the bunching of lease breaks at the same time. We will be doing is moving thoughtful way over time is what I would position it.
Thank you, ladies and gentlemen, that was the final question we have time for. Thank you for joining us. Please, we know there's many of you that have questions, please reach out to the IR team here and we will answer industries them as best we can. I should say that we gave back into the next quiet period in the first of December. So we have a comparatively short period. Management have been very generous with the time. We will try and get to as many of you as we can during that period. But please bear with us, we appreciate with an agreement as well as our results. We have a very busy few weeks ahead of us. Thank you very much indeed."
93624,312356229,883543,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you, again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day.",33,"Ladies and gentlemen, thank you, again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions]I'd now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Inv",47,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions]
I'd now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Investor Relations and Special Projects. You have the floor, sir."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Andrew. Good morning, or afternoon, or wherever you may be, to everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call.Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweat",268,"Thank you, Andrew. Good morning, or afternoon, or wherever you may be, to everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call.
Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our results on greater detail. Also joining us on the call and available for questions is Alex Gourlay, Executive Vice President of Walgreens Boots Alliance and President of Walgreens.
You can find the link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and the webcast will be archived on our website for 12 months.
Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions or otherwise.
Please see our second quarter Form 10-Q and subsequent filings, including our fiscal 2011 10-K when filed, for a discussion of risk factors as they relate to forward-looking statements.
As a reminder, today's presentation includes certain non-GAAP financial measures, and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.
With that, I'll hand you over to Stefano to make some opening comments."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a wholly combined company, but also, as you've seen, we",1066,"Thank you, Gerald. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a wholly combined company, but also, as you've seen, we are announcing the acquisition of Rite Aid, a transaction that would significantly accelerate our plan to expand our presence in the West. With this acquisition, we are accelerating long-term objective that we knew we needed to address, to strengthen our presence and coverage nationally throughout the U.S. I have to say that we have reached an agreement with Rite Aid that reflects what we believe to be very fair terms, which will help us to unlock real value from the transaction. 
The addition of Rite Aid will accelerate our strategy by completing our network, providing a larger and more comprehensive portfolio, of which we can deploy our knowledge and skill, and creating a more comprehensive and stronger platform for the development of our brand presence and the future growth of our business. 
Clearly, there is still a lot to be done to complete the transaction with Rite Aid. Our teams have done a lot of work on these, and we will work closely with the regulators to bring the transaction to a conclusion as soon as possible. George will give you more details about our agreement to acquire Rite Aid in a few moments. 
But first, let me review the progress we have made in the past year in our work to transform our businesses into right growth across the company. When I spoke to you in July, I refer to the extraordinary amount of work that has been going on inside the company to establish the processes and systems from which to being the more responsive, efficient and relevant business. This is critical for what is today a rapidly changing business environment, with new and different dynamics that the company [indiscernible]
In all of our markets, we faced tough challenges, be it from competitors or from governments, relentless drive to manage health care costs. That said, I don't believe any one on this forum not say the same thing on their business. Our job is [indiscernible] that we'll continue to be to identify, address and, if we can, lead the market to efficient scale insight and innovation. Of course, with the completion of our transaction to form Walgreens Boots Alliance in January and the subsequent executive and management changes, it has taken us a little time to come to [indiscernible] with the business. And as part of this, we have been actively working to strengthen and simplify our management reporting factor and system to ensure that we can build a reliable and accurate picture of our book and understand our strengths and weaknesses. 
We are ready to spend some time restructuring and refocusing a number of parts of the business and the number of areas of management. In some areas, we have found it necessary to bring in people and skills from outside the group, recognizing that for our U.S. business, to dovetail the management reporting of recent extensive international network that requires something different in terms of systems and expertise than running a U.S.-based domestic business. Internationally, our management there are ready take some time to understand how they are impacted by the shift in the nature of our business that is inevitable given the scale of our U.S. business. 
The practical and cultural issues that these changes have raised are complex but have been a helping part by the relationships and connections we begin to forge in the year before initial announcement of our deal and hits the final completion. And the margin around -- has been achieved within the company, but we remain very much at the beginning of our journey. Alex and his team have been working hard to ensure that we are operating in an efficient and effective manner, optimize as far as possible to the needs of the communities that it serves. 
They have made a lot of progress but there is a lot more to do. I want to understand the demand and potential for a more unique advantage of how our brand product using the Boots products as a base is now beyond the trial stage and is beginning to rollout in a managed way across the network. 
We are restructuring the front end of our stores to set us on the right path of future growth even if as anticipated. This is the short-term cost of something, however, this short-term impact is compensated for by the improved margins that this restructuring has delivered. We are also continuing to innovate in new channels to stay relevant and continue to pull the strengths of our brand individual growth. Every bit as much as in the physical one. I will be doing a great disservice to many people outside the U.S. if I did not mention that there are outstanding efforts as well. That this result -- resulted in solid performance from our international retail pharmacy and international sales businesses. 
So the fourth quarter results have been strong and the year as a whole has been good for us. We are confident that our synergy program is on track to deliver at least $1 billion in 2016. And as we have said, we are well into the process of reviewing and restructuring and refocusing our people to deliver on our plan for many years to come, reinvigorating and differentiating our business across every market we operate in. 
Let's say, after the completion of our formal synergy programs, resulting from the more recent Alliance Boots transaction, we will expect the result to work, so you can see there are more normalized economic growth profile for the business in 2017 and beyond. 
Overall, therefore, this is an exciting and busy time. And although I am never satisfied with what we have achieved as I believe in general that we can ensure our way to reach for more. I am also realistic and acknowledge the work that they've been done and recognize that this has been a good year for the company. 
I will now hand you over to George to talk through the results and give you a bit more detail on our recent [indiscernible] I will come back to you after that. George, please?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights into",4008,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights into the performance of our 3 divisions before updating you on the progress that we've made in our synergy and cost savings programs. I will conclude by providing some details on the Rite Aid agreement before taking you through our guidance for fiscal year 2016.
I will begin by reminding you that our fiscal year 2015 results are not likely comparable to fiscal 2014. This is primarily due to 3 key elements associated with completing the second step of our transaction on the 31st of December 2014. Firstly, we eliminated the 3-month reporting lag for Alliance Boots and recast prior year results with no lag. Secondly, segmental reporting from 1st January '15 includes the allocation of synergy benefits, including WBAD and combined corporate costs. And lastly, fiscal 2015 results include equity earnings in Alliance Boots for the 4 month of September to December 2014 and full consolidation of Alliance Boots earnings for the 8 months from January to August 2015. 
I'm proud of our achievements and accomplishments in fiscal 2015, closing out transaction, delivering strong financial performance and reporting a combined results for WBA require great teamwork across the organization. 
Looking now at our overall performance for the year. Net sales for fiscal year 2015 were $103.4 billion. On a GAAP basis, operating income was $4.7 billion; managed expense, $605 million. The tax rate was 19.9%, and net earnings attributable to Walgreens Boots Alliance was $4.2 billion or $4.00 per diluted share. 
On an adjusted basis, our operating income was $6.2 billion as compared to fiscal 2014, the key factors which drove our fiscal 2015 results for the full consolidation of Alliance Boots operations combined with growth in the Retail Pharmacy USA segment. Adjusted net interest expense for the year was $464 million, reflecting increased level of debt associated with the second step of the Alliance Boots transaction. 
Adjusted tax rate was 27.8%, which was lower than we were expecting due to business mix and certain discrete items that benefited us primarily in the fourth quarter. This result in adjusted net earnings attributable to Walgreens Boots Alliance in fiscal 2015 of $4.1 billion equating to $3.88 per diluted share. 
So now I will quickly take you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fiscal year. For GAAP earnings attributable to Walgreens Boots Alliance in fiscal year 2015 of $4.00 per diluted share reconciles the adjusted earnings of $3.88 per diluted share. The net adjustment of $0.12 per share reflects additions of $0.17 of LIFO provision costs in Retail Pharmacy USA, $0.35 of restructuring-related costs, that's from our cost optimization and store closure program, and a net favorable $0.02 transaction and acquisition-related items from executing step 2 of the merger with Alliance Boots. 
These additions were more than offset by removal of a $0.54 gain on our warrants to acquire AmerisourceBergen shares and an additional net $0.12 gain from special items. This reconciliation of all component items is included as an Appendix to the slides. 
So moving on to our fourth quarter results. Net sales in the fourth quarter were $28.5 billion, an increase of 50% versus the comparable quarter in the prior year. On a GAAP basis, operating income for the quarter was $836 million, and net earnings attributable to Walgreens Boots Alliance were $26 million, creating $0.02 per diluted share. 
On an adjusted basis, operating income increased to $1.5 billion, due primarily by the consolidation of Alliance Boots. Adjusted net earnings attributable to Walgreens Boots Alliance were $969 million or $0.88 per diluted share. This represents an increase of 14.3% on adjusted earnings per diluted share over the comparable quarter in the prior year. It should also be noted that the fourth quarter results last year included 3 months equity earnings as a result of Walgreens 45% interest in Alliance Boots compared to fully consolidated results in this year's fourth quarter. 
Let me now take you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fourth quarter. GAAP earnings of $0.02 per diluted share for the quarter reconciles the adjusted earnings of $0.88 per diluted share. The net adjustment of $0.86 per share incorporates the following additions: $0.05 of LIFO provision costs in Retail Pharmacy USA; $0.20 of restructuring-related costs; $0.21 of transaction and acquisition-related items in regard to step 2 of the merger with Alliance Boots; a $0.37 loss on our warrants to acquire AmerisourceBergen shares; and net $0.03 from special items. 
So now I will take you through the performance of each of our 3 divisions, starting with Retail Pharmacy USA. Firstly, please remember that we sold a majority stake in our infusion business on 7th of April, with a minority position of shared earnings in Option Care now flows through the income statement as post-tax earnings from equity method investments. So looking first in the division's fiscal year performance. Total sales were $81 billion, a year-over-year increase of 6.0%. Sales on a comparable store basis increased by 6.4% for the full year. On a GAAP basis for fiscal 2015, gross profit was $21.8 billion while SG&A was $18.2 billion, resulting in operating income of $3.9 billion. On an adjusted basis, gross profit for the full year was $22.1 billion, SG&A was $17.2 billion and operating income was $5.1 billion. 
Adjusted operating income increased 4.8%, driven by strong sales performance and tight cost control. Please remember when assessing this increase that the benefit of these 2 factors were partially offset by the inclusion of Walgreens share of equity earnings in Alliance Boots and operating income in the prior year. So excluding this impact, adjusted operating income in the division grew by 12.5%. 
Substantial progress was made in controlling SG&A during the year as a result of benefits associated with our cost-savings program. This was a significant driver of the division's year-on-year performance. On an adjusted basis, SG&A expenses decreased by 85 basis points year-over-year. At the end of fiscal year, the division operated 8,173 retail stores. 
So now let's turn to the division's fourth quarter performance. Retail Pharmacy USA's total sales in the quarter were $19.9 billion, an increase of 4.7% over the fourth quarter in the prior year. The total sales in comparable stores increased by 6.5%. 
On a GAAP basis for the quarter, gross profit of $5.3 billion while SG&A was $4.7 billion, resulting in operating income of $511 million. On an adjusted basis, gross profit was $5.4 billion while SG&A was $4.3 billion. Adjusted operating income in the fourth quarter of $1.1 billion was down 10.1% over the comparable quarter in the prior year. This was primarily due from the new equity earnings in Alliance Boots in current quarter versus 3 months in the comparable period. Excluding this impact, adjusted operating income grew by 1.2%.
We were able to increase adjusted gross profit dollars compared to the final quarter of fiscal 2014 despite lower gross margins, while at the same time, delivering SG&A efficiencies through our cost-savings program. 
So let's now look at pharmacy part of Retail Pharmacy USA in more detail. Comparable pharmacy sales were up 9.3% for the fiscal year. We filled 894 million prescriptions, including immunizations, that's on a 30-day adjusted basis, an increase of 4.4% over last year, with prescriptions filled in comparable stores, up 4.6% year-on-year. In the fourth quarter, comparable pharmacy sales were up 10.0% as we filled 222 million prescriptions, an increase of 4.6% over the equivalent quarter in the prior year, with prescriptions filled in comparable stores, up 5.1%. Year-over-year we continue to see a positive impact and further growth in Medicare Part D, an ACA-funded scripts, resulting in our retail prescription market share on a 30-day adjusted basis increasing to 19.1% for the year ended for the year ended 31st of August, an increase of approximately 20 basis points. 
The benefits of positive sales growth was, however, substantially offset by pharmacy gross margin pressure consistent with our expectations. Pharmacy margins were negatively impacted in the fiscal year by lower third-party reimbursements, an increase in Medicare Part D mix, including the strategy to continue driving 90-day prescriptions at retail and the mix of specialty products, which carry a lower margin percentage. 
The decrease in pharmacy margins is partially offset by additional branded to generic drug conversions compared with the prior fiscal year. While we continue to anticipate margin pressure, we remain confident in our strategies to drive access of clinical programs such us Medicare Part D and deepen our payer relationships to grow our pharmacy business over time. 
Moving now onto the retail products' performance within Retail Pharmacy USA. Retail sales increased by 1.9% for fiscal year 2015, while comparable sales increased 1.5%. As anticipated, the rate of sales growth was slightly slower in the fourth quarter as we continue to remove our more inefficient promotions, reduce store numbers and optimize store opening hours. Sales increased 0.8% in total and by 0.4% on a comparable sales basis. Overall, our strategy continues to be to drive sales growth and improve profitability, and I am pleased to report that gross profit margins have increased for the sixth quarter in succession. 
Over the past 18 months, we have improved our product mix, with our key health and wellness categories now contributing to higher proportion of total sales. We've also enhanced our merchandising tools, continued to optimize our promotional performance and upgraded on-shelf availability of the new products at in-store at the right price. And finally, we have improved sourcing with a higher level of our own branded products. 
In fiscal year 2016, we plan to continue to invest to drive our strategy and improve our customer offer. We will take what we've learned from our successful No7 test in Phoenix and New York City, where we saw a positive lift in both beauty and overall sales and rollout the new beauty offering to an additional 1,600 stores for a total of 2,000. With this new offer, we will elevate the customer experience, better fixtures, improve customer care, space optimization and selected store upgrades. We're also advancing the customization of our Balance Rewards program, with more offers targeted to our every day points program to our health and beauty customers. 
Through these efforts, we're striving to improve our customers' experience, expand our profit margin in the pharmacy store and continue to grow sales in key customer category. 
With that, let me turn to the results of our Retail Pharmacy International division, which is pharmacy-led health and beauty businesses in 8 countries. As a quick reminder, our biggest operations are Boots in the U.K. followed by Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. At the end of the fiscal year, the division operated 4,582 retail stores. I will focus my commentary for this division primarily on the most recent quarterly results as the fiscal year only has 8 months of data and, therefore, isn't all that meaningful, particularly, as it does not cover the important holiday season. 
Total sales in the division for the quarter were $3.5 billion, sales growth when compared with our third quarter was mainly due to the expected stronger sales in seasonal categories combined with currency benefits, mainly the British pound strengthening versus the dollar. On a GAAP basis for the fourth quarter, gross profit was $1.5 billion and SG&A was $1.3 billion, resulting in operating income of $196 million. 
On an adjusted basis, gross profit for the fourth quarter was $1.5 billion and SG&A expense was $1.2 billion, which resulted in operating income of $242 million. Adjusted operating margin was 7.0% for the quarter, which was in line with post-acquisition figure of the last 8 months of the fiscal year. 
To note, let's look more closely at the operating performance of the division. On a pro forma constant currency basis, comparable store sales growth for the quarter was 4.3%. Comparable store retail sales growth of 4.5%, being somewhat stronger than pharmacy at 4.1%. Comparable store sales growth in Boots U.K. was 3.5% in the quarter. Growth across all Boots U.K. retail sales categories resulted in comparable store retail sales growth of 4.9%, good performances in beauty and from online offering being the largest factors. 
In beauty, No7, our award winning beauty brand celebrated its 80th anniversary with another good quarter, with both skin care and cosmetics delivering double-digit sales growth in the U.K. Sales of No7 Protect & Perfect Advanced Serum continue to be strong, going 1 year on from their launch, supported by their continuing marketing program, which highlights the clinically proven product benefits, which I talked about on our last earnings call. 
During the quarter, we also launched No7 advanced day and night creams, with a new colored cosmetics campaign. Both of these initiatives were well received by our customers. Our U.K. website, boots.com, continued to see strong growth, with orders during the order up more than 65% over the same period last year. 
In the beginning of August, we further enhanced the convenience of our order and collect offer, now enabling customers to order by 8:00 p.m. and still collect in-store from 12 noon the following day. In the fourth quarter, nearly 70% of all our online orders in the U.K. were collected in-store. 
Outside the U.K., our businesses in Mexico, Thailand and the Republic of Ireland all delivered pro forma constant currency comparable store sales for the quarter, while above the average of the division as the Boots saw competition in the U.K. 
So turning now to our Pharmaceutical Wholesale division. Total sales in the Pharmaceutical Wholesale division in the fourth quarter were $5.8 billion. On a pro forma basis, assuming constant currency and excluding acquisitions and disposals in the space, sales increased by 5.0% over the same quarter in the prior year. 
Sales growth was particularly strong in Norway, where our wholesale business won a major new contract while hospital pharmacy, which began right on the start of calendar 2015, and 5 other countries, where our businesses each achieved double-digit comparable sales growth in the quarter. This included 2 of our largest wholesale businesses in Turkey and Germany. 
GAAP operating income in the fourth quarter was up $133 million while adjusted operating income was $158 million. Adjusted operating income margin for the quarter was 2.7% compared to 2.9% for the 8 months post-acquisition. This, in part, reflects the seasonal nature of pharmaceutical wholesaling. 
So having covered our divisional performance, I would now like to turn to our synergy program, one of the key drivers of profit growth. So combined net synergies for fiscal 2015 were $799 million, significantly above our target of at least $650 million. This includes $81 million plus prior net synergies in the fourth quarter, which relates to activities commencing in prior fiscal years. 
Consistent with our prior reporting, these synergies are allocated across each segment. They do not include any benefit from our long-term relationship with AmerisourceBergen or the benefits of refinancing the legacy Alliance Boots indebtedness at a lower cost. 
For fiscal year 2016, we continue to expect at least -- to reach at least $1 billion in combined net synergies. As time goes on and the combined management team works closely together, there are, of course, a number of other synergies being identified and actioned, but many of them are simply not practical to quantify as they blend into our core operations. 
So moving now to our cost-savings program, which is as you know, is another key area of focus. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. We expect the pretax charges associated with this program, as previously stated, between $1.6 billion and $1.8 billion, with cash component is expected to be approximately 60%. We continue to make good progress towards this goal and have achieved more than half of the program's expected savings as of the end of the fiscal year. 
In the Retail Pharmacy USA division, which is the primary driver of this program, this included closing 75 stores in the quarter, making a total of 84 store closures in fiscal 2015 as part of our plan to close approximately 200 stores in total. 
Actions taken during fiscal 2015 have resulted in pretax charges totaling $542 million, including $223 million for asset impairments, $202 million for real estate closures and $117 million for severance and other business transition and exit costs. 
So now I've now like to look at cash flow and capital deployment. GAAP operating profit cash flow was $5.7 billion for the full fiscal year and $1.5 billion in the quarter. Free cash flow was $4.4 billion for the full year and $1.1 billion in the quarter. 
Although it's hard for you to gauge our cash-generating abilities from today's results, I'd like to give you some insight into our operating cash flow and working capital priorities. We remain intensely focused in driving cash flow across our 3 business segments. 
Within our Retail Pharmacy USA division, during the year, we've improved inventory management in both pharmacy and retail products. We have more opportunities in inventory, covering huge focus on accounts receivable and accounts payable, all with the aim of driving further working capital savings. We will continue to apply the same discipline in Retail Pharmacy International and Pharmaceutical Wholesale. 
Total capital expenditure was $1.3 billion for the full fiscal year and $361 million in the quarter. After the merger, we put in place operational governance procedures to improve capital and ensure that we are prudently maintaining our infrastructure while investing in the right growth initiatives to generate return to shareholders. This process is working well. You will see a step-up in capital spend from the third to fourth quarter, which has lead to our renewed drive to invest in key areas and develop our customer proposition, including information technology. 
So moving onto our key financing activities. In line with our philosophy of having an efficient balance sheet, we completed $395 million of share repurchases in the quarter against our $3 billion authorization, bringing the total purchases under this program to $726 million by the fiscal year end. Since then, an existing 10b5-1 program has been being completed, in which we acquired an additional $110 million of shares. We now have $2.2 billion of value remaining under our authorized bond. 
In addition, as we previously announced, we redeemed the $1.75 billion of legacy Walgreens debt in August As we've said before, we remain committed to a long-term dividend payout rate -- payout target between 30% and 35% of adjusted net earnings. 
But before I finish and hand back to Stefano, let me just spend a few minutes on the impact of our agreement to acquire Rite Aid and on fiscal 2016 guidance. As you know, the agreed price per share for Rite Aid is $9, representing a total enterprise value of approximately $17.2 billion, including acquired net debt. The consideration for the shares will be paid in cash from existing new resource. The transaction is, as you would expect, subject to approval by Rite Aid shareholders, regulatory clearances and other customary closing conditions. We have done significant analysis on how we can bring the 2 companies together, including the antitrust analysis and we'll work closely with the regulators to bring the transaction to completion as soon as possible. That said, we anticipate the transaction closing in the second half of calendar 2016. The exact timing of this will clearly determine the impact on our financial results. 
Clearly, we are very confident in taking everything into account, the transaction will be suitably accretive for us. We have been prudent in our assumptions for the business and have been realistic about our expectations for the markets in which we operate. That said, we expect the transaction to be accretive during the first full year after completion on our usual adjusted basis. 
In addition to timing, there are a number of other factors that will impact us. We've identified an excess $1 billion of gross synergy that we must -- that we will start working to capture as soon as completion takes place. But we must recognize that while some of these are relatively easy to identify, others will require investment and will take time to deliver. 
As we are paying cash for the acquisition, we have taken the decision to suspend our share repurchase program and intend to redeploy that cash to partly fund the transaction. This means that in 2016, we will not enjoy the earnings accretion of the buybacks we originally planned. In fact, we'll be running a road to the inefficient balance sheet for a short period of time. 
The transaction will also cause a temporary increase in leverage, but this does not represent an underlying change in financial policy. We'll put in place a guide path to deliver metrics consistent with our commitment to solid investment grade. 
So with all that said, let me conclude by talking about our outlook for fiscal year 2016. As you know, we've previously had stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. We committed on our Analyst meeting in April, that on completion of our budgeting process, we would come back to you to give an updated view of 2016. 
Based on our budget and further evaluation of both risks and opportunity, we factored in our currency headwind of around $0.13 since the previous Walgreens management initially provided our FY '16 adjusted EPS goal back in August 2014. We're issuing new guidance for fiscal year 2016 of $4.25 to $4.55. This change is primarily to reflect the impact of suspending our share buyback program, to apply these funds towards the consideration for the transaction. This guidance assumes no material accretion from the planned acquisition of Rite Aid, which is expected to close in the second half of calendar 2016. 
Please also remember that we have clumsy the translational exposure primarily based on movements in the pound sterling versus the dollar. Not only does this impact our adjusted operating income and EPS, but it can also cause particularly volatility in the sales, gross margin and SG&A items as it did this quarter. 
As Stefano indicated, we anticipate to publish numerical synergy target from the merger between Walgreens and Alliance Boots to be met during 2016, and we'd advice you after we will have achieved that target. The synergies and benefits from the transaction with Rite Aid will be almost entirely within our U.S. Retail Pharmacy division, and so it will be reflected in these figures rather than separately itemized programs. 
Clearly, we will continue to drive hard efficiencies post the procurement, but we see this as normal working practice rather than unique and discrete projects. And so going further beyond 2016, we would expect our earnings growth to return to a more normal fiscal challenge in low double-digit growth. 
In terms of the shape of the quarters, please remember that both our first and second quarters of fiscal year '16 are noncomparable given that we close the merger on the 31st of December 2014. Seasonality is most prominent in our retail pharmacy segments, with the first quarter is typically the weakest. Our second quarter picks up most of the holiday season, which will be more prominent going forward as we will consolidate December results for Retail Pharmacy International. This would include Boots performance in December, which is typically it's most important trading month. We also expect the shape of the second half of the fiscal year to be generally consistent with what we saw in fiscal 2015, with adjusted earnings per share in Q3 and Q4 stepping down sequentially from Q2. 
So with that, I will turn the call back to Stefano."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So another good year, but a year of transition that brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our team on track and main",445,"Thank you, George. So another good year, but a year of transition that brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our team on track and maintain our momentum in our businesses, both in the U.S. and around the world, while at the same time be able to study and understand our new markets and deliver corporate expansion as we are doing with Rite Aid. 
As CEO, I very much recognize my role is both to support my team in achieving also partly their goals but also in creating the opportunities and direction for them to outperform and identify sources of growth and value enhancement while helping mark the route for sustained growth to secure the future for the company well beyond my tenure. As we said today, we have potential opportunities in many businesses, in many geographies. We continue to review all the opportunities open to us to assess where best to deploy our capital to provide the best return of our investors. 
The health care market is extraordinarily dynamic with many moving parts, and these dynamics create new opportunities and new ideas all the time. A key part of my role is to make sure that we pursue these opportunities where they are desirable to do so and not waste time and resources to where it is now and also to ensure that we do that without distracting our teams on delivering on our long- and short-term plans of our existing businesses. Over time, you can expect to see us complement the development of our existing businesses with further additions that will help us better define and differentiate our business. 
As we look at our opportunities around the globe, even the unique dynamic of the U.S. market, it is not surprising that the best opportunity we have found this year has been here, while elsewhere our expansion has been through the selective purchase event and a small bolt-on acquisition to our original business. 
The global health care market and perhaps the U.S. markets, more than any, are ready for change and openness to new ideas and new approaches while it provides care. As a leading global health care company, we have the potential to play a tiny role in this evolution. We have always married prudence with a willingness to find innovative solutions and think about things in new ways and these are qualities I am glad to be spreading across the group and I believe will form the foundation for the success of the business going forward. 
Now let's open up for questions. Gerald, please?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Andrew, we're ready to take questions now.",9,"Thank you. Andrew, we're ready to take questions now."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Edward Kelly from Crdit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Edward Kelly from Crdit Suisse."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call, by the way, didn't really have any reference to your appetite for FTC risk. So does the merger agreement have a divestiture cap? If it does, can",114,"Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call, by the way, didn't really have any reference to your appetite for FTC risk. So does the merger agreement have a divestiture cap? If it does, can you provide more detail here? And as you think about FTC, I mean, there is some history that we can sort of look back to, 2007, when Rite Aid bought Eckerd, for instance. In terms of the parameters that they look at, is that still a relevant way to think about it? Any thoughts related to all this, I think, would be very helpful for people."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's a very difficult to comment about that. Of course, before doing these decisions, taking the decisions and doing the steps, we have analyzed things very carefully. We have tried to figure out what would happen. But of course, this was done within the",77,"It's a very difficult to comment about that. Of course, before doing these decisions, taking the decisions and doing the steps, we have analyzed things very carefully. We have tried to figure out what would happen. But of course, this was done within the closed walls of our company. In this situation, it's very difficult for us to make public comments. When we have a public authorities, it's better for us not to interfere at all."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, just one follow-up to that, I mean, because the merger agreement is going to come out soon, I would think it so. How much divestiture risk are you assuming within this agreement? Is there a certain number of stores? How would you frame that in th",49,"I guess, just one follow-up to that, I mean, because the merger agreement is going to come out soon, I would think it so. How much divestiture risk are you assuming within this agreement? Is there a certain number of stores? How would you frame that in the agreement?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have put a top because, of course, we have to take certain precautions, but we are not speculating at all about the number of stores that we will have divested.",31,"We have put a top because, of course, we have to take certain precautions, but we are not speculating at all about the number of stores that we will have divested."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And just sorry, one -- I apologize, but could you give us the number that you sort of cap this at?",22,"Okay. And just sorry, one -- I apologize, but could you give us the number that you sort of cap this at?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I cannot give you the numbers and you know it.",10,"I cannot give you the numbers and you know it."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser from Morgan Stanley."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, so congratulations on your underwriting deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think about it? I",94,"Yes, so congratulations on your underwriting deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think about it? I mean, when you've kind of put together Alliance Boots and Walgreens, you've also communicated synergy number and you've kind of like allocated buckets to drug purchasing front end, et cetera. So if you can give us some similar context for the Rite Aid deal, it would be very helpful."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've not given the specific details on this but I'm sure you can imagine that as with any deal of this nature, there are different classifications of synergies. There are the procurement synergies, the G&A cost synergies or the other cost-saving syn",166,"Yes, we've not given the specific details on this but I'm sure you can imagine that as with any deal of this nature, there are different classifications of synergies. There are the procurement synergies, the G&A cost synergies or the other cost-saving synergies. And these we will -- these synergies we will access in a structured way much as we have done with the Walgreens Alliance Boots transaction. We've got a team here very experienced in accessing those synergies. We're very confident that we -- in our numbers. As ever, synergies -- these gross synergies take time to access. Some of them can be achieved faster than others. Some will require investment and we will work through that. But there will be an element of investment to get these synergies. But clearly, over the coming time, we will work through how best to achieve these. But we've done a lot of work as ever to be really feeling confident in the number that we have published."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But you understand that, in this case, the synergies are coming mainly by internal efficiency, by the fact that maybe we can have a better network to sell our brands, our products, which is still a fundamental component of our strategy. And so these will",53,"But you understand that, in this case, the synergies are coming mainly by internal efficiency, by the fact that maybe we can have a better network to sell our brands, our products, which is still a fundamental component of our strategy. And so these will not happen overnight, it will take some time."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Finally, to add to that, would be that -- I mean, this is -- the program, in a sense, is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to report the synergies separatel",69,"Finally, to add to that, would be that -- I mean, this is -- the program, in a sense, is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to report the synergies separately. And the way that we did from these were essentially being shared half and half between Alliance Boots and Walgreens."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But I want to stress what George has said. We have done a lot of work, and we are very confident that this deal will deliver for us.",28,"But I want to stress what George has said. We have done a lot of work, and we are very confident that this deal will deliver for us."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?",23,"Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Maybe Alex can give you. We have discussed this, about the -- their PBM business and Alex can do something about it.",22,"Maybe Alex can give you. We have discussed this, about the -- their PBM business and Alex can do something about it."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, as we know today, it's an important but relatively small PBM business. It's in the top 10, but not a big one. It's a [indiscernible] business with a lot of new capabilities in IT. So other movement we are really interested, one is to get beyo",153,"Yes, I mean, as we know today, it's an important but relatively small PBM business. It's in the top 10, but not a big one. It's a [indiscernible] business with a lot of new capabilities in IT. So other movement we are really interested, one is to get beyond the closure of the FTC review to understand more about the business and how it can really help us understand access to the Medicare better. I mean, a real compass view with the closed deal with Rite Aid is to improve the quality of pharmacy and to really reduce cost across the market the make sure we create a market which is more affordable, more accessible for everyone aligned with the government policy. So we think this could be our way into that in terms of Envision. But clearly, we need to understand more and we understand more once we're through the FTC review."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And then it will be a good opportunity for us to learn more and we are always open to learn.",20,"And then it will be a good opportunity for us to learn more and we are always open to learn."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Meredith Adler from Barclays.",12,"Our next question comes from the line of Meredith Adler from Barclays."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes.",36,"We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. It's Alex here. Yes, we moved to something called every day points here and we talked about it in the last earnings review as well. And this is where, for the majority of the front-end products, we're able to offer points and also extended the points",240,"Yes. It's Alex here. Yes, we moved to something called every day points here and we talked about it in the last earnings review as well. And this is where, for the majority of the front-end products, we're able to offer points and also extended the points in our pharmacy business to other schemes at Medicaid and Medicare where appropriate. We're really pleased with what's happening. The customers have signed into this program. We have, I think, about 27 million of customers signed into it and they have quite a few points. And more importantly, as we analyze how they're redeeming the points, we're seeing encouraging behavior where people are actually selecting more and more own-brand products and bigger baskets and products they may not otherwise have bought. So it's really early days. I mean, the program has been out there for only a matter of months, but the behavior we're seeing in these customers are encouraging and it is exactly the type of behavior we've seen in other loyalty programs that we know of well in the group. So that's where we are, and of course, we intend, as we have done progressively since we launched the program just over 3 years ago now, to invest wisely and carefully to ensure we get a return of that investment, and we're seeing the same here where can invest more in this program and will do so in the years ahead."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I have a question about Rite Aid. I think the company -- Rite Aid's management has been fairly upfront about the fact that they have a pretty large number of underperforming stores. I think they've been hesitant to close too many stores, plus t",73,"Great. And I have a question about Rite Aid. I think the company -- Rite Aid's management has been fairly upfront about the fact that they have a pretty large number of underperforming stores. I think they've been hesitant to close too many stores, plus the leases have not yet run out. Could you please talk about your observations of the store base and what your approach would be to those underperforming stores?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's very difficult to judge the operator, the management, because we should understand all the different events and all the different conditions in which the management has to operate. They have a lot of complaints, as you know. So I believe they have do",89,"It's very difficult to judge the operator, the management, because we should understand all the different events and all the different conditions in which the management has to operate. They have a lot of complaints, as you know. So I believe they have done a good job of the situation that they were in. We will approach in our usual way, in a very rational way, trying to do work to create value. So we are not emotional on that, and we will be rational as ever. Alex?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. And I think that it's clear that we are working hard here in Walgreens to really develop the front end, and again, George gave a good update again about some of the progress we've made here in terms of being able to improve our operational margin in",248,"Yes. And I think that it's clear that we are working hard here in Walgreens to really develop the front end, and again, George gave a good update again about some of the progress we've made here in terms of being able to improve our operational margin in the front end over the last 6 quarters. So as we develop the best 5 years in Walgreens, as we take the best 5 years from that from Alliance Boots and again George updated you that we intend to expand our beauty products into 2,000 Walgreens stores, having done a controlled test in both Phoenix and New York City. And also, as we really learn some of the excellent work from the outside that the Rite Aid team have done in their new wellness format, we have the opportunity to put all that together once we're through the FTC review and see how we can improve performance in all of our networks across America and to provide better front-end performance through a more appropriate offer for communities across America, supporting a better quality pharmacy experience and, of course, lower costs. So that's our intention. But obviously, once we're through the process of FTC, we'll be able to work more closely with the teams and understand that better. But we think there's opportunity both in Walgreens, and clearly, the team at Rite Aid has seen a good improvement in their wellness format and will be read in terms of the reporting."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I just have one more question. You highlight the sort of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel unc",55,"Great. And I just have one more question. You highlight the sort of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel uncomfortable working with a retail pharmacy that still sells tobacco."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, we've chosen to invest to help people to stop smoking, to lose weight. Balance Rewards for healthy choices programs we launched about 12 months ago has been incredibly successful, and we've chosen to invest there. Because we believe there was less",140,"I mean, we've chosen to invest to help people to stop smoking, to lose weight. Balance Rewards for healthy choices programs we launched about 12 months ago has been incredibly successful, and we've chosen to invest there. Because we believe there was less than 3% of tobaccos sold today in a drugstore channel, the choice tobacco is there already in many other places. Of course, we continue to review and reflect on this issue and other categories that we happen to sell. There are fundamental choices to best help people who are already prepared to stop and we've made really good progress there and what we've done. So at this stage, we have nothing else to update on apart from that we are pleased with the progress we've made with our investments to help people across America to stop smoking."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments that you feel like the company will need to make as you try to bring the 2 businesses together? I know the Walgreens executives have commented in the past",98,"I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments that you feel like the company will need to make as you try to bring the 2 businesses together? I know the Walgreens executives have commented in the past that the IT infrastructure at Walgreens needs a little bit of work. I think the same thing, safe to say, needs work at Rite Aid. I guess -- so as you try to think about gross synergies versus net synergies from your announcement, is there any more color you can give us there?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. Just a quick word on IT. I mean, as I touched in the presentation, one of the reasons that we saw a step-up in the fourth quarter versus the third quarter was IT program. And so we, as Walgreens Boots Alliance, have been doing a lot of work since th",244,"Okay. Just a quick word on IT. I mean, as I touched in the presentation, one of the reasons that we saw a step-up in the fourth quarter versus the third quarter was IT program. And so we, as Walgreens Boots Alliance, have been doing a lot of work since the merger, is basically to structure our IT so that we're able to use our global scale and capability to invest in IT in a cost-efficient way to best help the needs of both the business internationally, but most importantly our customers. So there's a lot of work on IT underway. In terms of the gross synergies, it's really -- I mean, these will come in U.S., as we have said, which is why it becomes harder to separate out than in the -- as we start to integrate the operations plus being able to complete the transaction. But the synergies that will come will be procurement synergies, where there clearly isn't an investment requirement but then it will be investment over time and there is like, in IT, upgrading the stores and we will do that in a thoughtful, structured way. We'll be looking at stores on a store-by-store basis as we always do, looking for the returns that we continue to seek. So the investment will always take a little bit longer to come. It will be done over time because of the nature of that part of the integration takes longer."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And maybe a quick follow-up for Alex, if you're still there. Can you provide us any early color on what the reimbursement rate environment is looking like for 2016? And how do you affect these conversations to evolve on a longer-term basis once ther",49,"Okay. And maybe a quick follow-up for Alex, if you're still there. Can you provide us any early color on what the reimbursement rate environment is looking like for 2016? And how do you affect these conversations to evolve on a longer-term basis once there are already transactions closed?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. I can't comment on a long-term basis. What I can tell you is that we really have anticipated the Med D season and we have an enrollment. We're pleased we've been able to expand our partnerships with peers. For example, we announced that Aetna as a ne",121,"Yes. I can't comment on a long-term basis. What I can tell you is that we really have anticipated the Med D season and we have an enrollment. We're pleased we've been able to expand our partnerships with peers. For example, we announced that Aetna as a new partner for us and we're really pleased with that. So we are feeling -- the rates are as planned. Of course, the reduction from last year's rates but as planned, as we had expected. And we've been able to drive our strategy of improving access and improving volumes to meet partnerships. The commercial ones, as you know, we're on 3-, 4-year contracts, and we don't comment on these contracts probably as you're aware."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Robert Jones from Goldman Sachs.",13,"Our next question comes from the line of Robert Jones from Goldman Sachs."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just one high level one for Stefano and then just a couple of quick ones for George. I guess, just from a big picture perspective, why was getting bigger in the retail space the right move strategically right now? And then, I guess, more specifically as i",68,"Just one high level one for Stefano and then just a couple of quick ones for George. I guess, just from a big picture perspective, why was getting bigger in the retail space the right move strategically right now? And then, I guess, more specifically as it relates to that, how much more negotiating leverage do you think this expanded network will give you versus payers and PBMs?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, we have not done these to increase our negotiating power. We stay on PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I would say from internal sources and the harmonization of",219,"Well, we have not done these to increase our negotiating power. We stay on PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I would say from internal sources and the harmonization of prices in terms of harmonization and not improvement, the harmonization of our know-how something in software, something, of course, in the combination of the stores as we were discussing before. There's something from our product lines. Well, we are not thinking of really improving our position with the payers because at the end of the day, we are in an environment where the margins are decreasing. So it was decreasing. We are in an environment where there is a lot of competition and the fact that we put together 2 companies would not reduce the competition. Not just the competition among pharmacies, think of the other tandem, think of the mail order, think of the people who are specialized in certain categories, like the specialty, for instance. So there are many people working in this area. I don't believe that these will really give us an additional power. But we have not accounted on that when we have put together our numbers. We have put together our numbers very, very carefully and very prudently."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Got it. And then I guess, George, just I'm sure you can appreciate it's very difficult for us to get visibility into the core pharmacy businesses just given a lot of the moving pieces, not the least of which is the synergies. It looks like the total syner",90,"Got it. And then I guess, George, just I'm sure you can appreciate it's very difficult for us to get visibility into the core pharmacy businesses just given a lot of the moving pieces, not the least of which is the synergies. It looks like the total synergies in the quarter were about $295 million. Is there any sense at all you can give us on how we should be allocating those across the businesses just to get a little bit better perspective on how the core businesses are tracking?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, we very much try and allocate the synergies based on the activities. So I do appreciate that's made the segment analysis a little tougher for you to follow. But by doing it on this basis of procurement, we really are therefore reflecting wher",210,"Yes, I mean, we very much try and allocate the synergies based on the activities. So I do appreciate that's made the segment analysis a little tougher for you to follow. But by doing it on this basis of procurement, we really are therefore reflecting where the volume is, where the activity is. Another result, obviously, with the Retail Pharmacy USA being, by far, our biggest segment, then you should think of the synergies being heavily, heavily weighted towards the U.S. segment. It's the basis that I would always think about. I think as we annualized through as we get to the third quarter, which I guess will be our first sort of clean year-on-year quarter, it will be a little bit easier for you to see. And of course, it's the hard synergies, which are the ones that we're quantifying. But really a lot of the -- of what are, in effect, synergies, but they're not the ones that we can quantify. These are the ones that are really coming through, as we know. Increasingly, an integrated combined management team are working very much together on many of the programs, sharing best practice, and that's very much business as usual now rather than run through each synergy work stream."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's really helpful. And then just the last one, more of clarification, George. Did I here you correctly that EPS growth beyond fiscal '16 is anticipated to be low double digits? And if that's right, any sense you can give us of what's contemplated in c",52,"That's really helpful. And then just the last one, more of clarification, George. Did I here you correctly that EPS growth beyond fiscal '16 is anticipated to be low double digits? And if that's right, any sense you can give us of what's contemplated in capital allocation relative to that target?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, yes, that's as far as we've indicated just to try and give you a sense of how we see the business going forward. So in relation to capital allocation...",31,"I mean, yes, that's as far as we've indicated just to try and give you a sense of how we see the business going forward. So in relation to capital allocation..."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Is that contemplated in the low double-digit target?",9,"Is that contemplated in the low double-digit target?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","That's got a typical investment program, so absolutely everything is in there. I mean, we're being quite prudent, as you would expect, in this area.",26,"That's got a typical investment program, so absolutely everything is in there. I mean, we're being quite prudent, as you would expect, in this area."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But when we are talking of next year, there was a point of next year, which if you take -- if you do the math and take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this is",161,"But when we are talking of next year, there was a point of next year, which if you take -- if you do the math and take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this is substantially an organic growth. So in a retail business, to have an organic growth of double digit, low double digit is not easy. We have done this for many, many areas. I have to say we have never had 1 year without double-digit growth in our history. But I can tell you that it's not easy because it's relatively easy to announce the earnings per share, buying back a lot of shares or buying additional businesses. The business, if we are buying this time, will not have an effect on next year. So you have the look at the numbers of next year as organic growth."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill from JPMorgan.",12,"Our next question comes from the line of Lisa Gill from JPMorgan."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, I just wanted to go about the synergies on the Rite Aid deal for a minute and just skip the time of your expectation on the procurement side. My understanding is that Rite Aid has a relationship with McKesson for procurement that runs through Marc",87,"George, I just wanted to go about the synergies on the Rite Aid deal for a minute and just skip the time of your expectation on the procurement side. My understanding is that Rite Aid has a relationship with McKesson for procurement that runs through March of 2019. So the assumption that there's a way to break that relationship and you'll get procurement earlier? Or is it that the time line is unknown on this because you may have to wait until the end of the contract?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Lisa, first of all, I have to say we have not taken any decisions about the contract. Not necessarily we have to change substantially the contract in order to get the synergies. We are -- we believe we can have -- and at the right time, we will discuss wi",147,"Lisa, first of all, I have to say we have not taken any decisions about the contract. Not necessarily we have to change substantially the contract in order to get the synergies. We are -- we believe we can have -- and at the right time, we will discuss with the contract, and of course, we will try to discuss in the interest of the -- of our company, that's obvious. But you don't have to assume the fact that we will change the contract or we will move the contract. Of course, we have very good relationship with ABC. But I have to tell you that we have a lot of respect for McKesson and a lot of respect for Hammergren and Julian and we will see. We will see at the time. It's obvious that we will try to extract as much value as possible."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And then, Stefano, you talked about the U.S. market open to change your belief in the playing a role. You answered an earlier question around the small PBM that's going to be part of this transaction. But can you maybe just give us a",86,"Okay, that's helpful. And then, Stefano, you talked about the U.S. market open to change your belief in the playing a role. You answered an earlier question around the small PBM that's going to be part of this transaction. But can you maybe just give us any idea as to how you think about that potential role that you play? And from your strategic view, how you think the U.S. market is changing and what role that the bigger Walgreens will play here in the U.S.?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, for sure I can tell you that I have several ideas. But before making these ideas public, I would like to check this idea with the reality, which is around that. So now we have just done a deal. We have just started -- announced a potential deal. We",89,"Well, for sure I can tell you that I have several ideas. But before making these ideas public, I would like to check this idea with the reality, which is around that. So now we have just done a deal. We have just started -- announced a potential deal. We started this deal. For a few months, we will really be absorbed in this deal. We will continue to think. But for a few months, we will not be able to tell you where we want to go next."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. There's a -- I'm sorry, just to say maybe the opportunity is the beginning of next year? We'll get together in January and maybe we'll have some incremental ideas as to how you'll think about this.",37,"Okay. There's a -- I'm sorry, just to say maybe the opportunity is the beginning of next year? We'll get together in January and maybe we'll have some incremental ideas as to how you'll think about this."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's always -- I think it's about the [indiscernible] and the customer having more apparently more choice. And I think with a fantastic group of people under Walgreens and the brand that they represent in communities across America, I think that's where w",50,"It's always -- I think it's about the [indiscernible] and the customer having more apparently more choice. And I think with a fantastic group of people under Walgreens and the brand that they represent in communities across America, I think that's where we have the biggest opportunity, I think."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, appreciate that, and congratulations on Rite Aid.",8,"Okay, appreciate that, and congratulations on Rite Aid."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you very much. We will have time to talk in the future.",13,"Thank you very much. We will have time to talk in the future."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And the last time that we have -- the last question that we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch.",31,"And the last time that we have -- the last question that we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, do you think you can raise from sale-leaseback deals in fiscal '16?",27,"Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, do you think you can raise from sale-leaseback deals in fiscal '16?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward. We've, obviously, as you can see, done quite a bit of sale and leaseback in the last particular year. We haven't set an internal target. We will continue",80,"Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward. We've, obviously, as you can see, done quite a bit of sale and leaseback in the last particular year. We haven't set an internal target. We will continue just to work through this in a normal but very committed to having an efficient balance sheet, as I said, on many occasion. That's the answer to the second one. So the first one was..."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","The Rite Aid NOLs?",4,"The Rite Aid NOLs?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The Rite Aid NOLs, we would anticipate over time being able to utilize the NOLs.",15,"The Rite Aid NOLs, we would anticipate over time being able to utilize the NOLs."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And just a clarity on the sale-leaseback. Walgreens had owned 20% of their stores. I mean, do you envision bringing that number down meaningfully over time, whatever the period?",30,"Okay. And just a clarity on the sale-leaseback. Walgreens had owned 20% of their stores. I mean, do you envision bringing that number down meaningfully over time, whatever the period?"
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, what I would answer is I'm not weighted on having to own retail pharmacy locations. Clearly, there will be certain occasions where it may be the right thing to do. But it's not something that I feel is necessary for our business model. We will con",126,"I mean, what I would answer is I'm not weighted on having to own retail pharmacy locations. Clearly, there will be certain occasions where it may be the right thing to do. But it's not something that I feel is necessary for our business model. We will continue to look at sale and leaseback where we believe it's the right thing to do. Really taking into account the timing of the tenure of leases and when the lease breaks off, so that we have a balance in our portfolio going forward and don't have the bunching of lease breaks over at the same time. So we'll be doing this -- looking at this in a thoughtful way over time is the way I would position it."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Ladies and gentlemen, that was the final question we have time for. Thank you for joining us. Please, we know that there's many of you that had questions. Please reach out to the IR team here and we will answer and address them as best we can.",130,"Thank you. Ladies and gentlemen, that was the final question we have time for. Thank you for joining us. Please, we know that there's many of you that had questions. Please reach out to the IR team here and we will answer and address them as best we can. I should say that we're going back into the -- our next quiet period on the 1st of December. So we have a comparatively short open period. Management have been very generous with the time. We will try and get to as many of you as we can during that period, but please bear with us. You'll appreciate with an agreement as well as our results. We have a very busy few weeks ahead of us. Thank you very much indeed."
93624,312356229,883890,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day.",33,"Ladies and gentlemen, thank you again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions]I'd now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Inv",47,"Good day, ladies and gentlemen, and welcome to the Walgreens Boots Alliance, Inc., Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions]
I'd now like to introduce your first speaker for today, Gerald Gradwell, Senior Vice President of Investor Relations and Special Projects. You have the floor, sir."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Andrew. Good morning, or afternoon, or wherever you may be, to everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweath",268,"Thank you, Andrew. Good morning, or afternoon, or wherever you may be, to everyone. Welcome to our fiscal year-end 2015 and fourth quarter earnings call. Today, Stefano Pessina, our Executive Vice Chairman and Chief Executive Officer; and George Fairweather, Executive Vice President and Global Chief Financial Officer, will take you through our results on greater detail. Also joining us on the call and available for questions is Alex Gourlay, Executive Vice President of Walgreens Boots Alliance and President of Walgreens.
You can find the link to our webcast on our Investor Relations website at investor.walgreensbootsalliance.com. After the call, this presentation and the webcast will be archived on our website for 12 months. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions or otherwise. Please see our second quarter Form 10-Q and subsequent filings, including our fiscal 2011 10-K when filed, for a discussion of risk factors as they relate to forward-looking statements.
As a reminder, today's presentation includes certain non-GAAP financial measures, and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.
With that, I'll hand you over to Stefano to make some opening comments."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Gerald. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a fully combined company, but also, as you've seen, we a",1069,"Thank you, Gerald. Good morning, everyone, and welcome to our fiscal 2015 full year earnings call. So this is an exciting time for us, not only are we today announcing the first full year results as a fully combined company, but also, as you've seen, we are announcing the acquisition of Rite Aid, a transaction that would significantly accelerate our plan to expand our presence in the West. With this acquisition, we are accelerating a long-term objective that we knew we needed to address, to strengthen our presence and coverage nationally throughout the U.S. I have to say that we have reached an agreement with Rite Aid that reflects what we believe to be very fair terms, which will help us to unlock real value from the transaction. 
The addition of Rite Aid will accelerate our strategy by completing our network, providing a larger and more comprehensive portfolio, off which we can deploy our knowledge and skill, and creating a more comprehensive and stronger platform for the development of our brand presence and the future growth of our business.  Clearly, there is still a lot to be done to complete the transaction with Rite Aid. Our teams have done a lot of work on this, and we will work closely with the regulators to bring the transaction to a conclusion as soon as possible. George will give you more details about our agreement to acquire Rite Aid in a few moments. 
But first, let me review the progress we have made in the past year in our work to transform our businesses and drive growth across the company. When I spoke to you in July, I referred to the extraordinary amount of work that has been going on inside the company to establish the processes and systems from which to being the more responsive, efficient and relevant business. This is critical for what is today a rapidly changing business environment, with new and different dynamics than those that the company has historically been used to.
In all of our markets, we face tough challenges, be they from competitors or from governments, relentless drive to manage health care costs. That said, I do not believe any one on this forum not say the same thing on their business. Our job is [indiscernible] that we'll continue to be to identify, address and, if we can, lead the market to efficient scale, insight and innovation. Of course, with the completion of our transaction to form Walgreens Boots Alliance in January and the subsequent executive and management changes, it has taken us a little time to come [indiscernible] with the business. And as part of this, we have been actively working to strengthen and simplify our management reporting structure and system to ensure that we can build a reliable and accurate picture of our book and understand our strengths and weaknesses. 
We are ready to spend some time restructuring and refocusing a number of parts of the business and the number of areas of management. In some areas, we have found it necessary to bring in people and skills from outside the group, recognizing that for our U.S. business, to dovetail the management reporting of what is an extensive international network that requires something different in terms of systems and expertise than running a U.S.-based domestic business. Internationally, our management there are ready take some time to understand how they are impacted by the shift in the nature of our business that is inevitable given the scale of our U.S. business. 
The practical and cultural issues that these changes have raised are complex but have been helped in part by the relationships and connections we began to forge in the year before initial announcement of our deal and since the final completion. An amazing amount has been achieved within the company, but we remain very much at the beginning of our journey. Alex and his team have been working hard to ensure that we are operating in an efficient and effective manner, optimized as far as possible to the needs of the communities that it serves. 
They have made a lot of progress but there is a lot more still to do. Our work to understand the demand and potential for a more unique advantage [ph] of our brand product using the Boots products as a base is now beyond the trial stage and is beginning to roll out in a managed way across the network. We are restructuring the front end of our stores to set us on the right path of future growth. Similarly, as anticipated, this is at the short-term cost of something, however, this short-term impact is compensated for by the improved margins that this restructuring has delivered. We are also continuing to innovate in new channels to stay relevant and continue to prove the strength of our brand individual growth, every bit as much as in the physical one. I will be doing a great disservice to many people outside the U.S. if I did not mention their outstanding efforts as well. That has resulted in solid performance from our international retail pharmacy and international sales businesses. 
So the fourth quarter results have been strong and the year as a whole has been good for us. We are confident that our synergy program is on track to deliver at least $1 billion in 2016. And as we have said, we are well into the process of reviewing and restructuring and refocusing our people to deliver on our plan for many years to come, reinvigorating and differentiating our business across every market we operate in. That said, after the completion of our formal synergy programs, resulting from the more recent Alliance Boots transaction, we will expect to revert to what we would consider a more normalized economic growth profile for the business in 2017 and beyond. 
Overall, therefore, this is an exciting and busy time. And although I am never satisfied with what we have achieved as I believe in general that we can ensure our way to reach for more. I am also realistic and acknowledge the work that has been done and recognize that this has been a good year for the company. 
I will now hand you over to George to talk through the results and give you a bit more detail on our recent [indiscernible]. I will come back to you after that. George, please?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights into",4000,"Thank you, Stefano. Good morning, everyone, and good afternoon to those listening in Europe. Today, I'll start by taking you through the highlights of our fiscal year ended 2015 full year and fourth quarter results. I will then give you some insights into the performance of our 3 divisions before updating you on the progress that we've made in our synergy and cost saving programs. I will conclude by providing some details on the Rite Aid agreement before taking you through our guidance for fiscal year 2016.
I will begin by reminding you that our fiscal year 2015 results are not likely comparable to fiscal 2014. This is primarily due to 3 key elements associated with completing the second step of our transaction on the 31st December 2014. Firstly, we eliminated the 3-month reporting lag for Alliance Boots and recast prior year results with no lag. Secondly, segmental reporting from 1st January '15 includes the allocation of synergy benefits, including WBAD and combined corporate costs. And lastly, fiscal 2015 results include equity earnings in Alliance Boots for the 4 month of September to December 2014 and full consolidation of Alliance Boots earnings for the 8 months from January to August 2015.  I'm proud of our achievements and accomplishments in fiscal 2015, closing our transaction, delivering strong financial performance and reporting a combined results for WBA require great teamwork across the organization. 
Looking now at our overall performance for the year. Net sales for fiscal year 2015 were $103.4 billion. On a GAAP basis, operating income was $4.7 billion; managed expense, $605 million. The tax rate was 19.9% and net earnings attributable to Walgreens Boots Alliance was $4.2 billion or $4.00 per diluted share.  On an adjusted basis, our operating income was $6.2 billion as compared to fiscal 2014, the key factors which drove our fiscal 2015 results for the full consolidation of Alliance Boots operations combined with growth in the Retail Pharmacy USA segment. Adjusted net interest expense for the year was $464 million, reflecting increased level of debt associated with the second step of the Alliance Boots transaction.  Adjusted tax rate was 27.8%, which was lower than we were expecting due to business mix and certain discrete items that benefited us primarily in the fourth quarter. This resulted in adjusted net earnings attributable to Walgreens Boots Alliance in fiscal 2015 of $4.1 billion equating to $3.88 per diluted share. 
So now I will quickly take you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fiscal year. So GAAP earnings attributable to Walgreens Boots Alliance in fiscal year 2015 of $4.00 per diluted share reconciles the adjusted earnings of $3.88 per diluted share. The net adjustment of $0.12 per share reflects additions of $0.17 of LIFO provision costs in Retail Pharmacy USA, $0.35 of restructuring-related costs, that's from our cost optimization and store closure program, and a net favorable $0.02 transaction and acquisition-related items from executing step 2 of the merger with Alliance Boots. These additions were more than offset by removal of a $0.54 gain on our warrants to acquire AmerisourceBergen shares and an additional net $0.12 gain from special items. And a detailed reconciliation of all component items is included as an Appendix to the slides. 
So moving on to our fourth quarter results. Net sales in the fourth quarter were $28.5 billion, an increase of 50% versus the comparable quarter in the prior year. On a GAAP basis, operating income for the quarter was $836 million, and net earnings attributable to Walgreens Boots Alliance were $26 million, creating $0.02 per diluted share. On an adjusted basis, operating income increased to $1.5 billion, driven primarily by the consolidation of Alliance Boots. Adjusted net earnings attributable to Walgreens Boots Alliance were $969 million or $0.88 per diluted share. This represents an increase of 14.3% on adjusted earnings per diluted share over the comparable quarter in the prior year. It should also be noted that the fourth quarter results last year included 3 months equity earnings as a result of Walgreens 45% interest in Alliance Boots compared to fully consolidated results in this year's fourth quarter. 
Let me now take you through the walk from GAAP diluted EPS to adjusted diluted EPS for the fourth quarter. GAAP earnings of $0.02 per diluted share for the quarter reconciles the adjusted earnings of $0.88 per diluted share. The net adjustment of $0.86 per share incorporates the following additions: $0.05 of LIFO provision costs in Retail Pharmacy USA; $0.20 of restructuring-related costs; $0.21 of transaction and acquisition-related items in regard to step 2 of the merger with Alliance Boots; a $0.37 loss on our warrants to acquire AmerisourceBergen shares; and net $0.03 from special items. 
So now I will take you through the performance of each of our 3 divisions, starting with Retail Pharmacy USA. Firstly, please remember that we sold a majority stake in our infusion business on 7th of April, with a minority position of shared earnings in Option Care now flows through the income statement as post-tax earnings from equity method investments. So looking first at the division's fiscal year performance. Total sales were $81 billion, a year-over-year increase of 6.0%. Sales on a comparable store basis increased by 6.4% for the full year. On a GAAP basis for fiscal 2015, gross profit was $21.8 billion while SG&A was $18.2 billion, resulting in operating income of $3.9 billion. On an adjusted basis, gross profit for the full year was $22.1 billion, SG&A was $17.2 billion and operating income was $5.1 billion. 
Adjusted operating income increased 4.8%, driven by strong sales performance and tight cost control. Please remember when assessing this increase that the benefit of these 2 factors were partially offset by the inclusion of Walgreens share of equity earnings in Alliance Boots and operating income in the prior year. So excluding this impact, adjusted operating income in the division grew by 12.5%.  Substantial progress was made in controlling SG&A during the year as a result of benefits associated with our cost-savings program. This was a significant driver of the division's year-on-year performance. On an adjusted basis, SG&A expenses decreased by 85 basis points year-over-year. At the end of fiscal year, the division operated 8,173 retail stores. 
So now let's turn to the division's fourth quarter performance. Retail Pharmacy USA's total sales in the quarter were $19.9 billion, an increase of 4.7% over the fourth quarter in the prior year. The total sales in comparable stores increased by 6.5%. On a GAAP basis for the quarter, gross profit was $5.3 billion while SG&A was $4.7 billion, resulting in operating income of $511 million. On an adjusted basis, gross profit was $5.4 billion while SG&A was $4.3 billion. Adjusted operating income in the fourth quarter of $1.1 billion was down 10.1% over the comparable quarter in the prior year. This was primarily due from having new equity earnings at Alliance Boots in current quarter versus 3 months in the comparable period. Excluding this impact, adjusted operating income grew by 1.2%. We were able to increase adjusted gross profit dollars compared to the final quarter of fiscal 2014 despite lower gross margins, while at the same time, delivering SG&A efficiencies through our cost-savings program. 
So let's now look at the pharmacy part of Retail Pharmacy USA in more detail. Comparable pharmacy sales were up 9.3% for the fiscal year. We filled 894 million prescriptions, including immunizations, that's on a 30-day adjusted basis, an increase of 4.4% over last year, with prescriptions filled in comparable stores up 4.6% year-on-year. In the fourth quarter, comparable pharmacy sales were up 10.0% as we filled 222 million prescriptions, an increase of 4.6% over the equivalent quarter in the prior year, with prescriptions filled in comparable stores, up 5.1%. Year-over-year we continue to see a positive impact and further growth in Medicare Part D and ACA-funded scripts, resulting in our retail prescription market share on a 30-day adjusted basis increasing to 19.1% for the year ended for the year ended 31st of August, an increase of approximately 20 basis points. 
The benefits of positive sales growth were, however, substantially offset by pharmacy gross margin pressure consistent with our expectations. Pharmacy margins were negatively impacted in the fiscal year by lower third-party reimbursements, an increase in Medicare Part D mix, including the strategy to continue driving 90-day prescriptions at retail and the mix of specialty products, which carry a lower margin percentage.  The decrease in pharmacy margins is partially offset by additional branded to generic drug conversions compared with the prior fiscal year. While we continue to anticipate margin pressure, we remain confident in our strategy to drive access of critical programs such as Medicare Part D and deepen our payer relationships to grow our pharmacy business over time. 
Moving now onto the retail products' performance within Retail Pharmacy USA. Retail sales increased by 1.9% for fiscal year 2015, while comparable sales increased 1.5%. As anticipated, the rate of sales growth was slightly slower in the fourth quarter as we continue to remove our more inefficient promotions, reduce store numbers and optimize store opening hours. Sales increased 0.8% in total and by 0.4% on a comparable sales basis. Overall, our strategy continues to be to drive sales growth and improve profitability, and I am pleased to report that gross profit margins have increased for the sixth quarter in succession. 
Over the past 18 months, we have improved our product mix, with our key health and wellness categories now contributing to higher proportion of total sales. We've also enhanced our merchandising tools, continued to optimize our promotional performance and upgraded on-shelf availability, ensuring products are in-store at the right price. And finally, we have improved sourcing with a higher level of our own branded products. 
In fiscal year 2016, we plan to continue to invest to drive our strategy and improve our customer offer. We will take what we've learned from our successful No7 test in Phoenix and New York City, where we saw a positive lift in both beauty and overall sales and rollout the new beauty offering to an additional 1,600 stores for a total of 2,000. With this new offer, we will elevate the customer experience through better fixtures, improved customer care, space optimization and selected store upgrades. We're also advancing the personalization of our Balance Rewards program, with more offers targeted to our everyday points program to our health and beauty customers. Through these efforts, we're striving to improve our customers' experience, expand our profit margin in the front of store and continue to grow sales in key customer categories. 
With that, let me turn to the results of our Retail Pharmacy International division, which is pharmacy-led health and beauty businesses in 8 countries. As a quick reminder, our biggest operations are Boots in the U.K. followed by Mexico. We also have retail pharmacies in Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. At the end of the fiscal year, the division operated 4,582 retail stores. I will focus my commentary for this division primarily on the most recent quarterly results as the fiscal year only has 8 months of data and, therefore, isn't all that meaningful, particularly, as it does not cover the important holiday season. 
Total sales in the division for the quarter were $3.5 billion. Sales growth when compared with our third quarter was mainly due to the expected stronger sales in seasonal categories combined with currency benefits, mainly the British pound strengthening versus the dollar. On a GAAP basis for the fourth quarter, gross profit was $1.5 billion and SG&A was $1.3 billion, resulting in operating income of $196 million. On an adjusted basis, gross profit for the fourth quarter was $1.5 billion and SG&A expense was $1.2 billion, which resulted in operating income of $242 million. Adjusted operating margin was 7.0% for the quarter, which was in line with post-acquisition figure of the last 8 months of the fiscal year. 
So now let's look more closely at the operating performance of the division. On a pro forma constant currency basis, comparable store sales growth for the quarter was 4.3%. Comparable store retail sales growth of 4.5%, being somewhat stronger than pharmacy at 4.1%. Comparable store sales growth in Boots U.K. was 3.5% in the quarter. Growth across all Boots U.K. retail sales categories resulted in comparable store retail sales growth of 4.0%, good performances in beauty and from online offering being the largest factors. 
In beauty, No7, our award winning beauty brand celebrated its 80th anniversary with another good quarter, with both skin care and cosmetics delivering double-digit sales growth in the U.K. Sales of No7 Protect & Perfect Advanced Serum continue to be strong, more than 1 year on from their launch, supported by their continuing marketing program, which highlights the clinically proven product benefits, which I talked about on our last earnings call.  During the quarter, we also launched No7 advanced day and night creams, with a new colored cosmetics campaign. Both of these initiatives were well received by our customers. 
Our U.K. website, boots.com, continued to see strong growth, with orders during the order up more than 65% over the same period last year.  In the beginning of August, we further enhanced the convenience of our order and collect offer, now enabling customers to order by 8:00 p.m. and still collect in-store from 12 noon the following day. In the fourth quarter, nearly 70% of all our online orders in the U.K. were collected in-store.  Outside the U.K., our businesses in Mexico, Thailand and the Republic of Ireland all delivered pro forma constant currency comparable store sales for the quarter, well above the average of the division, as did Boots Opticians in the U.K. 
So turning now to our Pharmaceutical Wholesale division. Total sales in the Pharmaceutical Wholesale division in the fourth quarter were $5.8 billion. On a pro forma basis, assuming constant currency and excluding acquisitions and disposals, on this basis sales increased by 5.0% over the same quarter in the prior year.  Sales growth was particularly strong in Norway, where our wholesale business won a major new contract [indiscernible] hospital pharmacy, which began right on the start of calendar 2015, and 5 other countries, where our businesses each achieved double-digit comparable sales growth in the quarter. This included 2 of our largest wholesale businesses in Turkey and Germany. 
GAAP operating income in the fourth quarter was up $133 million while adjusted operating income was $158 million. Adjusted operating income margin for the quarter was 2.7% compared to 2.9% for the 8 months post-acquisition. This, in part, reflects the seasonal nature of pharmaceutical wholesaling. 
So having covered our divisional performance, I would now like to turn to our synergy program, one of the key drivers of profit growth. The combined net synergies for fiscal 2015 were $799 million, significantly above our target of at least $650 million. This includes $81 million plus Pfizer synergies in the fourth quarter, which relates to activities commencing in prior fiscal years.  Consistent with our prior reporting, these synergies are allocated across each segment. They do not include any benefit from our long-term relationship with AmerisourceBergen or the benefits of refinancing the legacy Alliance Boots indebtedness at a lower cost.  For fiscal year 2016, we continue to expect at least -- to reach at least $1 billion in combined net synergies. As time goes on and the combined management team works closely together, there are, of course, a number of other synergies being identified and actioned, but many of them are simply not practical to quantify as they blend into our core operations. 
So moving now to our cost-savings program, which is as you know, is another key area of focus. As previously announced, we have a target of $1.5 billion of cost savings to be delivered by the end of fiscal 2017. We expect the pretax charges associated with this program, as previously stated, between $1.6 billion and $1.8 billion, with cash component is expected to be approximately 60%. We continue to make good progress towards this goal and achieve more than half of the program's expected savings as of the end of the fiscal year. 
In the Retail Pharmacy USA division, which is the primary driver of this program, this included closing 75 stores in the quarter, making a total of 84 store closures in fiscal 2015 as part of our plan to close approximately 200 stores in total.  Actions taken during fiscal 2015 have resulted in pretax charges totaling $542 million, including $223 million for asset impairments, $202 million for real estate closures and $117 million for severance and other business transition and exit costs. 
So now I'd now like to look at cash flow and capital deployment. GAAP operating profit cash flow was $5.7 billion for the full fiscal year and $1.5 billion in the quarter. Free cash flow was $4.4 billion for the full year and $1.1 billion in the quarter.  As it is hard for you to gauge our cash-generating abilities from today's results, I'd like to give you some insight into our operating cash flow and working capital priorities. We remain intensely focused in driving cash flow across our 3 business segments. Within our Retail Pharmacy USA division, during the year, we improved inventory management in both pharmacy and retail products. We have more opportunities in inventory and have a renewed focus on accounts receivable and accounts payable, all with the aim of driving further working capital savings. We will continue to apply the same discipline in Retail Pharmacy International and Pharmaceutical Wholesale. 
Total capital expenditure was $1.3 billion for the full fiscal year and $361 million in the quarter. After the merger, we put in place operational governance procedures to improve capital and ensure that we are prudently maintaining our infrastructure while investing in the right growth initiatives to generate return to shareholders. This process is working well. You will see a step-up in capital spend from the third to fourth quarter, which reflects our renewed drive to invest in key areas and develop our customer proposition, including information technology. 
So moving onto our key financing activities. In line with our philosophy of having an efficient balance sheet, we completed $395 million of share repurchases in the quarter against our $3 billion authorization, bringing the total purchases under this program to $726 million by fiscal year end. Since then, an existing 10b5-1 program has been completed, in which we acquired an additional $110 million of shares. We now have $2.2 billion of value remaining under our authorized plan.  In addition, as we previously announced, we redeemed the $1.75 billion of legacy Walgreens debt in August. As we've said before, we remain committed to a long-term dividend payout rate -- payout target between 30% and 35% of adjusted net earnings. 
Now before I finish and hand back to Stefano, let me just spend a few minutes on the impact of our agreement to acquire Rite Aid and on fiscal 2016 guidance. As you know, the agreed price per share for Rite Aid is $9, representing a total enterprise value of approximately $17.2 billion, including acquired net debt. The consideration for the shares will be paid in cash from existing new resource. The transaction is, as you would expect, subject to approval by Rite Aid shareholders, regulatory clearances and other customary closing conditions. We have done significant analysis on how we can bring the 2 companies together, including antitrust analysis and we'll work closely with the regulators to bring the transaction to completion as soon as possible. That said, we anticipate the transaction closing in the second half of calendar 2016. The exact timing of this will clearly determine the impact on our financial results. 
Clearly, we are very confident in taking everything into account, the transaction will be suitably accretive for us. We have been prudent in our assumptions for the business and have been realistic about our expectations for the markets in which we operate. That said, we expect the transaction to be accretive during the first full year after completion on our usual adjusted basis.  In addition to timing, there are a number of other factors that will impact us. We've identified in excess $1 billion of gross synergy that we must -- that we will start working to capture as soon as completion takes place. But we must recognize that while some of these are relatively easy to identify, others will require investment and will take time to deliver. 
As we are paying cash for the acquisition, we have taken the decision to suspend our share repurchase program and intend to redeploy that cash to partly fund the transaction. This means that in 2016, we will not enjoy the earnings accretion of the buybacks we originally planned. In fact, we'll be running a relatively inefficient balance sheet for a short period of time.  The transaction will also cause a temporary increase in leverage, but this does not represent an underlying change in financial policy. We'll put in place a glide path to deliver metrics consistent with our commitment to solid investment grade. 
So with all that said, let me conclude by talking about our outlook for fiscal year 2016. As you know, we previously had a stated adjusted EPS goal for fiscal year 2016 of $4.25 to $4.60. We committed at our Analyst meeting in April, that on completion of our budgeting process, we would come back to you to give an updated view of 2016.  Based on our budget and further evaluation of both risks and opportunity, we factored in our currency headwind of around $0.13 since the previous Walgreens management initially provided our FY '16 adjusted EPS goal back in August 2014. We're issuing new guidance for fiscal year 2016 of $4.25 to $4.55. This change is primarily to reflect the impact of suspending our share buyback program, to apply these funds towards the consideration for the transaction. This guidance assumes no material accretion from the planned acquisition of Rite Aid, which is expected to close in the second half of calendar 2016. 
Please also remember that we have currency translational exposure primarily based on movements in the pound sterling versus the dollar. Not only does this impact our adjusted operating income and EPS, but it can also cause particularly volatility in the sales, gross margin and SG&A items as it did this quarter.  As Stefano indicated, we anticipate to publish numerical synergy targets from the merger between Walgreens and Alliance Boots to be met during 2016, and we'll advise you after we have achieved that target. The synergies and benefits from the transaction with Rite Aid will be almost entirely within our U.S. Retail Pharmacy division, and so will be reflected in these figures rather than separately itemized programs.  Clearly, we will continue to drive hard efficiencies, costs and procurement, but we see this as normal working practice rather than unique and discrete projects. And so going further beyond 2016, we would expect our earnings growth to return to a more normal fiscal challenging low double-digit growth. 
In terms of the shape of the quarters, please remember that both our first and second quarters of fiscal year '16 are non-comparable given that we closed the merger on the 31st of December 2014. Seasonality is most prominent in our retail pharmacy segments, with the first quarter is typically the weakest. Our second quarter picks up most of the holiday season, which will be more prominent going forward as we will consolidate December results for Retail Pharmacy International. This will include Boots performance in December, which is typically its most important trading month. We also expect the shape of the second half of the fiscal year to be generally consistent with what we saw in fiscal 2015, with adjusted earnings per share in Q3 and Q4 stepping down sequentially from Q2. 
So with that, I will turn the call back to Stefano."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you, George. So another good year, but a year of transition that has brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our team on track and",446,"Thank you, George. So another good year, but a year of transition that has brought many challenges but also with many successes, including our announcement with Rite Aid. It has been particularly gratifying to have been able to keep our team on track and maintain our momentum in our businesses, both in the U.S. and around the world, while at the same time be able to study and understand our new markets and deliver corporate expansion as we are doing with Rite Aid. 
As CEO, I very much recognize my role is both to support my team in achieving also partly their goals but also in creating the opportunities and direction for them to outperform and identify sources of growth and value enhancement while helping mark the route for sustained growth to secure the future for the company well beyond my tenure. As we stand today, we have potential opportunities in many businesses, in many geographies. We continue to review all the opportunities open to us to assess where best to deploy our capital to provide the best return of our investors. 
The health care market is extraordinarily dynamic with many moving parts, and these dynamics create new opportunities and new ideas all the time. A key part of my role is to make sure that we pursue these opportunities where they are desirable to do so and not waste time and resources to where it is now and also to ensure that we do that without distracting our teams on delivering on our long- and short-term plans of our existing businesses. Over time, you can expect to see us complement the development of our existing businesses with further additions that will help us better define and differentiate our business. 
As we look at our opportunities around the globe, given the unique dynamic of the U.S. market, it is not surprising that the best opportunity we have found this year has been here, while elsewhere our expansion has been through the selective purchase event and a small bolt-on acquisitions to our original business.  The global health care market and perhaps the U.S. markets, more than any, are ready for change and openness to new ideas and new approaches while it provides care. As a leading global health care company, we have the potential to play a tiny role in this evolution. We have always married prudence with a willingness to find innovative solutions and think about things in new ways and these are qualities I am glad to be spreading across the group and I believe will form the foundation for the success of the business going forward. 
Now let's open up for questions. Gerald, please?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you. Andrew, we're ready to take questions now.",9,"Thank you. Andrew, we're ready to take questions now."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Edward Kelly from Crdit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Edward Kelly from Crdit Suisse."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call, by the way, didn't really have any reference to your appetite for FTC risk. So does the merger agreement have a divestiture cap? If it does, can",114,"Congratulations in the Rite Aid deal. I did want to start just on that front. Your press release and the call, by the way, didn't really have any reference to your appetite for FTC risk. So does the merger agreement have a divestiture cap? If it does, can you provide more detail here? And as you think about FTC, I mean, there is some history that we can sort of look back to, 2007, when Rite Aid bought Eckerd, for instance. In terms of the parameters that they looked at, is that still a relevant way to think about it? Any thoughts related to all this, I think, would be very helpful for people."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's very difficult to comment about that. Of course, before doing these decisions, taking these decisions and doing these steps, we have analyzed things very carefully. We have tried to figure out what would happen. But of course, this has been done with",76,"It's very difficult to comment about that. Of course, before doing these decisions, taking these decisions and doing these steps, we have analyzed things very carefully. We have tried to figure out what would happen. But of course, this has been done within the closed walls of our company. In this situation, it's very difficult for us to make public comments. When we have public authorities, it's better for us not to interfere at all."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, just one follow-up to that, I mean, because the merger agreement is going to come out soon, I would take it.  So how much divestiture risk are you assuming within this agreement? Is there a certain number of stores? How would you frame that in th",49,"I guess, just one follow-up to that, I mean, because the merger agreement is going to come out soon, I would take it.  So how much divestiture risk are you assuming within this agreement? Is there a certain number of stores? How would you frame that in the agreement?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","We have put a top because, of course, we have to take certain precautions, but we are not speculating at all about the number of stores that we will have divested.",31,"We have put a top because, of course, we have to take certain precautions, but we are not speculating at all about the number of stores that we will have divested."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And just sorry, one -- I apologize, but could you give us the number that you sort of capped this at?",22,"Okay. And just sorry, one -- I apologize, but could you give us the number that you sort of capped this at?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I cannot give you the numbers and you know it.",10,"I cannot give you the numbers and you know it."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser from Morgan Stanley."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Yes, so congratulations first of all on the Rite Aid deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think abou",99,"Yes, so congratulations first of all on the Rite Aid deal. Obviously, you've communicated $1 billion of synergies. Can you just help us think about the sources of synergies and kind of like how long will it take to capture it? I mean, should we think about it, I mean, when you've kind of like put together Alliance Boots and Walgreens, you've also communicated synergy number and you've kind of like allocated buckets to drug purchasing, front end, et cetera. So if you can give us some similar context for the Rite Aid deal, it would be very helpful."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","George?",1,"George?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, we've not given the specific details on this but I'm sure you can imagine that as with any deal of this nature, there are different classifications of synergies. There are the procurement synergies, the GNFR synergies, there will be other cost-saving",168,"Yes, we've not given the specific details on this but I'm sure you can imagine that as with any deal of this nature, there are different classifications of synergies. There are the procurement synergies, the GNFR synergies, there will be other cost-saving synergies. And these we will -- these synergies we will access in a structured way much as we have done with the Walgreens Alliance Boots transaction. We've got a team here very experienced in accessing those synergies. And we're very confident that we -- in our numbers. As ever, synergies take -- these gross synergies take time to access. Some of them can be achieved faster than others. Some will require investment and we will work through that. But there will be an element of investment to get these synergies. But clearly, over the coming time, we will work through how best to achieve these. But we've done a lot of work as ever to be really feeling confident in the number that we have published."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But you understand that, in this case, the synergies are coming mainly by internal efficiency, by the fact that maybe we can have a better network to sell our brands, our product, which is still a fundamental component of our strategy. And so this will no",53,"But you understand that, in this case, the synergies are coming mainly by internal efficiency, by the fact that maybe we can have a better network to sell our brands, our product, which is still a fundamental component of our strategy. And so this will not happen overnight, it will take some time."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, sure.  The other -- finally, to add to that, would be that -- I mean, this is -- the program, in a sense, is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to repor",74,"Yes, sure.  The other -- finally, to add to that, would be that -- I mean, this is -- the program, in a sense, is not between 2 companies. The acquisition will be in part of the Retail Pharmacy USA division. So it really doesn't make sense for us to report the synergies separately. And the way that we did from these were essentially being shared half and half between Alliance Boots and Walgreens."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But I want to stress what George has said. We have done a lot of work, and we are very confident that this deal will deliver for us.",28,"But I want to stress what George has said. We have done a lot of work, and we are very confident that this deal will deliver for us."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?",23,"Okay. And then Rite Aid has a small PBM business that they acquired recently. How do you think Envision fits within Walgreens Boots?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Maybe Alex can give you. We have discussed this, about the -- their PBM business and Alex can do something about it.",22,"Maybe Alex can give you. We have discussed this, about the -- their PBM business and Alex can do something about it."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, as we know today, it's an important but relatively small PBM business. It's in the top 10, but not a big one. It's a pass-through business with a lot of good capabilities in IT. So at the moment we are really interested, one is to get beyond",154,"Yes, I mean, as we know today, it's an important but relatively small PBM business. It's in the top 10, but not a big one. It's a pass-through business with a lot of good capabilities in IT. So at the moment we are really interested, one is to get beyond the closure of the FTC review to understand more about the business and how it can really help us understand access to the Medicare better. I mean, a real compass view with the closed deal with Rite Aid is to improve the quality of pharmacy and to really reduce cost across the market the make sure we create a market which is more affordable, more accessible for everyone aligned with the government policy. So we think this could be our way into that in terms of Envision. But clearly, we need to understand more and we understand more once we're through the FTC review."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","And then it will be a good opportunity for us to learn more and we are always open to learn.",20,"And then it will be a good opportunity for us to learn more and we are always open to learn."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Meredith Adler from Barclays.",12,"Our next question comes from the line of Meredith Adler from Barclays."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes.",36,"We haven't had an update in a little while on the loyalty program. I was wondering if you could give us just a little bit of comment on that. I think you're making some changes."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. Meredith, it's Alex here. Yes, we moved to something called every day points here and we talked about it in the last earnings review as well. And this is where, for the majority of the front-end products, we're able to offer points and also extended",240,"Yes. Meredith, it's Alex here. Yes, we moved to something called every day points here and we talked about it in the last earnings review as well. And this is where, for the majority of the front-end products, we're able to offer points and also extended the points in our pharmacy business to other schemes at Medicaid and Medicare where appropriate. We're really pleased with what's happened. Customers have signed into this program. We have, I think, about 27 million of customers signed into it and they have quite a few points. And more importantly, as we analyze how they're redeeming the points, we're seeing encouraging behavior where people are actually selecting more and more own-brand products and bigger baskets and products they may not otherwise have bought. So it's really early days. I mean, the program has been out there for only a matter of months, but the behavior we're seeing in these customers are encouraging and it is exactly the type of behavior we've seen in other loyalty programs that we know of well in the group. So that's where we are, and of course, we intend, as we have done progressively since we launched the program just over 3 years ago now, to invest wisely and carefully to ensure we get a return of that investment, and we're seeing the same here where can invest more in this program and will do so in the years ahead."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I have a question about Rite Aid. I think the company -- Rite Aid's management has been fairly upfront about the fact that they have a pretty large number of underperforming stores. I think they've been hesitant to close too many stores, the le",72,"Great. And I have a question about Rite Aid. I think the company -- Rite Aid's management has been fairly upfront about the fact that they have a pretty large number of underperforming stores. I think they've been hesitant to close too many stores, the leases have not yet run out. Could you please talk about your observations of the store base and what your approach would be to those underperforming stores?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's very difficult to judge the operator, the management, because we should understand all the different events and all the different conditions in which the management has to operate. They have a lot of complaints, as you know. So I believe they have do",90,"It's very difficult to judge the operator, the management, because we should understand all the different events and all the different conditions in which the management has to operate. They have a lot of complaints, as you know. So I believe they have done a good job of the situation that they were in. We will approach in our usual way, in a very rational way, trying to do what -- to create value. So we are not emotional on that, and we will be rational as ever. Alex?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes. And I think that it's clear that we are working hard here in Walgreens to really develop the front end, and again, George gave a good update again about some of the progress we've made here in terms of being able to improve our operational margin in",246,"Yes. And I think that it's clear that we are working hard here in Walgreens to really develop the front end, and again, George gave a good update again about some of the progress we've made here in terms of being able to improve our operational margin in the front end over the last 6 quarters. So as we develop the best 5 years in Walgreens, as we take the best 5 years from Alliance Boots and again George updated you that we intend to expand our beauty products into 2,000 Walgreens stores, having done a controlled test in both Phoenix and New York City. And also, as we really learn some of the excellent work from the outside that the Rite Aid team have done in their new wellness format, we have the opportunity to put all that together once we're through the FTC review and see how we can improve performance in all of our networks across America and to provide better front-end performance through a more appropriate offer for communities across America, supporting a better quality pharmacy experience and, of course, lower costs. So that's our intention. But obviously, once we're through the process of FTC, we'll be able to work more closely with the teams and understand that better. But we think there's opportunity both in Walgreens, and clearly, the team at Rite Aid has seen a good improvement in their wellness format and will be read in terms of the reporting."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Great. And I just have one more question. You highlight the sort of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel unc",55,"Great. And I just have one more question. You highlight the sort of health care aspects of this and how it's going to -- the merger is going to position you. Are you considering eliminating tobacco? It seems pretty clear that providers and payers feel uncomfortable working with a retail pharmacy that still sells tobacco."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, we've chosen to invest to help people to stop smoking, to lose weight. Our Balance Rewards for healthy choice programs we launched 12 months ago has been incredibly successful, and we've chosen to invest there. Because we believe that less than 3%",141,"I mean, we've chosen to invest to help people to stop smoking, to lose weight. Our Balance Rewards for healthy choice programs we launched 12 months ago has been incredibly successful, and we've chosen to invest there. Because we believe that less than 3% of tobacco sold today in a drugstore channel, the choice tobacco is there already in many other places. Of course, we continue to review and reflect on this issue and the other categories that we happen to sell. There are fundamental choices to invest to help people who are ready and prepared to stop and we've made really good progress there in what we've done. So at this stage, we have nothing else to update on apart from that we are pleased with the progress we've made with our investments to help people across America stop smoking."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments that you feel like the company will need to make as you try to bring the 2 businesses together? I know the Walgreens executives have commented in the past",97,"I guess, George, could you maybe talk a little bit about gross-to-net synergies and the investments that you feel like the company will need to make as you try to bring the 2 businesses together? I know the Walgreens executives have commented in the past that the IT infrastructure at Walgreens needs a little bit of work. I think the same thing, safe to say, needs work at Rite Aid. I guess so as you try to think about gross synergies versus net synergies from your announcement, is there any more color you can give us there?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. Just a quick word on IT. I mean, as I touched in the presentation, one of the reasons that we saw step-up in the fourth quarter versus the third quarter was our IT program. And so we, as Walgreens Boots Alliance, have been doing a lot of work since",244,"Okay. Just a quick word on IT. I mean, as I touched in the presentation, one of the reasons that we saw step-up in the fourth quarter versus the third quarter was our IT program. And so we, as Walgreens Boots Alliance, have been doing a lot of work since the merger, our best to structure our IT so that we're able to use our global scale and capability to invest in IT in a cost-efficient way to best serve the needs of both the business internally, but most importantly, our customers. So there's a lot of work on IT underway. In terms of the gross synergies, it's really -- I mean, these will come in U.S., as we have said, which is why it becomes harder to separate out than in the -- as we start to integrate the operations plus being able to complete the transaction. But the synergies that will come will be procurement synergies, where there clearly isn't an investment requirement but then it will be investment over time in areas like in IT and in upgrading the stores and we will do that in a thoughtful, structured way. We'll be looking at stores on a store-by-store basis as we always do, looking for the returns that we continue to seek. So the investment will always take a little bit longer to come. It'll be done over time because of the nature of that part of the integration takes longer."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And maybe a quick follow-up for Alex, if he's still there. Can you provide us any early color on what the reimbursement rate environment is looking like for 2016? And how do you affect these conversations to evolve on a longer-term basis once there",49,"Okay. And maybe a quick follow-up for Alex, if he's still there. Can you provide us any early color on what the reimbursement rate environment is looking like for 2016? And how do you affect these conversations to evolve on a longer-term basis once there are already transactions closed?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, and I can't comment on a long-term basis. What I can tell you is that we really have anticipated the Med D season would have an enrollment. We're pleased we've been able to expand our partnerships with peers. For example, we announced Aetna as a new",120,"Yes, and I can't comment on a long-term basis. What I can tell you is that we really have anticipated the Med D season would have an enrollment. We're pleased we've been able to expand our partnerships with peers. For example, we announced Aetna as a new partner for us and we're really pleased with that. So we are feeling -- the rates are as planned. Of course, the reduction from last year's rates but as planned, as we expected. And we've been able to drive our strategy of improving access and improving volumes through some new partnerships. The commercial ones, as you know, we're on 3-, 4-year contracts, and we don't comment on these contracts probably as you're aware."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Robert Jones from Goldman Sachs.",13,"Our next question comes from the line of Robert Jones from Goldman Sachs."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Just one high level one for Stefano and then just a couple quick ones for George. I guess, just from a big picture perspective, why was getting bigger in the retail space the right move strategically right now? And I guess, more specifically as it relates",66,"Just one high level one for Stefano and then just a couple quick ones for George. I guess, just from a big picture perspective, why was getting bigger in the retail space the right move strategically right now? And I guess, more specifically as it relates to that, how much more negotiating leverage do you think this expanded network will give you versus payers and PBMs?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, we have not done these to increase our negotiating power. We stay on PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I would say from internal sources and the harmonization of",219,"Well, we have not done these to increase our negotiating power. We stay on PBM. We have done this because we believe that we can extract a lot of synergies, rationalizing the combined company. So I would say from internal sources and the harmonization of prices in terms of harmonization and not improvement, the harmonization of our know-how something in software, something, of course, in the combination of the stores as we were discussing before. There's something from our product lines. Well, we are not thinking of really improving our position with the payers because at the end of the day, we are in an environment where the margins are decreasing. So it was decreasing. We are in an environment where there is a lot of competition and the fact that we put together 2 companies would not reduce the competition. Not just the competition among pharmacies, think of the other tandem, think of the mail order, think of the people who are specialized in certain categories, like the specialty, for instance. So there are many people working in this area. I don't believe that this will really give us an additional power. But we have not accounted on that when we have put together our numbers. We have put together our numbers very, very carefully and very prudently."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Got it. And then I guess, George, just I'm sure you can appreciate it's very difficult for us to get visibility into the core pharmacy businesses just given a lot of the moving pieces, not the least of which is the synergies. It looks like the total syner",90,"Got it. And then I guess, George, just I'm sure you can appreciate it's very difficult for us to get visibility into the core pharmacy businesses just given a lot of the moving pieces, not the least of which is the synergies. It looks like the total synergies in the quarter were about $295 million. Is there any sense at all you can give us on how we should be allocating those across the businesses just to get a little bit better perspective on how the core businesses are tracking?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Yes, I mean, we very much try and allocate the synergies based on the activities. So I do appreciate that's made the segmental analysis a little tougher for you to follow. But by doing it on this basis of procurement, we really are therefore reflecting wh",210,"Yes, I mean, we very much try and allocate the synergies based on the activities. So I do appreciate that's made the segmental analysis a little tougher for you to follow. But by doing it on this basis of procurement, we really are therefore reflecting where the volume is, where the activity is. Another result, obviously, with the Retail Pharmacy USA being, by far, our biggest segment, then you should think of the synergies being heavily, heavily weighted towards the U.S. segment. It's the basis that I would always think about. I think as we annualized through as we get to the third quarter, which I guess will be our first sort of clean year-on-year quarter, it will be a little bit easier for you to see. And of course, it's the hard synergies, which are the ones that we're quantifying. But really a lot of the -- of what are, in effect, synergies, but they're not the ones that we can quantify. These are the ones that are really coming through, as we know. Increasingly, an integrated combined management team are working very much together on many of the programs, sharing best practice, and that's very much business as usual now rather than run through each synergy work stream."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","That's actually really helpful. And then just the last one, more of a clarification, George. Did I here you correctly that EPS growth beyond fiscal '16 is anticipated to be low double digits? And if that's right, any sense you can give us of what's contem",54,"That's actually really helpful. And then just the last one, more of a clarification, George. Did I here you correctly that EPS growth beyond fiscal '16 is anticipated to be low double digits? And if that's right, any sense you can give us of what's contemplated in capital allocation relative to that target?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, yes, that's as far as we've indicated just to try and give you a sense of how we see the business going forward. Sorry, in relation to capital allocation...",31,"I mean, yes, that's as far as we've indicated just to try and give you a sense of how we see the business going forward. Sorry, in relation to capital allocation..."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Is that contemplated in the low double-digit target?",9,"Is that contemplated in the low double-digit target?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","That's got our typical investment program, so absolutely everything is in there. I mean, we're being quite prudent, as you would expect, in these areas.",26,"That's got our typical investment program, so absolutely everything is in there. I mean, we're being quite prudent, as you would expect, in these areas."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","But when we are talking of next year, there was a point of next year, which if you take -- if you do the math and take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this is",162,"But when we are talking of next year, there was a point of next year, which if you take -- if you do the math and take into account the fact that we will not be able to buy $2.2 billion in shares, you will see that the math is quite favorable. But this is substantially an organic growth. So in a retail business, to have an organic growth of double digit, low double digit is not easy. We have done this for many, many areas. I have to say we have never had 1 year without double-digit growth in our history. But I can tell you that it's not easy because it's relatively easy to announce the earnings per share, buying back a lot of shares or buying additional businesses. The business that we are buying at this time, will not have an effect on next year. So you have the look at the numbers of next year as organic growth."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Our next question comes from the line of Lisa Gill from JPMorgan.",12,"Our next question comes from the line of Lisa Gill from JPMorgan."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","George, I just wanted to go about the synergies on the Rite Aid deal for a minute and just skip the time of your expectation on the procurement side. My understanding is that Rite Aid has a relationship with McKesson for procurement that runs through Marc",88,"George, I just wanted to go about the synergies on the Rite Aid deal for a minute and just skip the time of your expectation on the procurement side. My understanding is that Rite Aid has a relationship with McKesson for procurement that runs through March of 2019. So is the assumption that there's a way to break that relationship and you'll get procurement earlier? Or is it that the time line is unknown on this because you may have to wait until the end of the contract?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Lisa, first of all, I have to say we have not taken any decision about the contract. Not necessarily we have to change substantially the contract in order to get the synergies. We are -- we believe we can have -- and at the right time, we will discuss wit",147,"Lisa, first of all, I have to say we have not taken any decision about the contract. Not necessarily we have to change substantially the contract in order to get the synergies. We are -- we believe we can have -- and at the right time, we will discuss with the contract, and of course, we will try to discuss in the interest of the -- of our company, that's obvious. But you don't have to assume the fact that we will change the contract or we will move the contract. Of course, we have very good relationship with ABC. But I have to tell you that we have a lot of respect for McKesson and a lot of respect for Hammergren and Julian and we will see. We will see at the time. It's obvious that we will try to extract as much value as possible."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, that's helpful. And then, Stefano, you talked about the U.S. market open to change your belief in the playing a role. You answered an earlier question around the small PBM that's going to be part of this transaction. But can you maybe just give us a",86,"Okay, that's helpful. And then, Stefano, you talked about the U.S. market open to change your belief in the playing a role. You answered an earlier question around the small PBM that's going to be part of this transaction. But can you maybe just give us any idea as to how you think about that potential role that you play? And from your strategic view, how you think the U.S. market is changing and what role that the bigger Walgreens will play here in the U.S.?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Well, for sure I can tell you that I have certain ideas. But before making these ideas public, I would like to check this idea with the reality, which is around that. So now we have just done a deal. We have just started -- announced a potential deal. We",90,"Well, for sure I can tell you that I have certain ideas. But before making these ideas public, I would like to check this idea with the reality, which is around that. So now we have just done a deal. We have just started -- announced a potential deal. We have started this deal. For a few months, we will be really absorbed in this deal. We will continue to think. But for a few months, we will not be able to tell you where we want to go next."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. There's a -- I'm sorry, just to say maybe the opportunity is the beginning of next year? We'll get together in January and maybe we'll have some incremental ideas as to how you'll think about this.",37,"Okay. There's a -- I'm sorry, just to say maybe the opportunity is the beginning of next year? We'll get together in January and maybe we'll have some incremental ideas as to how you'll think about this."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","It's always -- I think it's about the patient and the customer having more power and more choice. And I think with a fantastic group of people under Walgreens and the brand that they represent in communities across America, I think that's where we have th",51,"It's always -- I think it's about the patient and the customer having more power and more choice. And I think with a fantastic group of people under Walgreens and the brand that they represent in communities across America, I think that's where we have the biggest opportunity, I think."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay, appreciate that, and congratulations on Rite Aid.",8,"Okay, appreciate that, and congratulations on Rite Aid."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Thank you very much. We will have time to talk in the future.",13,"Thank you very much. We will have time to talk in the future."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","And the last time that we have -- the last question that we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch.",31,"And the last time that we have -- the last question that we have time for today will be from the line of Robert Willoughby from Bank of America Merrill Lynch."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, do you think you can raise from sale-leaseback deals in fiscal '16?",27,"Do you anticipate being able to utilize the Rite Aid NOLs? And how much, George, do you think you can raise from sale-leaseback deals in fiscal '16?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward. We've, obviously, as you can see, done quite a bit of sale and leaseback in the last particular year. We haven't set an internal target. We will continue",81,"Okay. On the last one, we're continuing to evaluate what is the best capital structure going forward. We've, obviously, as you can see, done quite a bit of sale and leaseback in the last particular year. We haven't set an internal target. We will continue just to work through this in a normal way, but very committed to having an efficient balance sheet, as I said, on many occasion. That's the answer to the second one. So the first one was..."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","The Rite Aid NOLs?",4,"The Rite Aid NOLs?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","The Rite Aid NOLs, we would anticipate over time being able to utilize the NOLs.",15,"The Rite Aid NOLs, we would anticipate over time being able to utilize the NOLs."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Analysts","Okay. And just a clarity on the sale-leaseback. Walgreens had owned 20% of their stores. I mean, do you envision bringing that number down meaningfully over time, whatever the period?",30,"Okay. And just a clarity on the sale-leaseback. Walgreens had owned 20% of their stores. I mean, do you envision bringing that number down meaningfully over time, whatever the period?"
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Executives","I mean, what I would answer is I'm not wedded on having to own retail pharmacy locations. Clearly, there will be certain occasions where it may be the right thing to do. But it's not something that I feel is necessary for our business model. We will conti",256,"I mean, what I would answer is I'm not wedded on having to own retail pharmacy locations. Clearly, there will be certain occasions where it may be the right thing to do. But it's not something that I feel is necessary for our business model. We will continue to look at sale and leaseback where we believe it's the right thing to do. Really taking into account the timing of the tenure of leases and when the lease breaks off, so that we have a balance in our portfolio going forward and don't have the bunching of lease breaks all at the same time. So we'll be doing this -- looking at this in a thoughtful way over time is the way I would position it.
Thank you. Ladies and gentlemen, that was the final question we have time for. Thank you for joining us. Please, we know that there's many of you that had questions. Please reach out to the IR team here and we will answer and address them as best we can. I should say that we go back into the -- our next quiet period on the 1st of December. So we have a comparatively short open period. Management have been very generous with the time. We will try and get to as many of you as we can during that period, but please bear with us. You'll appreciate with an agreement as well as our results, we have a very busy few weeks ahead of us. Thank you very much indeed."
93624,312356229,884232,"Walgreens Boots Alliance, Inc., Q4 2015 Earnings Call, Oct 28, 2015",2015-10-28,"Earnings Calls","Walgreens Boots Alliance, Inc.","Operator","Ladies and gentlemen, thank you again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day.",33,"Ladies and gentlemen, thank you again for your participation in today's conference. This now concludes the program, and you may all disconnect your telephones lines at this time. Everyone, have a great day."
